<SEC-DOCUMENT>0001214659-20-002568.txt : 20200312
<SEC-HEADER>0001214659-20-002568.hdr.sgml : 20200312
<ACCEPTANCE-DATETIME>20200312152405
ACCESSION NUMBER:		0001214659-20-002568
CONFORMED SUBMISSION TYPE:	1-A/A
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20200312
DATE AS OF CHANGE:		20200312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alzamend Neuro, Inc.
		CENTRAL INDEX KEY:			0001677077
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811822909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		1-A/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	024-11124
		FILM NUMBER:		20708541

	BUSINESS ADDRESS:	
		STREET 1:		3802 SPECTRUM BLVD,
		STREET 2:		SUITE C112C
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33612
		BUSINESS PHONE:		844-722-6333

	MAIL ADDRESS:	
		STREET 1:		3802 SPECTRUM BLVD,
		STREET 2:		SUITE C112C
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33612
</SEC-HEADER>
<DOCUMENT>
<TYPE>1-A/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/rega/oneafiler" xmlns:ns1="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>1-A/A</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0001677077</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
        <offeringFileNumber>024-11124</offeringFileNumber>
      </filer>
      <flags>
        <sinceLastFiling>true</sinceLastFiling>
      </flags>
    </filerInfo>
  </headerData>
  <formData>
    <employeesInfo>
      <issuerName>Alzamend Neuro, Inc.</issuerName>
      <jurisdictionOrganization>DE</jurisdictionOrganization>
      <yearIncorporation>2016</yearIncorporation>
      <cik>0001677077</cik>
      <sicCode>2834</sicCode>
      <irsNum>81-1822909</irsNum>
      <fullTimeEmployees>1</fullTimeEmployees>
      <partTimeEmployees>3</partTimeEmployees>
    </employeesInfo>
    <issuerInfo>
      <street1>3802 SPECTRUM BLVD,</street1>
      <street2>SUITE 112C</street2>
      <city>TAMPA</city>
      <stateOrCountry>FL</stateOrCountry>
      <zipCode>33612</zipCode>
      <phoneNumber>844-722-6333</phoneNumber>
      <connectionName>Henry Nisser</connectionName>
      <industryGroup>Other</industryGroup>
      <cashEquivalents>42606.00</cashEquivalents>
      <investmentSecurities>0.00</investmentSecurities>
      <accountsReceivable>205915.00</accountsReceivable>
      <propertyPlantEquipment>0.00</propertyPlantEquipment>
      <totalAssets>1500917.00</totalAssets>
      <accountsPayable>1104669.00</accountsPayable>
      <longTermDebt>0.00</longTermDebt>
      <totalLiabilities>1184002.00</totalLiabilities>
      <totalStockholderEquity>316915.00</totalStockholderEquity>
      <totalLiabilitiesAndEquity>1500917.00</totalLiabilitiesAndEquity>
      <totalRevenues>0.00</totalRevenues>
      <costAndExpensesApplToRevenues>0.00</costAndExpensesApplToRevenues>
      <depreciationAndAmortization>0.00</depreciationAndAmortization>
      <netIncome>-4862496.00</netIncome>
      <earningsPerShareBasic>-0.08</earningsPerShareBasic>
      <earningsPerShareDiluted>-0.08</earningsPerShareDiluted>
      <nameAuditor>Squar Milner LLP</nameAuditor>
    </issuerInfo>
    <commonEquity>
      <commonEquityClassName>Common Equity</commonEquityClassName>
      <outstandingCommonEquity>63662858</outstandingCommonEquity>
      <commonCusipEquity>000000000</commonCusipEquity>
      <publiclyTradedCommonEquity>N/A</publiclyTradedCommonEquity>
    </commonEquity>
    <commonEquity>
      <commonEquityClassName>Options to Purchase Common Stk</commonEquityClassName>
      <outstandingCommonEquity>23675000</outstandingCommonEquity>
      <commonCusipEquity>000000000</commonCusipEquity>
      <publiclyTradedCommonEquity>N/A</publiclyTradedCommonEquity>
    </commonEquity>
    <commonEquity>
      <commonEquityClassName>Warrants to Acquire Common Stk</commonEquityClassName>
      <outstandingCommonEquity>6652035</outstandingCommonEquity>
      <commonCusipEquity>000000000</commonCusipEquity>
      <publiclyTradedCommonEquity>N/A</publiclyTradedCommonEquity>
    </commonEquity>
    <preferredEquity>
      <preferredEquityClassName>Series A Preferred Equity</preferredEquityClassName>
      <outstandingPreferredEquity>750000</outstandingPreferredEquity>
      <preferredCusipEquity>000000000</preferredCusipEquity>
      <publiclyTradedPreferredEquity>N/A</publiclyTradedPreferredEquity>
    </preferredEquity>
    <debtSecurities>
      <debtSecuritiesClassName>Debt Securities</debtSecuritiesClassName>
      <outstandingDebtSecurities>0</outstandingDebtSecurities>
      <cusipDebtSecurities>000000000</cusipDebtSecurities>
      <publiclyTradedDebtSecurities>N/A</publiclyTradedDebtSecurities>
    </debtSecurities>
    <issuerEligibility>
      <certifyIfTrue>true</certifyIfTrue>
    </issuerEligibility>
    <applicationRule262>
      <certifyIfNotDisqualified>true</certifyIfNotDisqualified>
    </applicationRule262>
    <summaryInfo>
      <indicateTier1Tier2Offering>Tier2</indicateTier1Tier2Offering>
      <financialStatementAuditStatus>Audited</financialStatementAuditStatus>
      <securitiesOfferedTypes>Equity (common or preferred stock)</securitiesOfferedTypes>
      <offerDelayedContinuousFlag>Y</offerDelayedContinuousFlag>
      <offeringYearFlag>N</offeringYearFlag>
      <offeringAfterQualifFlag>N</offeringAfterQualifFlag>
      <offeringBestEffortsFlag>Y</offeringBestEffortsFlag>
      <solicitationProposedOfferingFlag>N</solicitationProposedOfferingFlag>
      <resaleSecuritiesAffiliatesFlag>N</resaleSecuritiesAffiliatesFlag>
      <securitiesOffered>6000000</securitiesOffered>
      <outstandingSecurities>63662858</outstandingSecurities>
      <pricePerSecurity>7.5000</pricePerSecurity>
      <issuerAggregateOffering>45000000.00</issuerAggregateOffering>
      <securityHolderAggegate>0.00</securityHolderAggegate>
      <qualificationOfferingAggregate>0.00</qualificationOfferingAggregate>
      <concurrentOfferingAggregate>0.00</concurrentOfferingAggregate>
      <totalAggregateOffering>45000000.00</totalAggregateOffering>
      <salesCommissionsServiceProviderName>Sales Commissions</salesCommissionsServiceProviderName>
      <salesCommissionsServiceProviderFees>4500000.00</salesCommissionsServiceProviderFees>
      <auditorServiceProviderName>Squar Milner LLP</auditorServiceProviderName>
      <auditorFees>35000.00</auditorFees>
      <legalServiceProviderName>Sichenzia Ross Ference LLP</legalServiceProviderName>
      <legalFees>7500.00</legalFees>
      <estimatedNetAmount>40457500.00</estimatedNetAmount>
      <clarificationResponses>The above table excludes fees to be paid to SOS Back Office Solutions, LLC but includes $4,500,000 for sales commissions that will be payable if the Company uses such a service provider</clarificationResponses>
    </summaryInfo>
    <juridictionSecuritiesOffered>
      <jurisdictionsOfSecOfferedSame>true</jurisdictionsOfSecOfferedSame>
      <issueJuridicationSecuritiesOffering>AL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AZ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>FL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>GA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>HI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ID</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>LA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ME</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NJ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NM</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ND</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>RI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TX</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>UT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PR</issueJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AZ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>FL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>GA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>HI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ID</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>LA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ME</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NJ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NM</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ND</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>RI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TX</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>UT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PR</dealersJuridicationSecuritiesOffering>
    </juridictionSecuritiesOffered>
    <securitiesIssued>
      <securitiesIssuerName>Alzamend Neuro, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Common Stock</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>11921072</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$2,221,608 for 1,921,072 shares of Common Stock at $1.50 per share and 960,536 Warrants with an exercise price of $3.00 per share; $15,000,000 note receivable from a related party for 10,000,000 shares of Common Stock at $1.50 per share and 5,000,000 Warrants with an exercise price of $3.00 per share</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <securitiesIssued>
      <securitiesIssuerName>Alzamend Neuro, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Warrants</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>5960536</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$2,221,608 for 1,921,072 shares of Common Stock at $1.50 per share and 960,536 Warrants with an exercise price of $3.00 per share; $15,000,000 note receivable from a related party for 10,000,000 shares of Common Stock at $1.50 per share and 5,000,000 Warrants with an exercise price of $3.00 per share</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <unregisteredSecuritiesAct>
      <securitiesActExcemption>Private Placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder.</securitiesActExcemption>
    </unregisteredSecuritiesAct>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PART II AND III
<SEQUENCE>3
<FILENAME>partiiandiii.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As submitted to the Securities and
Exchange Commission on March 12, 2020</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 1-A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGULATION A OFFERING CIRCULAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>ALZAMEND
NEURO, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of issuer as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation
or organization)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3802 Spectrum Blvd., Suite #112C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tampa, FL 33612</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (844) 722-6333</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">including area code of issuer&rsquo;s principal
executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4pt"><B>Corporation Service
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4pt"><B>2711 Centerville
Road, Suite 400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4pt"><B>Wilmington, Delaware
19808</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Henry Nisser, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alzamend Neuro, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>100 Park Avenue, Suite 1658</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (844) 722-6333</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2836</B></FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>81-1822909</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial<FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
</FONT>Classification Code Number)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
</FONT>Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt">The Offering Statement
of which this Offering Circular forms a part shall only be qualified upon order of the Commission, unless a subsequent amendment
is filed indicating the intention to become qualified by operation of the terms of Regulation A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt">This Preliminary Offering
Circular follows the offering circular format described in Part II of Form1-A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>An Offering Statement pursuant
to Regulation A relating to these securities has been filed with the Securities and Exchange Commission, which we refer to as the
Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities
may not be sold nor may offers to buy be accepted before the Offering Statement filed with the Commission is qualified. This Preliminary
Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these
securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under
the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice
within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the
offering statement in which such Final Offering Circular was filed may be obtained.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>PRELIMINARY OFFERING CIRCULAR MARCH
12, 2020</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="alzamendlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NO MINIMUM OFFERING </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$45,000,000 MAXIMUM OFFERING </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a public offering of securities
of Alzamend Neuro, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;). We are offering (the &ldquo;<B>Offering</B>&rdquo;)
a maximum of six million (6,000,000) shares (the &ldquo;<B>Offered Shares</B>&rdquo;) of our common stock, par value $0.0001 (the
&ldquo;<B>Common Stock</B>&rdquo;) at an offering price of $7.50 per share (the &ldquo;<B>Maximum Offering</B>&rdquo;) on a &ldquo;best-efforts,
no minimum&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We may conduct an initial closing (the
&ldquo;<B>Initial Closing</B>&rdquo;) at any time (the &ldquo;<B>Initial Closing Date</B>&rdquo;) provided that the Offering Statement
has been qualified by the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;). Thereafter, this Offering
will continue until the earliest of (i) our decision to terminate the Offering, (ii) September 1, 2020, subject to extension for
up to ninety (90) days in our sole and absolute discretion, or (iii) the date on which the Maximum Offering amount has been sold
(such earliest date, the &ldquo;<B>Termination Date</B>&rdquo;).&nbsp;If, on the Initial Closing Date, we have sold less than
the Maximum Offering, then we may hold one or more additional closings for additional sales (each an &ldquo;<B>Additional Closing</B>&rdquo;)
until the Termination Date. The Company will consider various factors in determining the timing of any Additional Closings, including
but not limited to the amount of proceeds received at the Initial Closing, any Additional Closings that have already been held,
and indications of interest shown by any additional prospective investors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From the date of qualification until
the Initial Closing Date, and thereafter pending any Additional Closings on subsequent closing dates (&ldquo;<B>Additional Closing
Dates,</B>&rdquo;<B>)</B> and with the Initial Closing Date, a &ldquo;<B>Closing Date</B>&rdquo;) the proceeds from the Offering
will be kept in an escrow account. Upon the Initial Closing Date and upon each Additional Closing, if any, the proceeds therefrom
will be distributed to the Company and the associated Offered Shares will be issued to the investors therein. If the Initial Closing
never occurs, the proceeds from the Offering will be promptly returned to investors, without deduction or interest. SOS Back Office
Solutions, LLC will serve as the escrow agent and will retain up to $10,000 of interest accrued from funds deposited in the escrow
account as partial compensation for serving as escrow agent. Checks should be made payable to &ldquo;SOS Back Office Solutions,
LLC FBO Alzamend Neuro, Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum purchase requirement per investor
is $750, or one hundred (100) Offered Shares; however, we can waive the minimum purchase requirement on a case-by-case basis in
our sole discretion. We expect to commence the sale of the Offered Shares as of the date on which the Offering Statement, of which
this Offering Circular is a part, is qualified by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no public market for our Common
Stock. We intend to list our Common Stock on a national securities exchange, under the symbol &ldquo;<B>ALZA,</B>&rdquo; if available.
Our Common Stock will not commence trading on a national securities exchange until a number of conditions are met, including that
we have raised the minimum amount of offering proceeds necessary for us to meet the initial listing requirements of the national
securities exchange selected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may engage a registered broker-dealer
as the underwriter (the &ldquo;<B>Underwriter</B>&rdquo;) to offer the Offered Shares to prospective investors in the United States
on a &ldquo;best-efforts&rdquo; basis, and our Underwriter will have the right to engage such other broker-dealers or agents as
it determines, subject to our approval, to assist in such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A maximum of $45,000,000 will be offered
worldwide. No sales of Offered Shares will be made anywhere in the world prior to the qualification of the Offering Statement by
the Commission in the United States. All Offered Shares will be initially offered in all jurisdictions at the same U.S. dollar
price that is set forth in this Offering Circular, except that: any underwriters who participate in the Offering, if any, will
receive a selling concession from the Underwriter, as further described in &ldquo;Underwriting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;Description of Securities&rdquo;
for a description of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act (the &ldquo;<B>JOBS Act</B>&rdquo;) and, as such, may elect to comply with
certain reduced reporting requirements for this Offering Circular and future filings after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our Common Stock involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; for a discussion of certain risks that you should consider in connection
with an investment in our Common Stock.</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Number&nbsp;of&nbsp;Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price&nbsp;to&nbsp;Public</B></P></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><BR> <B>Underwriting</B></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>discounts&nbsp;and</B></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>commissions&nbsp;(1)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><B>Proceeds&nbsp;to&nbsp;issuer&nbsp;(2)</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shares Offered by Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%">Per share:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">7.50</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 13%; text-align: center">TBD</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</font></TD>
    <TD STYLE="width: 16%; text-align: center">TBD</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Underwriter&rsquo;s Warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">TBD</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>$</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD><FONT STYLE="font-size: 10pt">$</font></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares of Common Stock <BR>
underlying underwriter&rsquo;s warrant:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</font></TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>$</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD><FONT STYLE="font-size: 10pt">$</font></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Minimum:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</font></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>$</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD><FONT STYLE="font-size: 10pt">$</font></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Maximum:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>$</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD><FONT STYLE="font-size: 10pt">$</font></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We refer you to &ldquo;Underwriting&rdquo; beginning on page&nbsp;74 of this Offering Circular for additional information regarding total underwriter compensation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include expenses of the offering, including costs of Blue Sky compliance, fees to be paid to legal counsel and our independent auditor or filing fees.&nbsp;See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>GENERALLY, NO SALE MAY BE MADE TO YOU
IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR YOUR NET WORTH.
DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES
NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON
INVESTING, WE ENCOURAGE YOU TO REFER TO&nbsp;WWW.INVESTOR.GOV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE U.S. SECURITIES AND EXCHANGE COMMISSION
DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS
UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT
TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE
SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;The date of this Offering Circular
is March 12, 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">SUMMARY</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">DILUTION</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">OUR BUSINESS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">DESCRIPTION OF PROPERTY</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">63</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">64</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">68</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">70</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">PRINCIPAL STOCKHOLDERS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">72</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">73</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">74</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">74</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">ADDITIONAL INFORMATION ABOUT THE OFFERING</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">76</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">77</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">EXPERTS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">77</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">78</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering to sell, and seeking offers
to buy, our securities only in jurisdictions where such offers and sales are permitted. You should rely only on the information
contained in this Offering Circular. We have not authorized anyone to provide you with any information other than the information
contained in this Offering Circular. The information contained in this Offering Circular is accurate only as of its date, regardless
of the time of its delivery or of any sale or delivery of our securities. Neither the delivery of this Offering Circular nor any
sale or delivery of our securities shall, under any circumstances, imply that there has been no change in our affairs since the
date of this Offering Circular. This Offering Circular will be updated and made available for delivery to the extent required by
the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, data contained
in this Offering Circular concerning the business of the Company are based on information from various public sources. Although
we believe that these data are generally reliable, such information is inherently imprecise, and our estimates and expectations
based on these data involve a number of assumptions and limitations. As a result, you are cautioned not to give undue weight to
such data, estimates or expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Offering Circular, unless the context
indicates otherwise, references to &ldquo;Alzamend,&rdquo; &ldquo;we,&rdquo; the &ldquo;Company,&rdquo; &ldquo;our,&rdquo; and
&ldquo;us&rdquo; refer to the activities of and the assets and liabilities of the business and operations of Alzamend Neuro, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements under &ldquo;Summary,&rdquo;
&ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
&ldquo;Our Business&rdquo; and elsewhere in this Offering Circular constitute forward-looking statements. Such forward-looking
statements include statements regarding, among others, (a) our expectations about possible business combinations, (b) our growth
strategies, (c) our future financing plans, and (d) our anticipated needs for working capital. Forward-looking statements, which
involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;approximate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;budget,&rdquo; &ldquo;could,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;might,&rdquo; &ldquo;predict,&rdquo; &ldquo;shall&rdquo; or &ldquo;project,&rdquo; or the negative
of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks,
uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from
the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be
found in this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on
our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the
forward-looking statements as a result of various factors, including, without limitation, changes in local, regional, national
or global political, economic, business, competitive, market (supply and demand) and regulatory conditions and the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to effectively execute our business plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to manage our expansion, growth and operating expenses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to evaluate and measure our business, prospects and performance metrics;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to compete and succeed in a highly competitive and evolving industry;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to respond and adapt to changes in technology and customer behavior; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We caution you therefore that you should
not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance.
All forward-looking statements speak only as of the date of this Offering Circular. We undertake no obligation to update any forward-looking
statements or other information contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding market and industry
statistics contained in this Offering Circular is included based on information available to us that we believe is accurate. It
is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis.
Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional
uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. Except
as required by U.S. federal securities laws, we have no obligation to update forward-looking information to reflect actual results
or changes in assumptions or other factors that could affect those statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary highlights selected information
contained elsewhere in this Offering Circular. This summary is not complete and does not contain all the information that you should
consider before deciding whether to invest in our Common Stock. You should carefully read the entire Offering Circular, including
the risks associated with an investment in the company discussed in the &ldquo;Risk Factors&rdquo; section of this Offering Circular,
before making an investment decision. Some of the statements in this Offering Circular are forward-looking statements. See the
section entitled &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed on February 26, 2016, as
Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and commercialize patented intellectual
property and know how to prevent, treat and cure the crippling and deadly Alzheimer&rsquo;s disease (&ldquo;<B>Alzheimer&rsquo;s</B>&rdquo;
or &ldquo;<B>AD</B>&rdquo;). We have developed a unique approach for combating Alzheimer&rsquo;s, namely through immunotherapy.
Current drugs approved by the FDA for Alzheimer&rsquo;s only address symptoms and provide no benefit to the impaired immune system
caused by Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2018, we implemented a 1-for-4
Reverse Stock Split of our Common Stock. The Reverse Stock Split became effective on December 13, 2018. As a result of the Reverse
Stock Split, every four (4) shares of our pre-Reverse Stock Split Common Stock were combined and reclassified into one share of
the Common Stock. The number of shares of Common Stock subject to outstanding options and warrants were also reduced by a factor
of four as of December 13, 2018 and their respective exercise prices were increased by a factor of four. All historical share and
per-share amounts reflected throughout the consolidated financial statements and other financial information in this Offering Circular
have been adjusted to reflect the Reverse Stock Split. Neither the authorized shares of capital stock nor the par value per share
of the Common Stock was affected by the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mailing address is Alzamend Neuro,
Inc., 3802 Spectrum Blvd., Suite #112C, Tampa, FL 33612 and our telephone number is (844) 722-6333. Our website addresses are&nbsp;www.alzamend.com
and www.thealzamendstory.com. The information contained therein or accessible thereby shall not be deemed to be incorporated into
this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzamend Neuro is a company focused on
the facilitation of bringing technologies to market which help with the treatment, prevention or cure of Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, we obtained a royalty-bearing,
exclusive worldwide license from the University of South Florida Research Foundation, Inc. (the &ldquo;<B>Licensor</B>&rdquo;),
to a mutant-peptide immunotherapy that is designed to be used both as a vaccine and prophylactic against Alzheimer&rsquo;s. This
treatment, known as AL002 (formerly known as CAO22W), has transitioned from early stage development to an extensive program of
preclinical study and evaluation with an anticipated completion date at the end of June 2020. AL002 will require extensive clinical
evaluation, regulatory review and approval, significant marketing efforts and substantial investment before it can provide us
with any revenue. We plan to file an Investigational New Drug Application (&ldquo;<B>IND</B>&rdquo;) with the United States Food
and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;) with respect to AL002 in the second quarter of 2020 and prepare to conduct
a Phase 1 Clinical Trial in the latter half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On July 2, 2018, we obtained two royalty-bearing,
exclusive worldwide licenses from the Licensor to a therapy known as AL001 (formerly known as LiProSal) to mitigate extreme agitation
and forestall other deterioration as displayed by patients with up to moderate AD. AL001 is an ionic cocrystal of lithium and
has been shown to exhibit improved nonclinical pharmacokinetics compared to current FDA-approved lithium products; it is also
bioactive in many in vitro models of Alzheimer&rsquo;s. AL001 is expected to provide clinicians with a major improvement over
current lithium-based treatments and may also constitute a means of treating Alzheimer&rsquo;s and other neurodegenerative diseases.
Based on nonclinical data, AL001 co-crystal technology has the potential to improve the therapeutic index of lithium providing
a greater bioavailability to the site of action (brain) in comparison to more traditional lithium dosage forms. Lithium has been
marketed for over 35 years and human toxicology regarding lithium use has been well characterized, mitigating the potential regulatory
burden for safety data. We submitted a pre-IND briefing package to the FDA in July&nbsp;2019 that argued against any further preclinical
safety studies. . Per the FDA response letter, we believe the proposed test parameters for AL001 appears reasonable to support
a Phase 1 study, thereby allowing Alzamend to conduct human clinical trials. Post Phase III clinical trials and in order to obtain
approval to commercialize AL001 via a New Drug Application (&ldquo;<B>NDA</B>&rdquo;), Alzamend has been asked to provide a scientific
bridge to a listed drug to support the adequacy of the nonclinical program. Per the FDA, the adequacy of the nonclinical data
will be a matter of review. If the adequacy of the nonclinical data is not sufficient for the FDA, Alzamend will then be required
to conduct a clinical pharmacokinetics animal study (6-weeks study) of AL001 in order to be considered for FDA approval. We received
feedback from the FDA regarding the pre-IND briefing package and have begun the process of finalizing the IND application and,
while FDA approval is not guaranteed, we expect to receive approval to begin a Phase 1 Clinical Trial with human subjects in the
third quarter 2020. While the FDA has not given us any indication as to whether AL001 will receive Breakthrough Therapy designation
or be permitted to use the 505(b)(2) regulatory pathway, we believe that AL001 is an ideal candidate to receive both a Breakthrough
Therapy designation as well as a section 505(b)(2) regulatory pathway for new drug approvals, enhancing the speed and reducing
the regulatory burden of FDA review. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>AL001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patented solution that we have licensed
and will first move to commercialization is an ionic cocrystal of lithium for the treatment of Alzheimer&rsquo;s and a method of
preparation for other pharmaceutical and industrial purposes. Lithium salts have a long history of human consumption beginning
in the 1800&rsquo;s. In psychiatry, they have been used to treat mania and as a prophylactic for depression since the mid-20th
century. Today, lithium salts are used as a mood stabilizer for the treatment of bipolar disorder. Although the FDA has approved
no medications as safe and effective treatments for suicidality, lithium has proven to be the only drug that consistently reduces
suicidality in patients with neuropsychiatric disorders. Despite these effective medicinal uses, current FDA-approved lithium pharmaceutics
(lithium carbonate and lithium citrate) are limited by a narrow therapeutic window that requires regular blood monitoring of plasma
lithium levels and blood chemistry by a clinician to mitigate adverse events. Because conventional lithium salts (carbonate and
citrate) are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic
plasma concentrations. However, existing lithium drugs such as lithium chloride and lithium carbonate suffer from chronic toxicity,
poor physicochemical properties and poor brain bioavailability. Because lithium is so effective at reducing manic episodes in patients
with bipolar disorder, it is still used clinically despite its narrow therapeutic index. This has led researchers to begin to look
for alternatives to lithium with similar bioactivities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inventors from the University of South
Florida (the &ldquo;<B>University</B>&rdquo;) have developed a new lithium cocrystal composition and method of preparation that
allow for lower dosages to achieve therapeutic brain levels of lithium for psychiatric disorders, broadening lithium&rsquo;s therapeutic
index. The compound offers improved physiochemical properties compared to existing forms of lithium, giving it the potential to
be developed as an anti-suicidal drug or for use against mood disorders. The formulation method may also be used for commercial/industrial
applications such as green chemistry, engineering low density porous materials, pesticides/herbicides, explosives/propellants,
and electronic materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent evidence suggests that lithium may
be efficacious for both the treatment and prevention of Alzheimer&rsquo;s. Unlike traditional medications which only address a
single therapeutic target, lithium appears to be neuroprotective through several modes of action. For example, it exerts neuroprotective
effects, in part, by increasing a brain-derived neurotrophic factor leading to restoration of learning and memory. Another neuroprotective
mechanism of lithium is attenuation of the production of inflammatory cytokines like IL-6 and nitric oxide in activated microglia.
Moreover, results from recent clinical studies suggest that lithium treatment may reduce dementia development while preserving
cognitive function and reducing biomarkers associated with AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With this in mind, the team of inventors
from the University have specifically designed, synthesized and characterized the novel ionic cocrystal of lithium (known as AL001).
AL001 has been shown to exhibit improved nonclinical pharmacokinetics compared to current FDA-approved lithium products; it is
also bioactive in many in vitro models of Alzheimer&rsquo;s. AL001 is expected to provide clinicians with a major improvement over
current lithium-based treatments and may also constitute a means of treating Alzheimer&rsquo;s and other neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A product can be designated as a Breakthrough
Therapy if it is intended <FONT STYLE="color: #333333">to treat a serious condition and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). </FONT>A
drug that receives a Breakthrough Therapy designation is eligible for fast track designation features, intensive guidance on an
efficient drug development program and FDA organizational commitment involving senior managers. We believe that AL001 is ideally
positioned for a Section 505(b)(2) regulatory pathway for new drug approvals. The Section 505(b)(2) regulatory pathway provides
manufacturers with an opportunity to obtain FDA approval without performing all the work that&rsquo;s required by an NDA. Those
drugs that qualify for the 505(b)(2) regulatory pathway are an option for drugs with a new aspect related to indication, dosage
form or regimen, strength, combination with other products, or other unique traits. If we receive approval through the 505(b)(2)
regulatory pathway AL001 would be eligible for 3-5 years of market exclusivity during which period AL001 would be protected from
competitors. If we successfully acquire a Breakthrough Therapy designation and the Section 505(b)(2) regulatory pathway for new
drug approvals, we believe we can receive FDA approval for AL001 in four years.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL001 will require extensive clinical evaluation,
regulatory review and approval, significant marketing efforts and substantial investment before it or any successors could provide
us with any revenue. As a result, if we do not successfully develop, achieve regulatory approval for and commercialize AL001, our
long-term business plans will not be met, and we may be unable to generate the revenue we have forecast for many years, if at all.
We do not anticipate that we will generate our maximum revenue for several years, or that we will achieve profitability for this
therapeutic at least a few years after generating material revenue, if at all. If we are unable to generate revenue, we may not
be able to pursue any expansion of our business or acquire additional intellectual property as we have planned, we will not become
profitable with this therapeutic agent, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AL002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The other patented solution that we have
licensed to move to commercialization is AL002, a mutant-peptide immunotherapy that is designed to be used both as a vaccine and
prophylactic against Alzheimer&rsquo;s. This therapy is intended to work by stimulating the body&rsquo;s own immune system to prevent
the formation and breakdown of beta amyloids, which build up in the brain to form a &ldquo;plaque,&rdquo; and subsequently block
the neurological brain signals, ultimately leading to the symptoms and onset of Alzheimer&rsquo;s. Immunotherapy is the treatment
of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies that are designed to elicit or amplify an
immune response are classified as activation immunotherapies, whereas immunotherapies that reduce or suppress an immune response
are classified as suppression immunotherapies. We believe that strategies to strengthen the immune system in the elderly, who are
most susceptible to the development of Alzheimer&rsquo;s, could greatly enhance the effectiveness of immune-based approaches towards
Alzheimer&rsquo;s. Our novel immune-based methodology attempts to inhibit the natural process of immunological aging by restoring
the balance of the immune system through immunomodulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beta amyloid protein has been directly
linked to Alzheimer&rsquo;s and the associated neurofibrillary tangles formation seen in Alzheimer&rsquo;s patients. Specifically,
increased levels of extracellular plaques in the brain composed of amyloid beta peptide 1-42 are seen in Alzheimer&rsquo;s patients
when compared to healthy people. In a healthy brain, protein fragments such as amyloid beta peptide 1-42 are broken down and eliminated.
However, in Alzheimer&rsquo;s, the fragments accumulate to form hard, insoluble plaques. Attempts have been made to help inhibit
plaque formation by reducing the amount of amyloid beta peptide 1-42 through vaccines that generate an immune response to the protein.
The challenge has been that though effective in reducing the amount of the protein, the inflammatory response has been such that
the intended benefits are not seen. These vaccines have used an adjuvant, or helper, to generate the necessary immune response
and it is believed that this adjuvant triggers the unwanted surplus inflammation. We have licensed rights to a vaccine using autologous
cells that does not require an adjuvant and therefore, we believe will trigger the immune response, which should help eliminate
the amyloid beta peptide 1-42 without generating the excess inflammation and therefore, have a positive clinical effect. We believe
that the vaccine, in addition to dealing with plaque formation, also ameliorates the impaired immune system that is thought to
be the major issue in Alzheimer&rsquo;s patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our data have demonstrated that these mutant-peptide
sensitized dendritic cells (&ldquo;<B>DC</B>&rdquo;) can act as a vaccine to generate a durable antibody response, as well as enhance
the number of CD8+ T-cells and increase the lifespan of CD8+ cells (T and DCs cells), compared to control subjects. These studies
will provide a further rationale and impetus for using this novel vaccine to determine potential efficacy in human clinical trials
against Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL002 has been researched for more
than ten (10) years and we are currently in the midst of completing its preclinical development and have begun both the pre-IND
and IND application process to the FDA, which is managed by TAMM Net, Inc., an experienced and highly-regarded regulatory consultancy
firm. In November 2018, we began a toxicological preclinical study for AL002 with Charles River Laboratories, Inc. (&ldquo;<B>CRL</B>&rdquo;)
in compliance with FDA requirements. Upon conclusion of this toxicological study, anticipated to occur in the second quarter of
2020, we expect to begin the process of finalizing the IND application process and move quickly forward to begin a Phase 1 Clinical
Trial with human subjects. AL002 will require extensive clinical evaluation, regulatory review and approval, significant marketing
efforts and substantial investment before it and any successors could provide us with any revenue. As a result, if we do not successfully
develop, achieve regulatory approval for and commercialize AL002, our long-term business plans will not be met, and we may be
unable to generate the revenue we have forecast for AL002 for many years, if at all. We do not anticipate that we will generate
our maximum revenue for several years, or that we will achieve profitability for this therapeutic at least a few years after generating
material revenue, if at all. If we are unable to generate revenue, we may not be able to pursue any expansion of our business
or acquire additional intellectual property as we have planned, we will not become profitable with this therapeutic agent, and
we may be unable to continue our operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Market</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, Alzheimer&rsquo;s is the 6<SUP>th</SUP>
leading cause of death in the U.S. and when extrapolated globally, the market for preventions, treatments, and cures of this crippling
disease is massive. The Alzheimer&rsquo;s Association estimates that the cost of caring for people with Alzheimer&rsquo;s and other
dementias will reach $290 billion in 2019 and that by 2050, these costs may rise as high as $1.1 trillion. Since 1990, life expectancy
has increased by 6 years and the worldwide average continues to increase. With the increase in the mean age of the population in
developed countries, the prevalence of deteriorating neurological diseases has also increased. According to the Alzheimer&rsquo;s
Association, in the United States alone, 1 in 10 persons over the age of 65 have Alzheimer&rsquo;s, with more than 5.8 million
Americans living with it. It is estimated that this number will increase to more than 14 million by 2050 if a cure is not found.
Many Alzheimer&rsquo;s related associations believe the actual number of adults with AD may be as much as 5 times more or 30 million
since current statistics do not take into account deaths from complications or from related diseases like pneumonia or heart attack.
These death certificates only list the most immediate cause. The fastest growing age group in the United States is the &ldquo;over
85&rdquo; group within which 1 in 3 individuals have Alzheimer&rsquo;s. Women are 2&frac12; times more likely to die from Alzheimer&rsquo;s
than from cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rate of deaths related to Alzheimer&rsquo;s
increased by 54.5 percent over 15 years, according to a report issued on May 27, 2017, by the U.S. Centers for Disease Control
and Prevention. There were 93,541 deaths related to Alzheimer&rsquo;s in 2014, a rate of 25.4 deaths per 100,000 people, up from
44,536 deaths in 1999, a rate of 16.5 deaths per 100,000 people, according to the report. The disease currently affects an estimated
5.8 million people in the U.S., but that number is expected to rise dramatically in people over the age of 65 to 14 million in
2050. The researchers examined death certificate data from the National Vital Statistics System to reach their findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Every 65 seconds, someone in the United
States develops AD. Of the 10 most fatal diseases in the United States, Alzheimer&rsquo;s is the only one with no cure, no known
way of deceleration and no known means of prevention.&nbsp;Alzamend was formed to commercialize patented intellectual property
in this space, by funding it from its present state through human clinical trials administered by the FDA and ultimately, if successful,
potentially make it available to the global market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Business Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our plan of operations is currently
focused on the development of both our therapeutic candidates, which are at different stages in development. We have begun the
process of finalizing the IND application for AL001 and expect to receive approval to begin a Phase 1 Clinical Trial with human
subjects in the third quarter 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to begin the process of finalizing
the IND application process for AL002 and move quickly forward to begin a Phase 1 Clinical Trial with human subjects during the
latter half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engaged Emory University, located
in Atlanta, Georgia, to develop and plan the Phase 1 Clinical Trial protocols, processes and plan. Dr. Ihab Hajjar, Neurologist
at the Emory Clinic, has been selected to be the Lead Investigator for this set of clinical activities. We have also retained
a division of the international Swiss manufacturer, Lonza, to develop the manufacturing protocols, processes and procedures. Lonza
is the worldwide leader in producing immunological proprietary and contracted pharma solutions. We anticipate selecting Emory
University as the host for the Phase 1 Clinical Trial, which will be led by Dr. Hajjar at the Emory Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we adopted a Charter
for our Scientific Advisory Board (&ldquo;<B>SAB</B>&rdquo;) and have announced the appointment of two SAB members, Dr. Thomas
Wisniewski (Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment) and Dr. Eric McDade (Associate Director
of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)). The SAB members have clinical specializations, including
extensive experience with AD and other neurological diseases. We intend to rely on these experts to help guide our therapies through
the related scientific and manufacturing initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of our current plan of
operations to completing our IND application and beginning the series of human clinical trials for each of our therapeutics requires
us to promptly raise significant additional capital. If we are successful in raising capital, we believe that we will have sufficient
cash resources to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our working capital requirements
depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining regulatory
approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive
and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations,
we will require additional financing to fund future operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>FDA consulting and active project planning
management</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have retained TAMM Net, Inc., an experienced
and highly-regarded regulatory consultancy firm based in Georgia for project management. In this capacity, TAMM Net will lead,
develop and manage our preclinical and clinical efforts, extending from the current status of each product candidate through the
exit or commercialization of the technologies that we have licensed. We may retain an experienced Canadian and European Union consulting
firm to commercialize these same technologies for these geographic markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Funding new AD research and acquisition
of licenses to treat or cure AD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have committed to funding new research
projects from Dr. Chuanhai Cao, the neuroscientist who developed AL002, and his medical team for at least the next three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We obtained two royalty-bearing, exclusive
worldwide licenses from the Licensor, originally calls LisPro, now given the name of AL001 for regulatory and company confidentiality,
a cocrystal biologic therapy intended to mitigate extreme agitation and forestall further deterioration of memory as displayed
by patients with up to moderate AD effective as of July 2, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to acquiring and supporting
new research to treat or cure AD and reserves the right to evaluate and pursue each opportunity as it may arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Intellectual Property and Licensing Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, we entered into the
License Agreement with the Licensor pursuant to which the Licensor granted us a royalty bearing, exclusive worldwide license,
limited to the field of Alzheimer&rsquo;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled &ldquo;Amyloid
Beta Peptides and Methods of Use&rdquo; (AL002), filed April&nbsp;7, 2009, and granted May 29, 2012.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to royalty payments of
4% on net sales of products developed from the licensed technology, we were required to pay a license fee of $100,000 on June
25, 2016, and December 31, 2016. As an additional licensing fee, the Licensor is entitled to receive that number of shares of
our Common Stock equal to five percent (5%) of the sum of the total number of issued and outstanding shares plus any securities
that are convertible into or exercisable or exchangeable for shares of Common Stock, subject to adjustment for additional issuances
until such time as we have received a total of $5 million in cash in consideration for our equity securities. As of April 30,
2019 we had issued 3,601,809 shares to the Licensor in full satisfaction of this additional licensing fee. Minimum royalties are
$20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the agreement. Additionally, we
are required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Pa<FONT STYLE="font-size: 10pt">yment</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Due Date</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Event</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon IND application filing</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon IND application filing</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;12 months from IND application filing date</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon first dosing of patient in first Phase I Clinical Trial</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">175,000</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;12 months from first patient dosed in Phase I</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon Completion of first Phase I Clinical Trial</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">500,000</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;24 months from completion of first Phase I Trial</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon Completion of first Phase II Clinical Trial</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;12 months from completion of the first Phase II Clinical
    Trial</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon first patient treated in a Phase III Clinical Trial</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,000,000</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;7 years from the effective date of the agreement</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;Upon FDA BLA Approval</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor was also granted a preemptive
right to acquire such shares or other equity securities that may be issued from time to time by us while Licensor remains the
owner of any equity securities of our company. Further, if we issue equity securities at a price per share that is less than the
price paid by investors in a transaction for aggregate consideration of at least $5,000,000 (the &ldquo;<B>Investment Price</B>&rdquo;),
then the number of shares owned by Licensee shall be increased upon such issuance. The amount of the increase shall be determined
by multiplying the number of shares then owned by Licensor by a fraction; the numerator of which shall be equal to the number
of shares of Common Stock outstanding immediately after the issuance of additional shares of Common Stock, and the denominator
of which shall be equal to the sum of (i) the number of shares of Common Stock outstanding immediately prior to the issuance of
additional shares of Common Stock plus (ii) the number of shares of Common Stock which the aggregate consideration for the total
number of additional shares of Common Stock so issued would purchase at the Investment Price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain license fees and
milestone payments required to be paid for the licensing of the AL001 technology, pursuant to the terms of two Standard Exclusive
License Agreements with Sublicensing Terms, both dated June 21, 2018, (the &ldquo;<B>AL001 License Agreements</B>&rdquo;) with
the Licensor and the University. In addition, a royalty payment of 3% is required pursuant to License #18110 while License #18111
requires a royalty payment of 1.5% on net sales of products developed from the licensed technology. For the two AL001 licenses,
in the aggregate, we paid initial license fees of $200,000. As an additional licensing fee, the Licensor is entitled to receive
that number of shares of Common Stock equal to three percent (3%) of the sum of the total number of issued and outstanding shares.
As of April 30, 2019 we had issued 2,227,925 shares to the Licensor in full satisfaction of this additional licensing fee. Minimum
royalties are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Additionally,
we are required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;November 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Pre-IND meeting</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">65,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;6 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in a clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,250,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II clinical trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;8 years from the Effective Date of the Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have met the Pre-IND meeting milestone
encompassing AL001. If we fail to meet a milestone by its specified date, the Licensor may terminate the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The license agreements above include
certain termination provisions. The Licensor may terminate the agreements if the Licensee is delinquent on any report or payment,
is not diligently developing and commercializing the licensed products and licensed processes, misses a milestone in advancing
through clinical trials, is in breach of any provision, provides any false report, goes into bankruptcy, liquidation or proposes
having a receiver control any assets, violates any laws or regulations of applicable government entities, ceases to carry on its
business pertaining to the licensed patents, or brings a patent challenge against the Licensor.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth
Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &ldquo;emerging growth
company&rdquo; as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure
and other requirements that are otherwise applicable generally to public companies. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">only two years of audited financial statements in addition to any required unaudited interim financial
statements with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations&rdquo; disclosure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reduced disclosure about our executive compensation arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">no non-binding advisory votes on executive compensation or golden parachute arrangements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">exemption from the auditor attestation requirement in the assessment of our internal control over
financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these exemptions
for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth
company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues
of $1 billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion
of our initial public offering; (iii)&nbsp;the date on which we have issued more than $1 billion in nonconvertible debt during
the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Commission.
We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements
in this Offering Circular. Accordingly, the information contained herein may be different from the information you receive from
other public companies in which you hold stock. We have irrevocably elected to &ldquo;opt out&rdquo; of the exemption for the delayed
adoption of certain accounting standards and will, therefore, be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Agreements with the Placement Agent</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engaged Spartan Capital Securities,
LLC (&ldquo;<B>Spartan</B>,&rdquo; or the &ldquo;<B>Placement Agent</B>&rdquo;) to act as a placement agent in a private placement
that was terminated on November 15, 2019 (the &ldquo;<B>Private Offering</B>&rdquo;) in which we sold an aggregate of 1,756,726
Units, with each such Unit consisting of (i) one (1) share of Common Stock and (ii) one warrant to purchase one half (0.5) share
of Common Stock, at a price of $1.50 per Unit. We raised aggregate proceeds of $2,635,089 and paid the Placement Agent an aggregate
of $420,263 in commission, fees and other payment for net proceeds of $2,214,826.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Private Offering,
we entered into a Placement Agent Agreement and an Uplisting Agreement with the Placement Agent. Certain provisions of these agreements
that are relevant to investors in the Offering are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Placement Agreement effective
as of June 10, 2019, we agreed with the Placement Agent to the cash compensation payable to the Placement Agent including, without
limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Placement Agent Compensation</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the initial closing of the Private
Offering we paid to the Placement Agent a non-refundable fee of Twenty-Five Thousand Dollars ($25,000) and issued to the Placement
Agent 500,000 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, we issued to the Placement Agent
175,672 warrants to purchase a number of shares of Common Stock (the &ldquo;<B>Placement Agent Warrants</B>&rdquo;), a figure equal
to ten percent (10%) of the number of shares of Common Stock sold in the Private Offering. The Placement Agent Warrants are exercisable
for a period of five (5) years after their date of issuance, have an exercise price of $1.75 per share and contain provisions pertaining
to cashless exercise, standard anti-dilution protection and piggyback registration rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Incurrence of Debt</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the two (2) years following the
final closing of Private Offering, we will not, without the prior written consent of the Placement Agent, incur indebtedness for
borrowed money in an aggregate amount in excess of $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Future Sales of Securities and Conversion
of the Series A Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the
final Closing and ending two years thereafter, provided that no Qualified Financing (as defined below) has occurred, if (i) we
issue any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Placement Agent&rsquo;s
consent, or (ii) any holder of our Series A Preferred Stock elects to convert such shares into Common Stock, then upon any such
issuance or conversion, as the case may be, the Placement Agent, its Affiliates and the investors in the Private Offering will
be entitled to receive a significant number of additional shares (the &ldquo;<B>Additional Shares</B>&rdquo;) of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares held by the foregoing
persons is approximately 8,500,000 (the &ldquo;<B>Protected Shares</B>&rdquo;). The number of Additional Shares issuable to these
persons is based on the effective equivalent of weighted anti-dilution protection. Thus, if the 750,000 shares of Series A Preferred
Stock were fully converted, we would issue 15,000,000 shares to its holder(s) for a deemed issuance price of $0.0004 per share
(the par value of the Series A Preferred Stock multiplied by 4 taking into effect our 1 for 4 reverse split). The purchase price
in the Private Offering would therefore be deemed to have been adjusted from $1.50 to approximately $1.2, resulting in an increase
in the number of Protected Shares arrived at by multiplying 8,500,000 by the quotient obtained by dividing 1.5 by 1.2, or 1.25,
or approximately 10,625,000. The number of Additional Shares is therefore approximately 2,000,000 shares, or approximately three
percent (3%) of the total number of shares of our company issued and outstanding prior to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">For purposes of the Placement Agreement, a &ldquo;<B>Qualified
Financing</B>&rdquo; means the sale of equity securities by us in a single transaction or a series of related transactions registered
under the Securities Act resulting in gross proceeds to us of not less than $25,000,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, during the period commencing
on the final Closing and ending two years thereafter, we have agreed not to enter into any transactions with Milton C. Ault, our
chairman of the board and principal stockholder or any Affiliate (as defined in Rule 405 of the Securities Act) thereof absent
the Placement Agent&rsquo;s consent. Notwithstanding the foregoing, the Placement Agent has consented to our potential entry into
an agreement whereby we would issue to an Affiliate of Mr. Ault 10,000,000 shares of Common Stock on terms substantially identical
to those of the Private Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Failure to File Reports under the Securities
Act</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that we do not file our annual
or semiannual reports with the Commission on a timely basis, then the Placement Agent will have the right to designate a replacement
for one of our members of the Board for a period of one (1) year following any such failure to file a periodic report on a timely
basis, provided that neither Mr. Ault nor William B. Horne shall be subject to this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreement with the Chief
Executive Officer</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon or before the initial Closing of the
Offering, the Company shall have entered into an employment agreement with Stephan Jackman having a term of at least two (2) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Corporate Governance</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the final
Closing and ending at such time as the Common Stock is listed on a national securities exchange, the Placement Agent will have
the right to designate one member of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Uplisting Agreement</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, we agreed to enter into the Uplisting
Agreement described immediately below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Uplisting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Uplisting Agreement effective
as of June 10, 2019, we have agreed with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will engage the Placement Agent as an
advisor (in such capacity, the &ldquo;<B>Advisor</B>&rdquo;) to, at our request, provide advisory services (the &ldquo;<B>Services</B>&rdquo;)
to us in connection with a potential public offering (an &ldquo;<B>IPO</B>&rdquo;). We expect that any such Services rendered would
consist principally of advising us on how to properly develop and implement strategies that would enhance our ability to successfully
complete an IPO and in connection therewith obtain a listing on a national securities exchange, provided that we meet any such
exchanges listing criteria at the applicable time as well as introduce us to appropriate underwriters that would lead or conduct
any such IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Uplisting Agreement, we
have issued, whether we request its assistance or not, the Advisor Five Hundred Thousand (500,000) shares of Common Stock as well
as made a cash payment to the Advisor in the amount of $475,000 and, in the event that we successfully consummate an IPO with an
underwriter introduced to us by the Advisor, we will pay the Advisor a fee equal to two percent (2%) of the gross proceeds raised
in the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If prior to a Qualified Financing we issue
any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Advisor&rsquo;s consent, then
upon any such issuance, the Advisor will be entitled to receive a significant number of additional shares of Common Stock (this
provision can, like its counterpart in the Placement Agreement described above, thus be deemed the functional equivalent of weighted
average anti-dilution protection).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that we engage in what the
Uplisting Agreement refers to as an &ldquo;Alternative Transaction&rdquo; during the term of such agreement or for a period of
two (2) years thereafter, we will be obligated to pay to the Advisor a fee in cash equal to three percent (3%) of the amount of
the consideration paid or received by us and/or our stockholders in the Alternative Transaction. For purposes of the Uplisting
Agreement, an &ldquo;<B>Alternative Transaction</B>&rdquo; means a business combination, including, any merger, acquisition or
sale of stock or assets (whether we are the acquiring or the acquired entity), joint venture, strategic alliance or other similar
transaction, and shall extend to any subsidiary of ours on the same terms as will be applicable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the Uplisting Agreement will
be two (2) years, subject to either party&rsquo;s right to terminate it in the event that the other party to the agreement breaches
it in any material way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 64%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Issuer:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Alzamend Neuro, Inc.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Securities offered by the Company:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 6,000,000 shares of our Common Stock, par value $0.0001 (&ldquo;<B>Common Stock</B>&rdquo;) at an offering price of $7.50 per share (the &ldquo;<B>Offered Shares</B>&rdquo;).</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Number of shares of Common Stock <BR>
outstanding before the offering:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">63,662,858 shares (1) </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Number of shares of Common Stock to <BR>
be outstanding after the offering:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">69,662,858 shares, if the Maximum Offering
        is sold.</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Price per share:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">$7.50</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Maximum Offering:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;6,000,000 shares at $7.50 per share, or $45,000,000</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Proposed U.S. listing:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">We intend to apply to list our Common Stock on a national securities exchange under the symbol &ldquo;<B>ALZA</B>.&rdquo; Our Common Stock will not commence trading on any national securities exchange until all of the following conditions are met: (i)&nbsp;at least the Initial Closing has occurred and we have raised the minimum amount of offering proceeds necessary for us to meet the initial listing requirements of the Company&rsquo;s selected national securities exchange; (ii)&nbsp;the Offering will have been terminated; and (iii)&nbsp;we have filed a post-qualification amendment to the Offering Statement and a registration statement on Form&nbsp;8-A (&ldquo;<B>Form&nbsp;8-A</B>&rdquo;) under the Securities Exchange Act of 1934 (the &ldquo;<B>Exchange Act</B>&rdquo;), and such post-qualification amendment is qualified by the Commission and the Form&nbsp;8-A has become effective. Pursuant to applicable rules under Regulation&nbsp;A, the Form&nbsp;8-A will not become effective until the SEC qualifies the post-qualification amendment. We intend to file the post-qualification amendment and request its qualification immediately prior to the termination of the Offering in order that the Form&nbsp;8-A may become effective as soon as practicable. As a result, you will experience a delay between the closing of your purchase of shares of our Common Stock and the commencement of exchange trading of our Common Stock.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Worldwide Offering:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may engage a registered broker-dealer
        as the underwriter (the &ldquo;<B>Underwriter</B>&rdquo;) to offer the Offered Shares to prospective investors worldwide on a &ldquo;best-efforts&rdquo;
        basis, and our Underwriter will have the right to engage such other broker-dealers or agents to assist in such offering.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A maximum of $45,000,000 of Offered Shares
        will be offered worldwide. No sales of Offered Shares will be made anywhere in the world prior to the qualification of the Offering
        Statement by the Commission in the United States. All Offered Shares will be initially offered everywhere in the world at the same
        U.S. dollar price that is set forth in this Offering Circular, except that any shares sold to securities dealers may be sold at
        a discount from the public offering price, as further described in &ldquo;<B>Underwriting</B>.&rdquo;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Use of proceeds:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">If we sell all of the Offered Shares, we estimate that our net proceeds (after underwriting discount and commissions and our estimated other offering expenses) will be approximately $40,500,000. We intend to use the net proceeds to us from this offering to move AL001 and AL002 forward with the remaining funds to be used for AD research, purchase of additional licensing of AD-oriented intellectual property and general corporate purposes, including working capital, raising new capital, marketing activities and general and administrative matters. See the section titled &ldquo;Use of Proceeds&rdquo; for additional information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 35%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 64%; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Risk factors:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Investing in our Common Stock involves a high degree of risk. See &ldquo;Risk Factors.&rdquo;</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">The number of shares of our Common Stock to be outstanding
    after this offering is based on 63,662,858 shares of Common Stock outstanding as of February 29, 2020 and excludes:</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 16.2pt"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 15,000,000
                                         shares of Common Stock issuable upon conversion of the Series A Preferred Stock; </P>


</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 16.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>20,000,000 shares of Common Stock reserved for issuance under 2016 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: 43.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 16.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>6,652,035 shares of Common Stock issuable upon exercise of warrants&nbsp;exercisable at an average price of $2.82 per share.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An investment in our common stock involves
a high degree of risk. You should carefully consider the risks described below, together with all of the other information included
in this Offering Circular, before making an investment decision. If any of the following risks actually occurs, our business, financial
condition or results of operations could suffer. In that case, the trading price of our shares of common stock could decline and
you may lose all or part of your investment. See &ldquo;Cautionary Note Regarding Forward Looking Statements&rdquo; above for a
discussion of forward-looking statements and the significance of such statements in the context of this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to Our Company</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have virtually no operating history
on which to judge our business prospects and management.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated on February 26, 2016
and commenced operations shortly thereafter. Accordingly, we have a very limited operating history upon which to base an evaluation
of our business and prospects. Operating results for future periods are subject to numerous uncertainties and we cannot assure
you that we will achieve or sustain profitability. Our prospects must be considered in light of the risks encountered by companies
in the early stage of development, particularly companies in new and rapidly evolving markets. Future operating results will depend
upon many factors, including our success in attracting and retaining motivated and qualified personnel, our ability to establish
short term credit lines or obtain financing from other sources, our ability to develop and market new products, control costs,
and general economic conditions. We cannot assure you that we will successfully address any of these contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are significantly influenced by our
officers, directors and entities affiliated with them.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the aggregate, beneficial ownership
of the shares of Common Stock by management and affiliated parties represents approximately 53.35% of our fully diluted shares
of Common Stock. These stockholders, if acting together, will be able to significantly influence all matters requiring approval
by stockholders, including the election of directors and the approval of mergers or other business combinations transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain provisions of our Certificate
of Incorporation allow concentration of voting power in one stockholder, which may, among other things, delay or frustrate the
removal of incumbent directors or a takeover attempt, even if such events may be beneficial to our stockholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of our Certificate of Incorporation
may delay or frustrate the removal of incumbent directors and may prevent or delay a merger, tender offer or proxy contest involving
our company that is not approved by our Board, even if those events may be perceived to be in the best interests of our stockholders.
Moreover, an affiliate of our company owns the Series A Preferred Stock. Such shares have significant voting power, among other
terms. Further, we may designate and issue separate classes of preferred stock that may entitle their holder(s) to exercise significant
control over us. Consequently, anyone to whom or which these shares are or were issued could have sufficient voting power to significantly
influence if not control the outcome of all corporate matters submitted to the vote of our common stockholders. Those matters could
include the election of directors, changes in the size and composition of the Board, and mergers and other business combinations
involving us. In addition, through any such person&rsquo;s control of the Board and voting power, the affiliate may be able to
control certain decisions, including decisions regarding the qualification and appointment of officers, dividend policy, access
to capital (including borrowing from third-party lenders and the issuance of additional debt or equity securities), and the acquisition
or disposition of assets by us. In addition, the concentration of voting power in the hands of an affiliate could have the effect
of delaying or preventing a change in control of our company, even if the change in control could benefit our stockholders and
may adversely affect the future market price of our Common Stock should a trading market therefor develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain provisions of our Certificate
of Incorporation, Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult
to complete, even if such a transaction were in the stockholders&rsquo; interest.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation, Bylaws
and certain provisions of Delaware State law could have the effect of making it more difficult or more expensive for a third party
to acquire, or discouraging a third party from attempting to acquire, control of our company, even when these attempts may be in
the best interests of our stockholders. For example, we are governed by Section 203 of the Delaware General Corporation Law. In
general, Section 203 prohibits a public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested
stockholder&rdquo; for a period of three years after the date of the transaction in which the person became an interested stockholder,
unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo; includes mergers, asset
sales or other transactions resulting in a financial benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns, or within three years did own, 15% or more of the corporation&rsquo;s outstanding
voting stock. These provisions may have the effect of delaying, deferring or preventing a change in control of our company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Director Liability and
Indemnification of Directors and Officers and Employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation limits
the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that directors of a corporation
will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for
any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">breach of their duty of loyalty to us or
        our stockholders;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">act or omission not in good faith or that
        involves intentional misconduct or a knowing violation of law;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">unlawful payments of dividends or unlawful
        stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">transaction from which the directors derived an improper personal benefit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These limitations of liability do not apply
to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies such
as injunctive relief or rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Bylaws provide that we will indemnify
our directors, officers and employees to the fullest extent permitted by law. Our Bylaws also provide that we are obligated to
advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding. We believe
that these provisions are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitation of liability in our Certificate
of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary
duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if
successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We will need but may be unable to obtain
funding on satisfactory terms, which could dilute our stockholders or impose burdensome financial restrictions on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have relied upon cash from financing
activities and in the future, we hope to rely on revenues generated from operations to fund all of the cash requirements of our
activities. However, it is extremely unlikely that we will be able to generate any significant cash from our operating activities
in the foreseeable future. Future financings may not be available on a timely basis, in sufficient amounts or on terms acceptable
to us, if at all. Any debt financing or other financing of securities senior to the Common Stock will likely include financial
and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a material adverse
effect on our business, prospects, financial condition and results of operations because we could lose our existing sources of
funding and impair our ability to secure new sources of funding. However, there can be no assurance that we will be able to generate
any investor interest in our securities. Further, any financing that we may wish to enter into may be subject to the consent of
Spartan Capital Securities, LLC (&ldquo;<B>Spartan</B>&rdquo;) and there can be no assurance that Spartan will provide its consent
to any such financing. If we do not obtain additional financing, our business will never commence, in which case you would likely
lose the entirety of your investment in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our financial situation creates substantial
doubt whether we will continue as a going concern</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since inception, we have generated no revenues
and have incurred losses. As of April&nbsp;30, 2019, we had cash of $42,606 and an accumulated deficit of $7,375,633. Since our
inception, we have incurred recurring losses and reported losses for the year ended April&nbsp;30, 2019 of $4,862,496. The report
of our independent registered public accounting firm on our April&nbsp;30, 2019, financial statements includes a going concern
explanatory paragraph which states that there is substantial doubt regarding our ability to continue as a going concern. There
can be no assurances that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations
or obtain additional financing through private placements, public offerings and/or bank financing necessary to support our working
capital requirements. To the extent that funds generated from any private placements, public offerings and/or bank financing are
insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available,
or if available, will be offered to us on acceptable terms. If adequate working capital is not available we may be forced to cease
or curtail our operations, which would cause investors to lose their entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are at an early stage of development
and currently have no source of revenue and may never become profitable.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a preclinical development stage
biopharmaceutical company. Currently, we have no products approved for commercial sale and, to date, we have not generated any
revenue. Our ability to generate revenue depends heavily on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&bull;</P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">demonstration in future clinical trials that AL001
and AL002 are safe and effective;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&bull;</P></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to seek
and obtain regulatory approvals, including with respect to the indications we are seeking;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&bull;</P></TD>
    <TD><FONT STYLE="font-size: 10pt">successful manufacture and commercialization of AL001 and AL002; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&bull;</P></TD>
    <TD><FONT STYLE="font-size: 10pt">market acceptance of AL001 and AL002.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We only have two product candidates, AL001
and AL002, which are in the IND stage and preclinical stage of development, respectively, and will require extensive clinical evaluation,
regulatory review and approval, significant marketing efforts and substantial investment before it and any successors could provide
us with any revenue. As a result, if we do not successfully develop, achieve regulatory approval and commercialize AL001 or AL002,
we will be unable to generate any revenue for many years, if at all. We do not anticipate that we will generate revenue for a few
years, at the earliest, or that we will achieve profitability for at least several years after generating material revenue, if
at all. If we are unable to generate revenue, we will not become profitable, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We must effectively manage the growth
of our operations, or our company will suffer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initiation of operations has resulted
in significantly higher operating expenses, which the net proceeds from this Offering, if any, are intended in part to offset.
Expansion of our operations, to include the development of AL001 and AL002, may also cause a significant demand on our management,
finances and other resources. Our ability to manage the anticipated future growth, should it occur, will depend upon a significant
expansion of our accounting and other internal management systems and the implementation and subsequent improvement of a variety
of systems, procedures and controls. In addition, we intend to expand the Board and the SAB. There can be no assurance that significant
problems in these areas will not occur. Any failure to expand these areas and implement and improve AL001 or AL002 or our procedures
and controls in an efficient manner at a pace consistent with our business could have a material adverse effect on our business,
financial condition and results of operations. There can be no assurance that our attempts to expand our marketing, sales, manufacturing
and customer support efforts will be successful or will result in additional sales or profitability in any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>We received a subpoena from the
Commission in the investigation now known as &ldquo;In the Matter of DPW Holdings, Inc.,&rdquo; the consequences of which are
unknown.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We received a subpoena from the Commission
that stated that the staff of the Commission is conducting an investigation now known as <I>&ldquo;<U>In the Matter of DPW Holdings,
Inc.</U>,&rdquo;</I> and that the subpoena was issued as part of an investigation as to whether DPW Holdings, Inc. and certain
of its officers, directors, employees, partners, subsidiaries and/or affiliates, and/or other persons or entities, directly or
indirectly, violated certain provisions of the Securities Act and the Exchange Act, in connection with the offer and sale of its
securities. Although the order states that the Commission may have information relating to such alleged violations, the subpoena
expressly provides that the inquiry is not to be construed as an indication by the Commission or its staff that any violations
of the federal securities laws have occurred. We have produced documents in response to the subpoena. The Commission may in the
future require us to produce additional documents or information, or seek testimony from other members of our management team.
We have received a notice from the Commission stating that its staff is investigating whether the Commission should issue an order
pursuant to Rule 258 of Regulation A of the Securities Act that would temporarily suspend the Company&rsquo;s Regulation A exemption. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are unaware of the scope or timing
of the Commissioner&rsquo;s investigation. As a result, we do not know how the Commission&rsquo;s investigation is proceeding
orwhen the investigation will be concluded. We also are unable to predict what action, if any, might be taken in the future by
the Commission or its staff as a result of the matters that are the subject to its investigation or what impact, if any, the cost
of continuing to respond to subpoenas might have on our financial position, results of operations, or cash flows. We have not
established any provision for losses in respect of this matter. In addition, complying with any such future requests by the Commission
for documents or testimony could distract the time and attention of our officers and directors or divert our resources away from
ongoing business matters. This investigation could result in significant legal expenses, the diversion of management&rsquo;s attention
from our business, damage to our business and reputation, and could subject us to a wide range of remedies, including an enforcement
action by the Commission. There can be no assurance that any final resolution of this and any similar matters will not have a
material adverse effect on our financial condition or results of operations. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to Our Product Candidates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have both operational and financial
milestones that must be met to maintain the licensing rights to our current technology and IP from the USF Research Foundations,
Inc. or those rights may be terminated.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain initial license fees
and milestone payments required to be paid by us to the Licensor pursuant to the terms of the License Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement requires us to
pay royalty payments of four percent (4%) on net sales of products developed from the licensed technology for AL002 while the
License Agreements for AL001 require that we pay combined royalty payments of four and one-half percent (4.5%) on net sales of
products developed from the licensed technology. We have already paid an initial license fee of $200,000 for AL002 and an initial
license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor received 3,601,809 shares
of Common Stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,925 shares
of Common Stock equal to three percent (3%) of the sum of the total number of such shares issued and outstanding plus any securities
that are convertible into or exercisable or exchangeable for shares of Common Stock until we have received a total of $5 million
in cash in consideration for our equity securities. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000
in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in
2023 and $50,000 in 2024 and every year thereafter, for the life of the agreement. Additionally, we are required to pay milestone
payments on the due dates to the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AL001:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Payment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;November 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Pre-IND meeting</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;6 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in a clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II clinical trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;8 years from the Effective Date of the Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AL002:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Payment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: left">&nbsp;Upon IND application filing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Upon IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND application filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">175,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosed in Phase I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;24 months from completion of first Phase I Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase II Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II Clinical Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;7 years from the effective date of the agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA BLA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have met the Pre-IND meeting milestone
encompassing AL001. If we fail to meet a milestone by the specified date, the Licensor may terminate the respective License Agreement.
If the Licensor were to terminate either License Agreement for whatever reason, it would materially and adversely affect our business,
financial position and future prospects and you would likely lose the entirety of your investment in us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor was also granted a preemptive
right to acquire such shares or other equity securities that may be issued from time to time by us while the Licensor remains
the owner of any of our equity securities. Further, if we issue equity securities at a price per share that is less than the price
paid by investors in a transaction for aggregate consideration of at least $5,000,000 then the number of shares owned by the Licensor
shall be increased upon such issuance. The amount of the increase shall be determined by multiplying the number of shares then
owned by Licensor by a fraction, the numerator of which shall be equal to the number of shares of Common Stock outstanding immediately
after the issuance of additional shares of Commons Stock, and the denominator of which shall be equal to the sum of (i) the number
of shares of Common Stock outstanding immediately prior to the issuance of additional shares of Common Stock plus (ii) the number
of shares of Common Stock which the aggregate consideration for the total number of additional shares of Common Stock so issued
would purchase at the Investment Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we fail to comply with our obligations
in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions
to our business relationships with the Licensor, we could lose license rights that are important to our business</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a party to these License Agreements
with the Licensor and expect to enter into additional license agreements in the future. The existing License Agreements impose,
and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations
on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required
to make certain payments to the Licensor, we may lose the exclusivity of our license, or the Licensor may have the right to terminate
the license, in which event we would not be able to develop or market products covered by the license. The Licensor or any future
licensor may take any of these actions, including terminating the License upon 60 days&rsquo; notice for any reason. Additionally,
the milestone and other payments associated with these licenses will make it less profitable for us to develop our product candidates.
If the Licensor were to terminate the License Agreement for whatever reason, it would materially and adversely affect our business,
financial position and future prospects and you would likely lose the entirety of your investment in us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some cases, patent prosecution of our
licensed technology is controlled solely by the Licensor. If the Licensor fails to obtain and maintain patent or other protection
for the proprietary intellectual property we license, we could lose our rights to the intellectual property or our exclusivity
with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases,
we control the prosecution of patents resulting from licensed technology. In the event that we breach any of our obligations related
to such prosecution, we may incur significant liability to the Licensor. Licensing of intellectual property is of critical importance
to our business and involves complex legal, business and scientific issues. Disputes may arise regarding intellectual property
subject to a licensing agreement, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the scope of rights granted under the license
        agreement and other interpretation-related issues;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the extent to which our technology and
        processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the sublicensing of patent and other rights;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our diligence obligations under each of
        the license agreements and what activities satisfy those diligence obligations;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the ownership of inventions and know-how
        resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the priority of invention of patented technology.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If disputes over intellectual property
and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable
terms, we may be unable to successfully develop and commercialize the affected product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are substantially dependent on the
success of our product candidates, which may not receive regulatory approval or be successfully commercialized.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, we hope to submit AL001
and AL002 and, potentially, other product candidates, for regulatory approval. Currently, however, neither AL001 nor AL002 has
been submitted for regulatory approval, which would be required before we seek to initiate commercial distribution. To date, we
have invested nearly all of our resources in establishing our company and the acquisition of the intellectual property of our product
candidates, AL001 and AL002. Our near-term prospects, including our ability to finance our company and to enter into strategic
collaborations and, ultimately, to generate revenue, are directly dependent upon the successful development and commercialization
of AL001 or AL002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercial success
of our product will depend on a number of factors, including, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%; text-align: justify"><FONT STYLE="font-size: 10pt">our timely initiation and successful completion of preclinical studies and clinical trials for AL001 or AL002;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our demonstration to the satisfaction of
        the FDA, the EMA and other applicable regulatory authorities the safety and efficacy of AL001 or AL002 as well as to obtain regulatory
        and marketing approval for AL001 or AL002 in the U.S., Europe and elsewhere;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our continued compliance with all clinical
        and regulatory requirements applicable to AL001 and AL002;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our maintenance of an acceptable safety
        profile of AL001 and AL002 following regulatory approval;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">competition with other treatments;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our creation, maintenance and protection
        of our intellectual property portfolio, including patents and trade secrets, and regulatory exclusivity for AL001 and AL002;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the effectiveness of our and our eventual
        partners&rsquo; marketing, sales and distribution strategy and operations;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the ability of our third-party manufacturers
        to manufacture supplies of our product and product candidates and to develop, validate and maintain commercially viable manufacturing
        processes;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our ability to launch commercial sales
        of AL002 or AL002 following regulatory approval, whether alone or in collaboration with others; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the acceptance of AL001 or AL002 by physicians, health care payers, patients and the medical community.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these factors are beyond our control,
and we cannot assure you that we will ever be able to generate sufficient revenue or any revenue from the sale of AL001 or AL002.
Our failure in any of the above factors, or in successfully commercializing AL001 or AL002 on a timely basis, could have a material
adverse effect on our business, results of operations and financial condition, and the value of your investment could substantially
decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AL001 and AL002 may not achieve market
acceptance, which would limit our ability to generate revenue from new products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we develop AL001 or AL002 and gain
regulatory approvals for either or both, unless physicians and patients accept our product candidates, we may not be able to sell
them and generate significant revenues. We cannot assure you that AL001, AL002, or any other potential products will achieve market
acceptance and revenue if and when they obtain the requisite regulatory approvals. Market acceptance of any product candidate depends
on a number of factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the indication and warnings approved by
        regulatory authorities in the product label;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">continued demonstration of efficacy and
        safety in commercial use;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">physicians&rsquo; willingness to prescribe
        the product;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">reimbursement from third-party payors such
        as government health care systems and insurance companies;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the price of the product;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the nature of any post-approval risk management
        plans mandated by regulatory authorities;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">competition; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the effectiveness of marketing and distribution support.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by AL001 or AL002 to achieve
market acceptance or commercial success could have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Problems in our manufacturing process,
failure to comply with manufacturing regulations or unexpected increases in our manufacturing costs could harm our business, results
of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are responsible for the manufacture
and supply of AL001 and AL002, independently of each other. The manufacturing of AL001 and AL002 necessitates compliance with the
FDA, EU and international current Good Manufacturing Practice (&ldquo;<B>cGMP</B>&rdquo;) and other international regulatory requirements.
Although we may in the future contract with third parties for a certain amount of the manufacturing of AL001 and AL002, the responsibility
to obtain market authorization for AL001 and AL002 remains with us. As such, even if we could potentially have a claim against
one or more third parties, we are legally liable for any noncompliance related to AL001 and AL002 and we expect to retain legal
responsibility for any future product candidates as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to manufacture, or contract
to manufacture, AL001 and AL002 in accordance with regulatory specifications, or if there are disruptions in the manufacturing
process due to damage, loss or failure to pass regulatory inspections of manufacturing facilities, we may not be able to meet the
demand for our products or supply sufficient product for use in clinical trials, and this may harm our ability to commercialize
AL001 and AL002 on a timely or cost-competitive basis, or preclude us from doing so at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we can begin commercial manufacture
of AL001, AL002, or any other product candidate that we may develop in the future, we must obtain FDA regulatory approval for the
product, which requires a successful FDA inspection of our manufacturing facilities, processes and quality systems in addition
to other product-related approvals. Even if we successfully pass an FDA Pre-Approval Inspection of any manufacturing facilities
we may establish or contract with, our pharmaceutical facilities would be continuously subject to inspection by the FDA and foreign
regulatory authorities, even after product approval. Due to the complexity of the processes that we anticipate will eventually
be used to manufacture AL001 and AL002, we may be unable to pass federal, state or international regulatory inspections in a cost-effective
manner, whether initially or at any time thereafter. If we are unable to comply with manufacturing regulations, we may be subject
to fines, unanticipated compliance expenses, recall or seizure of any approved products, or legal actions such as injunctions or
criminal or civil prosecution. These possible sanctions could materially and adversely affect our business, results of operations
and financial condition. See also &ldquo;Risks Related to Development and Regulatory Approval of Our Product.&rdquo; The regulatory
approval process is uncertain, requires us to utilize significant resources, and may prevent us or our commercial partners from
obtaining approvals for the commercialization of some or all of our drug candidates.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We expect to face substantial competition,
with other entities possibly discovering, developing or commercializing products before, or more successfully than, we do.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of
new therapy and vaccine products is highly competitive. We will face competition with respect to AL001, AL002 and any other product
candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical
companies and biotechnology companies worldwide. In addition to existing therapeutic treatments for the indications we are targeting
with AL001 and AL002, we also face potential competition from other drug candidates in development by other companies. Our potential
competitors include large health care companies, such as Celgene Corporation, Merck &amp; Co., Inc., Sanofi S.A., Eli Lilly and
Company, Bayer AG, Novartis AG and Boehringer Ingelheim GmbH. We also know of several smaller early stage companies that are developing
products for use in our segment of the market. Some of the potential competitive compounds referred to above are being developed
by large, well-financed and established pharmaceutical and biotechnology companies or have been partnered with such companies,
which may give them development, regulatory and marketing advantages over our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial opportunity could be reduced
or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side
effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or
other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected
in many cases by insurers or other third-party payers seeking to encourage the use of generic products. If AL001 or AL002 achieves
marketing approval, we expect that it will be priced at a significant premium over competing generic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the companies against which we
are competing or against which we may compete in the future have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These third parties compete
with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to compete successfully,
we may be unable to grow and sustain our revenue, which could materially and adversely affect our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Serious adverse events or other safety
risks could require us to abandon development and preclude, delay or limit approval of AL001 or AL002, or limit the scope of any
approved label or market acceptance.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If AL001, AL002 or any other product candidate
that we may develop in the future, prior to or after any approval for commercial sale, causes serious or unexpected side effects,
or become associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences
could result, including, without limitation, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">regulatory authorities may interrupt, delay
        or halt clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">regulatory authorities may deny regulatory
        approval of AL001 or AL002;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">regulatory authorities may require certain
        labeling statements, such as warnings or contraindications or limitations on the indications for use, or impose restrictions on
        distribution in the form of a Risk Evaluation and Mitigation Strategy &ldquo;<B>REMS</B>&rdquo;), in connection with approval,
        if any;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">regulatory authorities may withdraw their
        approval, require more onerous labeling statements or impose a more restrictive REMS of any product that is approved;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">we may be required to change the way the
        product is administered or conduct additional clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">any relationships that we may be able to
        form in the future with any commercial partners may suffer;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">we could be sued and held liable for harm
        caused to patients; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may voluntarily suspend or terminate
our clinical trials if at any time we believe that they present an unacceptable risk to participants or if preliminary data demonstrate
that either AL002 or AL001 is unlikely to receive regulatory approval or is unlikely to be successfully commercialized. In addition,
regulatory agencies, an Institutional Review Board (an &ldquo;<B>IRB</B>&rdquo;), or data safety monitoring boards may at any time
recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the
clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements,
or that they present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate a clinical
trial of AL001, AL002 or any other product candidate that we may in the future develop, the commercial prospects for that product
will be harmed and our ability to generate product revenue from that product may be delayed or eliminated. Furthermore, any of
these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could
substantially increase the costs of commercializing AL001 or AL002 and materially impair our ability to generate revenue from the
commercialization of AL001 or AL002 either by us or by any commercial partners that we may develop a relationship with in the future
and could have a material adverse effect on our reputation, business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we fail to obtain and sustain an
adequate level of reimbursement for our products by third-party payers, sales and profitability will be adversely affected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The course of medical treatment for human
patients is, and will continue to be, expensive. We expect that most patients and their families will not be capable of paying
for our products themselves. Accordingly, it is unlikely that there will be a commercially viable market for AL001 or AL002 without
reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of third-party
reimbursement is insufficient from the patient&rsquo;s perspective, our revenue and gross margins will be materially and adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A current trend in the U.S. health care
industry, as well as in other countries around the world, is toward cost containment. Large public and private payers, managed
care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding
the use of, and reimbursement levels for, particular treatments. Third-party payers, such as government programs, including Medicare
in the U.S., and private health care insurers, carefully review and have increasingly been challenging the coverage of, and prices
charged for, medical products and services. Many third-party payers limit coverage of or reimbursement for newly-approved health
care products. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and
other factors. Cost-control initiatives could decrease the price we or our partners establish for products, which could result
in lower product revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursement systems in international
markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.
Our eventual partners may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement
approvals. In many countries, products cannot be commercially launched until reimbursement is approved and the negotiation process
in some countries can exceed 12 months. In addition, pricing and reimbursement decisions in certain countries can be affected
by decisions taken in other countries, which can lead to mandatory price reductions and/or additional reimbursement restrictions
across a number of other countries, which may adversely affect our sales and profitability. If countries set prices that are not
sufficient to allow us or our partners to generate a profit, our partners may refuse to launch the product in such countries or
withdraw the product from the market, which would adversely affect our sales and profitability<FONT STYLE="color: blue">&nbsp;</FONT>and
could materially and adversely affect our business, results of operations and financial condition.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be successful in our efforts
to expand our pipeline of product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One element of our strategy is to expand
our pipeline of pharmaceuticals based on our technology and advance these product candidates through clinical development for the
treatment of a variety of indications. Although our research and development efforts to date have resulted in a number of development
programs based on our technology, we may not ultimately be able to develop product candidates that are safe and effective. Even
if we are successful in continuing to expand our pipeline, the potential product candidates that we identify may not be suitable
for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate
that they are unlikely to receive marketing approval and achieve market acceptance. In addition, if we attempt to apply our technology
to develop product candidates for indications outside of Alzheimer&rsquo;s, we will need to conduct genotoxicity and immunotoxicity
trials, in which the results are presently uncertain. If we do not successfully develop and commercialize product candidates based
upon our technological approach, we will not be able to obtain product revenue in future periods, which would make it unlikely
that we would ever achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Product recalls or inventory losses
caused by unforeseen events, cold chain interruption and testing difficulties may adversely affect our operating results and financial
condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL001 and AL002, individually, will be
manufactured and distributed, if ever, using technically complex processes requiring specialized facilities, highly specific raw
materials and other production constraints. The complexity of these processes, as well as the strict company and government standards
for the manufacture of our products, will subject us to production risks. While product batches released for use in clinical trials
or for commercialization undergo sample testing, some defects may only be identified following product release. In addition, process
deviations or unanticipated effects of approved process changes may result in these intermediate products not complying with stability
requirements or specifications. Most of our products must be stored and transported at temperatures within a certain range, which
is known as &ldquo;strict cold chain&rdquo; storage and transportation. If these environmental conditions deviate from the norm,
our products&rsquo; remaining shelf lives could be impaired or their efficacy and safety could become adversely affected, making
them no longer suitable for use. The occurrence or suspected occurrence of production and distribution difficulties can lead to
lost inventories, and in some cases product recalls, with consequential reputational damage and the risk of product liability.
The investigation and remediation of any identified problems can cause production delays, substantial expense, lost sales and
delays of new product launches, any of which could have a material adverse effect on our business, results of operations and financial
condition.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to Development and Regulatory
Approval of Our Product</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>There is a high rate of failure for
drug candidates proceeding through clinical trials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally speaking, there is a high rate
of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical trials similar
to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising
results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other regulatory
authorities may disagree with our interpretation of the data. For instance, any such differing interpretation could cause the FDA
to require additional trials. In the event that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 90%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">we obtain negative results from the AL001
        or AL002 from a clinical trial;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the FDA places a clinical hold on our clinical
        trials due to potential chemistry, manufacturing and controls issues or other hurdles, or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the FDA does not approve our NDA for AL001
        or our Biologics License Application (&ldquo;<B>BLA</B>&rdquo;) for AL002, then:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="vertical-align: top; width: 87%; text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to generate sufficient revenue or obtain financing to continue our operations;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our ability to execute our current business
        plan will be materially impaired;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">our reputation in the industry and in the
        investment community would likely be significantly damaged; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the price of the Common Stock, assuming a trading market has then developed therefor, would likely decrease significantly.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these results could materially and
adversely affect our business, results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical trials for AL001 or AL002 can
be expensive, time consuming, uncertain and susceptible to change, delay or termination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are expensive, time consuming
and difficult to design and implement. The result of a clinical trial may be undesirable and can result in a clinical trial cancellation
or the need for re-evaluation and supplementation. Even if the results of our clinical trials are favorable, the clinical trials
for AL001 or AL002 are expected to continue for a few years and may even take significantly longer to complete. In addition, we,
the FDA, an IRB, or other regulatory authority, including in the U.S., EU and elsewhere, may suspend, delay or terminate our clinical
trials at any time, for various reasons, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">lack of effectiveness of AL001 or AL002
        during clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">discovery of serious or unexpected toxicities
        or side effects experienced by trial participants or other safety issues;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">slower than expected rates of subject recruitment
        and enrollment rates in clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">difficulty in retaining subjects who have
        initiated a clinical trial but may have withdrawn due to adverse side effects from the therapy, insufficient efficacy, fatigue
        with the clinical trial process or for any other reason;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">delays or inability in manufacturing or
        obtaining sufficient quantities of materials for use in clinical trials due to manufacturing or regulatory constraints;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">inadequacy of or changes in our manufacturing
        process or product formulation;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">delays in obtaining regulatory authorization to commence a trial,
including experiencing &ldquo;clinical holds&rdquo; or delays requiring suspension or termination of a trial by a regulatory agency,
such as the FDA, before or after a trial is commenced;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">changes in applicable regulatory policies
        and regulations;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">delays or failure in reaching agreement
        on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">delay or failure to supply product for
        use in clinical trials which conforms to regulatory specification;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">unfavorable results from ongoing pre-clinical
        studies and clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">failure of any contract research organizations
        (&ldquo;<B>CROs</B>&rdquo;) that we may partner with in the future, or other third-party contractors, to comply with all contractual
        requirements or to perform their services in a timely or acceptable manner;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">failure by us, our employees, any CROs
        or their employees to comply with all applicable FDA or other regulatory requirements relating to the conduct of clinical trials;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">scheduling conflicts with participating
        clinicians and clinical institutions;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">failure to design appropriate clinical
        trial protocols; or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">regulatory concerns with pharmaceutical products generally and the potential for abuse.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of any of the foregoing
could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The regulatory approval process is uncertain,
requires us to utilize significant resources, and may prevent us or our commercial partners from obtaining approvals for the commercialization
of AL001 or AL002.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research, testing, manufacturing, labeling,
approval, sale, marketing and testing of AL001 and AL002 are and will be subject to extensive regulation by regulatory authorities
in the U.S., Europe and elsewhere, and regulatory requirements applicable to our product differ from country to country. Neither
we nor any commercial partner is permitted to market any of our current or future product candidates in the U.S. until we receive
approval from the FDA of either an NDA or BLA, respectively. Obtaining approval of an NDA or a BLA can be an uncertain process
that requires us to utilize significant resources. Furthermore, regulatory authorities possess broad discretion regarding processing
time and usually request additional information and raise questions which have to be answered. There is considerable uncertainty
regarding the times at which products may be approved. In addition, failure to comply with FDA and other applicable U.S. and foreign
regulatory requirements may subject us to administrative or judicially imposed sanctions, including: warning letters, civil and
criminal penalties, injunctions, withdrawal of approved products from the market, product seizure or detention, product recalls,
total or partial suspension of production, and refusal to approve pending applications or supplements to approved applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process required by the FDA and most
foreign regulatory authorities before human health care pharmaceuticals may be marketed generally involves nonclinical laboratory
and, in some cases, animal tests; submission of an IND, which must become effective before clinical trials may begin; adequate
and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use or uses;
pre-approval inspection of manufacturing facilities and clinical trial sites; and FDA approval of a NDA or BLA, which must occur
before a drug can be marketed or sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory approval of an NDA or BLA, or
any supplement thereof, is not guaranteed, and the approval process requires us to utilize significant resources, could take several
years, and is subject to the substantial discretion of the FDA. Despite the time and expense exerted, failure can occur at any
stage, and we could encounter problems that cause us to abandon or have to repeat or perform additional studies. If our product
or any of our future product candidates fails to demonstrate safety and efficacy in our studies, or for any other reason does not
gain regulatory approval, our business and results of operations will be materially and adversely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, separate regulatory approvals
are required in order to market any product in many jurisdictions, including the U.S., the European Economic Area, which consists
of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein, and many others. Approval procedures vary
among countries and can involve additional studies and testing, and the time required to obtain approval may differ from that required
to obtain FDA approval. Studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval
by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory
authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or
delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign
regulatory approval process may include all of the risks associated with obtaining FDA approval. We may be unable to file for regulatory
approvals or do so on a timely basis and, even if we are able to, we may not receive necessary approvals to commercialize our products
in any market. Any of these results could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Even if we receive regulatory approval
for any of our future product candidates, we will be subject to ongoing FDA and other regulatory body obligations and continued
regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, will
be subject to labeling and manufacturing requirements and could be subject to other restrictions. Failure to comply with these
regulatory requirements or the occurrence of unanticipated problems with our products could result in significant penalties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any regulatory approvals that we or any
of our collaborators receive for AL001, AL002 or any future product candidate may be subject to conditions of approval or limitations
on the approved indicated uses for which the product may be marketed or may contain requirements for potentially costly surveillance
to monitor the safety and efficacy of the product candidate. In addition, AL001, AL002 and any of our future product candidates,
if approved by the FDA or other regulatory bodies, will be subject to extensive and ongoing regulatory requirements regarding the
manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping.
These requirements will include submissions of safety and other post-marketing information and reports, registration, as well as
continued compliance with cGMP, Good Laboratory Practice and Good Clinical Practice for any studies that we conduct post-approval.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48px; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">restrictions on the marketing or manufacturing
        of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">fines, warning letters or holds on target
        studies;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">refusal by the FDA or other applicable
        regulatory body to approve pending applications or supplements to approved applications filed by us or our strategic collaborators,
        or suspension or revocation of product license approvals;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">product seizure or detention, or refusal
        to permit the import or export of products; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The policies of the FDA and other regulatory
bodies may change, and additional government regulations may be promulgated that could prevent, limit or delay regulatory approval
of AL001 or AL002. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the U.S. or elsewhere. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing
approval that we may have obtained, and we may not achieve or sustain profitability, which would materially and adversely affect
our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AL001 or AL002 and any of our future
product candidates, if approved, may cause or contribute to adverse medical events that we are required to report to the FDA and
regulatory authorities in other countries and, if we fail to do so, we could be subject to sanctions that would materially harm
our business.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are successful in commercializing
AL001, AL002 or any of our future product candidates, regulations promulgated by the FDA and by the regulatory authorities in other
countries require that we report certain information about adverse medical events if those products may have caused or contributed
to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event
as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We
may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as
an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to
comply with our reporting obligations, the FDA and regulatory authorities in other countries could take action including criminal
prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products,
which could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legislative or regulatory reforms with
respect to products may make it more difficult and costly for us to obtain regulatory clearance or approval of AL001, AL002 or
any of our future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, legislation is drafted
and introduced in the U.S. Congress and lawmaking bodies in other countries that could significantly change the statutory provisions
governing the testing, regulatory clearance or approval, manufacture, and marketing of regulated products. In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products.
Similar changes in regulations can occur in other countries. Any new regulations or revisions or reinterpretations of existing
regulations in the U.S. or in other countries may impose additional costs or lengthen review times of AL001, AL002 and any of our
future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies,
when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48px; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">requests for additional endpoints or studies;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">changes to manufacturing methods;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">recall, replacement, or discontinuance
        of certain products; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">additional record keeping.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of these would likely entail substantial
time and cost and could have a material adverse effect on our ability to obtain regulatory approval for our product candidates.
In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products could materially
and adversely affect our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our ability to market AL001, AL002 and
any future product candidates in the U.S., if approved, will be limited to use for the treatment of the indications for which they
are approved, and if we want to expand the indications for which we may market AL001, AL002 and any future product candidates,
we will need to obtain additional FDA approvals, which may not be granted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to seek full FDA approval in the
U.S. for AL001 and AL002 to treat Alzheimer&rsquo;s. If AL001 or AL002 is approved, the FDA will restrict our ability to market
or advertise it for the treatment of indications other than the one for which it is approved, which would limit its use. If we
decide to attempt to develop, promote and commercialize new treatment indications and protocols for AL001, AL002 and product candidates
in the future, we could not predict when, or if, we would ever receive the approvals required to do so. We would be required to
conduct additional studies to support such applications for additional use, which would consume additional resources and may produce
results that do not result in FDA approvals. If we do not obtain additional FDA approvals, our ability to expand our business in
the U.S. would be adversely affected,<FONT STYLE="color: blue">&nbsp;</FONT>which could materially and adversely affect our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The anticipated development of a REMS
for AL001 or AL002 could cause delays in the approval process and would add additional layers of regulatory requirements that
could impact our ability to commercialize AL001 and AL002 in the U.S. and reduce their market potential.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a condition of approval of an NDA or
a BLA, the FDA may require a REMS to ensure that the benefits of the drug outweigh the potential risks. REMS elements can include
medication guides, communication plans for health care professionals, and elements to assure safe use (&ldquo;<B>ETASU</B>&rdquo;).
ETASU&rsquo;s can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing
only under certain circumstances, special monitoring, and the use of patient registries. Moreover, product approval may require
substantial post-approval testing and surveillance to monitor the drug&rsquo;s safety or efficacy. We may be required to adopt
a REMS for AL001 or AL002 to ensure that the benefits outweigh the risks of abuse, misuse, diversion and other potential safety
concerns. Even if the risk of abuse, misuse or diversion are not as high as for some other products, there can be no assurance
that the FDA will approve a manageable REMS for AL001 or AL002, which could create material and significant limits on our ability
to successfully commercialize AL001 and AL002 in the U.S. Delays in the REMS approval process could result in delays in the NDA
or BLA approval process, respectively. In addition, as part of the REMS, the FDA could require significant restrictions, such as
restrictions on the prescription, distribution and patient use of the product, which could significantly impact our ability to
effectively commercialize AL001 or AL002, and dramatically reduce their market potential thereby adversely impacting our business,
financial condition and results of operations. Even if initial REMS are not highly restrictive, if, after launch, AL001, AL002
and other drug candidates were to become subject to significant abuse/non-medical use or diversion from licit channels, this could
lead to negative regulatory consequences, including a more restrictive REMS, which could materially and adversely affect our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we are found in violation of &ldquo;fraud
and abuse&rdquo; laws, we may be required to pay a penalty and/or be suspended from participation in government-run health care
programs, which may adversely affect our business, financial condition and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are successful in obtaining marketing
approval for our products in the U.S. and elsewhere, we will be subject to various health care &ldquo;fraud and abuse&rdquo; laws,
including anti-kickback laws, false claims laws and other laws intended to reduce fraud and abuse in government-run health care
programs, which could affect us, particularly upon successful commercialization of our products in the U.S. For example, the Medicare
and Medicaid Patient Protection Act of 1987 (generally known as the federal &ldquo;<B>Anti-Kickback Statute</B>&rdquo;) makes it
illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully
solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order
or prescription of a particular drug for which payment may be made under a U.S. health care program such as Medicare or Medicaid.
Under U.S. federal government regulations, some arrangements, known as safe harbors, are deemed not to violate the Anti-Kickback
Statute. Although we intend to seek to structure our business arrangements in compliance with all applicable requirements, these
laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances.
Accordingly, it is possible that our practices may be challenged under the Anti-Kickback Statute and similar laws in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, false claims laws prohibit anyone
from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers,
reimbursement claims for drugs or services that are false or fraudulent, claims for items or services that were not provided as
claimed, or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label
promotion of pharmaceutical products or the payment of kickbacks to pharmaceutical providers has resulted in the submission of
false claims to governmental health care programs. Under laws such as the Health Insurance Portability and Accountability Act of
1996 in the U.S., we are prohibited from knowingly and willfully executing a scheme to defraud any health care benefit program,
including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.
Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and/or exclusion or suspension
from government-run health care programs such as Medicare and Medicaid and debarment from contracting with the U.S. and other governments.
In addition, in the U.S. individuals have the ability to bring actions on behalf of the government under the federal False Claims
Act as well as under state false claims laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many states in the U.S. have adopted laws
similar to the Anti-Kickback Statute, some of which apply to the referral of patients for health care services reimbursed by any
source, not just governmental payers. In addition, California and a few other states in the U.S. have passed laws that require
pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical
Manufacturers and/or the Pharmaceutical Research and Manufacturers of America Code on Interactions with Health Care Professionals.
In addition, several states impose other marketing restrictions or require pharmaceutical companies to make marketing or price
disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to
comply with an applicable state law requirement we could be subject to penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have yet to receive definitive guidance
on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing
these laws, and it is possible that some of our future practices may be challenged under these laws. While we believe we will
be able to structure our business arrangements to comply with these laws, it is possible that the government could in the future
allege violations of, or convict us of violating, these laws. If we are found in violation of one of these laws, we could be required
to pay a penalty and could be suspended or excluded from participation in certain government-run health care programs, and our
business, results of operations and financial condition may be materially and adversely affected.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to Our Business and
Industry</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we fail to attract and keep senior
management and key scientific personnel, we may be unable to successfully develop AL001, AL002 or any future product candidates,
conduct our in-licensing and development efforts or commercialize AL001, AL002 or any of our future product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future growth and success depend in
part on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. We are highly
dependent upon our senior management, particularly Stephan Jackman, our Chief Executive Officer, Kenneth Cragun, our Chief Financial
Officer as well as on our consultant, Dr. Chuanhai Cao, the neuroscientist who developed AL002, and Dr. Roland &ldquo;Doug&rdquo;
Shytle, one of the investors of AL001 and other members of our senior management team. The loss of services of any of these individuals
could delay or prevent the successful development of our current or future product pipeline, completion of our planned development
efforts or the commercialization of AL001 or AL002. It is possible that current or former employees of ours could put forward claims
for an alleged right to our patents and demand compensation therefor. If one or more of the key personnel were to leave us and
engage in competing operations, our business, results of operations and financial condition could be materially and adversely affected.
To date, none of our key personnel has left us without a suitable replacement having been identified prior to such departure or,
to our knowledge, engaged in competing operations, nor has any departure of key personnel had any material effect on our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may have trouble hiring additional
qualified personnel.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we expand our development and commercial
activities, we will need to hire additional personnel and could experience difficulties attracting and retaining qualified employees.
Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess
the skills and experience required by that industry. We may not be able to attract and retain quality personnel on favorable terms,
or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that such personnel
have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers
own their research output. Any of these difficulties could have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are subject to risks relating to
legal proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various claims and legal
actions arising in the ordinary course of our business. Any such litigation could be very costly and could distract our management
from focusing on operating our business. The existence of any such litigation could harm our business, results of operations and
financial condition. Results of actual and potential litigation are inherently uncertain. An unfavorable result in a legal proceeding
could adversely affect our reputation, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If product liability lawsuits are brought
against us, we will incur substantial liabilities and may be required to limit the commercialization of AL001 or AL002.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and our partners face potential product
liability exposure related to the testing of AL001 or AL002 in clinical trials. We will face exposure to claims by an even greater
number of persons if we begin to market and distribute our products commercially in the U.S. and elsewhere, including those relating
to misuse of AL001 or AL002. Now, and in the future, an individual may bring a liability claim against us alleging that AL001 or
AL002 caused an injury. While we intend to take what we believe to be appropriate precautions, we may be unable to avoid significant
liability if any product liability lawsuit is brought against us. If we cannot successfully defend ourselves against product liability
claims, we will incur substantial liabilities. Even if we successfully defend any such action, the costs associated with such defense
could prove exorbitant. Regardless of merit or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48px; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">decreased demand for AL001 or AL002, if
        such product candidate is approved;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">injury to our reputation;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">withdrawal of clinical trial participants;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">costs of related litigation;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">substantial monetary awards to patients and others;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48px; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">increased cost of liability insurance;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">loss of revenue; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to successfully commercialize our products.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, in the future there may be
a need to expand the scope of our insurance coverage, which could result in significantly increased costs or the inability to obtain
sufficient insurance coverage.<B>&nbsp;</B>Any of these occurrences could have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Failure of our information technology
systems could significantly disrupt the operation of our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to execute our business plan
and to comply with regulatory requirements with respect to data control and data integrity depends, in part, on the continued and
uninterrupted performance of our information technology systems (&ldquo;<B>IT systems</B>&rdquo;). These systems are vulnerable
to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters.
Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic
break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated
problems that could affect our IT systems, there are no assurances that electronic break-ins, computer viruses and similar disruptive
problems, and/or sustained or repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt
our ability to generate and maintain data will not occur. The occurrence of any of the foregoing with respect to our IT systems
could have a material adverse effect on our business, results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We will be subject to the U.S. Foreign
Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws
governing our anticipated operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties,
other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations, if initiated, will be subject
to certain anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (&ldquo;<B>FCPA</B>&rdquo;), and other anti-corruption
laws that apply in countries where we do business. The FCPA and other anti-corruption laws generally prohibit us and our employees
and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain
or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that
pose a high risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions
could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature,
scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which
existing laws might be administered or interpreted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also anticipate becoming subject to
other laws and regulations governing our international operations, including regulations administered in the U.S. and in the EU,
including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency
exchange regulations (collectively, &ldquo;<B>Trade Control Laws</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that we will
be completely effective in ensuring our compliance with all applicable anticorruption laws, including the FCPA or other legal
requirements, such as Trade Control Laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or
Trade Control Laws by U.S., EU or other authorities could have an adverse impact on our reputation, our business, results of operations
and financial condition. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or
Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures,
as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity,
as well as on our business, results of operations and financial condition.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to Our Intellectual
Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may be forced to litigate to enforce
or defend our intellectual property rights, or the intellectual property rights of our licensors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be forced to litigate to enforce
or defend our intellectual property rights against infringement and unauthorized use by competitors. In so doing, we may place
our intellectual property at risk of being invalidated, held unenforceable, or narrowed in scope. Further, an adverse result in
any litigation or defense proceedings may place pending applications at risk of non-issuance. In addition, if any licensor fails
to enforce or defend its intellectual property rights, this may adversely affect our ability to develop and commercialize AL001
or AL002 as well as our ability to prevent competitors from making, using, and selling competing products. Any such litigation
could be very costly and could distract our management from focusing on operating our business. The existence or outcome of any
such litigation could harm our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
and proprietary information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our Common Stock, should a market
therefor ever develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may be unable to adequately prevent
disclosure of trade secrets and other proprietary information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our
proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable.
However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants,
outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information.
These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the
event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets
and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our
proprietary rights. Failure to obtain or maintain trade secret protection or failure to adequately protect our intellectual property
could enable competitors to develop generic products or use our proprietary information to develop other products that compete
with our products or cause additional, material adverse effects upon our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer of technology and knowledge
to contract manufacturers pursuant to the production of our products also creates a risk of uncontrolled distribution and copying
of concepts, methods and processes relating to our products. Such uncontrolled distribution and copying could have a material adverse
effect on the value of our products if used for the production of competing drugs or otherwise used commercially without our obtaining
financial compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may become subject to third parties&rsquo;
claims alleging infringement of patents and proprietary rights or seeking to invalidate our patents or proprietary rights, which
would be costly, time-consuming and, if successfully asserted against us, delay or prevent the development and commercialization
of AL001 or AL002.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been substantial litigation and
other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry, as well as patent challenge
proceedings, including interference and administrative law proceedings before the U.S. Patent and Trademark Office (&ldquo;<B>U.S.
PTO</B>&rdquo;) and the European Patent Office (&ldquo;<B>EPO</B>&rdquo;), and oppositions and other comparable proceedings in
other jurisdictions. Recently, under U.S. patent reform laws, new procedures including inter parts review and post grant review
have been implemented. As stated below, the novel implementation of such reform laws presents uncertainty regarding the outcome
of challenges to our patents in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that AL001, AL002
or any of our future product candidates will not infringe existing or future patents. We may be unaware of patents that have already
issued that a third party might assert are infringed by AL001, AL002 or one of our future product candidates. Because patent applications
can take many years to issue and may be confidential for eighteen months or more after filing, there may be applications now pending
of which we are unaware of and which may later result in issued patents that we may infringe by commercializing AL001, AL002 or
any of our future product candidates. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. Moreover, we may face claims from non-practicing entities (commonly referred to as patent trolls),
which have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to third-party claims
in the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us,
could cause us to pay substantial damages, including treble damages and attorney&rsquo;s fees if we are found to be willfully infringing
a third party&rsquo;s patents. If a patent infringement suit were brought against us or our collaborators, we or our collaborators
could be forced to stop or delay research, development, manufacturing or sales of AL001 or AL002. As a result of patent infringement
claims, or in order to avoid potential claims, we or our collaborators may choose to seek, or be required to seek, a license from
the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available
on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive,
which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing
a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened
patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms. Even if we are successful
in defending such claims, infringement and other intellectual property litigation can be expensive and time-consuming to litigate
and divert management&rsquo;s attention from our core business. Any of these events could harm our business significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to infringement claims against
us, if third parties have prepared and filed patent applications in the U.S. that also claim technology to which we have rights,
we may have to participate in interference proceedings in the U.S. PTO to determine the priority of invention. Third parties may
also attempt to initiate reexamination, post grant review or inter partes review of our patents in the U.S. PTO. We may also become
involved in similar opposition proceedings in the EPO or comparable offices in other jurisdictions regarding our intellectual property
rights with respect to our products and technology.<FONT STYLE="color: blue">&nbsp;</FONT>Any of these claims could have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If our efforts to protect the proprietary
nature of the intellectual property related to AL001, AL002 or any of our potential future product candidates are not adequate,
we may not be able to compete effectively in our market.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to rely upon a combination of
patents, trade secret protection as well as confidentiality and license agreements to protect the intellectual property related
to our product and our current product candidates and our development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Composition-of-matter patents on an active
pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical
products, as such patents provide protection without regard to any particular method of use or manufacture. We cannot be certain
that the claims in any patent application that we may submit covering composition-of-matter of AL001, AL002 and any potential future
product candidates will be considered patentable by the U.S. PTO and courts in the U.S., or by the patent offices and courts in
foreign countries. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent
a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of
the patented method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The strength of patents involves complex
legal and scientific questions and can be uncertain. The patent applications that we may in the future own or license may fail
to result in issued patents in the U.S. or in other foreign countries. Even if the patents do successfully issue, third parties
may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held
unenforceable. Furthermore, even if they are unchallenged, any of our future patents and patent applications may not adequately
protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection
provided by the patent applications we may in the future own, in-license or pursue with respect to AL001, AL002 or any future product
candidates is threatened, it could threaten our ability to commercialize AL001, AL002 or any future product candidates. Further,
if we encounter delays in our development efforts, the period of time during which we could market AL001, AL002 or any future product
candidates under patent protection would be reduced. Since patent applications in the U.S. and most other countries are confidential
for a period of time after filing, we cannot be certain that we were the first to file any patent application related to AL001,
AL002, or any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even where laws provide protection, costly
and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome
of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors
could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property
portfolios than we have.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will also rely on trade secret protection
and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult
to enforce and any other elements of our product development processes that involve proprietary know-how, information or technology
that is not covered by patents. Although we endeavor to execute confidentiality agreements with all of our employees, consultants,
advisors and any third parties who have access to our proprietary know-how, information or technology, we cannot be certain that
we have executed such agreements with all parties who may have helped to develop our intellectual property or had access to our
proprietary information, nor that our agreements will not be breached. We cannot guarantee that our trade secrets and other confidential
proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently
develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary
rights to the same extent or in the same manner as the laws of the EU or the U.S. As a result, we may encounter significant problems
in protecting and defending our intellectual property both in the U.S. and elsewhere. If we are unable to prevent material disclosure
of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive
advantage in our market, which could materially and adversely affect our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any disclosure to or misappropriation by
third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological
achievements, thus eroding our competitive position in our market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in patent law could diminish
the value of patents in general, thereby impairing our ability to protect AL001 and AL002.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with other biopharmaceutical
companies, our success will be heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents
in the biopharmaceutical industry involves both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical
patents is costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing
wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in other situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal
courts, and the U.S. PTO, the laws and regulations governing patents could change in ways that would weaken our ability to obtain
patents and to enforce patents that we might obtain in the future. Similarly, changes in EU patent law and elsewhere could negatively
affect the value of our patents registered outside of the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with any of these requirements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. PTO and various foreign governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent
process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter
the market earlier than would otherwise have been the case, which could have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be able to protect our intellectual
property rights throughout the world.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing, prosecuting and defending patents
on AL001, AL002 and any future product candidates throughout the world is prohibitively expensive. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise
infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S.
These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and our patent
claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents
or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Risks Related to this Offering</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>There is no public market for our Common
Stock, and an active market in which investors can resell their shares may not develop.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no public market for our Common
Stock and we cannot predict when or if one may develop. Even if a public market were to develop, we cannot predict how active such
a market would be, how it will develop or be sustained after this Offering, or how the development of such a market might affect
the market price of our Common Stock. The offering price of the Offered Shares in this Offering is based on a number of factors,
including market conditions in effect at the time of the Offering, and it may not be in any way indicative of the price at which
our shares will trade following the completion of this Offering. Investors may not be able to resell Offered Shares at or above
the offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may require additional capital to
support business growth, and this capital might not be available on acceptable terms, if at all.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We need sufficient capital to fund our
ongoing operations and continue our development. We intend to continue to make investments to support our business growth and may
require additional funds to respond to business challenges. As a result, we may need to engage in equity or debt financings to
secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing
stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges
superior to those of holders of our Common Stock. Any debt financing secured by us in the future could involve restrictive covenants
relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us
to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, we may not be
able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing
on terms satisfactory to us, when and if we require it, our ability to continue to support our business growth, and to respond
to business challenges could be significantly impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Investors in this Offering will
experience immediate and substantial dilution: further, investors may suffer additional dilution as a result of the Placement
Agreement and the SPA.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If all of the Offered Shares offered hereby
are sold, investors in this Offering will own 8.6% of the then outstanding shares of Common Stock but will have paid 63.6% of the
total consideration for our outstanding shares, resulting in a dilution of $6.90 per share. See the section entitled &ldquo;Dilution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Placement Agreement
includes a weighted-average anti-dilution protective provision for certain current stockholders that would take effect upon conversion
of the Series A Preferred Stock. Should all such 750,000 shares of Series A Preferred Stock be converted into Common Stock, we
would be obligated to issue to those current stockholders a number of shares of Common Stoc roughly equal to 2,000,000 such shares,
or approximately three percent (3%) of the total number of shares of our company issued and outstanding prior to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Further, the SPA discussed in the risk
factor entitled &ldquo;<I>Pursuant to the Securities Purchase Agreement we entered into with ALSF, we agreed to certain provisions
that limit our flexibility</I>&rdquo; below could further increase the dilution you would experience as a result of certain of
its provisions, including the full ratchet anti-dilution protection conferred on ALSF by the SPA. While the degree of any dilution
caused by the SPA&rsquo;s anti-dilution protection is not quantifiable, it would only affect any issuances of Common Stock or
Common Stock equivalents at a price below $1.50 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Placement Agent will have a significant
degree of influence over our company, and its interests may diverge from ours and those of our stockholders. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the covenants we have made with the
Placement Agent in the Placement Agreement and the Uplisting Agreement, which include a number of significant constraints on how
we operate our business and on our ability to obtain financing, in addition to enabling it to nominate a candidate to the Board,
the Placement Agent will be able to significantly influence many of our decisions as well as all matters requiring approval by
stockholders, including the election of directors and the approval of mergers or other business combinations transactions as well
as other matters that will considered by the Board. There can be no assurance that the interests of the Placement Agent will coincide
with our own, that of our stockholders or any of the investors in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Greater risk of loss to the early investors
than to later investors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no minimum offering. Consequently,
we can close on any sum raised and do so on a rolling basis. As a result, there can be no assurance that we will raise a sufficient
amount of capital enabling us to continue operations. If we fail to raise a sufficient amount of capital to continue our business,
such failure may lead to investors losing their entire investment. In addition, if we raise an appreciable sum that is nevertheless
substantially less than the Maximum Offering, we may have insufficient funds to fully implement our business strategy. Therefore,
the sale of Offered Shares in an amount significantly less than the Maximum Offering could have material, adverse consequences
on our business, financial condition and future outlook.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pursuant to the Securities Purchase
Agreement we entered into with ALSF, we agreed to certain provisions that limit our flexibility.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Pursuant to the Securities Purchase Agreement (the &ldquo;<B>SPA</B>&rdquo;)
we entered into with ALSF, we agreed to certain provisions that limit our flexibility notwithstanding the fact that ALSF has not
funded the purchase of the shares that it acquired (the &ldquo;<B>ALSF Shares</B>&rdquo;) in cash but through the issuance of
a promissory note to us (the &ldquo;<B>ALSF Note</B>&rdquo;). While the ALSF Shares have been pledged to us as collateral for
the repayment of the $15,000,000 for the 10,000,000 shares of our Common Stock and ALSF is not entitled to vote such ALSF Shares
or receive any distributions from us until the ALSF Note has been repaid (on a pro rata basis), we are bound by certain covenants
contained in the SPA. These covenants include, but are not limited to: (i) full ratchet anti-dilution protection, (ii) most-favored
nation status, (iii) denying us the right to enter into a variable rate transaction absent ALSF&rsquo;s consent, (iv) a right
to participate in any future financing we may consummate, and (v) to have all the ALSF Shares to which ALSF is entitled under
the SPA be registered under the Securities Act within 180 days of the final closing of an initial public offering that we may
conduct. See the SPA attached hereto as Exhibit 3.1.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The offering price of the Offered Shares
was arbitrarily determined.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering price of the Offered Shares
was determined by our management. The price of the Offered Shares does not necessarily bear any relationship to established valuation
criteria such as earnings, book value or assets. Rather, the price of the Offered Shares was based upon various factors including
prevailing market conditions, our future prospects and our capital structure. This price does not necessarily accurately reflect
the actual value of the Offered Shares or the price that may be realized upon disposition of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not satisfy a national securities
exchange&rsquo;s initial listing standards and, even if we do, we may experience a delay in the initial trading of our Common Stock
on a national securities exchange.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to apply to list our Common Stock
on a national securities exchange under the symbol &ldquo;<B>ALZA</B>.&rdquo; Our Common Stock will not commence trading on a national
securities exchange until a number of conditions are met, including that we have raised the minimum amount of offering proceeds
necessary for us to meet the initial listing requirements of a national securities exchange, which we currently estimate to be
approximately $4,000,000. There is no guarantee that we will be able to sell a sufficient number of Offered Shares to meet this
requirement. Assuming we sell a sufficient number of Offered Shares to list on a national securities exchange, we expect trading
to commence following the Termination Date of this Offering. However, we may wait before terminating the Offering and commencing
the trading of our Common Stock on the national securities exchange the Company has selected in order to raise additional proceeds.
In addition, in order to list, we will be required to, among other things, file with the Commission a post-qualification amendment
to the Offering Statement, and then file a Form 8-A in order to register our shares under the Exchange Act. The post-qualification
amendment of the Offering Statement is subject to review by the Commission, and there is no guarantee that such amendment will
be qualified quickly after filing. Any delay in the qualification of the post-qualification amendment may cause a delay in the
initial trading of our Common Stock on the national securities exchange the Company has selected. For all of the foregoing reasons,
you may experience a delay between the closing of your purchase&nbsp;of the Offered Shares and the commencement of exchange trading
of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The national securities exchange on
which the Common Stock will be traded, assuming a successful application, may delist our Common Stock from trading, which would
limit stockholders&rsquo; ability to trade their shares of our Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event we are able to list our Common
Stock on the NYSE American or any other national securities exchange, the NYSE American or such other national securities exchange
will require us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue
the listing of our Common Stock. If we fail to meet these continued listing requirements, our Common Stock may be subject to delisting.
If our Common Stock is delisted and we are not able to list our Common Stock on another national securities exchange, we expect
our securities would be quoted on an over-the-counter market. If this were to occur, our stockholders could face significant material
adverse consequences, including limited availability of market quotations for our Common Stock and reduced liquidity for the trading
of our securities. In addition, we could experience a decreased ability to issue additional securities and obtain additional financing
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may fail to meet our publicly announced
guidance or other expectations about our business, which would cause our stock price to decline.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to provide guidance regarding
our expected financial and business performance, such as projections regarding sales and production, as well as anticipated future
revenues, gross margins, profitability and cash flows. Correctly identifying key factors affecting business conditions and predicting
future events is inherently an uncertain process and our guidance may not ultimately be accurate. Our guidance is based on certain
assumptions such as those relating to anticipated production and sales volumes and average sales prices, supplier and commodity
costs, and planned cost reductions. If our guidance is not accurate or varies from actual results due to our inability to meet
our assumptions or the impact on our financial performance that could occur as a result of various risks and uncertainties, the
market value of our Common Stock could decline significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Offered Shares
is speculative and there can be no assurance of any return on any such investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An investment in the Offered Shares is
speculative and there is no assurance that investors will obtain any return on their investment. Investors will be subject to
substantial risks involved in an investment in the Company, including the risk of losing their entire investment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Offered Shares will be offered by
us on a &ldquo;best-efforts, no minimum&rdquo; basis.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offered Shares will be offered by us,
or through the Underwriter, on a &ldquo;best-efforts, no minimum&rdquo; basis. In a &ldquo;best-efforts, no minimum&rdquo; offering
such as the one described in this Offering Circular, there is no assurance that we will sell the Maximum Offering. Accordingly,
we may close upon amounts less than the Maximum Offering which may not provide us with sufficient funds to fully implement our
business plan. If the Maximum Offering is not sold, we may need to incur additional debt or raise additional equity financing to
sustain our operations. Increasing the amount of debt would increase our debt service obligations and make less cash available
for distribution to our stockholders or for other purposes, such as the development of our business, that could lead to an appreciation
of our enterprise value. Further, increasing the amount of additional equity we are required to raise could further dilute investors
participating in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No assurance regarding amount of proceeds of Offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of this Offering,
we will offer up to $45,000,000 in Offered Shares on a &ldquo;best-efforts, no minimum&rdquo; basis. Accordingly, investors will
not know in advance whether the gross proceeds of this Offering will be a de minimis figure or up to $45,000,000 (in each case,
net of commissions and expenses), if any. There can be no assurance that the subscriptions for any dollar amount will be received
or accepted by the Company or the Underwriter, if any. If we are only able to close on an amount that is significantly less than
the Maximum Offering, our chances of effectuating our proposed plan of operations would be drastically reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The market price of our Common Stock
may fluctuate, and you could lose all or part of your investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering price for our Common Stock
is based on a number of factors. Assuming a market for the Common Stock ever develops, the price of our Common Stock may decline
following the initial listing on any such market. Further, it is possible that the initial listing price of the shares will be
less than the price of the Offered Shares offered hereby. The stock market in general, and the market price of our Common Stock,
will likely be subject to fluctuation, whether due to, or irrespective of, our operating results, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial performance, our industry&rsquo;s
overall performance, changing consumer preferences, technologies and advertiser requirements, government regulatory action, tax
laws and market conditions in general could have a significant impact on the future market price of our Common Stock. Some of the
other factors that could negatively affect our share price or result in fluctuations in our share price include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">actual or anticipated variations in our periodic operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 50px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">increases in market interest rates that lead purchasers of our Common Stock to demand a higher yield;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">changes in earnings estimates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">changes in market valuations of similar companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">actions or announcements by our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse market reaction to any increased indebtedness we may incur in the future;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">additions or departures of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">actions by stockholders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">speculation in the press or investment community; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our intentions and ability to list our Common Stock on a national securities exchange and our subsequent ability to maintain such listing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because we do not have a compensation
committee, stockholders will have to rely on our directors, only one of whom is independent, to perform these functions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have a compensation committee
comprised of an independent director. The Board performs these functions as a whole.&nbsp;Only one member of the Board is an independent
director. Thus, there is a potential conflict in that board members who are also part of management will participate in discussions
concerning management compensation and audit issues that may affect management decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our failure to maintain effective internal
controls over financial reporting could have an adverse impact on us</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to establish and maintain
appropriate internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once
established, could adversely impact our public disclosures regarding our business, financial condition or results of operations.
In addition, management's assessment of internal controls over financial reporting may identify weaknesses and conditions that
need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors.
Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting, disclosure
of management's assessment of our internal controls over financial reporting or disclosure of our public accounting firm's attestation
to or report on management's assessment of our internal controls over financial reporting may have an adverse impact on the price
of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Upon the completion of this Offering,
we may elect to become a public reporting company under the Exchange Act, and thereafter publicly report on an ongoing basis as
an &ldquo;emerging growth company&rdquo; under the reporting rules set forth under the Exchange Act. If we elect not to do so,
we will be required to publicly report on an ongoing basis under the reporting rules set forth in Regulation A for Tier 2 issuers.
In either case, we will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for
companies that are not &ldquo;emerging growth companies,&rdquo; and our stockholders could receive less information than they might
expect to receive from more mature public companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the completion of this offering, we
may elect to become a public reporting company under the Exchange Act. If we do so, we will be required to publicly report on an
ongoing basis as an &ldquo;emerging growth company&rdquo; (as defined in the Jumpstart Our Business Startups Act of 2012, which
we refer to as the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an &ldquo;emerging
growth company,&rdquo; we may take advantage of certain exemptions from various reporting requirements that are applicable to other
Exchange Act reporting companies that are not &ldquo;emerging growth companies,&rdquo; including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">taking advantage of extensions of time to comply with certain new or revised financial accounting standards;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to take advantage of these reporting
exemptions until we are no longer an emerging growth company. We would remain an &ldquo;emerging growth company&rdquo; for up to
five years, although if the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of any October
31 before that time, we would cease to be an &ldquo;emerging growth company&rdquo; as of the following April 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we elect not to become a public reporting
company under the Exchange Act, we will continue to be required to publicly report on an ongoing basis under the reporting rules
set forth in Regulation A for Tier 2 issuers. The ongoing reporting requirements under Regulation A are more relaxed than for &ldquo;emerging
growth companies&rdquo; under the Exchange Act. The differences include, but are not limited to, being required to file only annual
and semiannual reports, rather than annual and quarterly reports. Annual reports are due within 120 calendar days after the end
of the issuer's fiscal year, and semiannual reports are due within 90 calendar days after the end of the first six months of the
issuer's fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In either case, we will be subject to ongoing
public reporting requirements that are less rigorous than Exchange Act rules for companies that are not &ldquo;emerging growth
companies,&rdquo; and our stockholders could receive less information than they might expect to receive from more mature public
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The requirements of being a public company
may strain our resources, divert management&rsquo;s attention and affect our ability to attract and retain qualified board members.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we will continue to
incur significant legal, accounting and other expenses, including costs associated with public company reporting requirements.
If we elect to become subject to Section 12 of the Exchange Act (which we would be required to do before becoming a listed company),
we also will incur costs associated with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Act and related
rules implemented or to be implemented by the Commission. The expenses incurred by public companies generally for reporting and
corporate governance purposes have been increasing. For so long as we qualify as an emerging growth company under the JOBS Act,
we may make certain elections that would subject us to reduced reporting and corporate governance requirements. Nonetheless, we
expect the rules and regulations associated with being a public company to increase our legal and financial compliance costs and
to make some activities more time-consuming and costly, although we are currently unable to estimate these costs with any degree
of certainty. These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance,
including director and officer liability insurance, and we may be forced to accept constraints on policy limits and coverage or
incur substantially higher costs to obtain coverage. These laws and regulations could also make it more difficult for us to attract
and retain qualified persons to serve on our Board, our board committees or as our executive officers and may divert management&rsquo;s
attention. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our
Common Stock, fines, sanctions and other regulatory action and potentially civil litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The preparation of our financial statements
involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates,
judgments or assumptions prove to be inaccurate.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial statements prepared in accordance
with accounting principles generally accepted in the United States of America (<B>&ldquo;GAAP&rdquo;</B>) typically require the
use of estimates, judgments and assumptions that affect the reported amounts. Often, different estimates, judgments and assumptions
could reasonably be used that would have a material effect on such financial statements, and changes in these estimates, judgments
and assumptions may occur from period to period over time. These estimates, judgments and assumptions are inherently uncertain
and, if our estimates were to prove to be wrong, we would face the risk that charges to income or other financial statement changes
or adjustments would be required. Any such charges or changes could harm our business, including our financial condition and results
of operations and the price of our securities. See &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and
Results of Operations&rdquo; for a discussion of the accounting estimates, judgments and assumptions that we believe are the most
critical to an understanding of our consolidated financial statements and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If securities industry analysts do not
publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our Common
Stock could be negatively affected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any trading market for our Common Stock
will be influenced in part by any research reports that securities industry analysts publish about us. We do not currently have
and may never obtain research coverage by securities industry analysts. If no securities industry analysts commence coverage of
us, the market price and market trading volume of our Common Stock could be negatively affected. In the event we are covered by
analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues coverage
or us, the market price and market trading volume of our Common Stock could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have significant discretion over the use of the net proceeds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maximum net proceeds to us from the
sale of the Offered Shares, after deducting the expenses associated with the Offering, will be approximately $40,000,000. The net
proceeds of this Offering will be used for research and development activities and for specific purposes set forth under the heading
&ldquo;Use of Proceeds&rdquo; below. Accordingly, our management will have broad discretion as to the application of such proceeds.
The proceeds may be used to carry out our business plan, pay salaries to our employees, and satisfy our expenses, foreseeable and
unforeseeable. As is the case with any business, it should be expected that certain expenses unforeseeable to management at this
juncture will arise in the future. This uncertainty would apply in particular to the development and commercialization of AL001,
AL002 or any future product candidates, as we have not yet generated any revenues because we have no products approved for commercial
sale. There can be no assurance that management&rsquo;s use of proceeds generated through this Offering will prove optimal or translate
into revenue or profitability for the Company. Investors are urged to consult with their attorneys, accountants, and personal investment
advisors prior to making a decision to invest in the Company. See the section entitled &ldquo;Use of Proceeds&rdquo; herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The forecasts of market growth included
in this Offering Circular may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth,
we cannot assure you our business will grow at similar rates, if at all.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Growth forecasts are subject to significant
uncertainty and are based on assumptions and estimates, which may not prove to be accurate. Forecasts relating to the expected
success of medicinal products or the date of FDA approvals, in particular including the forecasts or projections referenced in
this Offering Circular, may prove to be inaccurate. Even if these markets experience the forecasted growth, we may not grow our
business at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business
strategy, which is subject to many risks and uncertainties. Accordingly, the forecasts of market growth included in this Offering
Circular should not be taken as indicative of our future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We do not expect to declare or pay dividends
in the foreseeable future.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not expect to declare or pay dividends
in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business.
Therefore, holders of our Common Stock will not receive any return on their investment unless they sell their securities, and holders
may be unable to sell their securities on favorable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the sale by us of the Maximum
Offering of $45,000,000 and estimated expenses and commissions of $4,500,000, the total net proceeds to us would be $40,500,000,
which we currently intend to use as set forth below. We expect from time to time to evaluate the acquisition of businesses, products
and technologies for which a portion of the net proceeds will be used. As of the date of this Offering Circular, we cannot specify
with certainty all of the particular uses for the net proceeds to us from the sale of Common Stock. Accordingly, we will retain
broad discretion over the use of these proceeds, if any. The following table represents Management&rsquo;s best estimate of the
uses of the net proceeds received from the sale of Common Stock assuming the sale of, respectively, 100%, 75%, 50% and 25% of the
Offered Shares offered for sale in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Proceeds</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">100%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">75%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">50%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">25%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Licensing fees, pre-clinical activities and ongoing project support</P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0">for the University of South Florida</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FDA consulting and active project planning management</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance and grant procurement activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Establishment of advisory board, initial meetings, corporate</P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0">development and initial consulting</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Phase 1 clinical trial - AL002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Phase 1 clinical trial - AL001</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Working capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,500,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,375,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,250,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,125,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">TOTAL</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">40,500,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,375,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,250,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,125,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts set forth above are estimates,
and we cannot be certain that actual costs will not vary from these estimates. Our management has significant flexibility and broad
discretion in applying the net proceeds received in this Offering. We cannot assure you that our financial performance estimates
will prove to be accurate or that unforeseen events, problems or delays will not occur that would require us to seek additional
debt and/or equity funding, which may not be available on favorable terms, or at all. See &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe opportunities may exist from
time to time to expand our current business through license or acquisitions of, or investments in, complementary businesses, products
or technologies. While we currently have no agreements or commitments to complete any such transaction at this time, we may use
a portion of the net proceeds for these purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors
including the results of our research and development efforts, the timing and success of preclinical studies or clinical trials
we expect to commence in the near future, the timing of regulatory submissions, and any unforeseen cash needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pending their uses, we plan to invest the
net proceeds of this offering in short-term, interest-bearing, investment-grade instruments, certificates of deposit or direct
or guaranteed obligations of the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Alzamend will continue to incur legal,
executive, operational, financial, and support expenses as it pursues a listing with a national securities exchange following
completion of this Offering, transitions from completing the latter pre-clinical stages into the IND processes for AL002 and finishes
developing the IND plans and processes to transition into beginning the initial stage of clinical trials for the AL001 technology.
Only since the fall of 2018, has an individual worked full-time to achieve our goals. On November 2, 2018, we accepted the resignation
of our former President and CEO, Philip Mansour, and appointed Stephan Jackman as our current CEO. Mr. Jackman is an executive
with a biopharma background and will lead Alzamend through its maturation process until such time as other full-time staff becomes
necessary. The Company finalized the terms of this offering during the winter of 2018 and, as of December 15, 2018, we accepted
the resignation of our former CFO, William B. Horne and appointed our current CFO, Kenneth S. Cragun, endeavoring to become publicly
traded while preparing to begin our clinical trials sometime in the third quarter of 2020. On May 1, 2019 we hired Henry Nisser
to be our General Counsel and Executive Vice President. Travel will be required to facilitate the timely setup and project management
of all facets of the Company. The Company intends to use a part of the proceeds raised from this offering, if any, to fund the
compensation payable to its three officers, any new staff as required by its activities and its Executive Chairman of the Board
described under &ldquo;Our Business &ndash; Employees&rdquo; below. Funds to compensate these individuals will be drawn from the
working capital item in the table above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you purchase shares in this offering,
your ownership interest in our Common Stock will be diluted immediately, to the extent of the difference between the price to the
public charged for each share in this offering and the net tangible book value per share of our Common Stock after this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our historical net tangible book value
as of April 30, 2019 was $316,915 or $0.01 per then outstanding share of our Common Stock. Historical net tangible book value per
share equals the amount of our total tangible assets less total liabilities, divided by the total number of shares of our Common
Stock outstanding, all as of the date specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates the per
share dilution to new investors discussed above, assuming the sale of, respectively, 100%, 75%, 50% and 25% of the shares offered
for sale in this offering (after our estimated offering expenses of $4,500,000, $3,375,000, $2,250,000 and $1,125,000, respectively):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">100%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">75%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">50%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">25%</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Price to the public charged for each share in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Historical net tangible book value per share as of April 30, 2019 (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Increase in net tangible book value per share attributable to new</P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0">investors in this offering (2)</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.59</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.31</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net tangible book value per share, after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution per share to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.90</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.04</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.18</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.34</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 3px">&nbsp;</TD>
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on net tangible book value as of April 30, 2019, of $316,915 and 61,878,465 outstanding shares of Common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">After deducting our estimated offering expenses of $4,500,000, $3,375,000, $2,250,000 and $1,125,000, respectively.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, assuming
the sale of, respectively, 100%, 75%, 50% and 25% of the shares offered for sale in this offering (after our estimated offering
expenses of $4,500,000, $3,375,000, $2,250,000 and $1,125,000, respectively), as of October 31, 2019, the total number of shares
previously sold to existing stockholders, the total consideration paid for the foregoing and the average price paid per share.
As the table shows, new investors purchasing shares may in certain circumstances pay an average price per share substantially higher
than the average price per share paid by our existing stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Average Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold">Assuming 100% of shares sold:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">63,662,858</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">91.4</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,191,345</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">36.4</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.36</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">New investors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,000,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.6</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,500,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63.6</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.75</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">69,662,858</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">63,691,345</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.91</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Average Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold">Assuming 75% of shares sold:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">63,662,858</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">93.4</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,191,345</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">43.3</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.36</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">New investors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,500,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.6</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,375,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56.7</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.75</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">68,162,858</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">53,566,345</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.79</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Average Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold">Assuming 50% of shares sold:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">63,662,858</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">95.5</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,191,345</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">53.4</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.36</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">New investors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,000,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.5</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,250,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46.6</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.75</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">66,662,858</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43,441,345</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.65</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Average Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold">Assuming 25% of shares sold:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">63,662,858</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">97.7</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,191,345</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">69.6</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.36</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">New investors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,500,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.3</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,125,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30.4</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.75</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">65,162,858</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,316,345</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.51</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should read the following discussion
and analysis of our financial condition and results of our operations together with our consolidated financial statements and the
notes thereto appearing elsewhere in this Offering Circular. This discussion contains forward-looking statements reflecting our
current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events may differ
materially from those stated in or implied by these forward-looking statements due to a number of factors, including those discussed
in the sections entitled &ldquo;Risk Factors,&rdquo; &ldquo;Cautionary Statement regarding Forward-Looking Statements&rdquo; and
elsewhere in this Offering Circular. Please see the notes to our Financial Statements for information about our Significant Accounting
Policies and Recent Accounting Pronouncements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>On May 29, 2018, we implemented a 1-for-4
Reverse Stock Split of our Common Stock. The Reverse Stock Split became effective on December 13, 2018. As a result of the Reverse
Stock Split, every four (4) shares of our pre-Reverse Stock Split Common Stock were combined and reclassified into one share of
the Common Stock. The number of shares of Common Stock subject to outstanding options and warrants were also reduced by a factor
of four as of December 13, 2018 and their respective exercise prices were increased by a factor of four. All historical share and
per-share amounts reflected throughout the consolidated financial statements and other financial information in this filing have
been adjusted to reflect the Reverse Stock Split. Neither the authorized shares of capital stock nor the par value per share of
the Common Stock was affected by the Reverse Stock Split.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Summary of Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED OCTOBER
31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">The following
table summarizes the results of our operations for the six months ended October 31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ALZAMEND NEURO,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Statements of
Operations (Unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">&nbsp;Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">399,916</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,757,776</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,264,976</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">376,232</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt">&nbsp;Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,664,892</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,134,008</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,664,892</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,134,008</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OTHER INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Interest income - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,893</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,767</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Total other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,893</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,767</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,655,999</TD><TD STYLE="padding-bottom: 2.5pt; white-space: nowrap; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,050,241</TD><TD STYLE="padding-bottom: 2.5pt; white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Basic and diluted weighted average common</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,408,014</TD><TD STYLE="padding-bottom: 2.5pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,958,276</TD><TD STYLE="padding-bottom: 2.5pt; white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Alzamend Neuro, Inc. was formed on February 26, 2016, to
acquire and commercialize patented intellectual property and know-how to prevent, treat and cure the crippling and deadly disease,
Alzheimer&rsquo;s. We currently have only two product candidates, AL001 and AL002. These products are in the early stage of development
and will require extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts
and substantial investment before they and any successors could provide us with any revenue. We did not generate any revenues
during the six months ended October&nbsp;31, 2019 and 2018, and we do not anticipate that we will generate revenue for the foreseeable
future.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General and administrative expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses
for the six months ending October&nbsp;31, 2019 and 2018, were $1,264,976 and $376,232, respectively. As reflected in the table
below, general and administrative expenses primarily consisted of the following expense categories: management services, professional
fees, stock compensation expense, salaries and benefits. The remaining general and administrative expenses of $69,396 and $70,674,
respectively, primarily consisted of payments for advertising and promotion, transfer agent fees, travel, and other office expenses,
none of which is significant individually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">&nbsp;Management Services</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">120,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">293,222</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,560</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,661</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Salary and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,697</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Other general and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">69,396</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,672</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">&nbsp;Total general and administrative expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,264,976</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">376,232</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Management services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 31, 2019, we had one
full-time and two part-time employees. We accepted the resignation of our previous President and CEO, Philip Mansour, effective
on November 18, 2018, and appointed Mr. Stephan Jackman as CEO as of November 30, 2018. Mr. Jackman is a full-time executive with
extensive scientific and medical experience in developing immunotherapies and their commercialization to lead Alzamend&rsquo;s
activities. As of December 15, 2018, we accepted the resignation of our former CFO, William B. Horne and retained our current
CFO, Kenneth S. Cragun. On May 1, 2019 we hired Henry Nisser to be our General Counsel and Executive Vice President. Prior to
hiring Mr. Jackman, Mr. Cragun and Mr. Nisser, management services were provided by our two previous executive officers and Executive
Chairman pursuant to the terms of a management services agreement (the &ldquo;MSA&rdquo;) entered into with Avalanche International,
Corp. (&ldquo;Avalanche&rdquo;), a related party, on May 1, 2016. Avalanche provided management, consulting and financial services
to us. Such services included advice and assistance concerning any and all aspects of operations, planning and financing of Alzamend
and conducting relations with accountants, attorney, financial advisors and other professionals. The term of the MSA, as amended,
was for the period May 1, 2016 to December 31, 2017, and was extended by written agreement. We initially paid $40,000 per month
for these services and, beginning February 2017, began paying $20,000 per month. During the six months ended October&nbsp;31,
2018, we recognized $120,000 in management fees in connection with this agreement. The MSA expired as of December&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Professional fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second largest component of our
general and administrative expenses is professional fees. During the six months ended October&nbsp;31, 2019 and 2018, we reported
professional fees of $293,222 and $185,560, respectively, which are principally comprised of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Six Months Ended October 31, 2019</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In
                                         June 2107, we entered into a five year consulting agreement with Spartan Capital Securities,
                                         LLC (&ldquo;Spartan&rdquo;) pursuant to which Spartan has agreed to provide consulting
                                         services with respect to general corporate matters, including, but not limited to, advice
                                         and input with respect to raising capital, potential merger and acquisition transactions,
                                         identifying suitable personnel for management, developing corporate structure and finance
                                         strategies, assisting us with strategic introductions, assisting management with enhancing
                                         corporate and shareholder value and introducing us to potential investors. In December
                                         2017, since the maximum amount was raised in the prior private placement, we paid to
                                         Spartan a consulting fee of $1,400,000 for the services to be rendered over the sixty
                                         (60) month term of this consulting agreement. During the six months ended October 31,
                                         2019, we recorded an expense of $140,000 as a result of this consulting agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>During the
                                         six months ended October 31, 2019, we incurred $52,070 in legal fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>During the
                                         six months ended October 31, 2019, we incurred $47,396 in audit fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Six Months Ended October 31, 2018</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During
                                         the six months ended October 31, 2018, we recorded an expense of $140,000 as a result
                                         of the Spartan consulting agreement discussed above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>During the
                                         six months ended October 31, 2018, we incurred $41,916 in legal fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock Compensation Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October
31, 2019, we incurred $713,661 in general and administrative stock compensation expense related to stock option grants to executives,
employees and consultants. All option grants are granted at the per share fair value on the grant date. Vesting of options differs
based on the terms of each option. We valued the options at their date of grant utilizing the Black Scholes option pricing model.
Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our Common Stock from
authorized shares instead of settling such obligations with cash payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Salaries and Benefits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October
31, 2019, we incurred $188,697, in employee-related expenses. As of October 31, 2019, we had one full-time and two part-time employees.
We appointed Mr. Stephan Jackman as CEO as of November 30, 2018. As of December 15, 2018, we retained our current CFO, Kenneth
S. Cragun. On May 1, 2019 we hired Henry Nisser to be our General Counsel and Executive Vice President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and development expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Research and development expenses for the six months ending
October&nbsp;31, 2019 and 2018, were $399,916 and $2,757,776, respectively. As reflected in the table below, research and development
expenses primarily consisted of professional fees as well as licenses and fees.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">&nbsp;Licenses and fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">50,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,489,600</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,043</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,439</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,873</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Other research and development expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,737</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">&nbsp;Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">399,916</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,757,776</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Licenses and fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain initial license fees
and milestone payments required to be paid to the University of South Florida and the USF Research Foundation, for the licenses
of the Technologies, pursuant to the terms of the License Agreement with Sublicensing Terms (the &ldquo;License Agreement&rdquo;)
with the Licensor and a direct support organization of the University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement for AL002 requires
us to pay royalty payments of 4% on net sales of products developed from the licensed technology while the AL001 License Agreements
require us to pay combined royalty payments of four and one-half percent (4.5%) on net sales of products developed from the licensed
technology. We have already paid an initial license fee of $200,000 for AL002 and an initial license fee of $200,000 for AL001.
As an additional licensing fee for the license of AL002, the Licensor received 3,601,809 shares of Common Stock. As an additional
licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares Common Stock. Additionally, we
are required to pay milestone payments on the due dates to the Licensor for the license of the AL002 technology and for the AL001
technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October&nbsp;31,
2019, we incurred $50,000 in license fees related to achieving the milestone of conducting pre-IND discussions with the FDA regarding
AL001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">During the six months ended October&nbsp;31, 2018, we incurred
$2,489,600 in licenses and fees, $2,227,923 of which related to non-cash charges from the issuances of Common Stock to the Licensor.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Professional fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October&nbsp;31,
2019 and 2018, the Company reported professional fees of $234,043 and $264,439, respectively, which are principally comprised
of professional fees attributed to various types of scientific services, including FDA consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock Compensation Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October
31, 2019, we incurred $115,873 in research and development stock compensation expense related to stock option grants to executives,
employees and consultants. All option grants are granted at the per share fair value on the grant date. Vesting of options differs
based on the terms of each option. We valued the options at their date of grant utilizing the Black Scholes option pricing model.
Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our Common Stock from
authorized shares instead of settling such obligations with cash payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other income (expense), net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the six months ended October&nbsp;31, 2019 and 2018,
the Company reported interest income, related party of $8,893 and $83,767, respectively, relating to a promissory note from Avalanche.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Current and deferred income taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">As of October 31, 2019 and 2018, the Company had deferred
tax assets totaling $2,194,303 and $1,186,674, respectively. The ultimate realization of deferred tax assets is dependent upon
the existence, or generation, of taxable income in the periods when those temporary differences and net operating loss carryovers
are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in carryover years, projected
future taxable income, available tax planning strategies, and other factors in making this assessment. Based on available evidence,
management believes it is less likely than not that all of the deferred tax assets will be realized. Accordingly, the Company
has established a 100% valuation allowance. As a result of the full valuation allowance, the Company did not record an income
tax benefit during the six months ended October 31, 2019 and 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESULTS OF OPERATIONS FOR THE YEARS ENDED APRIL 30, 2019
AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The following table summarizes the results
of our operations for the years ended April 30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">&nbsp;Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,700,083</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">323,403</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,308,800</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">575,027</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt">&nbsp;Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,008,883</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">898,430</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,008,883</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(898,430</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OTHER INCOME (EXPENSE), NET</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Interest income - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,387</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,341</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,259</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Interest expense - debt discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,315</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Total other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,387</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,233</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,862,496</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(931,663</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.08</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;Basic and diluted weighted average common<BR>
&nbsp;shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,843,040</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">45,389,196</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzamend Neuro, Inc. was formed on February
26, 2016, to acquire and commercialize patented intellectual property and know-how to prevent, treat and cure the crippling and
deadly disease, Alzheimer&rsquo;s. We currently have only two product candidates, AL001 and AL002. These products are in the early
stage of development and will require extensive clinical study, review and evaluation, regulatory review and approval, significant
marketing efforts and substantial investment before they and any successors could provide us with any revenue. We did not generate
any revenues during the years ended April&nbsp;30, 2019 and 2018, and we do not anticipate that we will generate revenue for the
foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and administrative expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for
the years ending April&nbsp;30, 2019 and 2018, were $1,308,800 and $575,027, respectively. As reflected in the table below, general
and administrative expenses primarily consisted of the following expense categories: management services, professional fees, stock
compensation expense, salaries and benefits, and advertising and promotion. The remaining general and administrative expenses of
$85,360 and $55,298, respectively, primarily consisted of payments for consulting, transfer agent fees, travel, and other office
expenses, none of which is significant individually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">&nbsp;Management services</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">160,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">240,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">545,771</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,820</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,170</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Salary and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,460</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Advertising and promotion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,039</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,909</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Other general and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85,360</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">55,298</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">&nbsp;Total general and administrative expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,308,800</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">575,027</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Management services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April&nbsp;30, 2019, we had two full-time
and one part-time employee. We accepted the resignation of our previous President and CEO, Philip Mansour, effective on November
18, 2018, and appointed Mr. Stephan Jackman as CEO as of November 30, 2018. Mr. Jackman is a full-time executive with extensive
scientific and medical experience in developing immunotherapies and their commercialization to lead Alzamend&rsquo;s activities.
As of December 15, 2018, we accepted the resignation of our former CFO, William B. Horne and retained our current CFO, Kenneth
S. Cragun. Prior to hiring Mr. Jackman and Mr. Cragun, the services of our two officers and Executive Chairman were provided pursuant
to the terms of an MSA entered into with Avalanche, a related party, on May 1, 2016. Avalanche provided management, consulting
and financial services to us. Such services included advice and assistance concerning any and all aspects of operations, planning
and financing of Alzamend and conducting relations with accountants, attorney, financial advisors and other professionals. The
term of the MSA, as amended, was for the period May&nbsp;1, 2016 to December&nbsp;31, 2017, and was extended by written agreement.
We initially paid $40,000 per month for these services and, beginning February 2017, began paying $20,000 per month. During the
years ended April&nbsp;30, 2019 and 2018, we recognized $160,000 and $240,000, respectively, in management fees in connection with
this agreement. At April&nbsp;30, 2019 and April&nbsp;30, 2018, $75,000 and $3,000, respectively, was included within related party
payable on our balance sheet. The MSA expired as of December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Professional fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second largest component of our general
and administrative expenses is professional fees. During the years ended April&nbsp;30, 2019 and 2018, we reported professional
fees of $545,771 and $249,820, respectively, which are principally comprised of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Year Ended April 30, 2019</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In June 2017, we entered into a five year consulting agreement with Spartan pursuant to which Spartan
has agreed to provide consulting services with respect to general corporate matters, including, but not limited to, advice and
input with respect to raising capital, potential merger and acquisition transactions, identifying suitable personnel for management,
developing corporate structure and finance strategies, assisting us with strategic introductions, assisting management with enhancing
corporate and shareholder value and introducing us to potential investors. In December 2017, since the maximum amount was raised
in a prior private placement, we paid to Spartan a consulting fee of $1,400,000 for the services to be rendered over the sixty
(60) month term of this consulting agreement. During the year ended April&nbsp;30, 2019, we recorded an expense of $280,000 in
connection with this consulting agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the year ended April 30, 2019, we incurred $130,524 in legal fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the year ended April 30, 2019, we incurred $75,903 in audit fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Year Ended April 30, 2018</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the year ended April 30, 2018, we incurred $82,202 in audit fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During January 2017, we entered into consulting agreements with two consultants. Both consulting
agreements had a term of one year and provided for aggregate compensation of $50,000. The consulting services included assistance
in evaluating strategic opportunities, business advice and services related to sales, marketing, investor relation and other incidental
services on behalf of our company. During the year ended April&nbsp;30, 2018, we recorded an expense of $35,617 as a result of
these two consulting agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During the year ended April&nbsp;30, 2018, we recorded an expense of $93,333 in connection with
the Spartan consulting agreement referred to above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advertising and promotion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended April 30, 2019 and
2018, we incurred $25,039 and $29,909, respectively, in advertising and promotion related expenses. The majority of these expenditures
was related to direct advertising of our Offering Statement on Google and Facebook and the development of a web and social media
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and development expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">Research and development
expenses for the years ending April&nbsp;30, 2019 and 2018, were $3,700,083 and $323,403, respectively. As reflected in the table
below, research and development expenses primarily consisted of licenses and fees as well as professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">&nbsp;Licenses and fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,489,600</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">219,162</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,142,887</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,277</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Other research and development expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">67,596</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,964</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">&nbsp;Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,700,083</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">323,403</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Licenses and fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain initial license fees
and milestone payments required to be paid to the University and the USF Health Byrd Alzheimer&rsquo;s Institute, a multi-disciplinary
center at the University, for the licenses of the technologies, pursuant to the terms of the License Agreement with the Licensor
and a direct support organization of the University.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement for AL002 requires
us to pay royalty payments of 4% on net sales of products developed from the licensed technology while the License Agreement for
AL001 requires us to pay combined royalty payments of four and one-half percent (4.5%) on net sales of products developed from
the licensed technology. We have already paid an initial license fee of $200,000 for AL002 and an initial license fee of $200,000
for AL001. As an additional licensing fee for the license of AL002, the Licensor received 3,601,809 shares of Common Stock. As
an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,925 shares Common Stock. Additionally,
we are required to pay milestone payments on the due dates to the Licensor for the license of the AL002 technology and for the
AL001 technologies</P>


 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended April 30, 2019
and 2018, we incurred $2,227,923 and $218,417, respectively, in non-cash charges from issuances of Common Stock to the Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Professional fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second largest component of our research
and development expenses is professional fees. During the years ended April&nbsp;30, 2019 and 2018, we reported professional fees
of $1,142,887 and $101,277, respectively, which are principally comprised of professional fees incurred by us during the year ended
April&nbsp;30, 2018, are attributed to various types of scientific services, including FDA consulting services. The increase in
professional fees during the year ended April 30, 2019, relates primarily to fees incurred to conduct a preclinical toxicology
mice study and an evaluation of AL002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other (expense) income, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended April&nbsp;30, 2019,
we reported other income from related parties of $146,387.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended April&nbsp;30, 2018,
we reported other expense, net, of $33,233. Other expense includes interest expense of $30,259 and amortization of original issue
discounts on notes payable and notes payable, related parties of $10,315, partially offset by $7,341 of interest income, related
parties. At April 30, 2019 and 2018, we had no outstanding borrowings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Current and deferred income taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have made the decision to fully reserve
our net deferred tax assets. As a result of this decision, we did not record an income tax benefit during the year ended April&nbsp;30,
2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate realization of deferred tax
assets is dependent upon the existence, or generation, of taxable income in the periods when those temporary differences and net
operating loss carryovers are deductible. Management considers the scheduled reversal of deferred tax liabilities, taxes paid in
carryover years, projected future taxable income, available tax planning strategies, and other factors in making this assessment.
Based on available evidence, management believes it is less likely than not that all of the deferred tax assets will be realized.
Accordingly, we have established a 100% valuation allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Current Plan of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our plan of operations is currently
focused on the development of both our therapeutic candidates which are at different stages in development. We have begun the
process of finalizing the IND application for AL001 and expect to receive approval to begin a Phase 1 Clinical Trial with human
subjects in the third quarter 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we began a toxicological
preclinical study for AL002 with CRL in compliance with FDA requirements. Upon conclusion of this toxicological study, anticipated
to occur in the second quarter of 2020, we expect to begin the process of finalizing the IND application process and move quickly
forward to begin a Phase 1 Clinical Trial with human subjects during the latter half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engaged Emory University, located
in Atlanta, Georgia, to develop and plan the Phase 1 Clinical Trial protocols, processes and plan. Dr. Ihab Hajjar, Neurologist
at the Emory Clinic, has been selected to be the Lead Investigator for this set of clinical activities. We have also retained
a division of the international Swiss manufacturer, Lonza, to develop the manufacturing protocols, processes and procedures. Lonza
is the worldwide leader in producing immunological proprietary and contracted pharma solutions. We anticipate selecting Emory
University as the host for the Phase 1 Clinical Trial, which will be led by Dr. Hajjar at the Emory Clinic.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we adopted a Charter
for our Scientific Advisory Board (&ldquo;<B>SAB</B>&rdquo;) and have announced the appointment of two SAB members, Dr. Thomas
Wisniewski (Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment) and Dr. Eric McDade (Associate Director
of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)). The SAB members have clinical specializations, including
extensive experience with AD and other neurological diseases. We intend to rely on this advisory group of experts to help guide
our therapies through the related scientific and manufacturing initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of our current plan of
operations to completing our IND application and beginning the series of human clinical trials for each of our therapeutics requires
us to promptly raise significant additional capital. If we are successful in raising capital, we believe that we will have sufficient
cash resources to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our working capital requirements
depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining regulatory
approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive
and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations,
we will require additional financing to fund future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>FDA consulting and active project planning
management</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have retained TAMM Net, Inc., an experienced
and highly-regarded regulatory consultancy firm based in Georgia for project management; to lead, develop and manage our preclinical
and clinical efforts, extending from the current status of each product candidate through the exit or commercialization of the
technologies that we have licensed. We may retain an experienced Canadian Health and European Union consulting firm to commercialize
these same technologies for these geographic markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Funding new AD research and acquisition
of licenses to treat or cure AD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have committed to funding new research
projects from Dr. Cao and his medical team for up to the next three years or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We obtained two royalty-bearing, exclusive
worldwide licenses from the Licensor, originally called LisPro, now given the name of AL001 for regulatory and company confidentiality,
a cocrystal biologic therapy to mitigate extreme agitation and forestall further deterioration of memory as displayed by patients
with up to moderate AD effective as of July 2, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to acquiring and supporting
new research to treat or cure AD and reserve the right to evaluate and pursue each opportunity as it may arise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continually evaluate our plan of operations
discussed above to determine the manner in which we can most effectively utilize our limited cash resources. The timing of completion
of any aspect of our plan of operations is highly dependent upon the availability of cash to implement that aspect of the plan
and other factors beyond our control.&nbsp;There is no assurance that we will successfully obtain the required capital or revenues,
or, if obtained, that the amounts will be sufficient to fund our ongoing operations.&nbsp;The inability to secure additional capital
would have a material adverse effect on us, including the possibility that we would have to sell or forego a portion or all of
our assets or cease operations.&nbsp;If we discontinue our operations, we will not have sufficient funds to pay any amounts to
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we raise additional capital, if
our current and planned clinical trials for AL001 and AL002 in the United States do not demonstrate continuing progress toward
taking our product to market, our ability to raise additional capital in the future to fund our product development efforts would
likely be seriously impaired.&nbsp;The ability of a biotechnology company, such as Alzamend, to raise additional capital in the
marketplace to fund its continuing development operations, is conditioned upon moving the development of products toward regulatory
approval and commercialization.&nbsp;If in the future we are not able to demonstrate adequate progress in the development of our
product, we will not be able to raise the capital we need to continue our then current business operations and business activities,
and we will likely not have sufficient liquidity or cash resources to continue operating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our working capital requirements
depend upon numerous factors, including progress of our research and development programs, pre-clinical and clinical testing,
timing and cost of obtaining regulatory approvals, changes in levels of resources that we devote to the development of manufacturing
and marketing capabilities, competitive and technological advances, status of competitors, and our ability to establish collaborative
arrangements with other organizations, there can be no assurance that our current cash resources will be sufficient to fund our
operations beyond the next twelve months.&nbsp;At present, we have no committed external sources of capital, and do not expect
any significant product revenues for the foreseeable future.&nbsp;Thus, in the future we will require additional financing to
fund future operations.&nbsp;There can be no assurance, however, that we will be able to obtain funds on acceptable terms, if
at all.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LIQUIDITY AND CAPITAL RESOURCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements
have been prepared on the basis that the Company will continue as a going concern. As of October&nbsp;31, 2019, the Company had
cash of $165,617 and an accumulated deficit of $9,031,632. The Company has incurred recurring losses and reported losses for the
six months ended October&nbsp;31, 2019 totaled $1,656,999. In the past, the Company has financed its operations principally through
issuances of promissory notes and equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to
incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations
sufficient to fund its development and commercial operations. Based on our current business plan, we believe that our cash and
cash equivalents at October&nbsp;31, 2019, are not sufficient to meet our anticipated cash requirements during the twelve-month
period subsequent to the issuance of the financial statements included in this Offering Circular. Management believes that the
Company has access to capital resources through potential public or private issuance of debt or equity securities. However, the
Company cannot be certain that additional funding will be available on acceptable terms, or at all, in which case it may have
to significantly delay, scale back or discontinue the development and/or commercialization of its products. The Company may also
be required to (a) seek collaborators for its product at an earlier stage than otherwise would be desirable and on terms that
are less favorable than might otherwise be available; or (b) relinquish or otherwise dispose of rights to technology or its product
that the Company would otherwise seek to deploy or commercialize. These matters raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might become
necessary should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2019, we entered into
securities purchase agreements for the purchase of 157,346 shares of Common Stock for a total purchase price of $236,023, or $1.50
per share with 78,672 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The purchase
price of $236,023 was paid in cash. In May 2019, an additional 27,667 shares of Common Stock were sold under the same terms for
a total purchase price of $41,501.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, we entered into a securities
purchase agreement for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per
share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total
purchase price of $15,000,000 was in the form of a note receivable initially with a 12-month term from Ault Life Sciences Fund,
LLC, a related party. The term of the note receivable was extended to December 31, 2020. While this transaction did not provide
immediate liquidity, as the note receivable is paid, we expect this to be a source of future capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2018, Avalanche issued
a promissory note (the &ldquo;AVLP Note&rdquo;) to evidence our loan of up to $995,500 for a period ending on April 30, 2019,
subject to the terms and conditions stated in the AVLP Note. The AVLP Note accrues interest at 10% per annum and includes a 10%
original issue discount. During the year ended April 30, 2019, $105,000 was repaid. The balance outstanding on the AVLP Note as
of October 31, 2019, was $100,915.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Between June 25, 2019 and October 31, 2019, the Company
entered into subscription agreements for the purchase of 1,756,726 units at $1.50 for each unit purchased pursuant to its 2019
private offering (the &ldquo;Private Offering&rdquo;). Each unit consisted of one (1) share of Common Stock and one (1) warrant
to purchase one half (0.5) share of Common Stock. In aggregate, the 1,756,726 units represents 1,756,726 shares of Common Stock
and 878,363 warrants with an exercise price of $3.00 per share for an aggregate purchase price of $2,635,089, or $1.50 per share.
The Private Offering was conducted pursuant to the terms of a Confidential Private Placement Memorandum dated June 12, 2019 (the
&ldquo;2019 PPM&rdquo;). As of October 31, 2019, in conjunction with the 2019 PPM, the Company incurred $395,263 in placement
fees resulting in net proceeds to the Company of $2,239,826.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTRACTUAL OBLIGATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, the Company entered
into the License Agreement with the Licensor pursuant to which the Licensor granted the Company a royalty bearing, exclusive worldwide
license, limited to the field of Alzheimer&rsquo;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled
&ldquo;Amyloid Beta Peptides and Methods of Use&rdquo;, filed April&nbsp;7, 2009 and granted May 29, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">In addition to royalty payments of 4% on net sales of products
developed from the licensed technology, the Company was required to pay a license fee of $100,000 on June 25, 2016, and December
31, 2016. As an additional licensing fee, the Licensor was entitled to receive that number of shares of our Common Stock equal
to five percent (5%) of the sum of the total number of issued and outstanding shares plus any securities that are convertible
into or exercisable or exchangeable for shares of Common Stock, subject to adjustment for additional issuances until such time
as the Company has received a total of $5 million in cash in consideration for the Company&rsquo;s equity securities. The Company
issued 3,601,809 shares to the Licensor in full satisfaction of this additional licensing fee. Minimum royalties are $20,000 in
2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the agreement. Additionally, the Company
is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: left">&nbsp;Upon IND application filing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Upon IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND application filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">175,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosed in Phase I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;24 months from completion of first Phase I Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase II Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II Clinical Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;7 years from the effective date of the agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA BLA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of these milestones was met as of
the date of this Offering Circular. If we fail to meet a milestone by its specified date, the Licensor may terminate the License
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor was also granted a preemptive
right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains
the owner of any equity securities of the company. Further, if the Company issue equity securities at a price per share that is
less than the price paid by investors in a transaction for aggregate consideration of at least $5,000,000 (the &ldquo;Investment
Price&rdquo;), then the number of shares owned by Licensee shall be increased upon such issuance. The amount of the increase shall
be determined by multiplying the number of shares then owned by Licensor by a fraction; the numerator of which shall be equal
to the number of shares of Common Stock outstanding immediately after the issuance of additional shares of Common Stock, and the
denominator of which shall be equal to the sum of (i) the number of shares of Common Stock outstanding immediately prior to the
issuance of additional shares of Common Stock plus (ii) the number of shares of Common Stock which the aggregate consideration
for the total number of additional shares of Common Stock so issued would purchase at the Investment Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain license fees and
milestone payments required to be paid for the licensing of the AL001 technology, pursuant to the terms of the two Standard Exclusive
License Agreements with Sublicensing Terms, both dated June 21, 2018 (the &ldquo;AL001 License Agreements&rdquo;), with the Licensor
and the University. In addition, a royalty payment of 3% is required pursuant to License #18110 while License #18111 requires
a royalty payment of 1.5% on net sales of products developed from the licensed technology. For the two AL001 licenses, in the
aggregate, the Company paid initial license fees of $200,000. As an additional licensing fee, the Licensor received that number
of shares of Common Stock equal to three percent (3%) of the sum of the total number of issued and outstanding shares. The Company
issued 2,227,925 shares to the Licensor in full satisfaction of this additional licensing fee. Minimum royalties are $25,000 in
2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Additionally, the Company
is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;November 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Pre-IND meeting</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">65,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;6 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in a clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,250,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II clinical trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;8 years from the Effective Date of the Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzamend Neuro is a company focused on
the facilitation of bringing technologies to market which help with the treatment, prevention or cure of Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On May 1, 2016, we obtained a royalty-bearing,
exclusive worldwide license from the University of South Florida Research Foundation, Inc. (the &ldquo;<B>Licensor</B>&rdquo;),
to a mutant-peptide immunotherapy that is designed to be used both as a vaccine and prophylactic against Alzheimer&rsquo;s. This
treatment, known as AL002, has transitioned from early stage development to an extensive program of preclinical study and evaluation
with an anticipated completion date at the end of June 2020. AL002 will require extensive clinical evaluation, regulatory review
and approval, significant marketing efforts and substantial investment before it can provide us with any revenue. We plan to file
an Investigational New Drug Application (&ldquo;<B>IND</B>&rdquo;) with the United States Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;)
with respect to AL002 in the third quarter of 2020 and prepare to conduct a Phase 1 Clinical Trial in the latter half of 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On July 2, 2018, we obtained two royalty-bearing,
exclusive worldwide licenses from the Licensor to a therapy known as AL001 (formerly known as LiProSal) to mitigate extreme agitation
and forestall other deterioration as displayed by patients with up to moderate AD. AL001 is an ionic cocrystal of lithium and
has been shown to exhibit improved nonclinical pharmacokinetics compared to current FDA-approved lithium products; it is also
bioactive in many in vitro models of Alzheimer&rsquo;s. AL001 is expected to provide clinicians with a major improvement over
current lithium-based treatments and may also constitute a means of treating Alzheimer&rsquo;s and other neurodegenerative diseases.
Based on nonclinical data, AL001 co-crystal technology has the potential to improve the therapeutic index of lithium providing
a greater bioavailability to the site of action (brain) in comparison to more traditional lithium dosage forms. Lithium has been
marketed for over 35 years and human toxicology regarding lithium use has been well characterized, mitigating the potential regulatory
burden for safety data. We submitted a pre-IND briefing package to the FDA in July&nbsp;2019 that argued against any further preclinical
safety studies. . Per the FDA response letter, we believe the proposed test parameters for AL001 appears reasonable to support
a Phase 1 study, thereby allowing Alzamend to conduct human clinical trials. Post Phase III clinical trials and in order to obtain
approval to commercialize AL001 via a New Drug Application (&ldquo;<B>NDA</B>&rdquo;), Alzamend has been asked to provide a scientific
bridge to a listed drug to support the adequacy of the nonclinical program. Per the FDA, the adequacy of the nonclinical data
will be a matter of review. If the adequacy of the nonclinical data is not sufficient for the FDA, Alzamend will then be required
to conduct a clinical pharmacokinetics animal study (6-weeks study) of AL001 in order to be considered for FDA approval. We received
feedback from the FDA regarding the pre-IND briefing package and have begun the process of finalizing the IND application and,
while FDA approval is not guaranteed, we expect to receive approval to begin a Phase 1 Clinical Trial with human subjects in the
third quarter 2020. While the FDA has not given us any indication as to whether AL001 will receive Breakthrough Therapy designation
or be permitted to use the 505(b)(2) regulatory pathway, we believe that AL001 is an ideal candidate to receive both a Breakthrough
Therapy designation as well as a section 505(b)(2) regulatory pathway for new drug approvals, enhancing the speed and reducing
the regulatory burden of FDA review. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>AL001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patented solution that we have licensed
and will first move to commercialization is an ionic cocrystal of lithium for the treatment of Alzheimer&rsquo;s and a method of
preparation for other pharmaceutical and industrial purposes. Lithium salts have a long history of human consumption beginning
in the 1800&rsquo;s. In psychiatry, they have been used to treat mania and as a prophylactic for depression since the mid-20th
century. Today, lithium salts are used as a mood stabilizer for the treatment of bipolar disorder. Although the FDA has approved
no medications as safe and effective treatments for suicidality, lithium has proven to be the only drug that consistently reduces
suicidality in patients with neuropsychiatric disorders. Despite these effective medicinal uses, current FDA-approved lithium pharmaceutics
(lithium carbonate and lithium citrate) are limited by a narrow therapeutic window that requires regular blood monitoring of plasma
lithium levels and blood chemistry by a clinician to mitigate adverse events. Because conventional lithium salts (carbonate and
citrate) are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic
plasma concentrations. However, existing lithium drugs such as lithium chloride and lithium carbonate suffer from chronic toxicity,
poor physicochemical properties and poor brain bioavailability. Because lithium is so effective at reducing manic episodes in patients
with bipolar disorder, it is still used clinically despite its narrow therapeutic index. This has led researchers to begin to look
for alternatives to lithium with similar bioactivities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inventors from the University have
developed a new lithium cocrystal composition and method of preparation that allow for lower dosages to achieve therapeutic brain
levels of lithium for psychiatric disorders, broadening lithium&rsquo;s therapeutic index. The compound offers improved physiochemical
properties compared to existing forms of lithium, giving it the potential to be developed as an anti-suicidal drug or for use against
mood disorders. The formulation method may also be used for commercial/industrial applications such as green chemistry, engineering
low density porous materials, pesticides/herbicides, explosives/propellants, and electronic materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent evidence suggests that lithium may
be efficacious for both the treatment and prevention of Alzheimer&rsquo;s. Unlike traditional medications which only address a
single therapeutic target, lithium appears to be neuroprotective through several modes of action. For example, it exerts neuroprotective
effects, in part, by increasing a brain-derived neurotrophic factor leading to restoration of learning and memory. Another neuroprotective
mechanism of lithium is attenuation of the production of inflammatory cytokines like IL-6 and nitric oxide in activated microglia.
Moreover, results from recent clinical studies suggest that lithium treatment may reduce dementia development while preserving
cognitive function and reducing biomarkers associated with AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With this in mind, the team of inventors
from the University have specifically designed, synthesized and characterized the novel ionic cocrystal of lithium (known as AL001).
AL001 has been shown to exhibit improved nonclinical pharmacokinetics compared to current FDA-approved lithium products, it is
also bioactive in many in vitro models of Alzheimer&rsquo;s. AL001 is expected to provide clinicians with a major improvement over
current lithium-based treatments and may also constitute a means of treating Alzheimer&rsquo;s and other neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> A product can be designated as a Breakthrough
Therapy designation if it is intended to treat a serious condition
and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a
clinically significant endpoint(s). A drug that receives Breakthrough Therapy designation is eligible for fast track designation
features, intensive guidance on an efficient drug development program and FDA organizational commitment involving senior managers.
While the FDA has not given us any indication as to whether AL001 will receive Breakthrough Therapy designation or be permitted
to use the 505(b)(2) regulatory pathway, we believe that AL001 is an ideal candidate to receive both a Breakthrough Therapy designation
as well as a section 505(b)(2) regulatory pathway for new drug approvals, enhancing the speed and reducing the regulatory burden
of FDA review. The Section 505(b)(2) regulatory pathway provides manufacturers with an opportunity to acquire FDA approval without
performing all the work that&rsquo;s required with an NDA. Those drugs that qualify for the 505(b)(2) regulatory pathway are an
option for drugs with a new aspect related to indication, dosage form or regimen, strength, combination with other products, or
other unique traits. If we receive approval through the 505 (b)(2) regulatory pathway AL001 is eligible for 3-5 years of market
exclusivity during which period AL001 would be protected from competitors. If we successfully acquire a Breakthrough Therapy designation
and the Section 505(b)(2) regulatory pathway for new drug approvals, we believe we can receive FDA approval for AL001 in four
years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL001 will require extensive clinical evaluation,
regulatory review and approval, significant marketing efforts and substantial investment before it or any successors could provide
us with any revenue. As a result, if we do not successfully develop, achieve regulatory approval for and commercialize AL001, our
long-term business plans will not be met, and we may be unable to generate the revenue we have forecast for many years, if at all.
We do not anticipate that we will generate our maximum revenue for several years, or that we will achieve profitability for this
therapeutic at least a few years after generating material revenue, if at all. If we are unable to generate revenue, we may not
be able to pursue any expansion of our business or acquire additional intellectual property as we have planned, we will not become
profitable with this therapeutic agent, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AL002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The other patented solution that we have
licensed to move to commercialization is AL002, a mutant-peptide immunotherapy that is designed to be used both as a vaccine and
prophylactic against Alzheimer&rsquo;s. This therapy is intended to work by stimulating the body&rsquo;s own immune system to prevent
the formation and breakdown of beta amyloids, which build up in the brain to form a &ldquo;plaque,&rdquo; and subsequently block
the neurological brain signals, ultimately leading to the symptoms and onset of Alzheimer&rsquo;s. Immunotherapy is the treatment
of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies that are designed to elicit or amplify an
immune response are classified as activation immunotherapies, whereas immunotherapies that reduce or suppress are classified as
suppression immunotherapies. We believe that strategies to strengthen the immune system in the elderly, who are most susceptible
to the development of Alzheimer&rsquo;s, could greatly enhance the effectiveness of immune-based approaches against Alzheimer&rsquo;s.
Our novel immune-based methodology attempts to inhibit the natural process of immunological aging by restoring the balance of the
immune system through immunomodulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beta amyloid protein has been directly
linked to Alzheimer&rsquo;s and the associated neurofibrillary tangles formation seen in Alzheimer&rsquo;s patients. Specifically,
increased levels of extracellular plaques in the brain composed of amyloid beta peptide 1-42 are seen in Alzheimer&rsquo;s patients
when compared to healthy people. In a healthy brain, protein fragments such as amyloid beta peptide 1-42 are broken down and eliminated.
However, in Alzheimer&rsquo;s, the fragments accumulate to form hard, insoluble plaques. Attempts have been made to help inhibit
plaque formation by reducing the amount of amyloid beta peptide 1-42 through vaccines that generate an immune response to the protein.
The challenge has been that though effective in reducing the amount of the protein, the inflammatory response has been such that
the intended benefits are not seen. These vaccines have used an adjuvant, or helper, to generate the necessary immune response
and it is believed that this adjuvant triggers the unwanted surplus inflammation. We have licensed rights to a vaccine using autologous
cells that does not require an adjuvant and therefore, we believe will trigger the immune response, which should help eliminate
the amyloid beta peptide 1-42 without generating the excess inflammation and therefore, have a positive clinical effect. We believe
that the vaccine, in addition to dealing with plaque formation, also ameliorates the impaired immune system that is thought to
be the major issue in Alzheimer&rsquo;s patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our data have demonstrated that these mutant-peptide
sensitized dendritic cells (&ldquo;<B>DC</B>&rdquo;) can act as a vaccine to generate a durable antibody response, as well as enhance
the number of CD8+ T-cells and increase the lifespan of CD8+ cells (T and DCs cells), compared to control subjects. These studies
will provide a further rationale and impetus for using this novel vaccine to determine potential efficacy in human clinical trials
against Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL002 has been researched for more
than ten (10) years and we are currently in the midst of completing its preclinical development and have begun both the pre-IND
and IND application process to the FDA, which is managed by TAMM Net, Inc., an experienced and highly-regarded regulatory consultancy
firm. In November 2018, we began a toxicological preclinical study for AL002 with CRL in compliance with FDA requirements. Upon
conclusion of this toxicological study, anticipated to occur in the second quarter of 2020, we expect to begin the process of
finalizing the IND application process and move quickly forward to begin a Phase 1 Clinical Trial with human subjects. AL002 will
require extensive clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment
before it and any successors could provide us with any revenue. As a result, if we do not successfully develop, achieve regulatory
approval for and commercialize AL002, our long-term business plans will not be met, and we may be unable to generate the revenue
we have forecast for AL002 for many years, if at all. We do not anticipate that we will generate our maximum revenue for several
years, or that we will achieve profitability for this therapeutic at least a few years after generating material revenue, if at
all. If we are unable to generate revenue, we may not be able to pursue any expansion of our business or acquire additional intellectual
property as we have planned, we will not become profitable with this therapeutic agent, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Market</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, Alzheimer&rsquo;s is the 6<SUP>th</SUP>
leading cause of death in the U.S. and when extrapolated globally, the market for preventions, treatments, and cures of this crippling
disease is massive. The Alzheimer&rsquo;s Association estimates that the cost of caring for people with Alzheimer&rsquo;s and other
dementias will reach $290 billion in 2019 and that by 2050, these costs may rise as high as $1.1 trillion. Since 1990, life expectancy
has increased by 6 years and the worldwide average continues to increase. With the increase in the mean age of the population in
developed countries, the prevalence of deteriorating neurological diseases has also increased. According to the Alzheimer&rsquo;s
Association, in the United States alone, 1 in 10 persons over the age of 65 have Alzheimer&rsquo;s, with more than 5.8 million
Americans living with it. It is estimated that this number will increase to more than 14 million by 2050 if a cure is not found.
Many Alzheimer&rsquo;s related associations believe the actual number of adults with AD may be as much as 5 times more or 30 million
since current statistics do not take into account deaths from complications or from related diseases like pneumonia or heart attack.
These death certificates only list the most immediate cause. The fastest growing age group in the United States is the &ldquo;over
85&rdquo; group within which 1 in 3 individuals have Alzheimer&rsquo;s. Women are 2&frac12; times more likely to die from Alzheimer&rsquo;s
than from cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rate of deaths related to Alzheimer&rsquo;s
increased by 54.5 percent over 15 years, according to a report issued on May 27, 2017, by the U.S. Centers for Disease Control
and Prevention. There were 93,541 deaths related to Alzheimer&rsquo;s in 2014, a rate of 25.4 deaths per 100,000 people, up from
44,536 deaths in 1999, a rate of 16.5 deaths per 100,000 people, according to the report. The disease currently affects an estimated
5.8 million people in the U.S., but that number is expected to rise dramatically in people over the age of 65 to 14 million in
2050. The researchers examined death certificate data from the National Vital Statistics System to reach their findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Every 65 seconds, someone in the United
States develops AD. Of the 10 most fatal diseases in the United States, Alzheimer&rsquo;s is the only one with no cure, no known
way of deceleration and no known means of prevention.&nbsp;Alzamend was formed to commercialize patented intellectual property
in this space, by funding it from its present state through human clinical trials administered by the FDA and ultimately, if successful,
potentially make it available to the global market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Business Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our plan of operations is currently
focused on the development of both our therapeutic candidates, which are at different stages in development. We have begun the
process of finalizing the IND application for AL001 and expect to receive approval to begin a Phase 1 Clinical Trial with human
subjects in the third quarter 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we began a toxicological
preclinical study for AL002 with CRL in compliance with FDA requirements. Upon conclusion of this toxicological study, anticipated
to occur in the second quarter of 2020, we expect to begin the process of finalizing the IND application process and move quickly
forward to begin a Phase 1 Clinical Trial with human subjects during the latter half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We engaged Emory University, located
in Atlanta, Georgia, to develop and plan the Phase 1 Clinical Trial protocols, processes and plan. Dr. Ihab Hajjar, Neurologist
at the Emory Clinic, has been selected to be the Lead Investigator for this set of clinical activities. We have also retained
a division of the international Swiss manufacturer, Lonza, to develop the manufacturing protocols, processes and procedures. Lonza
is the worldwide leader in producing immunological proprietary and contracted pharma solutions. We anticipate selecting Emory
University as the host for the Phase 1 Clinical Trial, which will be led by Dr. Hajjar at the Emory Clinic.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, we adopted a Charter
for our Scientific Advisory Board (&ldquo;<B>SAB</B>&rdquo;) and have announced the appointment of two SAB members, Dr. Thomas
Wisniewski (Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment) and Dr. Eric McDade (Associate Director
of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)). The SAB members have clinical specializations, including
extensive experience with AD and other neurological diseases. We intend to rely on these experts to help guide our therapies through
the related scientific and manufacturing initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuation of our current plan of
operations to completing our IND application and beginning the series of human clinical trials for each of our therapeutics requires
us to promptly raise significant additional capital. If we are successful in raising capital, we believe that we will have sufficient
cash resources to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our working capital requirements
depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining regulatory
approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive
and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations,
we will require additional financing to fund future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>FDA consulting and active project planning
management</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have retained TAMM Net, Inc., an experienced
and highly-regarded regulatory consultancy firm based in Georgia for project management. In this capacity, TAMM Net will lead,
develop and manage our preclinical and clinical efforts, extending from the current status of each product candidate through the
exit or commercialization of the technologies that we have licensed. We may retain an experienced Canadian and European Union consulting
firm to commercialize these same technologies for these geographic markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Funding new AD research and acquisition
of licenses to treat or cure AD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have committed to funding new research
projects from Dr. Chuanhai Cao, the neuroscientist who developed AL002, and his medical team for up to the next three years or
more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We obtained two royalty-bearing, exclusive
worldwide licenses from the Licensor, originally called LisPro, now given the name of AL001 for regulatory and company confidentiality,
a cocrystal biologic therapy intended to mitigate extreme agitation and forestall further deterioration of memory as displayed
by patients with up to moderate AD effective as of July 2, 2018.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dedicated to acquiring and supporting
new research to treat or cure AD and intend to evaluate and pursue each opportunity as it may arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Our Product Candidates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AL001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patented solution that we have licensed
and will first move to commercialization is an ionic cocrystal of lithium for the treatment of Alzheimer&rsquo;s and a method of
preparation for other pharmaceutical and industrial purposes. Lithium salts have a long history of human consumption beginning
in the 1800&rsquo;s. In psychiatry, they have been used to treat mania and as a prophylactic for depression since the mid-20th
century. Today, lithium salts are used as a mood stabilizer for the treatment of bipolar disorder. Although the FDA has approved
no medications as safe and effective treatments for suicidality, lithium has proven to be the only drug that consistently reduces
suicidality in patients with neuropsychiatric disorders. Despite these effective medicinal uses, current FDA-approved lithium pharmaceutics
(lithium carbonate and lithium citrate) are limited by a narrow therapeutic window that requires regular blood monitoring of plasma
lithium levels and blood chemistry by a clinician to mitigate adverse events. Because conventional lithium salts (carbonate and
citrate) are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic
plasma concentrations. However, existing lithium drugs such as lithium chloride and lithium carbonate suffer from chronic toxicity,
poor physicochemical properties and poor brain bioavailability. Because lithium is so effective at reducing manic episodes in patients
with bipolar disorder, it is still used clinically despite its narrow therapeutic index. This has led researchers to begin to look
for alternatives to lithium with similar bioactivities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inventors from the University have
developed a new lithium cocrystal composition and method of preparation that allow for lower dosages to achieve therapeutic brain
levels of lithium for psychiatric disorders, broadening lithium&rsquo;s therapeutic index. The compound offers improved physiochemical
properties compared to existing forms of lithium, giving it the potential to be developed as an anti-suicidal drug or for use against
mood disorders. The formulation method may also be used for commercial/industrial applications such as green chemistry, engineering
low density porous materials, pesticides/herbicides, explosives/propellants, and electronic materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent evidence suggests that lithium may
be efficacious for both the treatment and prevention of Alzheimer&rsquo;s. Unlike traditional medications which only address a
single therapeutic target, lithium appears to be neuroprotective through several modes of action. For example, it exerts neuroprotective
effects, in part, by increasing a brain-derived neurotrophic factor leading to restoration of learning and memory. Another neuroprotective
mechanism of lithium is attenuation of the production of inflammatory cytokines like IL-6 and nitric oxide in activated microglia.
Moreover, recent clinical studies suggest that lithium treatment may reduce dementia development while preserving cognitive function
and reducing biomarkers associated with AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> With this in mind, the team of inventors
from the University have specifically designed, synthesized and characterized the novel ionic cocrystal of lithium (known as AL001).
AL001 has been shown to exhibit improved nonclinical pharmacokinetics compared to current FDA-approved lithium products, it is
also bioactive in many in vitro models of Alzheimer&rsquo;s. AL001 is expected to provide clinicians with a major improvement
over current lithium-based treatments and may also constitute a means of treating Alzheimer&rsquo;s and other neurodegenerative
diseases. Based on nonclinical data, AL001 co-crystal technology has the potential to improve the therapeutic index of lithium
providing a greater bioavailability to the site of action (brain) in comparison to more traditional lithium dosage forms. Lithium
has been marketed for over 35 years and human toxicology regarding lithium use has been well characterized, mitigating the potential
regulatory burden for safety data We submitted a pre-IND briefing package to the FDA in July&nbsp;2019 that argued against any
further preclinical safety studies. . Per the FDA response letter, we believe the proposed test parameters for AL001 appears reasonable
to support a Phase 1 study, thereby allowing Alzamend to conduct human clinical trials. Post Phase III clinical trials and in
order to obtain approval to commercialize AL001 via a New Drug Application (&ldquo;<B>NDA</B>&rdquo;), Alzamend has been asked
to provide a scientific bridge to a listed drug to support the adequacy of the nonclinical program. Per the FDA, the adequacy
of the nonclinical data will be a matter of review. If the adequacy of the nonclinical data is not sufficient for the FDA, Alzamend
will then be required to conduct a clinical pharmacokinetics animal study (6-weeks study) of AL001 in order to be considered for
FDA approval. We received feedback from the FDA regarding the pre-IND briefing package and have begun the process of finalizing
the IND application and, while FDA approval is not guaranteed, we expect to receive approval to begin a Phase 1 Clinical Trial
with human subjects in the third quarter 2020. While the FDA has not given us any indication as to whether AL001 will receive
Breakthrough Therapy designation or be permitted to use the 505(b)(2) regulatory pathway, we believe that AL001 is an ideal candidate
to receive both a Breakthrough Therapy designation as well as a section 505(b)(2) regulatory pathway for new drug approvals, enhancing
the speed and reducing the regulatory burden of FDA review. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A product can be designated as a Breakthrough
Therapy designation <FONT STYLE="color: #3D5567">if it is </FONT><FONT STYLE="color: #333333">intended to treat a serious condition
and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a
clinically significant endpoint(s). </FONT>A drug that receives Breakthrough Therapy designation is eligible for fast track designation
features, intensive guidance on an efficient drug development program and FDA organizational commitment involving senior managers.
We further believe that AL001 is ideally situated for Section 505(b)(2) regulatory pathway for new drug approvals. The Section
505(b)(2) regulatory pathway provides manufacturers with an opportunity to acquire FDA approval without performing all the work
that&rsquo;s required with an NDA. Those drugs that qualify for the 505(b)(2) regulatory pathway are an option for drugs with
a new aspect related to indication, dosage form or regimen, strength, combination with other products, or other unique traits.
If we receive approval through the 505 (b)(2) regulatory pathway AL001 is eligible for 3-5 years of market exclusivity during
which period AL001 would be protected from competitors. If we successfully acquire a Breakthrough Therapy designation and the
Section 505(b)(2) regulatory pathway for new drug approvals, we believe we can receive FDA approval for AL001 in four years.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL001 will require extensive clinical evaluation,
regulatory review and approval, significant marketing efforts and substantial investment before it or any successors could provide
us with any revenue. As a result, if we do not successfully develop, achieve regulatory approval for and commercialize AL001, our
long-term business plans will not be met, and we may be unable to generate the revenue we have forecast for many years, if at all.
We do not anticipate that we will generate our maximum revenue for several years, or that we will achieve profitability for this
therapeutic at least a few years after generating material revenue, if at all. If we are unable to generate revenue, we may not
be able to pursue any expansion of our business or acquire additional intellectual property as we have planned, we will not become
profitable with this therapeutic agent, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>AL002</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The other patented solution that we have
licensed to move to commercialization is AL002, a mutant-peptide immunotherapy that is designed to be used both as a vaccine and
prophylactic against Alzheimer&rsquo;s. This therapy is intended to work by stimulating the body&rsquo;s own immune system to prevent
the formation and breakdown of beta amyloids, which build up in the brain to form a &ldquo;plaque,&rdquo; and subsequently block
the neurological brain signals, ultimately leading to the symptoms and onset of Alzheimer&rsquo;s. Immunotherapy is the treatment
of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies that are designed to elicit or amplify an
immune response are classified as activation immunotherapies, whereas immunotherapies that reduce or suppress are classified as
suppression immunotherapies. We believe that strategies to strengthen the immune system in the elderly, who are most susceptible
to the development of Alzheimer&rsquo;s, could greatly enhance the effectiveness of immune-based approaches against Alzheimer&rsquo;s.
Our novel immune-based methodology attempts to inhibit the natural process of immunological aging by restoring the balance of the
immune system through immunomodulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beta amyloid protein has been directly
linked to Alzheimer&rsquo;s and the associated neurofibrillary tangles formation seen in Alzheimer&rsquo;s patients. Specifically,
increased levels of extracellular plaques in the brain composed of amyloid beta peptide 1-42 are seen in Alzheimer&rsquo;s patients
when compared to healthy people. In a healthy brain, protein fragments such as amyloid beta peptide 1-42 are broken down and eliminated.
However, in Alzheimer&rsquo;s, the fragments accumulate to form hard, insoluble plaques. Attempts have been made to help inhibit
plaque formation by reducing the amount of amyloid beta peptide 1-42 through vaccines that generate an immune response to the protein.
The challenge has been that though effective in reducing the amount of the protein, the inflammatory response has been such that
the intended benefits are not seen. These vaccines have used an adjuvant, or helper, to generate the necessary immune response
and it is believed that this adjuvant triggers the unwanted surplus inflammation. We have licensed rights to a vaccine using autologous
cells that does not require an adjuvant and therefore, we believe will trigger the immune response, which should help eliminate
the amyloid beta peptide 1-42 without generating the excess inflammation and therefore, have a positive clinical effect. We believe
that the vaccine, in addition to dealing with plaque formation, also ameliorates the impaired immune system that is thought to
be the major issue in Alzheimer&rsquo;s patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our data have demonstrated that these mutant-peptide
sensitized dendritic cells (&ldquo;<B>DC</B>&rdquo;) can act as a vaccine to generate a durable antibody response, as well as enhance
the number of CD8+ T-cells and increase the lifespan of CD8+ cells (T and DCs cells), compared to control subjects. These studies
will provide a further rationale and impetus for using this novel vaccine to determine potential efficacy in human clinical trials
against Alzheimer&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AL002 has been researched for more
than ten (10) years and we are currently in the midst of completing its preclinical development and have begun both the pre-IND
and IND application process to the FDA, which is managed by TAMM Net, Inc., an experienced and highly-regarded regulatory consultancy
firm. In November 2018, we began a toxicological preclinical study for AL002 with CRL in compliance with FDA requirements. Upon
conclusion of this toxicological study, anticipated to occur in the second quarter of 2020, we expect to begin the process of
finalizing the IND application process and move quickly forward to begin a Phase 1 Clinical Trial with human subjects. AL002 will
require extensive clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment
before it and any successors could provide us with any revenue. As a result, if we do not successfully develop, achieve regulatory
approval for and commercialize AL002, our long-term business plans will not be met, and we may be unable to generate the revenue
we have forecast for AL002 for many years, if at all. We do not anticipate that we will generate our maximum revenue for several
years, or that we will achieve profitability for this therapeutic at least a few years after generating material revenue, if at
all. If we are unable to generate revenue, we may not be able to pursue any expansion of our business or acquire additional intellectual
property as we have planned, we will not become profitable with this therapeutic agent, and we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Science</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #47106B">
    <TD STYLE="width: 12%; border-top: white 1pt solid; border-left: black 1pt solid; border-bottom: black 1pt solid; border-right: white 1pt solid; font-size: 10pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: White"><B>Therapeutic</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: White"><B>Drug</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: White"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="width: 33%; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="color: white"><B>Synopsis</B></FONT></TD>
    <TD STYLE="width: 35%; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="color: white"><B>Strength</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: white 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="color: white"><B>Status</B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt">&nbsp;<B>AL001</B></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Use of patented Ionic Cocrystal (ICC) technology delivering a therapeutic combination of Lithium, Proline, and Salicylate</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Lithium as a treatment of agitation and other possible symptoms in patients with indication of Alzheimer&rsquo;s disease</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Other potential indications: Dementia, Parkinson&rsquo;s Disease, ALS, Depression, Bi-Polar Disorder, Mania, Post Traumatic
        Stress Disorder (PTSD), Suicidality, etc.</P></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Exclusive license for Cocrystal delivery system for AD and psychiatric indications</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Eligible for &ldquo;breakthrough therapy&rdquo; designation from FDA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Seeking a 505(b)(2) clinical trial pathway from FDA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Formulation may importantly expand the range of therapeutic categories amenable to lithium treatments, with enhanced safety</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Has the potential of becoming the replacement for all lithium therapy on the market</P></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Filed Pre-IND in Q3, 2019</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"> <FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Filing IND in Q3, 2020 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"> <FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Commencing Phase 1 human clinical trials in Q3, 2020 </P></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><B>&nbsp;AL002</B></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque
        and seeks to restore the ability of the patient&rsquo;s immunological system to combat Alzheimer&rsquo;s disease.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Also seeks to mitigate adverse reactions from a patient&rsquo;s immunological system experienced during pre-clinical trials
        including the highly publicized Elan study (AN-1972)</P></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Adjuvant-free therapeutic vaccine designed for the treatment and prophylactics of AD</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Difficult to manufacture and hence not easily replicated by competitors</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Eligible for &ldquo;breakthrough therapy&rdquo; status via FDA</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Antibody responses induced after one inoculation (Pre-Clinical) and lasted for 4 months</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Inflammation cytokines like IL1 and TNF.alpha, which are considered being related to inflammation didn't increase with antibody
        level increase</P></TD>
    <TD STYLE="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Completing pre-clinical studies Q4, 2019</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Filing IND in Q2, 2020</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
        </FONT>&nbsp;&nbsp;&nbsp;Commencing Phase 1 human clinical trials in Q3, 2020</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Alzheimer&rsquo;s Association estimates
that the cost of caring for people with Alzheimer&rsquo;s will reach $290 billion dollars in 2019 and by 2050, these costs may
rise as high as $1.1 trillion. Currently, Alzheimer&rsquo;s is the 6<SUP>th</SUP> leading cause of death in the U.S. and when extrapolated
globally, the market for preventions, treatments, and cures of this crippling disease is massive. Alzamend Neuro was formed to
develop and commercialize patented intellectual property/treatments for Alzheimer&rsquo;s, by funding it from pre-clinical through
FDA Clinical Trials and ultimately, if successful, make it available to the global market. Additionally, we are supporting ongoing
research at the USF Health College of Medicine and plan to support others with first rights of refusal on technologies for treating
terminal diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In an article jointly issued on April 8,
2016, Allergan and Heptares cited currently significant unmet medical needs and a heavy economic burden caused by cognitive impairment
and dementia across multiple diseases, noting that currently available drugs for treating Alzheimer&rsquo;s provide limited and
transient effects on cognition. They cited projections of healthcare costs, including nursing home care, associated with Alzheimer&rsquo;s
and dementia (currently estimated to be in excess of $640 billion for North America, Western Europe, and Asia-Pacific), that are
continuing to grow based on data from the World Health Organization, Alzheimer&rsquo;s International, the National Institute of
Mental Health, and the Lewy Body Dementia Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This medical shortfall puts a spotlight
on an urgent need for development of new therapies capable of treating the estimated more than 45 million people worldwide suffering
from Alzheimer&rsquo;s today - 5.8 million in North America, 7.5 million in Western Europe, and 3.6 million in Asia-Pacific - a
number expected to increase to more than 130 million by 2050. Alzheimer&rsquo;s is the most common cause of dementia, estimated
to be associated with some 60 to 70 percent of cases. An additional estimated 1.4 million patients in the U.S. suffer from Lewy
body dementia. The potential marketplace for a commercialized therapy or treatment would be tremendously significant with large
financial support available from numerous national and international pharmaceutical companies and various governments and worldwide
agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These statistics were recently affirmed
domestically in an article regarding the death rate and pervasiveness of Alzheimer&rsquo;s. The rate of deaths related to Alzheimer&rsquo;s
jumped by 54.5 percent over 15 years, according to a report issued on May 27, 2017 from the U.S. Centers for Disease Control and
Prevention. There were 93,541 deaths related to Alzheimer&rsquo;s in 2014, a rate of 25.4 deaths per 100,000 people, up from 44,536
deaths in 1999, a rate of 16.5 deaths per 100,000 people, according to the report. The disease currently affects an estimated 5.8
million people in the U.S., but that number is expected to rise dramatically in people over the age of 65 to 14 million in 2050.
The researchers examined death certificate data from the National Vital Statistics System to reach their findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any in-house manufacturing
capabilities. We intend to outsource the manufacturing of our products to third party contractors, with special capabilities to
manufacture chemical drugs and biologic drug candidates for submission and clinical testing under FDA guidelines. We believe there
are several sources of manufacturing available once a therapy or treatment can achieve Phase 2 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For AL001 and AL002 we have selected the
worldwide leader and authority in the manufacturing of immunological peptides, Lonza, which is a Swiss multinational, chemicals
and biotechnology company, headquartered in Basel, Switzerland, with major facilities in Europe, North America and South Asia.
Lonza was established in the late 19th-century in Switzerland. Lonza provides product development services to the pharmaceutical
and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical
synthesis capabilities, detection systems and services for the bioscience sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Distribution &amp; Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to develop AL001 and AL002 through
successive de-risking milestones towards regulatory approval and seek marketing approval of AL001 and AL002, or effect partnering
transactions with biopharmaceutical companies seeking to strategically fortify pipelines and fund the costly later-stage clinical
development required to achieve successful commercialization. We do not anticipate selling products directly into the marketplace,
although we may do so depending on market conditions. Our focus is to strategically effect partnering transactions which will provide
distribution and marketing capabilities to sell products into the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials, the pharmaceutical approval
process, and the marketing of pharmaceutical products, are intensively regulated in the U.S. and in all major foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Human Health Product Regulation in the
U.S.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., the FDA regulates pharmaceuticals
under the Federal Food, Drug, and Cosmetic Act and related regulations. Pharmaceuticals are also subject to other federal, state,
and local statutes and regulations. Failure to comply with applicable U.S. regulatory requirements at any time during the product
development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These
sanctions could include the imposition by the FDA of an Institutional Review Board (&ldquo;<B>IRB</B>&rdquo;), a clinical hold
on trials, a refusal to approve pending applications, withdrawal of an approval, warning letters, product recalls, product seizures,
total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency
or judicial enforcement action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and comparable regulatory agencies
in state and local jurisdictions impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical
products. These agencies and other federal, state and local entities regulate research and development activities and the testing,
manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising and
promotion of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA&rsquo;s policies may change, and
additional government regulations may be enacted that could prevent or delay regulatory approval of new disease indications or
label changes. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future
legislative or administrative action, either in the U.S. or elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Marketing Approval</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process required by the FDA before
human health care pharmaceuticals may be marketed in the U.S. generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">nonclinical laboratory and, at times, animal tests;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">adequate and well-controlled human clinical trials to establish the safety and efficacy of the
proposed drug for its intended use or uses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">pre-approval inspection of manufacturing facilities and clinical trial sites; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">FDA approval of a Biologics License Application (&ldquo;<B>BLA</B>&rdquo;), which must occur before
a drug can be marketed or sold.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need to successfully complete extensive
clinical trials in order to be in a position to submit a BLA or NDA to the FDA. We must reach agreement with the FDA on the proposed
protocols for our future clinical trials in the U.S. A separate submission to the FDA must be made for each successive clinical
trial to be conducted during product development. Further, an independent IRB for each site proposing to conduct the clinical trial
must review and approve the plan for any clinical trial before it commences at that site, and an informed consent must also be
obtained from each study subject. Regulatory authorities, a data safety monitoring board or the sponsor, may suspend or terminate
a clinical trial at any time on numerous grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of BLA or NDA approval for
human health products, human clinical trials are typically conducted in phases that may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">Phase I. The drug is initially introduced into healthy human subjects and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases,
especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing
is often conducted in patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">Phase II. This phase involves trials in a limited subject population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine
dosage tolerance and optimal dosage. Phase II studies may be sub-categorized to Phase IIa studies which are smaller, pilot studies
to evaluate limited drug exposure and efficacy signals, and Phase IIb studies which are larger studies testing both safety and
efficacy more rigorously.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">&bull;</TD><TD STYLE="text-align: justify">Phase III. This phase involves trials undertaken to further evaluate dosage, clinical efficacy
and safety in an expanded subject population, often at geographically dispersed clinical trial sites. These trials are intended
to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of these trials must be conducted in
accordance with Good Clinical Practice (&ldquo;<B>GCP</B>&rdquo;) requirements in order for the data to be considered reliable
for regulatory purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>New Drug and Biologics License Applications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to obtain approval to market a
pharmaceutical in the U.S., a marketing application must be submitted to the FDA that provides data establishing to the FDA&rsquo;s
satisfaction the safety and effectiveness of the investigational drug for the proposed indication. Each NDA or BLA submission requires
a substantial user fee payment unless a waiver or exemption applies (such as with the Orphan Drug Designation discussed below).
The NDA or BLA submission fee currently exceeds $1,958,000, and the manufacturer and/or sponsor under an approved NDA or BLA are
also subject to annual product and establishment user fees, currently exceeding $98,000 per product and $526,000 per establishment.
These fees are typically increased annually. The NDA or BLA includes all relevant data available from pertinent non-clinical studies
and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating
to the product&rsquo;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored
clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including
studies initiated by investigators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA will initially review the NDA or
BLA for completeness before it accepts it for filing. The FDA has 60 days from its receipt of an NDA or BLA to determine whether
the application will be accepted for filing based on the agency&rsquo;s threshold determination that the application is sufficiently
complete to permit substantive review. After the NDA or BLA submission is accepted for filing, the FDA reviews the NDA or BLA to
determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product
is being manufactured in accordance with current Good Manufacturing Practices (&ldquo;<B>cGMP</B>&rdquo;) to assure and preserve
the product&rsquo;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products
that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and
other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on pivotal Phase III trial results
submitted in an NDA or BLA, upon the request of an applicant, the FDA may grant a Priority Review designation to a product, which
sets the target date for FDA action on the application at six to eight months, rather than the standard ten to twelve months. The
FDA can extend these reviews by three months. Priority Review is given where preliminary estimates indicate that a product, if
approved, has the potential to provide a significant improvement compared to marketed products or offers a therapy where no satisfactory
alternative therapy exists. Priority Review designation does not change the scientific/medical standard for approval or the quality
of evidence necessary to support approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the FDA completes its initial review
of an NDA or BLA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response
letter to communicate that the NDA or BLA will not be approved in its current form and inform the sponsor of changes that must
be made or additional clinical, nonclinical or manufacturing data that must be received before the application can be approved,
with no implication regarding the ultimate approvability of the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA or BLA, the FDA
will inspect the facilities at which the product is manufactured, even if such facilities are located overseas. The FDA will not
approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, before approving an NDA or
BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that any of the application,
manufacturing process or manufacturing facilities is not acceptable, it typically will outline the deficiencies and often will
request additional testing or information. This may significantly delay further review of the application. If the FDA finds that
a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine that the data generated by the
clinical site should be excluded from the primary efficacy analyses provided in the NDA or BLA. Additionally, notwithstanding the
submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The testing and approval process for a
drug requires substantial time, effort and financial resources, and this process may take up to several years to complete. Data
obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay,
limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties
or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing
our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called Phase IV studies may be made a condition to be satisfied
for continuing drug approval. The results of Phase IV studies can confirm the effectiveness of a product candidate and can provide
important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market
studies to specifically address safety issues identified by the agency. Any approvals that we may ultimately receive could be withdrawn
if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm the commercial prospects
for AL001 or AL002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also has authority to require a
Risk Evaluation and Mitigation Strategy (&ldquo;<B>REMS</B>&rdquo;) from manufacturers to ensure that the benefits of a drug or
biological product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA or BLA submission. The
need for a REMS is determined as part of the review of the NDA or BLA. Based on statutory standards, elements of a REMS may include
&ldquo;dear doctor letters,&rdquo; a medication guide, more elaborate targeted educational programs, and in some cases restrictions
on distribution. These elements are negotiated as part of the NDA or BLA approval, and in some cases if consensus is not obtained
until after the Prescription Drug User Fee Act review cycle, the approval date may be delayed. Once adopted, REMS are subject to
periodic assessment and modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if AL001 or AL002 receive regulatory
approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant
limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans,
restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval is obtained, later
discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of
the product from the market. Any delay in obtaining, or failure to obtain, regulatory approval for AL001 or AL002, or obtaining
approval only for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental
regulations may arise from future U.S. or foreign governmental action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Disclosure of Clinical Trial Information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sponsors of clinical trials of certain
FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information
on a public website maintained by the U.S. National Institutes of Health. Information related to the product, patient population,
phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the registration.
Sponsors are also obligated to disclose the results of these trials after completion. Disclosure of the results of these trials
can be delayed until the product or new indication being studied has been approved. Competitors may use this publicly-available
information to gain knowledge regarding the design and progress of our development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The Drug Price Competition and Patent
Term Restoration Act</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Drug Price Competition and Patent Term
Restoration Act, also known as the Hatch-Waxman Act, requires pharmaceutical companies to divulge certain information regarding
their products which has the effect of making it easier for other companies to manufacture generic drugs to compete with those
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Patent Term Extension.</I> After an
NDA or BLA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term
extension is calculated as half of the drug&rsquo;s testing phase - the time between IND submission and NDA or BLA submission -
and all of the review phase - the time between either NDA or BLA submission and approval up to a maximum of five years. The time
can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the
extension may not exceed 14 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For patents that might expire during the
application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term
by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension
is reduced by one year. The director of the PTO must determine that approval of the drug covered by the patent for which a patent
extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA or BLA has not been
submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Environmental Regulations.</I> The U.S.
generally requires an environmental assessment, which discusses a company&rsquo;s proposed action, possible alternatives to the
action, and whether the further analysis of an environmental impact statement is necessary. Certain exemptions are available from
the requirement to perform an environmental assessment and an environmental impact statement. Once an exemption is claimed, a company
must state to the FDA that no extraordinary circumstances exist that may significantly affect the environment. We may claim an
exemption, under the category for biologic products, from the requirement to provide an environmental assessment and an environmental
impact statement for AL001 or AL002 and may furthermore state to the FDA that to our knowledge, no extraordinary circumstances
exist that would significantly affect the environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>FDA Post-Approval Requirements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the approval of an NDA or BLA,
the FDA continues to require adverse event reporting and submission of periodic reports. The FDA also may require post-marketing
testing, known as Phase IV testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place
conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture,
packaging, and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors
are required to register their establishments with FDA and certain state agencies. Registration with the FDA subjects entities
to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance
with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control
to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company
fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized
problems are subsequently discovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Patient Protection and Affordable Care
Act</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2010, the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &ldquo;<B>ACA</B>&rdquo;),
which includes measures that have significantly changed the way health care is financed by both governmental and private insurers,
became law in the U.S. The ACA is a sweeping measure intended to expand health care coverage within the U.S., primarily through
the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. The ACA has significantly
impacted the pharmaceutical industry. The ACA requires discounts under the Medicare drug benefit program and increased rebates
on drugs covered by Medicaid. In addition, the ACA imposes an annual fee, which increases annually, on sales by branded pharmaceutical
manufacturers. At this time, the financial impact of these discounts, increased rebates and fees and the other provisions of the
ACA on our business are unclear. However, the fees, discounts and other provisions of this law are expected to have a significant
negative effect on the profitability of pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Health Product Regulation in the
European Union</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the U.S.,
we may eventually be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions
governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not we obtain FDA approval for
a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement of
clinical trials or marketing of the product in those countries. Certain countries outside of the U.S. have a process that requires
the submission of a clinical trial application prior to the commencement of human clinical trials. In Europe, for example, a Clinical
Trial Application (&ldquo;<B>CTA</B>&rdquo;) must be submitted to the competent national health authority and to independent ethics
committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a
country&rsquo;s requirements, clinical trial development may proceed in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The requirements and process governing
the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is
already some degree of legal harmonization in the EU Member States resulting from the national implementation of underlying EU
legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To obtain regulatory approval of an investigational
drug under EU regulatory systems, we must submit a marketing authorization application. This application is similar to the BLA
in the U.S., with the exception of, among other things, country-specific document requirements. Drugs can be authorized in the
EU by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralized procedure
or (iv) national authorization procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The European Medicines Agency (&ldquo;<B>EMA</B>&rdquo;)
implemented the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout
the EU. This procedure results in a single marketing authorization granted by the European Commission that is valid across the
EU, as well as in Iceland, Liechtenstein and Norway (the &ldquo;<B>European Economic Area</B>&rdquo;). The centralized procedure
is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new
active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated orphan drugs, and (iv) advanced-therapy
medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request
of the applicant also be used for human drugs which do not fall within the above mentioned categories if the human drug (a) contains
a new active substance which, on the date of entry into force of Regulation (EC) No. 726/2004, was not authorized in the European
Economic Area; or (b) the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical
innovation or that the granting of authorization in the centralized procedure is in the interests of patients at European Economic
Area level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the centralized procedure in the
EU, the maximum timeframe for the evaluation of a Marketing Authorization Application (&ldquo;<B>MAA</B>&rdquo;) by the EMA is
210 days, though the date count stops whenever the Committee for Medicinal Products for Human Use (&ldquo;<B>CHMP</B>&rdquo;) asks
the applicant for additional written or oral information, with adoption of the actual marketing authorization by the European Commission
thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, as when a medicinal product is expected to
be of a major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: (i)
the seriousness of the disease to be treated; (ii) the absence of an appropriate alternative therapeutic approach; and (iii) anticipation
of exceptional high therapeutic benefit. In this circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed
within 150 days and the opinion issued thereafter. We plan to submit an application for marketing authorizations in the United
States for AL001 and AL002 in the latter half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Mutual Recognition Procedure (&ldquo;<B>MRP</B>&rdquo;),
for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the
EU. Essentially, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is
applicable to the majority of conventional medicinal products and is based on the principle of recognition of an already existing
national marketing authorization by one or more Member States.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The characteristic of the MRP is that the
procedure builds on an already existing marketing authorization in a Member State of the EU that is used as reference in order
to obtain marketing authorizations in other EU Member States. In the MRP, a marketing authorization for a drug already exists in
one or more Member States of the EU and subsequently marketing authorization applications are made in other EU Member States by
referring to the initial marketing authorization. The Member State in which the marketing authorization was first granted will
then act as the reference Member State. The Member States where the marketing authorization is subsequently applied for act as
concerned Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MRP is based on the principle of the
mutual recognition by EU Member States of their respective national marketing authorizations. Based on a marketing authorization
in the reference Member State, the applicant may apply for marketing authorizations in other Member States. In such case, the reference
Member State shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of
the report are sent to all Member States, together with the approved summary of product characteristics, labeling and package leaflet.
The concerned Member States then have 90 days to recognize the decision of the reference Member State and the summary of product
characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement
of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should any Member State refuse to recognize
the marketing authorization by the reference Member State, on the grounds of potential serious risk to public health, the issue
will be referred to a coordination group. Within a timeframe of 60 days, Member States shall, within the coordination group, make
all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The
opinion of this EMA Committee is then forwarded to the Commission, for the start of the decision-making process. As in the centralized
procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human
Medicinal Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Health Product Regulation in the
Rest of World</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For other countries outside of the EU,
such as countries in Eastern Europe or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing
and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and
the other applicable regulatory requirements. If we fail to comply with applicable foreign regulatory requirements, we may be subject
to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls,
seizure of products, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Regulatory Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Labeling, Marketing and Promotion</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once an NDA or BLA is approved, a product
will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and
promotion of pharmaceuticals, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored
scientific and educational activities and promotional activities on the internet and elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While doctors are free to prescribe any
pharmaceutical approved by the FDA for any use, a company can only make claims relating to the safety and efficacy of a pharmaceutical
that are consistent with the FDA approval, and is only allowed to actively market a pharmaceutical for the particular indication
approved by the FDA. Changes to some of the conditions established in an approved application, including changes in indications,
labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or BLA or NDA/BLA supplement
before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in
the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing NDAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any claims we make for our
products in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately
substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising,
injunctions and potential civil and criminal penalties. Government regulators recently have increased their scrutiny of the promotion
and marketing of pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Anti-Kickback and False Claims Laws</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., we are subject to complex
laws and regulations pertaining to health care &ldquo;fraud and abuse,&rdquo; including, but not limited to, The Medicare and Medicaid
Patient Protection Act of 1987 (also known as the federal &ldquo;<B>Anti-Kickback Statute</B>&rdquo;), the federal False Claims
Act, state false claims acts and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any
person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive,
offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription
of a particular pharmaceutical, for which payment may be made under a federal health care program, such as Medicare or Medicaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal False Claims Act prohibits
anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid)
claims for items or services, including pharmaceuticals, that are false or fraudulent, claims for items or services not provided
as claimed, or claims for medically unnecessary items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are also an increasing number of
state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain
ambiguities as to what is required to comply with the laws. In addition, beginning in 2013, a similar federal law requires manufacturers
to track and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar
year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens
on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could
be subject to the penalty provisions of the pertinent state, and soon federal, authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Health Care Laws and Compliance
Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., our activities are potentially
subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare
and Medicaid Services (formerly the Health Care Financing Administration), other divisions of the U.S. Department of Health and
Human Services (e.g., its Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within
the Department of Justice, and state and local governments. For example, sales, marketing and scientific/educational grant programs
must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, the privacy provisions of
the Health Insurance Portability and Accountability Act, and similar state laws, each as amended. Pricing and rebate programs must
comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act
of 1992 (&ldquo;<B>VHCA</B>&rdquo;), each as amended. If products are made available to authorized users of the Federal Supply
Schedule of the General Services Administration, additional laws and requirements will apply. Under the VHCA, drug companies are
required to offer certain drugs at a reduced price to a number of federal agencies including U.S. Department of Veteran Affairs
and U.S. Department of Defense, the Public Health Service and certain private Public Health Service designated entities in order
to participate in other federal funding programs including Medicare and Medicaid. Recent legislative changes require that discounted
prices be offered for certain U.S. Department of Defense purchases for its TRICARE program via a rebate system. Participation under
the VHCA requires submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as
well as the entry into government procurement contracts governed by the Federal Acquisition Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to distribute products commercially,
we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products
in a state, including, in certain states, manufacturers and distributors that ship products into the state even if such manufacturers
or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors
to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others
to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have
enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the
state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities or register their sales
representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health care entities from
providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing and prohibiting certain
other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection, unfair
competition and other laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview of Alzheimer&rsquo;s</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzheimer&rsquo;s is a chronic neurodegenerative
disorder affecting millions of people worldwide. It is the number one form of dementia in the world. The risk of being afflicted
with Alzheimer&rsquo;s increases with age, with one in ten people over the age of 65 having the disease. The prevalence of the
disease is approximately 5.8 million individuals in the US. Alzheimer&rsquo;s is also the sixth leading cause of death across all
ages in the United States and its prevalence is expected to quadruple by 2050. Per the 2010 U.S. Census and the Chicago Health
and Aging Project, a population-based study of chronic health conditions of older people, the average annual incidence in people
ages 65-74 was 0.4 percent (meaning four of every 1,000 people will develop Alzheimer&rsquo;s in any given year); in people ages
75-84, the annual incidence was 3.2 percent (32 of every 1,000 people), and for ages 85 and older (the &ldquo;oldest-old&rdquo;),
the incidence was 7.6 percent (76 of every 1,000 people). It is estimated that the cost of caring for people with Alzheimer&rsquo;s
and other dementias will increase from an estimated $290 billion in 2019 to a projected $1.1 trillion per year by 2050 with Medicare
and Medicaid covering approximately 70% of such costs. Over 16 million Americans provide unpaid care for people with Alzheimer&rsquo;s
or other dementias. It is estimated by the Alzheimer&rsquo;s Association that in 2019 caregivers to people with Alzheimer&rsquo;s
will provide 18.5 billion hours of care valued at $234 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cause and progression of Alzheimer&rsquo;s
are not well understood. As of 2019, more than 2,085 clinical trials have been or are being conducted to find ways to treat the
disease, but it is unknown if any of the tested treatments will work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Alzheimer&rsquo;s Foundation
of America, it is widely accepted that with the increasing trend towards a longer lifespan coupled with the baby-boomer population
approaching retirement, the incidence of Alzheimer&rsquo;s is likely to double in the next 20 years. The exponential increase in
the expected number of patients presenting with Alzheimer&rsquo;s not only represents a major area of unmet medical need, but it
also constitutes a significant market opportunity for diagnostics for this disease. Alzheimer&rsquo;s biomarker sales in 2011 were
reported at $1.5 billion but are expected have doubled in 2018 to over $3 billion. (BCC research 2013, &ldquo;Advances in biomarker
and monitoring diagnostics: Great markets, not so great health effects&rdquo; by Bj&oslash;rn Hofmann PhD and H. Gilbert Welch
MD, MPH, 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current clinical research focuses on the
early phases of the disease. However, to our knowledge, no accurate and convenient tools are available today for pre-dementia diagnosis
of Alzheimer&rsquo;s to support these efforts. Currently Alzheimer&rsquo;s is diagnosed as a clinical entity using a process that
combines cognition assessments with imaging- and spinal-fluid (&ldquo;<B>CSF</B>&rdquo;) tests. This diagnostic procedure may last
for several months to a year and is usually initiated late in the disease development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Several companies are focusing on blood
as a test material. Typically, these companies employ a multi-assay strategy (multiple RNAs or proteins) combined with advanced
statistical tools/algorithms to develop disease-specific diagnostic models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are able to protect our technology from
unauthorized use by third parties only to the extent that it is covered by valid and enforceable patents or is effectively maintained
as a trade secret or is protected by confidentiality agreements. Accordingly, patents or other proprietary rights are an essential
element of our business. Currently, we do not own a patent although we do possess a license for an immunotherapy technology and
two licenses for a lithium salt and proline co-crystal technology from the University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents extend for varying periods according
to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained.
The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of
its coverage and the availability of legal remedies in the country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the licensed patents is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Patent Number </U></B></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Therapy</U></B></FONT></TD>
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Patent Title</U></B></FONT></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Patent Type</U></B></FONT></TD>
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Date Filed</U></B></FONT></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Date Issued</U></B></FONT></TD>
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Expiration Date</U></B></FONT></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Jurisdiction</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9,840,521 (USA)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WO2012129568A2 (Europe)</P></TD>
    <TD><FONT STYLE="font-size: 10pt">AL001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Organic Anion Lithium Ionic Cocrystal Compounds and Compositions</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Composition of Matter</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">04/19/2013</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">12/12/2017</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">04/19/2033</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">USA and Europe</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">9,603,869 (USA)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AL001</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Lithium Cocrystals and an Additional Neuropsychiatric Agent for Treatment of Neuropsychiatric
    Disorders</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Method of Use</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">05/21/2016</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">03/28/2017</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">05/21/2036</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">USA</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">8,188,046 (USA)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">AL002 </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amyloid beta peptides and methods of use </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Method of Use</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10/12/2007</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">05/29/2012</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">02/12/2028</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">USA</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While trade secret protection is an essential
element of our business and we take security measures to protect our proprietary information and trade secrets, we cannot give
assurance that our unpatented proprietary technology will afford us significant commercial protection. We seek to protect our
trade secrets by entering into confidentiality agreements with third parties, employees and consultants. Our employees and consultants
also sign agreements requiring that they assign us their interests in intellectual property arising from their work for us. All
employees sign an agreement not to engage in any conflicting employment or activity during their employment and not to disclose
or misuse confidential information. However, it is possible that these agreements may be breached or invalidated, and if so, there
may not be an adequate corrective remedy available. Accordingly, we cannot ensure that our employees, consultants or any third
parties will not breach the confidentiality provisions in our contracts, infringe or misappropriate our trade secrets and other
proprietary rights or that measures we take to protect our proprietary rights will be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, third parties may file claims
asserting that our technologies or products infringe on their intellectual property. We cannot predict whether third parties will
assert such claims against us or against the licensors of technology licensed to us, or whether those claims will harm our business.
If we are forced to defend ourselves against such claims, whether they are with or without merit and whether they are resolved
in favor of, or against, our licensors or ourselves, we may face costly litigation and the diversion of our management&rsquo;s
attention and resources. As a result of such disputes, we may have to develop costly non-infringing technology or enter into licensing
agreements. These agreements, if necessary, may be unavailable on terms acceptable to us, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently possess four service trademarks
with the U.S. PTO that include our corporate name, Alzamend Neuro; two for our corporate slogan and one for our trade name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our industry is highly competitive and
subject to rapid and significant technological change. While we have some, albeit limited, development experience and scientific
knowledge, we will face competition from both large and small pharmaceutical and biotechnology companies, including specialty pharmaceutical
companies and generic drug companies, as well as academic institutions, government agencies and research institutions, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competition will be determined in part
by the potential indications for which our products are developed and ultimately approved by regulatory authorities. It is likely
that the timing of market introductions of some of our potential products or our competitors&rsquo; products will be an important
competitive factor. Accordingly, the speed with which we can develop our products, conduct preclinical studies and clinical trials
to obtain approval and manufacture or obtain supplies of commercial quantities of any approved products should also be important
competitive factors. We expect that competition among products approved for sale will be based on additional factors, such as product
efficacy, safety, reliability, availability, price and patent position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Alzheimer&rsquo;s Therapeutic Landscape</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><IMG SRC="chart2.jpg" ALT="" STYLE="width: 754px; height: 262px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 1pt; color: White">Percent Change Phase
2 Facts 2018 ,PrOrry&quot;t21C7hangc Phase 3 Facts 2018 from 2017 Number of Drugs: 68 I 17% Number of Drugs: - 3% Commercial Launch:
8 Drugs could reach the Commercial Launch: Drugs could reach _ % % market in the next five years the market in the next five years
Number of Symptomatic Drugs: 13 -24% Number of Symptomatic Drugs: 12 % Number of Disease Modifying Drugs: I 34% Number of Disease
Modifying Drugs: 19 -14% Prevention Trials: Prevention Trials: % % drugs are in prevention trials drugs are in prevention trials
Mechanism of Action: I I drugs are classified as Tau I 57% Mechanism of Action: drugs are classified as Neurotransmission % drugs
are classified as Amyloid 20%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Current Drugs for Alzheimer&rsquo;s Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #47106B">
    <TD STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid; border-left: white 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: White">Aricept</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: White">&nbsp;</FONT></P></TD>
    <TD STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid"><FONT STYLE="color: white">Exelon</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid"><FONT STYLE="color: white">Namenda</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: white 1pt solid; border-bottom: white 1.5pt solid"><FONT STYLE="color: white">Razadyne</FONT></TD>
    <TD STYLE="border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="background-color: #EDEDED">
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid; border-left: white 1.5pt solid"><B>Year Approved: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">1996</TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Year Approved: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">2000</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Year Approved: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">2003</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Year Approved: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">2004</TD></TR>
<TR STYLE="background-color: #EDEDED">
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid; border-left: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Peak Revenue</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Per Year: </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$3,454,000,000</TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Peak Revenue</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Per Year: </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$1,067,000,000</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Peak Revenue<BR>
 Per Year: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$2,575,000,000</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Peak Revenue<BR>
 Per Year: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$428,000,000</TD></TR>
<TR STYLE="background-color: #EDEDED">
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid; border-left: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Cost Per</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Patient Per</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Year: </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$4,404</TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Cost Per</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Patient Per</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Year: </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$3,768</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Cost Per <BR>
Patient Per<BR>
 Year: </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$3,456</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Cost Per</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Patient Per
<BR>
Year: </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$3,120</TD></TR>
<TR STYLE="background-color: #EDEDED">
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid; border-left: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Total Revenue</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>(2017): </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$268,000,000</TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Total Revenue</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>(2017): </B></P></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$381,000,000</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Total Revenue<BR>
 (2017): </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$452,000,000</TD>
    <TD COLSPAN="2" STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid"><B>Total Revenue<BR>
 (2017): </B></TD>
    <TD STYLE="border-right: white 1.5pt solid; border-bottom: white 1.5pt solid">$152,000,000</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Aricept &ndash; Eisai Co., Ltd. Third Quarter Financial Results (https://www.eisai.com/ir/library/settlement/pdf/e2018Q3_52.pdf).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Exelon &ndash; Novartis Pharmaceutical Co. Q4/FY 2017 Financial Report (https://www.novartis.com/sites/www.novartis.com/files/2018-01-interim-financial-report-en.pdf).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Namenda &ndash; Allergan Q4/FY 2017 Financial Report (https://www.prnewswire.com/news-releases/allergan-reports-solid-finish-to-2017-with-12-increase-in-fourth-quarter-gaap-net-revenues-to-43-billion-300593801.html).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Razadyne &ndash; Takeda FY2017 Data Book (https://www.takeda.com/siteassets/system/investors/report/quarterlyannouncements/fy2017/fy2017-full-year-results/qr2017_q4_d_en.pdf).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Thomson Reuters Report - (https://www.researchgate.net/publication/274930518_Spotlight_on_Alzheimers_disease_a_Thomson_Reuters_Pharma_Matters_report).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diagnostics for Alzheimer&rsquo;s Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cerebrospinal Fluid (CSF)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CSF samples and protein assays of particular
analytes remain today the best tools in the diagnosis of Alzheimer&rsquo;s and encephalitis. The procedure involves a lumbar puncture
- the insertion of a hallow cannula or needle into the lower spinal column in order to collect 5-10 ml of blood free CSF.&nbsp;Until
recently there have not been any in vitro diagnostic quality assays available to replace the lumbar puncture diagnostic procedure
and there may not be until Saladax/Ortho Clinical Diagnostics or Roche Diagnostics release publicly their report CSF Ab42 and CSF
Tau assays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Positron Emission Tomography (PET)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PET requires large, multi-million-dollar
cameras which collect the radioactive decay of minute quantities of hot radioactive tracers injected into the blood stream. The
tracers emit correlated photo pairs which indicate where the tracer is staining tissue in vivo. FDG-PET is an FDA-approved tracer
which measures glucose metabolism and has been successfully used to image brain energy consumption. More recently Amyvid from Avid
Radiopharmaceuticals, now Lilly Diagnostics, received FDA approval as an in vivo radiotracer to label the amyloid plaques of the
brain. These studies typically cost $3,000-$5,000 per imaging session per patient and require patients travel to a facility with
a PET facility rather than receive a diagnostic test in their clinician&rsquo;s office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Magneto encephalography (MEG)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MEG instruments, which are both physically
large and costly to facilities wishing to purchase them, employ advanced superconducting magnets operating in near absolute zero
temperature to measure minute brain currents. They are scarcely available in the US and Japan, let alone any other country in
the world. They are primarily used for research and will likely never become commonplace in clinical practice due to their size
and cost.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Magnetic Resonance Imaging (MRI)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MRI instruments are able to measure the
gross anatomy of the brain within the skull with resolution approaching 100 microns in a standard 1.5T clinical MRI. Although they
are costly and accessible only at an imaging center (inpatient or outpatient), they are standard of care to ensure that there is
no gross brain tumor or evidence of white matter infarct, typical after sub-clinical or mini-strokes have occurred.&nbsp;In one
costly modality, functional MRI test is conducted whereby a patient is given tasks to complete while they are lying in an MRI brain
scanner and asked to participate in task-based maneuvers to understand which anatomical structures are active during which dynamic
task. These diagnostic studies are costly and difficult to implement with satisfactory results due to the distractions of motion
artifacts and noise. In routine clinical practice, they are not commonly conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are many companies creating computerized
cognitive assessments of a human subject from a neuropsychological perspective. Many of these are considered reliable and easily
administered in a clinician&rsquo;s office. Some of the cognitive assessment tools in the market today are the CogState battery
of tasks, the CNS Vital Signs, the ImPACT test and the CANTAB battery. However, these cognition assessment tools have limitations
on their ability to accurately and objectively measure brain function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Offering Circular,
we had one full-time and three part-time employees. The services of two former officers and Executive Chairman of Alzamend were
provided pursuant to the terms of a management services agreement (the &ldquo;<B>MSA</B>&rdquo;) entered into with Avalanche International
Corp. (&ldquo;<B>Avalanche</B>&rdquo;), a related party, on May 1, 2016. In 2018, we retained each officer directly which provided
us with management, consulting and financial services. Such services included advice and assistance concerning any and all aspects
of operations, planning and financing of Alzamend and conducting relations with accountants, attorneys, financial advisors and
other professionals. The term of the MSA, as amended, was for the period May 1, 2016 to December&nbsp;31, 2018, with Avalanche
having initially received $40,000 per month and, beginning February 2017, receiving $20,000 per month for the remainder of 2017.
The MSA was terminated as of December 31, 2018. We accepted the resignation of our previous President and CEO, Philip Mansour,
effective on November 18, 2018, and appointed Mr. Stephan Jackman as CEO as of November 30, 2018. Mr. Jackman is a full-time executive
with extensive scientific and medical experience in developing immunotherapies and commercialization to lead our activities. As
of December 15, 2018, we accepted the resignation of our former CFO, William B. Horne and appointed our current CFO, Kenneth S.
Cragun. On May 1, 2019 we hired Henry Nisser to be our General Counsel and Executive Vice President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mailing address is Alzamend Neuro, Inc., 3802 Spectrum Blvd.,
Suite #112C, Tampa, FL 33612 and our telephone number is (844) 722-6333. Our website address is&nbsp;www.alzamend.com and the www.TheAlzamendStory.com.
The information contained therein or accessible thereby shall not be deemed to be incorporated into this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently maintain our corporate offices
at the University&rsquo;s Incubator Center located next to the USF Innovation Center featuring shared labs and extensive research
facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>directors,
executive officers and corporate governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
regarding our executive officers, directors and significant employees, including their ages as of the date of this Offering Circular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%; border-bottom: black 1pt solid"><B>Name</B></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid; text-align: center"><B>Age</B></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 22%; border-bottom: black 1pt solid"><B>Position</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: black 1pt solid"><B>Term of Office</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 26%; border-bottom: black 1pt solid"><B>Approximate hours per week <BR>
for part-time
    employees</B></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom">Stephan Jackman</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">44</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Chief Executive Officer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">November 2018 to present</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Full-time</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">Kenneth S. Cragun</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">59</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Chief Financial Officer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">December 2018 to present</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">20 hours per week</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> Henry Nisser </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>General Counsel and Executive Vice President</TD>
    <TD>&nbsp;</TD>
    <TD>May 2019 to present</TD>
    <TD>&nbsp;</TD>
    <TD>8 hours per week</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>Milton C. Ault, III</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">50</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>Executive Chairman &amp; Director</TD>
    <TD>&nbsp;</TD>
    <TD>February 2016 to present</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom">Philip E. Mansour</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">52</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Director</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">June 2016 to present</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">William B. Horne</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">51</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Director</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">June 2016 to present</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors serve until the next annual meeting
and until their successors are elected and qualified. Officers are appointed to serve for one year until the meeting of the Board
following the annual meeting of stockholders and until their successors have been elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephan Jackman</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Mr.
Jackman began working for Alzamend on November 1, 2018. He has played an intricate role in the development of therapeutic treatments,
products and programs from the research stage to market and commercialization. Mr. Jackman has demonstrated a dedicated dual focus
of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet
and exceed goals. Prior to joining Alzamend Neuro, from October 2017 to November 2018, Mr. Jackman was the Chief Operating Officer
of Ennaid Therapeutics, an emerging biopharmaceutical focusing on cures for mosquito borne infectious diseases, such as Zika and
Dengue viruses. Mr. Jackman was Chief Operating Officer of Exit 9 Technologies, from October 2015 to October 2017, a technology
startup with a digital platform that connects retailers, publisher and customers. Additionally, from August 2014 to October 2015,
he has been an independent project and management consultant assisting start-ups, Fortune 500 companies and non-profits with major
strategic initiatives. He has held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L&rsquo;Or&eacute;al
USA, SBM Management Services, and Family Intervention Services. Mr. Jackman holds a Master of Science in Management, and a Bachelor
of Engineering in Mechanical Engineering, from Stevens Institute of Technology. We believe Mr. Jackman is qualified to serve as
our Chief Executive Officer because of his extensive leadership experience and industry knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Kenneth S. Cragun</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Cragun began working for Alzamend on
a part-time basis on December 15, 2018. He served as a CFO Partner at Hardesty, LLC, a national executive services firm since October
2016. His assignments at Hardesty included serving as CFO of CorVel Corporation, a $1.1 billion market cap publicly traded company
(NASDAQ: CRVL) and a nationwide leader in technology driven, healthcare-related, risk management programs and of RISA Tech, Inc.
a private structural design and optimization software company. Mr. Cragun was also CFO of two NASDAQ-listed companies, Local Corporation,
from April 2009 to September 2016, which operated Local.com, a U.S. top 100 website, and Modtech Holdings, Inc., from June 2006
to March 2009, a supplier of modular buildings. Prior thereto, he had financial leadership roles with increasing responsibilities
at MIVA, Inc., ImproveNet, Inc., NetCharge Inc., C-Cube Microsystems, Inc, and 3-Com Corporation. Mr. Cragun is currently the Chief
Accounting Officer of DPW Holdings, Inc., formerly known as Digital Power Corporation (NYSE: DPW) and (&ldquo;<B>DPW</B>&rdquo;)
and serves on the Board of Directors and Chairman of the Audit Committee of Verb Technology Company, Inc. (NASDAQ: VERB). Mr. Cragun
began his professional career at Deloitte. Mr. Cragun holds a Bachelor of Science degree in accounting from Colorado State University-Pueblo.
Mr. Cragun&rsquo;s industry experience is vast with extensive experience in fast-growth environments and building teams in more
than 20 countries. Mr. Cragun has led multiple financing transactions, including IPOs, PIPEs, convertible debt, term loans, and
lines of credit. For these reasons, we believe that he is well qualified to serve as our CFO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Henry Nisser</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Nisser began working for Alzamend on
a part-time basis on May 1, 2019. From October 31, 2011 through April 26, 2019, Mr. Nisser was an associate and subsequently a
partner with Sichenzia Ross Ference LLP (&ldquo;<B>SRF</B>&rdquo;), a law firm based in New York City. While with SRF, his practice
was concentrated in national and international corporate law, with a particular focus on U.S. securities compliance, public as
well as private M&amp;A, equity and debt financings and corporate governance. Mr. Nisser drafted and negotiated a variety of agreements
related to reorganizations, share and asset purchases, indentures, public and private offerings, tender offers and going private
transactions. Mr. Nisser also represented clients&rsquo; special committees established to evaluate M&amp;A transactions and advised
such committees&rsquo; members with respect to their fiduciary duties. Mr. Nisser is fluent in French and Swedish as well as conversant
in Italian. Mr. Nisser received his B.A. from Connecticut College in 1992, where he majored in International Relations and Economics.
He received his LLB from the University of Buckingham School of Law in 1999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Milton C. Ault, III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Ault founded Alzamend Neuro, Inc.,
a biotechnology firm dedicated to finding the treatment, prevention and cure for Alzheimer&rsquo;s on February 25, 2016 and has
served as our Executive Chairman since November 2, 2018 and as our Chairman since inception. Mr. Ault is a seasoned business professional
and entrepreneur who has spent more than twenty-seven years identifying value in various financial markets including equities,
fixed income, commodities, and real estate. On March 16, 2017, Mr. Ault was appointed Executive Chairman of the Board of DPW and
on December 28, 2017, Mr. Ault was appointed Chief Executive Officer of DPW. Mr. Ault has served as Chairman of Ault &amp; Company,
a holding company since December 2015, and as Chairman of Avalanche, a publicly traded company, since September 2014. Since January
2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Mr. Ault has consulted
for a few publicly traded and privately held companies, which range from development stage to seasoned businesses, providing each
of them the benefit of his diversified experience. We believe that Mr. Ault&rsquo;s business background demonstrates he has the
qualifications to serve as one of our directors and as Executive Chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Philip E. Mansour</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Mansour has served as a director and
as the President and Chief Executive Officer of Avalanche since May 2014. Additionally, Mr. Mansour has provided executive coaching
services. Mr. Mansour was the CEO of Alzamend from 2016 through 2018. Mr. Mansour worked as the Chief Operational Officer with
the RXtra Solutions organization. The organization was a privately-owned set of health care development companies which had footprints
in the compounding pharmacy, diagnostics, medical equipment, chemical distribution and wellness provider spaces. He has also served
as Vice President, corporate development for Conceivex, Inc., a private company focused on At-Home Infertility treatment. His prior
experience includes leading the research and development for some prominent educational technology companies for more than 2 decades
and leading multi-million-dollar government grants with leading universities. His entrepreneurial and significant corporate experience
is expected to benefit us. We believe that Mr. Mansour&rsquo;s business background demonstrates he has the qualifications to serve
as one of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William B. Horne</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Horne has served as director for Alzamend
Neuro since June 1, 2016. Mr. Horne served as the Chief Financial Officer from June 2016 through December 2018. Mr. Horne has been
a member of the board of directors of DPW since October 2016. On January 25, 2018, Mr. Horne was appointed as DPW&rsquo;s Chief
Financial Officer. Mr. Horne is a director and Chief Financial Officer of Avalanche, a publicly traded company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Horne previously held the position
of Chief Financial Officer in various companies in the healthcare and high-tech field, including OptimisCorp, from January 2008
to May 2013, a privately held, diversified healthcare technology company located in Los Angeles, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Horne served as the Chief Financial
Officer of Patient Safety Technologies, Inc. (OTCBB: PSTX), a medical device company located in Irvine, California, from June 2005
to October 2008 and as the interim Chief Executive Officer from January 2007 to April 2008. In his dual role at Patient Safety
Technologies, Mr. Horne was directly responsible for structuring the divestiture of non-core assets, capital financings and debt
restructuring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Horne has also held supervisory positions
at Price Waterhouse, LLP and has a Bachelor of Arts Magna Cum Laude in Accounting from Seattle University. We believe that Mr.
Horne&rsquo;s extensive financial and accounting experience in diversified industries and with companies involving complex transactions
gives him the qualifications and skills to serve as one of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure and Risk
Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board oversees our business and considers
the risks associated with our business strategy and decisions. The Board currently implements its risk oversight function as a
whole. On November 2, 2018, the Board adopted a charter that establishes an Audit Committee and a Nomination &amp; Governance Committee.
Each of the Board committees will provide risk oversight in respect of its areas of concentration and reports material risks to
the board for further consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Term of Office</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors serve until the next annual meeting
and until their successors are elected and qualified. Officers are appointed to serve for one year until the meeting of the Board
following the annual meeting of stockholders and until their successors have been elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We use the definition of &ldquo;independence&rdquo;
of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an &ldquo;independent director&rdquo;
is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion
of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.&nbsp;The
NASDAQ listing rules provide that a director cannot be considered independent if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the director is, or at any time during the past three years was, an employee of the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the director or a family member of the director accepted any compensation from the company in excess
of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject
to certain exemptions, including, among other things, compensation for board or board committee service);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the director or a family member of the director is a partner in, controlling stockholder of, or
an executive officer of an entity to which the company made, or from which the company received, payments in the current or any
of the past three fiscal years that exceed 5% of the recipient&rsquo;s consolidated gross revenue for that year or $200,000, whichever
is greater (subject to certain exemptions);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the director or a family member of the director is employed as an executive officer of an entity
where, at any time during the past three years, any of the executive officers of the company served on the compensation committee
of such other entity; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the director or a family member of the director is a current partner of the company&rsquo;s outside
auditor, or at any time during the past three years was a partner or employee of the company&rsquo;s outside auditor, and who worked
on the company&rsquo;s audit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under such definitions, we have no independent
directors. However, our Common Stock is not currently quoted or listed on any national exchange or interdealer quotation system
with a requirement that a majority of our Board be independent and, therefore, we are not subject to any director independence
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationships among
any of our officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed below, to our knowledge,
none of our current directors or executive officers has, during the past five years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
traffic violations and other minor offenses);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">had any bankruptcy petition filed by or against the business or property of the person, or of any
partnership, corporation or business association of which he was a general partner or executive officer, either at the time of
the bankruptcy filing or within two years prior to that time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending
or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings
and loan, or insurance activities, or to be associated with persons engaged in any such activity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed,
suspended, or vacated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">been the subject of, or a party to, any federal or state judicial or administrative order, judgment,
decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private
litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation
respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order
of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as
defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that
has disciplinary authority over its members or persons associated with a member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">Mr. Cragun served as Chief Financial Officer of Local Corporation (April 2009 to September 2016),
formerly based in Irvine, California, and, in June 2015, Local Corporation filed a voluntary petition in the United States Bankruptcy
Court for the Central District of California seeking relief under the provisions of Chapter 11 of Title 11 of the United States
Code (the &ldquo;Bankruptcy Code&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth in our discussion below
in &ldquo;Certain Relationships and Related Transactions,&rdquo; none of our directors or executive officers has been involved
in any transactions with us or any of our directors, executive officers, affiliates or associates which are required to be disclosed
pursuant to the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently a party to any legal
proceedings, the adverse outcome of which, individually or in the aggregate, we believe will have a material adverse effect on
our business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted a written code of
business conduct and ethics, revised effective May 29, 2018, that applies to our directors, officers and employees, including our
principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing
similar functions. We have posted on our website a current copy of the code and all disclosures that are required by law in regard
to any amendments to, or waivers from, any provision of the code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation of our two most highly paid
executive officers or directors for the year ended April&nbsp;30, 2019 was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Cash</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Compensation ($)</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Other</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Compensation ($)</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(1)</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Total</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Compensation ($)</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Stephan Jackman, Chief Executive Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">50,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,317,557</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,367,557</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kenneth S. Cragun, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,147,549</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,167,549</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The values reported in the &ldquo;Other
Compensation&rdquo; column represents the aggregate grant date fair value, computed in accordance with Accounting Standards Codification
(&ldquo;<B>ASC</B>&rdquo;) 718 Share Based Payments,&nbsp;of grants of stock options to each of our named executive officers and
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The services of the two former officers
and Executive Chairman of our company were provided pursuant to the terms of an MSA entered into with Avalanche, a related party,
on May 1, 2016. Pursuant to the terms of the MSA, Avalanche provided management, consulting and financial services to Alzamend.
Such services included advice and assistance concerning any and all aspects of operations, planning and financing of Alzamend
and conducting relations with accountants, attorney, financial advisors and other professionals. The term of the MSA, as amended,
was for the period May 1, 2016 to December&nbsp;31, 2018, with Avalanche having initially received $40,000 per month and, beginning
February 2017, receiving $20,000 per month for the remainder of 2017. During the years ended April&nbsp;30, 2019 and 2018, we
recognized $160,000 and $240,000, respectively, in management fees. At April&nbsp;30, 2019 and April&nbsp;30, 2018, $75,000 and
$3,000, respectively, was included within related party payable on our balance sheet. The MSA was terminated as of December 31,
2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> In December 2018, we entered into a consulting agreement
with Mr. Horne to provide 12 months of CFO transition consulting services for $50,000. For the year ended April 30, 2019, $12,500
was paid to Mr. Horne under the consulting agreement. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment agreement with Stephan Jackman</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On November 30, 2018, we entered into
an offer letter with Stephan Jackman to serve as our Chief Executive Officer. Based on the terms set forth in the offer letter,
the we intend to enter into a four-year employment agreement with Mr. Jackman. For his services, Mr. Jackman will be paid a base
salary of $150,000 per annum, which sum will be increased to $180,000 upon the approval of the FDA IND application for AL001,
and to $225,000 upon the approval of the FDA IND application for AL002. In addition, Mr. Jackman shall be eligible to receive
an annual cash bonus equal to a percentage of his annual base salary based on achievement of applicable performance goals determined
by the Board. The Annual Bonus, if any, shall in part be determined based upon the successful attainment of the following milestones
(no bonuses have been paid as of the date of this Offering Circular): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Second Phase Clinical Trial for AL002; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Third Phase Clinical Trial for AL002; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Third Phase Clinical Trial for AL001; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Equity
                                         or debt financings </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, Mr. Jackman received an option to purchase 5,000,000
shares of Common Stock exercisable for a period of ten (10) years from November 16, 2018, at a per share price of $1.00, which
option will vest as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Three million (3,000,000) shares of Common Stock shall vest ratably over 48 months beginning on
November 16, 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>One million (1,000,000) shares of Common Stock shall vest upon approval of an NDA for AL001 by the FDA within 36 months from
November 1, 2018; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>One million (1,000,000) shares of Common Stock shall vest upon approval of an NDA for AL002 by the FDA within 48 months from
November 1, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2019, Mr. Jackman&rsquo;s
base salary was increased to $225,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> On November 26, 2019, the Board of Directors granted 2,000,000
performance- and market-contingent awards to Mr. Jackman. These awards have an exercise price of $1.50 per share. These awards
have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing
prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company&rsquo;s initial
public offering for its common stock, or (ii) stepped target prices for a change in control transaction. The target prices range
from $15 per share to $40 per share. In the event any the stock price milestones are not achieved within three years, the unvested
portion of the performance options will be reduced by 25%. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment agreement with Ken Cragun</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On November 30, 2018, we entered into
an offer letter with Kenneth Cragun to serve as our Chief Financial Officer. Based on the terms set forth in the offer letter,
we intend to enter into a four-year employment agreement Mr. Cragun. For his services, Mr. Cragun will be paid a base salary of
$60,000 per annum, which sum will be increased to $120,000 upon the approval of a listing application submitted on behalf of our
company to have our shares of Common Stock listed on a national securities exchange. In addition, Mr. Cragun shall be eligible
to receive an annual cash bonus equal to a percentage of his annual base salary based on achievement of applicable performance
goals determined by the Board. The Annual Bonus, if any, shall in part be determined based upon the successful attainment of the
following milestones (no bonuses have been paid as of the date of this Offering Circular): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Second Phase Clinical Trial for AL002; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Third Phase Clinical Trial for AL002; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Approval
                                         to conduct a Third Phase Clinical Trial for AL001; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Equity
                                         or debt financings </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> While the offer letter for Mr. Cragun
stated an option life of seven (7) years, Mr. Cragun received a board-approved option to purchase 1,500,000 shares of Common Stock
exercisable for a period of ten (10) years from December&nbsp;15, 2018, at a per share price of $1.00. The option will vest ratably
over 48 months beginning on December 15, 2018; however, 500,000 shares of Common Stock will vest immediately upon the approval
of a listing application submitted on behalf of our company to have our shares of Common Stock listed on a national securities
exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2019, Mr. Cragun&rsquo;s
base salary was increased to $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On November 26, 2019, the Board of
Directors granted 1,000,000 performance- and market-contingent awards to Mr. Cragun. These awards have an exercise price of $1.50
per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of
stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the
Company&rsquo;s initial public offering for its common stock, or (ii) stepped target prices for a change in control transaction.
The target prices range from $15 per share to $40 per share. In the event any the stock price milestones are not achieved within
three years, the unvested portion of the performance options will be reduced by 25%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment agreement with Henry Nisser</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 20, 2019, we entered into a four-year
employment agreement having an effective date of May 1, 2019, with Henry Nisser to serve our Executive Vice President and General
Counsel. For his services, Mr. Nisser will be paid a base salary of $50,000 per annum. In addition, Mr. Nisser shall be eligible
to receive an annual cash bonus equal to a percentage of his annual base salary based on achievement of applicable performance
goals determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, Mr. Nisser shall be entitled
to receive an option an option to purchase 1,250,000 shares of Common Stock exercisable for a period of five (5) years at a per
share exercise price of $1.50. The shares of Common Stock underlying the option shall vest ratably over 48 months beginning on
June 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consulting Agreement with Dr. Chuanhai
Cao</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2017, we entered into a five-year
consulting agreement with Dr. Chuanhai Cao to support the design and incremental work to obtain FDA approval for AL002. The agreement
included an initial payment of $6,000 and monthly payments of $3,000 per month plus 500,000 options at $1.00 per share that vest
ratably over the term of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scientific Advisory Board Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into consulting agreements with
Dr. Thomas Wisniewski and Dr. Eric McDade on February&nbsp;1, 2019 and May&nbsp;1, 2019, respectively. The annual cash compensation
under the consulting agreements is $12,000 per committee member and options to purchase 50,000 shares at $1.00 per share with a
three-year life, vesting over two years.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Eric McDade is a cognitive neurologist
actively involved in the field of Alzheimer disease treatment. Dr. McDade is the Principal Investigator at the DIAN Expanded Registry
and Associate Professor at the Washington University School of Medicine. He received his Doctor of Osteopath, Medicine from the
Chicago College of Osteopathic Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Thomas Wisniewski is the Director of
the Center for Cognitive Neurology at NYU Langone&rsquo;s Alzheimer&rsquo;s Disease Center. Dr. Wisniewski received his MD from
the University of London.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transactions with Related Persons</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April 30, 2016, we had sold 1,000,000
shares of Series A Convertible Preferred Stock to MCKEA Holdings, LLC (&ldquo;<B>MCKEA</B>&rdquo;), a related party for a purchase
price of $8,000. The Series A Convertible Preferred Stock is convertible at a rate of 20:1 into shares of our Common Stock yet
carry the voting power on a convertible basis at a rate of 50:1. Kristine L. Ault is the managing member of MCKEA Holdings, LLC
and is the wife of Milton C. Ault, III, Executive Chairman of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, we entered into an MSA
with Avalanche, a related party. Messrs. Ault, Horne and Mansour are also officers and directors of Avalanche. Further, MCKEA is
the majority member of Philou Ventures, LLC, which is the controlling shareholder of Avalanche. Pursuant to the terms of the MSA,
Avalanche provided management, consulting and financial services to Alzamend. Such services included advice and assistance concerning
any and all aspects of operations, planning and financing of Alzamend and conducting relations with accountants, attorney, financial
advisors and other professionals. The term of the MSA, as amended, was for the period May 1, 2016 to December 31, 2017, and was
extended by written agreement. We initially paid $40,000 per month for these services and, beginning February 2017, began paying
$20,000 per month. During the years ended April&nbsp;30, 2019 and 2018, we recognized $160,000 and $240,000, respectively, in management
fees. At April&nbsp;30, 2019 and April&nbsp;30, 2018, $75,000 and $3,000, respectively, was included within related party payable
on our balance sheet. The MSA expired on December&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> In December 2018, we entered into a consulting agreement
with Mr. Horne to provide 12 months of CFO transition consulting services for $50,000.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2017, MCKEA and Spartan
Capital Securities, LLC (&ldquo;<B>Spartan</B>&rdquo;) entered into a five-year consulting agreement (the &ldquo;<B>MCKEA Consulting
Agreement</B>&rdquo;). Pursuant to the MCKEA Consulting Agreement, upon the receipt by us of no less than $2,500,000 in gross
proceeds from a Private Placement Memorandum dated August 17, 2017, MCKEA transferred to Spartan 5,000,000 shares of Alzamend
Common Stock. During the term of the MCKEA Consulting Agreement, Spartan will provide consulting services related to general corporate
and other matters related to MCKEA&rsquo;s investment in us such as advice on mergers and acquisition transactions, finance strategies,
identification of potential management candidates and other strategic introductions. The 5,000,000 shares of Common Stock were
transferred by MCKEA to Spartan on January&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount due at April 30, 2019 and 2018,
to MCKEA and our officers for reimbursement of expenses paid and incurred by these related parties was $6,736 and $6,636, respectively.
The amounts are included within related party payable on our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no amounts due at April 30,
2018, to related parties from short-term loans. The amount due at April 30, 2017, to related parties from short-term loans, inclusive
of unamortized original discount of $6,271, was $253,829. The amount is included within notes payable, related parties, on our
balance sheet (See Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2018, Avalanche, issued the
AVLP Note to evidence our loan of up to $995,500 for the period ending on April 30, 2019, subject to the terms and conditions stated
in the AVLP Note. The AVLP Note accrues interest at 10% per annum and includes a 10% original issue discount. During the year ended
April&nbsp;30, 2019, we provided loans to Avalanche in the principal amount of $792,085, of which $558,000 was repaid. The balance
outstanding on the AVLP Note as of April&nbsp;30, 2019 was $205,915.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On April 30, 2019, we entered into
a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with
5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance (the &ldquo;<B>ALSF Warrants</B>&rdquo;).
The total purchase price of $15,000,000 was in the form of a Note from Ault ALSF. The control person of ALSF is Mr. Ault, the
Executive Chairman of our company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Note is secured by a pledge of
the purchased shares. While the SPA provides for ALSF&rsquo;s ability to pledge the securities acquired thereby, given that the
purchased securities are subject to the SPA, we and ALSF agree that such securities may not be pledged to any third party until
the current pledge agreement has been terminated through full repayment of the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the SPA, ALSF is entitled
to full ratchet anti-dilution protection, most-favored nation status, denying the Company the right to enter into a variable rate
transaction absent its consent, and the right to participate in any future financing the Company may consummate. All these rights,
other than the right to participate in future financings which will not terminate until ALSF no longer holds any shares of Common
Stock or any ALSF Warrants, will terminate on the earlier to occur of such date that we have (i) completed a Qualified Financing,
or (ii) received approval by the FDA for any of our product candidates in Phase 3 clinical trial. For purposes of the SPA, a &ldquo;Qualified
Financing&rdquo; means the sale of equity securities by us in a single transaction or a series of related transactions whether
or not registered under the Securities Act, resulting in gross proceeds to us of no less than $25,000,000. If we were to sell
shares of Common Stock in this Offering for gross proceeds of at least $25,000,000, then the foregoing rights (other than the
right to participate in future financings) would be terminated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> In addition, the SPA entitles ALSF the right to have all
the shares of Common Stock to which it is entitled under the SPA be registered under the Securities Act within 180 days of the
final closing of an initial public offering.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company agreed to enter into the
SPA with ALSF primarily as a result of the provision in the Placement Agreement that required the Company to provide anti-dilution
protection to the Placement Agent, certain of its related parties and the investors in the Private Placement but not the Company&rsquo;s
other shareholders in the event that MCKEA were to convert its Series A Preferred Stock into Common Stock. ALSF and MCKEA are
related parties, so the Company believes that it was fair and reasonable to permit ALSF to acquire shares of Common Stock for
the same purchase price paid by the investors in the Private Placement in light of the constraints imposed on MCKEA&rsquo;s ability
to convert its shares of Series A Preferred Stock as the Company&rsquo;s other shareholders would be harmed to some degree if
MCKEA were to convert its Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the additional funds that
would be received by the Company from ALSF do not include any cash or equity based fees and are therefore far less expensive for
the Company and less dilutive to its shareholders than funds received from the Private Offering. Finally, the term of the Note
was intended to approximate the timing of when additional funds would be required by the Company, based on the assumption that
a portion of the purchase would be funded throughout the term of the Note.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> To the best of our knowledge, from
inception to our most recent fiscal year end on April 30, 2019, other than as set forth above, there were no material transactions,
or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were
or are to be a party, in which the amount involved exceeds $19,585, and in which any director or executive officer, or any security
holder who is known by us to own of record or beneficially own more than 5% of any class of our Common Stock, or any member of
the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers and directors in
the ordinary course of business).&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The following table shows the beneficial
ownership of our Common Stock as of February 29, 2020, held by (i) each person known to us to be the beneficial owner of more
than five percent (5%) of any class of our shares; (ii) each director; (iii) each executive officer; and (iv) all directors and
executive officers as a group. As of February 29, 2020, there were 63,662,858 shares of Common Stock issued and outstanding and
750,000 shares of Series A Convertible Preferred Stock issued and outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
with the rules of the Commission, and generally includes voting power and/or investment power with respect to the securities held.&nbsp;Shares
of Common Stock subject to options and warrants currently exercisable or which may become exercisable within 60 days of the date
of this Offering Circular, are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes
of computing the number of shares and percentage beneficially owned by such person, but are not deemed outstanding for purposes
of computing the percentage beneficially owned by any other person. Except as indicated in the footnotes to this table, the persons
or entities named have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned
by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, the principal
address of each of the persons below is c/o Alzamend Neuro, Inc., 3802 Spectrum Blvd., Suite #112C, Tampa, FL 33612.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Directors and Officers</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Number of shares of Common</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Stock Beneficially Owned</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Percentage of Shares</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Beneficially Owned</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Philip E. Mansour (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3.78</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Milton C. Ault, III (2)(3)(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50.62</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">William B. Horne (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.78</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stephan Jackman (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,062,500 </TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1.64 </TD><TD STYLE="white-space: nowrap; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kenneth S. Cragun (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 500,000 </TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 0.78 </TD><TD STYLE="white-space: nowrap; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Henry Nisser (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 286,458 </P>


</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 0.45 </TD><TD STYLE="white-space: nowrap; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">All directors and named executive <BR> officers as a group (6 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> 61,848,958 </P>


</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 53.54 </TD><TD STYLE="white-space: nowrap; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Greater than 10% Beneficial Owners:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">MCKEA Holdings, LLC (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37.07</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ault Life Sciences Fund, LLC (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.85</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 1) Consists of options to purchase
2,500,000 shares of Common Stock that are exercisable within 60 days of February 29, 2020.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> (2) Includes options to purchase 2,500,000
shares of Common Stock that are exercisable within 60 days of February 29, 2020.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Includes MCKEA Holdings&rsquo; 750,000
Series A Preferred Shares that are convertible into 15,000,000 shares of Common Stock but carry the voting power of 37,500,000
shares of Common Stock. Kristine L. Ault is the managing member of MCKEA Holdings, LLC and is the wife of Milton C. Ault, III,
Executive Chairman of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> (4) Includes 10,000,000 shares of Common
Stock and warrants to purchase 5,000,000 shares of Common Stock held by Ault Life Sciences Fund, LLC that are exercisable within
60 days of February 29, 2020. The control person of Ault Life Sciences Fund, LLC is Mr. Ault, the Executive Chairman of our company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> (5) Represents options to purchase
shares of Common Stock that are exercisable within 60 days of February 29, 2020. Mr. Nisser&rsquo;s address is 100 Park Avenue,
Suite 1658, New York, NY 10017. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the rights
of our capital stock as provided in our certificate of incorporation and bylaws. For more detailed information, please see our
certificate of incorporation and bylaws, which have been filed as exhibits to the Offering Statement of which this Offering Circular
is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue two
classes of stock. The total number of shares of stock which the Company is authorized to issue is three hundred and ten million
(310,000,000) shares, consisting of three hundred million (300,000,000) shares of Common Stock, $0.0001 par value and ten million
(10,000,000) shares of preferred stock, $0.0001 par value (the <B>&ldquo;Preferred Stock&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Offering Circular,
the Company had 63,662,858 shares of Common Stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Common Stock are entitled
to one vote for each share held at all meetings of shareholders (and written actions in lieu of meeting). There shall be no cumulative
voting. The holders of shares of Common Stock are entitled to dividends when and as declared by the Board from funds legally available
therefor, and upon liquidation are entitled to share pro rata in any distribution to holders of Common Stock. There are no preemptive,
conversion or redemption privileges, nor sinking fund provisions with respect to the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Authorized Number</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of authorized shares of Common
Stock may be increased or decreased subject to the Company&rsquo;s legal commitments at any time and from time to time to issue
them, by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Stock may be issued from
time to time in one or more series. The Board is authorized to fix the number of shares of any series of Preferred Stock and to
determine the designation of any such series. The Board is also authorized to determine or alter the rights, preferences, privileges,
and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock and, within the limits and restrictions
stated in any resolution or resolutions of the Board originally fixing the number of shares constituting any series, to increase
or decrease (but not below the number of shares of such series than outstanding) the number of shares of any such series subsequent
to the issue of shares of that series. Currently, 750,000 shares of Preferred Stock are designated as Series A Convertible Preferred
Stock, all of which are issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board originally designated 1,360,000
shares of its Preferred Stock as &ldquo;Series A Convertible Preferred Stock&rdquo; (the <B>&ldquo;Series A Preferred Shares&rdquo;</B>).
While the Company originally and issued all such shares as shown in the table in the section entitled &ldquo;Security Ownership
of Certain Beneficial Owners and Management&rdquo; above, 610,000 Series A Preferred Shares have been converted into shares of
Common Stock. As a result, there are presently 750,000 Series A Preferred Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares convey no
dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for
that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Series A Preferred Shares are
entitled to 50 non-cumulative votes per share on all matters presented to our stockholders for action. This right could adversely
affect the voting power of the holders of Common Stock and could have the effect of making it more difficult for a third party
to acquire or could discourage or delay a third party from acquiring, a majority of our outstanding stock. In addition, the affirmative
vote of the holders of a majority of the Series A Preferred then outstanding, voting as a separate class, is required for the Company
to do any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">amend, alter or repeal any of the preferences or rights of the Series A Preferred Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">authorize any reclassification of the Series A Preferred Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increase the authorized number of Series A Preferred Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">create any class or series of shares ranking prior to the Series A Preferred Shares as to dividends
or liquidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares are not entitled
to preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of any dissolution, liquidation
or winding up of the Company, whether voluntary or involuntary, the Holders of Series A Preferred Shares shall be entitled to participate
in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Series A Preferred Shares have
the right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common
Stock for every one (1) Series A Preferred Stock Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to retain any earnings for the
foreseeable future for our operations. We have never paid any dividends on our Common Stock and do not anticipate paying any cash
dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board and
will depend on our financial condition, operating results, capital requirements and such other factors as our Board deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may enter into an underwriting agreement
with the Underwriter, with respect to the shares of our Common Stock in this offering. The Underwriter may offer and sell, up to
6,000,000 shares of our Common Stock, on a &ldquo;best-efforts, no minimum&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate the shares of our Common
Stock will be listed on a national securities exchange under the symbol &ldquo;ALZA.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table&nbsp;summarizes the
underwriting compensation, if any, we may pay:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Public&nbsp;Offering<BR> Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Underwriting<BR> Commissions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Proceeds&nbsp;to&nbsp;Us,<BR> Before&nbsp;Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-indent: -10pt; padding-left: 10pt">Per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7.50</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">.75</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6.75</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Total maximum offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to apply to have our Common
Stock approved for listing on the NYSE American under the symbol &ldquo;ALZA.&rdquo; If the application is approved, trading of
our Common Stock on NYSE American is expected to begin within five days after the date of initial issuance of the Common Stock.
Our receipt of a listing approval letter is not the same as an actual listing on a national securities exchange. The listing approval
letter will serve only to confirm that, if we sell a number of shares in this &ldquo;best-efforts&rdquo; offering sufficient to
satisfy applicable listing criteria, our Common Stock will in fact be listed.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been
no public market for our Common Stock. The initial public offering price has been determined by negotiations between us and&nbsp;the
Underwriter. In determining the initial public offering price, we and the Underwriter have considered a number of factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the information set forth in this Offering Circular and otherwise available to the Underwriter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">our
prospects and the history and prospects for the industry in which we compete;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">an assessment of our management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">our prospects for future earnings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the general condition of the securities markets at the time of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the recent market prices of, and demand for, publicly traded Common Stock of generally comparable
companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">other factors deemed relevant by the Underwriter and us.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither we nor the Underwriter can assure investors that an
active trading market will develop for shares of our Common Stock, or that the shares will trade in the public market at or above
the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOS Back Office Solutions, LLC will serve as transfer agent
to maintain stockholder information on a book-entry basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADDITIONAL INFORMATION ABOUT THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investment Limitations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, no sale may be made to you in
this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please
see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural persons. Before making
any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C)
of Regulation A. For general information on investing, we encourage you to refer to <B><I>www.investor.gov</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because this is a Tier 2, Regulation A
offering, most investors must comply with the 10% limitation on investment in the offering. The only investor in this offering
exempt from this limitation is an &ldquo;accredited investor&rdquo; as defined under Rule 501 of Regulation D under the Securities
Act (an <B>&ldquo;Accredited Investor&rdquo;</B>). If you meet one of the following tests you should qualify as an Accredited Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-size: 10pt">You are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the current year;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase Offered Shares (please see below on how to calculate your net worth);</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are an executive officer or general
        partner of the issuer or a manager or executive officer of the general partner of the issuer;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Offered Shares, with total assets in excess of $5,000,000;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940 (the <B>&ldquo;Investment Company Act&rdquo;</B>), or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(vii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are a trust with total assets in excess of $5,000,000, your purchase of Offered Shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the Offered Shares; or</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(viii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offering Period and Expiration Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering will start on or immediately
prior to the date on which the Commission initially qualifies this Offering Statement (the <B>&ldquo;Qualification Date&rdquo;</B>)
and will terminate on the Termination Date.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Procedures for Subscribing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you decide to subscribe for Offered
Shares in this offering, you should:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Go to&nbsp;www.AlzamendRegA.com, click
on the &ldquo;Reserve Shares&rdquo; button and follow the procedures as described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-size: 10pt">Electronically receive, review, execute and deliver to us a subscription agreement; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-size: 10pt">Deliver funds directly by wire or electronic
    funds transfer via ACH to the specified account maintained by SOS Back Office Solutions, LLC, the official Escrow Agent for
    this Offering, or mail payment in the form of check, money order or cashier&rsquo;s check directly to SOS Back Office FBO
    Alzamend Neuro, Inc. 512 SE Salmon Street, Portland, Oregon 97214.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any potential investor will have ample
time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only
deliver such subscription agreement upon request after a potential investor has had ample opportunity to review this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right to Reject Subscriptions. After we
receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred
to the escrow account, we have the right to review and accept or reject your subscription in whole or in part, for any reason or
for no reason. We will return all monies from rejected subscriptions immediately to you, without interest or deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acceptance of Subscriptions. Upon our acceptance
of a subscription agreement, we will countersign the subscription agreement and issue the shares subscribed at closing provided,
however, that we reserve the right to reject any subscription, in whole or in part, for any reason or for no reason. Once you submit
the subscription agreement and it is accepted, you may not revoke or change your subscription or request your subscription funds.
All accepted subscription agreements are irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Rule 251 of Regulation A, non-accredited,
non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater
of the purchaser's revenue or net assets (as of the purchaser's most recent fiscal year end). A non-accredited, natural person
may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on
how to calculate your net worth).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE: For the purposes of calculating your
net worth, it is defined as the difference between total assets and total liabilities. This calculation must exclude the value
of your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value
of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied
by the beneficiary of the account or by the fiduciary, if the fiduciary directly or indirectly provides funds for the purchase
of the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to purchase Offered Shares and
prior to the acceptance of any funds from an investor, an investor will be required to represent, to the Company&rsquo;s satisfaction,
that he is either an accredited investor or is in compliance with the 10% of net worth or annual income limitation on investment
in this offering.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters with respect to
the shares of Common Stock offered hereby will be passed upon by Sichenzia Ross Ference LLP, New York, NY.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of Alzamend
Neuro, Inc. as of April 30, 2019 and 2018 and for each of the years in the two-year period ended April 30, 2019 have been audited
by Squar Milner LLP, an independent registered public accounting firm, as stated in their report thereon (which report expresses
an unqualified opinion and includes an explanatory paragraph relating to the entity&rsquo;s ability to continue as a going concern),
and included in this Offering Circular and Offering Statement in reliance upon such report and upon the authority of such firm
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the Commission a Regulation
A Offering Statement on Form 1-A under the Securities Act of 1993, as amended, with respect to the shares of Common Stock offered
hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set
forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Common
Stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained
in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering
Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such
contract or other document filed as an exhibit to the Offering Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Upon the completion of this offering, and provided that
we register our shares of Common Stock under the Exchange Act by filing a registration statement on Form 8-A, we will be required
to file periodic reports, proxy statements, and other information with the Commission pursuant to that Act. Until such time, we
will continue to be required to file annual reports on Form 1-K, semiannual reports on Form 1-SA and current reports on Form 1-U.
You may read and copy this information at the Commission&rsquo;s Public Reference Room, 100 F Street, N.E., Room 1580, Washington,
D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.
The Commission also maintains an Internet website that contains reports, proxy statements and other information about issuers,
including us, that file electronically with the Commission. The address of this site is&nbsp;www.sec.gov.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD><B>For the Six Months Ended October 31, 2019</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Balance Sheets as of October 31, 2019 (unaudited) and April 30, 2019</TD>
    <TD STYLE="width: 13%; text-align: right">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Operations for the six months ended October 31, 2019 and 2018 (unaudited)</TD>
    <TD STYLE="text-align: right">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Cash Flows for the six months ended October 31, 2019 and 2018 (unaudited)</TD>
    <TD STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Changes in Stockholders&rsquo; Equity for the six months ended October 31, 2019 and 2018 (unaudited)</TD>
    <TD STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Notes to Financial Statements (unaudited)</TD>
    <TD STYLE="text-align: right">F-6 &ndash; F-15</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><B>For the Fiscal Year Ended April 30, 2019</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Report of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: right">F-16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Balance Sheets as of April 30, 2019 and 2018</TD>
    <TD STYLE="text-align: right">F-17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Operations for the years ended April 30, 2019 and 2018</TD>
    <TD STYLE="text-align: right">F-18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Cash Flows for the years ended April 30, 2019 and 2018</TD>
    <TD STYLE="text-align: right">F-19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Statements of Changes in Stockholders&rsquo; Equity for the years ended April 30, 2019 and 2018</TD>
    <TD STYLE="text-align: right">F-20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Notes to Financial Statements</TD>
    <TD STYLE="text-align: right">F-21 &ndash; F-36</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheets</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">&nbsp;Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">165,617</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">42,606</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Note receivable, related party, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,915</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,915</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,097,402</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,252,396</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,363,934</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,363,934</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">503,982</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,104,669</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Related party payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81,167</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,333</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;TOTAL CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">585,149</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,184,002</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;TOTAL LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">585,149</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,184,002</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Series A Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;750,000 shares issued and outstanding as of October 31, 2019 and April 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;Common stock, $0.0001 par value: 300,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;63,662,858 and 61,878,465 shares issued and outstanding as of October 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;and April 30, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,366</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,188</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,803,976</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,686,285</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Note receivable &ndash; related party for common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,031,632</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,375,633</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;TOTAL STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,778,785</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">316,915</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,363,934</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">&nbsp;Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">399,916</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,757,776</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,264,976</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">376,232</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt">&nbsp;Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,664,892</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,134,008</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,664,892</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,134,008</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;OTHER INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Interest income - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,893</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,767</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;Total other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,893</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,767</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,655,999</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,050,241</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;Basic and diluted weighted average common</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,408,014</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,958,276</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">&nbsp;Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,655,999</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(3,050,241</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">&nbsp;Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt">&nbsp;Accretion of original issue discount on notes receivable &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,250</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">&nbsp;Issuance of common stock for license fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,227,923</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt">&nbsp;Stock-based compensation to employees and consultants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">829,534</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">&nbsp;Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt">&nbsp;Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(356,444</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,483</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt">&nbsp;Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(600,687</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,394</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">&nbsp;Related party payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,834</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">&nbsp;Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,781,762</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(431,191</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">&nbsp;Loans to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;Proceeds from repayment of loans to related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">386,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">&nbsp;Net cash provided by (used in) investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(172,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;Proceeds from issuance of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,799,773</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,799,773</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Net increase (decrease) in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,011</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(603,191</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;Cash at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,606</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">545,001</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;Cash at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">165,617</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(58,190</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Non-cash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">&nbsp;Issuance of common stock for subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">481,554</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Six Months Ended October 31, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Series A Convertible</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Note Receivable
    -</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Preferred
    Stock</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Paid-In</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Related
    Party for</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Capital</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Deficit</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 20%"><FONT STYLE="font-size: 8pt">&nbsp;BALANCES, April 30, 2019</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">750,000</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">75</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">61,878,465</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">6,188</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">22,686,285</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">(15,000,000</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">(7,375,633</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="white-space: nowrap; width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">316,915</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Issuance of common stock</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">1,784,393</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">178</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">2,288,157</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">2,288,335</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Stock-based compensation to employees and consultants</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">829,534</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">829,534</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;Net loss</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">(1,655,999</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">(1,655,999</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;BALANCES, October 31, 2019</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">750,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">75</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">63,662,858</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">6,366</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">25,803,976</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">(15,000,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">(9,031,632</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><FONT STYLE="font-size: 8pt">1,778,785</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Six Months Ended October 31, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Series A Convertible</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Note Receivable
    -</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Preferred
    Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Paid-In</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Related
    Party for</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Capital</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Deficit</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 20%"><FONT STYLE="font-size: 8pt">&nbsp;BALANCES, April 30, 2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">750,000</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">75</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">49,493,196</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">4,949</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">4,827,408</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">(2,513,137</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 8pt">2,319,295</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;Issuance of common stock for license fees</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,227,923</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">223</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,227,700</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,227,923</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;Net loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(3,050,241</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(3,050,241</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;BALANCES, October 31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">750,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">75</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">51,721,119</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,172</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">7,055,108</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(5,563,378</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,496,977</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS &mdash;
Unaudited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. DESCRIPTION OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzamend Neuro, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Alzamend&rdquo;), is a specialty pharmaceutical company that was formed on February 26, 2016, to develop and commercialize
patented intellectual property to prevent, treat and cure Alzheimer&rsquo;s disease (&ldquo;Alzheimer&rsquo;s&rdquo; or &ldquo;AD&rdquo;).
The Company has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer&rsquo;s
and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with
up to moderate AD and possibly other neurodegenerative diseases (collectively, the &ldquo;Technology&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is devoting substantially all
its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its Common Stock.
The Company expects to continue to incur net losses in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. LIQUIDITY, GOING CONCERN AND MANAGEMENT&rsquo;S PLANS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared on the basis that the Company will continue as a going concern. As of October&nbsp;31, 2019, the Company had cash
of $165,617 and an accumulated deficit of $9,031,632. The Company has incurred recurring losses for the six months ended October&nbsp;31,
2019 totaling $1,655,999. In the past, the Company has financed its operations principally through issuances of promissory notes
and equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to incur
losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient
to fund its development and commercial operations. Based on our current business plan, we believe that our cash and cash equivalents
at October&nbsp;31, 2019, are not sufficient to meet our anticipated cash requirements during the twelve-month period subsequent
to the issuance of the financial statements included in this Semiannual Report on Form 1-SA. Management believes that the Company
has access to capital resources through potential public or private issuance of debt or equity securities. However, the Company
cannot be certain that additional funding will be available on acceptable terms, or at all, in which case it may have to significantly
delay, scale back or discontinue the development and/or commercialization of its product. The Company may also be required to (a)
seek collaborators for its product at an earlier stage than otherwise would be desirable and on terms that are less favorable than
might otherwise be available; or (b) relinquish or otherwise dispose of rights to Technology or its product that the Company would
otherwise seek to deploy or commercialize. These matters raise substantial doubt about the Company&rsquo;s ability to continue
as a going concern. The accompanying financial statements do not include any adjustments that might become necessary should the
Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and pursuant
to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.
In management&rsquo;s opinion, the accompanying statements reflect adjustments necessary to present fairly the financial position,
results of operations, and cash flows for those periods indicated, and contain adequate disclosure to make the information presented
not misleading. Adjustments included herein are of a normal, recurring nature unless otherwise disclosed in the footnotes. The
financial statements and notes thereto should be read in conjunction with the Company&rsquo;s audited financial statements and
notes thereto for the year ended April&nbsp;30, 2019 included in the Company&rsquo;s Annual Report on Form&nbsp;1-K, as filed
with the SEC on August 28, 2019. The accompanying balance sheet at October&nbsp;31, 2019 has been derived from the audited balance
sheet at April&nbsp;30, 2019 contained in the above referenced Form 1-K. Results of operations for interim periods are not necessarily
indicative of the results of operations for a full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2018, the board of directors
approved a 1-for-4 Reverse Stock Split of the Company&rsquo;s Common Stock. The Reverse Stock Split became effective on December&nbsp;13,
2018. As a result of the Reverse Stock Split, every four (4) shares of the Company&rsquo;s pre-Reverse Stock Split Common Stock
were combined and reclassified into one share of the Company&rsquo;s Common Stock. The number of shares of Common Stock subject
to outstanding options and warrants were also reduced by a factor of four as of December 13, 2018. All historical share and per-share
amounts reflected throughout the financial statements and other financial information in this filing have been adjusted to reflect
the Reverse Stock Split. The authorized capital and par value per share of the Company&rsquo;s Common Stock was not affected by
the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounting Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements,
in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The Company&rsquo;s critical accounting policies that involve significant
judgment and estimates include share-based compensation and valuation of deferred income taxes. Actual results could differ from
those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October&nbsp;31, 2019
and April&nbsp;30, 2019, the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Value of Financial Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financial instruments
are accounts payable, notes payable and notes payable, related party. The recorded values of accounts payable approximate their
fair values based on their short-term nature. The recorded values of notes payable and notes payable, related party are recorded
at their carrying value, net of any unamortized debt discount, which approximates their fair value based on their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. GAAP defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value
hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable
and the last is considered unobservable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1: Quoted prices in active markets for identical assets
or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2: Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 assumptions: Unobservable inputs
that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 31, 2019 and April 30, 2019,
the Company did not have any assets or liabilities recorded at fair value on a recurring or non-recurring basis.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines its income taxes
under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated
and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable
to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities.
Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related
asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods
in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income
tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes tax liabilities
by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized
and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods,
disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon
examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the
technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater
than fifty percent likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters
is different than the amount recorded, such differences impact income tax expense in the period in which such determination is
made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense.
U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has
taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities.
Management of the Company has evaluated tax positions taken by the Company and has concluded that as of October&nbsp;31, 2019,
there are no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require
disclosure in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed
as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other
entities that conduct certain research and development activities on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has acquired and may continue
to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license,
product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided
that there is no alternative future use of the rights in other research and development projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock option awards
in accordance with Financial Accounting Standards Board Accounting Standards Codification (&ldquo;FASB ASC&rdquo;) Topic No. 718,
<I>Compensation-Stock Compensation</I>. Under FASB ASC Topic No. 718, compensation expense related to stock-based payments is recorded
over the requisite service period based on the grant date fair value of the awards. Compensation previously recorded for unvested
stock options that are forfeited is reversed upon forfeiture. The Company uses the Black-Scholes option pricing model for determining
the estimated fair value for stock-based awards. The Black-Scholes model requires the use of assumptions which determine the fair
value of stock-based awards, including the option&rsquo;s expected term and the price volatility of the underlying stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Loss per Common Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes FASB ASC Topic No.
260, <I>Earnings per Share</I>. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator
is increased to include the number of additional common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution
that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in
the issuance of Common Stock that then shared in the earnings of the entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the effects of outstanding options,
warrants and convertible preferred stock are anti-dilutive in the period presented, shares of Common Stock underlying these instruments
have been excluded from the computation of loss per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following sets forth the number of
shares of Common Stock underlying outstanding convertible preferred stock, options and warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Series A convertible preferred stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,475,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,652,035</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">39,127,035</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,543,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reclassifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been
reclassified for comparative purposes to conform to the current period financial statement presentation. These reclassifications
had no effect on previously reported results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (&ldquo;FASB&rdquo;), or other standard setting bodies and adopted by the
Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet
effective are not expected to have a material impact on the Company&rsquo;s financial position or results of operations upon adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <I>Leases</I> (&ldquo;Topic 842&rdquo; or &ldquo;ASU 2016-02&rdquo;), which supersedes
the guidance in former ASC 840, Leases. The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, Codification
Improvements to Topic 842, Leases and ASU 2018-11, Leases (Topic 842): Targeted Improvements. The new standard requires lessees
to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the
lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized
based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record
a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification.
Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The standard
is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and is required to
be adopted using a modified retrospective approach. The Company adopted this standard on May 1, 2019. Upon adoption of this subtopic,
the impact was immaterial on its financial position, results of operations, cash flows, or financial statement disclosures as our
only lease, which is related to office space, has a term of less than 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No.
2017-11, <I>Earnings per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic
815) </I>(&ldquo;ASU 2017-11&rdquo;). ASU 2017-11 consists of two parts. The amendments in Part I of this update change the classification
analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether
certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes
equity classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. The amendments also clarify
existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument
(or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence
of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present
earnings per share (&ldquo;EPS&rdquo;) in accordance with Topic 260 to recognize the effect of the down round feature when it
is triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic EPS.
Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance
for contingent beneficial conversion features (in Subtopic 470-20, Debt&mdash;Debt with Conversion and Other Options), including
related EPS guidance (in Topic 260). The amendments in Part II of this update re-characterize the indefinite deferral of certain
provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments
do not have an accounting effect. For public business entities, the amendments in Part I of this update are effective for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments
in Part I of this update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years
beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an
entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal
year that includes that interim period. The amendments in Part II of this update do not require any transition guidance because
those amendments do not have an accounting effect. The Company chose to early adopt ASU 2017-11 for the fiscal year ended April
30, 2019. The early adoption allowed the Company to reduce the cost and complexity of accounting for financial instruments that,
due to down round provisions, would otherwise require fair value measurement each reporting period and eliminated the corresponding
impact and unnecessary volatility in reported earnings created by the revaluation when the Company&rsquo;s share value changes.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,
<I>Improvements to Nonemployee Share-Based Payment Accounting</I>, (&ldquo;ASU 2018-07&rdquo;). ASU 2018-07 simplifies the accounting
for share-based payments granted to nonemployees for goods and services. Under ASU 2018-07, most of the guidance on such payments
to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take effect for
public companies for fiscal years starting after Dec. 15, 2018, including interim periods within that fiscal year. The adoption
of this standard did not have a material impact on the Company&rsquo;s financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has considered all other recently
issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. NOTE RECEIVABLE, RELATED PARTY, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2018, Avalanche International
Corp., a related party (&ldquo;Avalanche&rdquo;), issued a promissory note (the &ldquo;AVLP Note&rdquo;) to the Company. Pursuant
to the AVLP Note, the Company agreed to provide Avalanche a loan of up to $995,500 for a period ending on April 30, 2019, subject
to the terms and conditions stated in the AVLP Note. The AVLP Note accrues interest at 10% per annum and includes a 10% original
issue discount. During the six months ended October&nbsp;31, 2019, the Company received payments on loans to Avalanche in the principal
amount of $105,000. During the six months ended October&nbsp;31, 2018, the Company provided loans to Avalanche in the principal
amount of $558,000, of which $386,000 was repaid as of October 31, 2018. As of October&nbsp;31, 2019, the balance of the loan receivable
from Avalanche is $100,915.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with FASB ASC No. 310, Receivables
(&ldquo;ASC 310&rdquo;), the Company accounts for its AVLP Note at amortized cost, which represents the amount at which the promissory
note was acquired, adjusted for accrued interest and accretion of original issue discount. Interest is accreted using the effective
interest method. The Company records interest on an accrual basis and recognizes it as earned in accordance with the contractual
terms of the promissory note. During the six months ended October&nbsp;31, 2019, the Company recorded contractual interest income
from the stated interest rate of $8,893. During the six months ended October&nbsp;31, 2018, the Company recorded $20,000 of interest
income for the discount accretion and recorded contractual interest income from the stated interest rate of $38,517.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company and Ault
Life Sciences Fund, LLC (&ldquo;ALSF&rdquo;) entered into a securities purchase agreement (the &ldquo;SPA&rdquo;) for the purchase
of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with
a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in
the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. In November 2019, the term
of the note receivable was extended to December 31, 2020. The note is secured by a pledge of the purchased shares. As the note
receivable from ALSF is related to the issuance of common stock, it is recorded as an offset to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses and other current assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Prepaid assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,527,517</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,172,957</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">481,554</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,121</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,229</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,210</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,210</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,097,402</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,252,396</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. STOCK-BASED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2016, the Company&rsquo;s
shareholders approved the Company&rsquo;s 2016 Stock Incentive Plan (the &ldquo;Plan&rdquo;). The Plan provides for the issuance
of a maximum of 12,500,000 shares of the Company&rsquo;s Common Stock to be offered to the Company&rsquo;s directors, officers,
employees, and consultants. Options granted under the Plan have an exercise price equal to or greater than the fair value of the
underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant.
The options expire between 5 and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to
a vesting period determined at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended October&nbsp;31,
2018, the Company did not grant any equity-based awards from the Plan and did not recognize any stock-based compensation expense
from previous grants made pursuant to the Plan. Pursuant to the terms of the License Agreement, during the six months ended October
31, 2018, the Company issued 2,227,923 shares of its Common Stock and recognized $2,227,923 in license fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All options that the Company grants are
granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the issuance of these financial
statements, there was not an active public market for the Company&rsquo;s shares. Accordingly, the fair value of the underlying
options was determined based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available
on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified
method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation
is a non-cash expense because the Company settles these obligations by issuing shares of the Company&rsquo;s Common Stock from
its authorized shares instead of settling such obligations with cash payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activity for the period April 30,
2019 to October 31, 2019, is presented below:&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Outstanding Options</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Shares</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Remaining</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Aggregate</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Available for</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number of</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercise</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contractual</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intrinsic</B></FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Grant</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Life (years)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Value</B></FONT></TD><TD STYLE="padding-bottom: 1pt; white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 25%">April 30, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">4,290,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,710,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">0.52</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7.51</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">15,352,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; text-align: left">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,800,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,800,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 1pt">Options cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.00</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">October 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,525,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,475,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.61</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.10</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">15,486,340</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at October 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,475,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.56</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.69</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">14,609,500</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">Options exercisable at October 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,191,134</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.19</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">6.85</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">12,027,462</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value in the table
above represents the total pretax intrinsic value (i.e., the difference between the fair value price on the respective date and
the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options. There have not been any options exercised during the six months ended October 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Value: 10; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock options granted to employees
and consultants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated fair value of stock options
granted to employees and consultants during the six months ended October&nbsp;31, 2019, was calculated using the Black-Scholes
option-pricing model using the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap"></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">For the Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">October 31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2019</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%">Weighted average risk-free interest rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2.25</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average life (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.2</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average grant-date fair value per&nbsp;share of options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.59</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Term:</I> The expected term
represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based
on the mid-point between the vesting date and the end of the contractual term).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Volatility:</I> The Company
uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company does not have trading history for its common
stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility
of its own stock price becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Risk-Free Interest Rate:</I> The Company
based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Dividend:</I> The Company has
not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Performance-contingent stock options
granted to employee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, the Board of Directors
granted 2,000,000 performance-contingent options to the Chief Executive Officer. These options have an exercise price of $1.00
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These options have two separate performance
triggers for vesting based upon our therapies achieving certain FDA approval milestones within a specified timeframe. By definition,
the performance condition in these options can only be achieved after the performance condition of FDA approval has been achieved.
As such, the requisite service period is based on the estimated period over which the market condition can be achieved. When a
performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense
commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will terminate and
no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $1.2 million of general and administrative expense if all of the performance conditions are achieved as stated in the
option agreement. Due to the significant risks and uncertainties associated with FDA approvals, through October&nbsp;31, 2019,
the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation
cost has been recognized for these awards.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-based compensation expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s results of operations
include expenses relating to stock-based compensation as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="text-align: center"><B>For the Six Months Ended October 31,
</B></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><B>2019</B></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><B>2018</B></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">&nbsp;Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">115,873</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">713,661</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 10pt">&nbsp;Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">829,534</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October&nbsp;31, 2019, total unamortized
stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $4.4 million.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately 3.1 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with a private offering
of securities between June 25, 2019 and October 31, 2019, the Company issued 878,358 warrants with an exercise price of $3.00 per
share. In addition, the Company issued to the placement agent of the private offering 175,672 warrants to purchase a number of
shares of Common Stock (the &ldquo;Placement Agent Warrants&rdquo;), a figure equal to ten percent (10%) of the number of shares
of Common Stock sold in the private offering. The Placement Agent Warrants are exercisable for a period of five years after their
date of issuance, have an exercise price of $1.75 per share and contain provisions pertaining to cashless exercise, standard anti-dilution
protection and piggyback registration rights. The grant date fair value of the Placement Agent Warrants was $95,467 and was recorded
within additional paid-in capital. The estimated fair value of the Placement Agent Warrants, was calculated using the Black-Scholes
option-pricing model using the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap"></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">For the Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Months Ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">October 31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2019</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">Risk-fee interest rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.52</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information
about Common Stock warrants outstanding at October 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Outstanding </B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;Exercisable </B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 19%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 14%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 16%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 13%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted</B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Remaining</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Average</B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercise</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contractual</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercise</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercise</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Outstanding</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Life (years)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exercisable</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Price</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.00 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">500,000</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58,333</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.00</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.20 </FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,500</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.20</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,972</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.20</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.75 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">175,672</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.0</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.75</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.75</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$3.00 </FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,970,863</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$3.00</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">532,361</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$3.00</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: black 2.25pt double; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1.00 - $3.00</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,652,035</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.8</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$2.82</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">594,666</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$2.79</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8. OTHER RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to hiring our current executive
team, management services were provided by our two previous executive officers and Executive Chairman pursuant to the terms of
an MSA entered into with Avalanche, a related party, on May 1, 2016. Avalanche provided management, consulting and financial services
to us. Such services included advice and assistance concerning any and all aspects of operations, planning and financing of Alzamend
and conducting relations with accountants, attorneys, financial advisors and other professionals. The term of the MSA, as amended,
was for the period May 1, 2016 to December 31, 2017, and was extended by written agreement. We initially paid $40,000 per month
for these services and, beginning February 2017, began paying $20,000 per month. During the six months ended October&nbsp;31,
2018, we recognized $120,000 in management fees in connection with this agreement. The MSA expired as of December&nbsp;31, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2018, Avalanche issued the
AVLP Note to the Company. Pursuant to the AVLP Note, the Company agreed to provide Avalanche a loan of up to $995,500 for a period
ending on April 30, 2019, subject to the terms and conditions stated in the AVLP Note. The AVLP Note accrues interest at 10% per
annum and includes a 10% original issue discount. During the six months ended October&nbsp;31, 2019, the Company received payments
on loans to Avalanche in the principal amount of $105,000. During the six months ended October&nbsp;31, 2018, the Company provided
loans to Avalanche in the principal amount of $558,000, of which $386,000 was repaid as of October 31, 2018. As of October&nbsp;31,
2019, the balance of the loan receivable from Avalanche is $100,915.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC No. 310, Receivables
(&ldquo;ASC 310&rdquo;), the Company accounts for its AVLP Note at amortized cost, which represents the amount at which the promissory
note was acquired, adjusted for accrued interest and accretion of original issue discount. Interest is accreted using the effective
interest method. The Company records interest on an accrual basis and recognizes it as earned in accordance with the contractual
terms of the promissory note. During the six months ended October&nbsp;31, 2019, the Company recorded contractual interest income
from the stated interest rate of $8,893. During the six months ended October&nbsp;31, 2018, the Company recorded $20,000 of interest
income for the discount accretion and recorded contractual interest income from the stated interest rate of $38,517 (See Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company and ALSF
entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per
share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total
purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related
party. In November 2019, the term of the note receivable was extended to December 31, 2020. The note is secured by a pledge of
the purchased shares. As the note receivable from ALSF is related to the issuance of common stock, it is recorded as an offset
to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9. NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During January 2017, the Company entered
into a promissory note and received net proceeds of $65,000. As consideration for this loan, the Company issued a promissory note
in the aggregate principal amount of $75,000, which included an OID and fees of $10,000. The OID was amortized as non-cash interest
expense over the term of the debt. The promissory note accrued interest at 15% per year. This loan was repaid during the six months
ended October&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. EQUITY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is
authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board of Directors has designated 1,360,000 shares
as Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Shares&rdquo;), The rights, preferences, privileges and
restrictions on the remaining authorized 8,640,000 shares of Preferred Stock have not been determined. The Company&rsquo;s Board
of Directors is authorized to create additional series of preferred shares and determine the number of shares, as well as the
rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. <FONT STYLE="background-color: white">As
of April 30, 2019, there were 750,000 shares of Series A Preferred Shares and no other shares of Preferred Stock issued or outstanding.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series A Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares convey no
dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for
that purpose. Holders of Series A Preferred Shares are entitled to 50 non-cumulative votes per share on all matters presented to
our stockholders for action. In addition, the affirmative vote of the holders of a majority of the Series A Preferred then outstanding,
voting as a separate class, is required for the Company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amend, alter or repeal any of the preferences or rights of the Series A Preferred Shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize any reclassification of the Series A Preferred Shares;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase the authorized number of Series A Preferred Shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>create any class or series of shares ranking prior to the Series A Preferred Shares as to dividends or liquidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares are not entitled
to preemptive rights. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary,
the Holders of Series A Preferred Shares shall be entitled to participate in any distribution out of the assets of the Company
on an equal basis per share with the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Series A Preferred Shares have
the right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common
Stock for every one (1) Series A Preferred Share. The conversion rate is not subject to anti-dilution adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2016, the Company&rsquo;s Board
of Directors approved a Certificate of Amendment to the Company&rsquo;s Certificate of Incorporation increasing its authorized
shares of Common Stock from 150,000,000 to 300,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2019, we entered into securities
purchase agreements for the purchase of 157,346 shares of Common Stock for a total purchase price of $236,023, or $1.50 per share
with 78,672 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The purchase price
of $236,023 was paid in cash. In May 2019, an additional 27,667 shares of Common Stock were sold under the same terms for a total
purchase price of $41,501.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company and ALSF
entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per
share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total
purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related
party. In November 2019, the term of the note receivable was extended to December 31, 2020. The note is secured by a pledge of
the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored nation status,
denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any future
financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered
under the Securities Act within 180 days of the final closing of an initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2019 Placement Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between June&nbsp;25, 2019 and October
31, 2019, the Company entered into subscription agreements for the purchase of 1,756,726 units at $1.50 for each unit purchased
pursuant to its 2019 private offering (the &ldquo;Private Offering&rdquo;). Each unit consists of one (1) share of Common Stock
and one (1) warrant to purchase one half (0.5) share of Common Stock. In aggregate, the 1,756,726 units represents 1,756,726 shares
of Common Stock and 878,363 warrants with an exercise price of $3.00 per share for an aggregate purchase price of $2,635,089, or
$1.50 per share. The Private Offering was conducted pursuant to the terms of a Confidential Private Placement Memorandum dated
June&nbsp;12, 2019 (the &ldquo;2019 PPM&rdquo;). As of October 31, 2019, in conjunction with the 2019 PPM, the Company incurred
$395,263 in placement fees resulting in net proceeds to the Company of $2,239,826.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2019 Placement Agreement
effective as of June 10, 2019 entered into in connection with the 2019 PPM, the Company has agreed with the Placement Agent to
certain cash compensation payable to the Placement Agent and, without limitation, to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Placement Agent Compensation</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the initial closing of the 2019 PPM
the Company must pay to the Placement Agent a non-refundable fee of Twenty-Five Thousand Dollars ($25,000) and issue to the Placement
Agent 500,000 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the Company has issued to the
Placement Agent warrants to purchase a number of shares of Common Stock (the &ldquo;Placement Agent Warrants&rdquo;) equal to
ten percent (10%) of the number of shares of Common Stock sold in the 2019 PPM. The Placement Agent Warrants are exercisable for
a period of five (5) years after their date of issuance, have an exercise price of $1.75 per share and contain provisions pertaining
to cashless exercise, standard anti-dilution protection and piggyback registration rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Proceeds</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will apply the net proceeds
from the Offering primarily: (i) for licensing and other fees to the University and the Byrd Institute; (ii) to pay certain fees
to the FDA; (iii) to pay for third-party research; (iv) to pay certain marketing-related fees, and (v) for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Incurrence of Debt</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the two (2) years following the
final Closing, the Company will not, without the prior written consent of the Placement Agent, incur indebtedness for borrowed
money in an aggregate amount in excess of $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Additional Shares Issuable to the Placement
Agent, its Affiliates and the Investors in this Offering</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to take certain
actions within prescribed time periods. If the Company fails to do so on a timely basis, the Company has agreed to issue to the
Placement Agent, its Affiliates and the investors in the 2019 PPM a significant number of additional shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Future Sales of Securities and Conversion
of the Series A Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the final
Closing and ending two years thereafter, provided that no Qualified Financing (as defined below) has occurred, if (i) the Company
issues any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Placement Agent&rsquo;s
consent, or (ii) any holder of the Company&rsquo;s Series A Preferred Stock elects to convert such shares into Common Stock, then
upon any such issuance or conversion, as the case may be, the Placement Agent, its Affiliates and the Investors in this Offering
will be entitled to receive a significant number of additional shares of Common Stock (this provision can thus be deemed the functional
equivalent of weighted average anti-dilution protection). For purposes of the 2019 Placement Agreement, a &ldquo;Qualified Financing&rdquo;
means the sale of equity securities by us in a single transaction or a series of related transactions registered under the Securities
Act resulting in gross proceeds to us of not less than $25,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, during the period commencing
on the final Closing and ending two years thereafter, the Company has agreed not to enter into any transactions with Milton C.
Ault, our chairman of the board and principal stockholder or any Affiliate (as defined in Rule 405 of the Securities Act) thereof
absent the Placement Agent&rsquo;s consent. Notwithstanding the foregoing, the Placement Agent has consented to our potential entry
into an agreement whereby the Company would issue to an Affiliate of Mr. Ault 10,000,000 shares of Common Stock on terms substantially
identical to those of the 2019 PPM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Failure to File Reports under the Securities
Act</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Company does not
file its annual or semiannual reports with the Commission on a timely basis, then the Placement Agent will have the right to designate
a replacement for one of our members of our Board for a period of one (1) year following any such failure to file a periodic report
on a timely basis, provided that neither Mr. Ault nor William B. Horne shall be subject to this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreement with the Chief
Executive Officer</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon or before the initial Closing of the
2019 PPM, the Company shall have entered into an employment agreement with Stephan Jackman having a term of at least two (2) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Corporate Governance</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the final
closing of the 2019 PPM and ending at such time as the Common Stock is listed on a national securities exchange, the Placement
Agent will have the right to designate one member of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Uplisting Agreement</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Uplisting Agreement effective
as of June 10, 2019, the Company has agreed with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will engage the Placement Agent
as an advisor (in such capacity, the &ldquo;Advisor&rdquo;) to, at our request, provide advisory services (the &ldquo;Services&rdquo;)
to us in connection with a potential public offering (an &ldquo;IPO&rdquo;). The Company expects that any such Services rendered
would consist principally of advising us on how to properly develop and implement strategies that would enhance our ability to
successfully complete an IPO and in connection therewith obtain a listing on a national securities exchange, provided that the
Company meets any such exchange&rsquo;s listing criteria at the applicable time as well as introduce us to appropriate underwriters
that would lead or conduct any such IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Uplisting Agreement,
the Company will, whether the Company requests its assistance or not, be obligated to issue to the Advisor Five Hundred Thousand
(500,000) shares of Common Stock as well as make a cash payment to the Advisor in the amount of $475,000 once the Company has
raised no less than $1,000,000 in gross proceeds in the 2019 PPM and, in the event that the Company successfully consummates an
IPO with an underwriter introduced to us by the Advisor, pay the Advisor a fee equal to two percent (2%) of the gross proceeds
raised in the IPO.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If prior to a Qualified Financing the Company
issues any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Advisor&rsquo;s consent,
then upon any such issuance, the Advisor will be entitled to receive a significant number of additional shares of Common Stock
(this provision can, like its counterpart in the 2019 Placement Agreement described above, thus be deemed the functional equivalent
of weighted average anti-dilution protection).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Company engages in
what the Uplisting Agreement refers to as an &ldquo;Alternative Transaction&rdquo; during the term of such agreement or for a period
of two (2) years thereafter, the Company will be obligated to pay to the Advisor a fee in cash equal to three percent (3%) of the
amount of the consideration paid or received by us and/or our stockholders in the Alternative Transaction. For purposes of the
Uplisting Agreement, an &ldquo;Alternative Transaction&rdquo; means a business combination, including, any merger, acquisition
or sale of stock or assets (whether the Company is the acquiring or the acquired entity), joint venture, strategic alliance or
other similar transaction, and shall extend to any subsidiary of ours on the same terms as will be applicable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the Uplisting Agreement will
be two (2) years, subject to either party&rsquo;s right to terminate it in the event that the other party to the agreement breaches
it in any material way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with FASB ASC 855-10, the
Company has analyzed its operations subsequent to October 31, 2019 and has determined that it does not have any material subsequent
events to disclose in these financial statements except for the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Performance option grant</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In November 2019, the Board of Directors
granted 4,250,000 performance- and market-contingent awards to members of the senior leadership team. These awards have an exercise
price of $1.50 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful
achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180
days after the Company&rsquo;s initial public offering for its common stock, or (ii) stepped target prices for a change in control
transaction. The target prices range from $15 per share to $40 per share. In the event any the stock price milestones are not
achieved within three years, the unvested portion of the performance options will be reduced by 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Value: 15; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of Alzamend Neuro, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheets of Alzamend Neuro, Inc<B>.</B> (the &ldquo;Company&rdquo;) as of April 30, 2019 and 2018, and the related statements of
operations, changes in stockholders&rsquo; equity and cash flows for the years then ended and the related notes to the financial
statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company&nbsp;as of April 30, 2019 and 2018, and the results of its operations and its cash flows
for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going Concern Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the
Company has a history of significant recurring losses from operations through April 30, 2019, and does not have sufficient working
capital at April 30, 2019 to fund its planned operations during the twelve-month period subsequent to the issuance of these financial
statements. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard
to these matters also are described in Note 2. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>/s/ SQUAR MILNER LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company's auditor
since 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">San Diego, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">August 28, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Value: 16; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">42,606</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">545,001</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Note receivable, related party, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,915</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">403,333</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,252,396</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,467,685</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,416,019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,416,019</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,104,669</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">90,088</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Related party payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,333</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,636</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">TOTAL CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,184,002</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,724</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">designated; 750,000 shares issued and outstanding as of April 30, 2019 and 2018, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Common stock, $0.0001 par value: 300,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>61,878,465 and 49,493,196 shares issued and outstanding as of</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>April 30, 2019 and 2018, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,188</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,949</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,686,285</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,827,408</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Note receivable &ndash; related party for common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,375,633</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,513,137</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">316,915</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,319,295</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,500,917</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,416,019</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,700,083</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">323,403</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,308,800</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">575,027</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,008,883</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">898,430</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,008,883</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(898,430</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE), NET</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest income - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,387</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,341</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,259</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest expense - debt discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,315</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,387</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,233</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,862,496</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(931,663</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.08</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">Basic and diluted weighted average common<BR>
shares outstanding</P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">58,843,040</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">45,389,196</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(4,862,496</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(931,663</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest expense -- debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,315</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Legal expense -- debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,809</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accretion of original issue discount on notes receivable &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,667</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,333</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Issuance of common stock for license fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,227,923</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,417</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Stock-based compensation to employees and consultants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,170</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,289</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,415,368</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,014,581</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,877</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,045,200</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,051,700</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Loans to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(840,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Proceeds from repayment of loans to related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">792,085</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">440,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash provided by (used in) investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234,085</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(400,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,023</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,615,236</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Advances from related party payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,697</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(259,411</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Proceeds from notes payable, related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Payments on notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Payments on notes payable, related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(427,600</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 27pt">&nbsp;Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,720</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,991,725</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease) increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(502,395</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">540,025</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">545,001</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,976</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">42,606</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">545,001</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,569</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-cash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Fair value of warrants issued in connection with promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,235</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Issuance of notes payable from related party in payment of accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">29,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Issuance of common stock upon conversion of convertible preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,220</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Issuance of common stock for note receivable &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.
</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Years Ended April 30, 2019 and April
30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Series A Convertible</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Note Receivable -</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Related Party for</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; white-space: nowrap">BALANCES, April 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,360,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">136</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">32,874,342</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">3,287</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">993,121</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(1,581,474</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(584,930</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,203,887</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">421</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,614,815</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,615,236</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">&nbsp;Issuance of common stock for conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">&nbsp;of Series A preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(610,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,200,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,220</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,159</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Issuance of common stock for license fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214,967</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,396</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,417</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Fair value of warrants issued in connection</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">with promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,235</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,235</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; white-space: nowrap">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(931,663</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(931,663</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap">BALANCES, April 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,493,196</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,949</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,827,408</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,513,137</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,319,295</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,346</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,007</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,023</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Issuance of common stock to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,999,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Stock-based compensation to employees and consultants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,170</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,170</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Issuance of common stock for license fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,227,923</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,227,700</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,227,923</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; white-space: nowrap">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,862,496</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,862,496</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 2.5pt">BALANCES, April 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">750,000</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,878,465</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,188</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,686,285</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(15,000,000</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,375,633</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">316,915</TD><TD STYLE="white-space: nowrap; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALZAMEND NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. DESCRIPTION OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alzamend Neuro, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Alzamend&rdquo;), is a specialty pharmaceutical company that was formed on February 26, 2016, to develop and commercialize
patented intellectual property to prevent, treat and cure Alzheimer&rsquo;s disease (&ldquo;Alzheimer&rsquo;s&rdquo; or &ldquo;AD&rdquo;).
The Company has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer&rsquo;s
and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with
up to moderate AD and possibly other neurodegenerative diseases (collectively, the &ldquo;Technology&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2018, the Company implemented
a 1-for-4 Reverse Stock Split of its Common Stock. The Reverse Stock Split became effective on December 13, 2018. As a result of
the Reverse Stock Split, every four (4) shares of the Company&rsquo;s pre-Reverse Stock Split Common Stock were combined and reclassified
into one share of the Company&rsquo;s Common Stock. The number of shares of Common Stock subject to outstanding options and warrants
were also reduced by a factor of four as of December 13, 2018; further, their respective exercise prices were increased by a factor
of four as of the foregoing date. All historical share and per-share amounts reflected throughout the consolidated financial statements
and other financial information in this filing have been adjusted to reflect the Reverse Stock Split. The authorized capital and
par value per share of the Company&rsquo;s Common Stock was not affected by the Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is devoting substantially all
its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its Common Stock.
The Company expects to continue to incur net losses in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. LIQUIDITY, GOING CONCERN AND MANAGEMENT&rsquo;S PLANS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared on the basis that the Company will continue as a going concern. As of April 30, 2019, the Company
had cash of $42,606 and an accumulated deficit of $7,375,633. The Company has incurred recurring losses and for the year ended
April 30, 2019, such losses totaled $4,862,496. In the past, the Company has financed its operations principally through issuances
of promissory notes and equity securities. During the year ended April 30, 2019, the Company continued to obtain additional equity
and debt financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to continue to incur
losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient
to fund its development and commercial operations. Based on our current business plan, the Company believes that our cash at April
30, 2019, is not sufficient to meet our anticipated cash requirements during the twelve-month period subsequent to the issuance
of the financial statements included in this Offering Circular. Management believes that the Company has access to capital resources
through potential public or private issuance of debt or equity securities. However, the Company cannot be certain that additional
funding will be available on acceptable terms, or at all, in which case it may have to significantly delay, scale back or discontinue
the development and/or commercialization of its product. The Company may also be required to (a) seek collaborators for its product
at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or
(b) relinquish or otherwise dispose of rights to technology or its product that the Company would otherwise seek to deploy or commercialize.
These matters raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The accompanying financial
statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and pursuant
to the rules and regulations of the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounting Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements,
in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Our critical accounting policies that involve significant judgment and estimates
include share-based compensation and valuation of deferred income taxes. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
investments with a remaining maturity of three months or less when purchased to be cash equivalents. The recorded carrying amounts
of the Company&rsquo;s cash and cash equivalents approximate their fair value. As of April&nbsp;30, 2019 and 2018, the Company
had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Value of Financial Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments are accounts
payable, notes payable and notes payable, related party. The recorded values of accounts payable approximate their fair values
based on their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. GAAP defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value
hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable
and the last is considered unobservable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1: Quoted prices in active markets
for identical assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2: Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 assumptions: Unobservable inputs
that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines its income taxes
under the asset and liability method. Under the asset and liability approach, deferred income tax assets and liabilities are calculated
and recorded based upon the future tax consequences of temporary differences by applying enacted statutory tax rates applicable
to future periods for differences between the financial statements carrying amounts and the tax basis of existing assets and liabilities.
Generally, deferred income taxes are classified as current or non-current in accordance with the classification of the related
asset or liability. Those not related to an asset or a liability are classified as current or non-current depending on the periods
in which the temporary differences are expected to reverse. Valuation allowances are provided for significant deferred income tax
assets when it is more likely than not that some or all of the deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes tax liabilities
by prescribing a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized
and also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods,
disclosure and transition. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon
examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the
technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater
than fifty percent likely of being realized upon ultimate settlement. To the extent that the final tax outcome of these matters
is different than the amount recorded, such differences impact income tax expense in the period in which such determination is
made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense.
U.S. GAAP also requires management to evaluate tax positions taken by the Company and recognize a liability if the Company has
taken uncertain tax positions that more likely than not would not be sustained upon examination by applicable taxing authorities.
Management of the Company has evaluated tax positions taken by the Company and has concluded that as of April 30, 2019, there are
no uncertain tax positions taken, or expected to be taken, that would require recognition of a liability that would require disclosure
in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock option awards
in accordance with Financial Accounting Standards Board Accounting Standards Codification (&ldquo;FASB ASC&rdquo;) Topic No. 718,
<I>Compensation-Stock Compensation</I>. Under FASB ASC Topic No. 718, compensation expense related to stock-based payments is recorded
over the requisite service period based on the grant date fair value of the awards. Compensation previously recorded for unvested
stock options that are forfeited is reversed upon forfeiture. The Company uses the Black-Scholes option pricing model for determining
the estimated fair value for stock-based awards. The Black-Scholes model requires the use of assumptions which determine the fair
value of stock-based awards, including the option&rsquo;s expected term and the price volatility of the underlying stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our accounting policy for equity instruments
issued to consultants and vendors in exchange for goods and services follows the provisions of FASB ASC Topic No. 505-50, <I>Equity
Based Payments to Non-Employees</I>. Accordingly, the measurement date for the fair value of the equity instruments issued is determined
at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at
which the consultant or vendor&rsquo;s performance is complete. In the case of equity instruments issued to consultants, the fair
value of the equity instrument is recognized over the term of the consulting agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are expensed
as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other
entities that conduct certain research and development activities on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has acquired and may continue
to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license,
product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided
that there is no alternative future use of the rights in other research and development projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Loss per Common Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes FASB ASC Topic No.
260, <I>Earnings per Share</I>. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator
is increased to include the number of additional common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution
that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in
the issuance of Common Stock that then shared in the earnings of the entity. The Company has included 7,500,000 stock options,
with an exercise price of $0.0004, in its loss per share calculation for the years ended April&nbsp;30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the effects of outstanding options,
warrants and convertible preferred stock are anti-dilutive in the period presented, shares of Common Stock underlying these instruments
have been excluded from the computation of loss per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following sets forth the number of
shares of Common Stock underlying outstanding convertible preferred stock, options and warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 49.5pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Series A convertible preferred stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">15,000,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock options (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,210,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,584,172</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,794,172</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,043,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD STYLE="text-align: justify; padding-right: 49.5pt">The Company has excluded 7,500,000 stock options, with an exercise price
of $0.0004, from its anti-dilutive securities.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reclassifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been
reclassified for comparative purposes to conform to the current period financial statement presentation. These reclassifications
had no effect on previously reported results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board, (&ldquo;FASB&rdquo;), or other standard setting bodies and adopted by the
Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet
effective will not have a material impact on the Company&rsquo;s financial position or results of operations upon adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued No. 2016-02,
<I>Leases</I> (&ldquo;Topic 842&rdquo; or &ldquo;ASU 2016-02&rdquo;), which supersedes the guidance in former ASC 840, Leases.
The FASB issued further updates to this guidance in July 2018 through ASU 2018-10, Codification Improvements to Topic 842, Leases
and ASU 2018-11, Leases (Topic 842): Targeted Improvements. The new standard requires lessees to apply a dual approach, classifying
leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase
by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or
on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability
for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less
will be accounted for similar to existing guidance for operating leases today. The standard is effective for interim and annual
periods beginning after December&nbsp;15, 2018, with early adoption permitted, and is required to be adopted using a modified retrospective
approach. The Company plans to adopt this standard on May&nbsp;1, 2019. Upon adoption of this subtopic, the Company expects the
impact to be immaterial on its financial position, results of operations, cash flows, or financial statement disclosures as our
only lease, which is related to office space, has a term of less than 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No. 2017-11,
<I>Earnings&nbsp;per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)</I>
(&ldquo;ASU 2017-11&rdquo;). ASU 2017-11 consists of two parts. The amendments in Part I of this update change the classification
analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether
certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes
equity classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. The amendments also clarify
existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument
(or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence
of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present
earnings per share (&ldquo;EPS&rdquo;) in accordance with Topic 260 to recognize the effect of the down round feature when it is
triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic EPS. Convertible
instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent
beneficial conversion features (in Subtopic 470-20, Debt&mdash;Debt with Conversion and Other Options), including related EPS guidance
(in Topic 260). The amendments in Part II of this update re-characterize the indefinite deferral of certain provisions of Topic
480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting
effect. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this update are
effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December
15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the
amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that
interim period. The amendments in Part II of this update do not require any transition guidance because those amendments do not
have an accounting effect. The Company chose to early adopt ASU 2017-11 for the fiscal year ended April 30, 2019. The early adoption
allows the Company to reduce the cost and complexity of accounting for financial instruments that, due to down round provisions,
would otherwise require fair value measurement each reporting period and eliminate the corresponding impact and unnecessary volatility
in reported earnings created by the revaluation when the Company&rsquo;s share value changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,&nbsp;<I>Improvements
to Nonemployee Share-Based Payment Accounting</I>, (&ldquo;ASU 2018-07&rdquo;). ASU 2018-07 simplifies the accounting for share-based
payments granted to nonemployees for goods and services. Under ASU 2018-07, most of the guidance on such payments to nonemployees
would be aligned with the requirements for share-based payments granted to employees. The changes take effect for public companies
for fiscal years starting after Dec. 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments
are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December
15, 2020. Early adoption is permitted, but no earlier than an entity&rsquo;s adoption date of Topic 606. The Company is currently
evaluating the impact of adopting this standard on its consolidated financial statements and related disclosures but does not expect
it to have a material impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has considered all other recently
issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. NOTE RECEIVABLE, RELATED PARTY, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2018, Avalanche International
Corp., a related party (&ldquo;Avalanche&rdquo;), issued a promissory note (the &ldquo;AVLP Note&rdquo;) to the Company pursuant
to which the Company agreed to provide Avalanche a loan of up to $995,500 for the period ending on April 30, 2019, subject to the
terms and conditions stated in the AVLP Note. The AVLP Note accrues interest at 10% per annum and includes a 10% original issue
discount. At April 30, 2018, the Company has provided loans to Avalanche in the principal amount of $800,000, of which $400,000
was repaid, resulting in net loans to Avalanche of $400,000 and an original issue discount of $40,000. During the year ended April&nbsp;30,
2019, the Company provided loans to Avalanche in the principal amount of $558,000 and received payments of $792,085. As of April&nbsp;30,
2019, the balance of the loan receivable from Avalanche was $205,915.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC No. 310, Receivables
(&ldquo;ASC 310&rdquo;), the Company accounts for its AVLP Note at amortized cost, which represents the amount at which the promissory
note was acquired, adjusted for accrued interest and accretion of original issue discount. Interest is accreted using the effective
interest method. The Company records interest on an accrual basis and recognizes it as earned in accordance with the contractual
terms of the promissory note. The original issue discount of $90,500 was amortized as interest income through the maturity date.
During the year ended April 30, 2019, the Company recorded $87,167 of interest income for the discount accretion and recorded contractual
interest income from the stated interest rate of $59,220. During the year ended April 30, 2018, the Company recorded $3,333 of
interest income for the discount accretion and recorded contractual interest income from the stated interest rate of $4,008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company and Ault
Life Sciences Fund, LLC (&ldquo;ALSF&rdquo;) entered into a securities purchase agreement (the &ldquo;<B>SPA</B>&rdquo;) for the
purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants
with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000
was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. The note is secured
by a pledge of the purchased shares. As the note receivable from ALSF is related to the issuance of common stock, it is recorded
as an offset to additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepaid expenses and other current assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Prepaid assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,172,957</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,446,667</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,229</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,008</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,210</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,010</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,252,396</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,467,685</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Spartan Consulting Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company entered into a five year consulting
agreement with Spartan pursuant to which Spartan has agreed to provide consulting services with respect to general corporate matters,
including, but not limited to, advice and input with respect to raising capital, potential merger and acquisition transactions,
identifying suitable personnel for management, developing corporate structure and finance strategies, assisting the Company with
strategic introductions, assisting management with enhancing corporate and shareholder value and introducing the Company to potential
investors. In December 2017, since the maximum amount was raised in the Offering, the Company paid to Spartan a consulting fee
of $1,400,000 for the services to be rendered over the sixty (60) month term of this consulting agreement. As of April&nbsp;30,
2019 the unamortized balance under this agreement was $1,026,667, which is included in prepaid expenses and other current assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. INCOME TAXES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has fully reserved the net
deferred income tax assets by taking a full valuation allowance against these assets. As a result of this decision, during the
years ended April 30, 2019 and 2018, the Company did not recognize any income tax benefit as a result of its net loss. The table
below shows the balances for the deferred income tax assets and liabilities as of the date indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred income tax asset:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 11pt">Net operating loss carryover</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,541,317</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">517,972</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Other temporary differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,739</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,637</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 11pt">Total deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,662,056</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525,609</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,662,056</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(525,609</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 22pt">Deferred income tax asset, net of allowance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.1pt">The income tax provision (benefit) consists
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Federal and State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 11pt">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-indent: 11pt">Deferred</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(1,662,056</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(525,609</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,662,056</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">525,609</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 11pt">Income tax provision (benefit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the U.S. Congress
enacted the Tax Cuts and Jobs Act (&ldquo;tax reform&rdquo; or &ldquo;Tax Act&rdquo;) which, among other things, lowered the U.S.
statutory tax rate from 35% to 21% effective January 1, 2018. Consequently, the Company applied a blended U.S. statutory federal
income tax rate of 29.7% for fiscal 2018. During the years ended April 30, 2019 and 2018, the Company did not recognize income
tax expense. Our effective tax rate was 0% for the years ended April&nbsp;30, 2019 and 2018. The effective tax rate differed primarily
due to the change in the valuation allowance, primarily related to the revaluation of deferred tax assets and liabilities to reflect
the new federal tax rate. The reconciliation of income tax attributable to operations computed at the U.S. Federal statutory income
tax rate to income tax expense is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Tax benefit at U.S. Federal statutory tax rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-21.0</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-29.7</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase (decrease) in tax rate resulting from:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 11pt">Allowance against deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.9</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-1.0</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 11pt">Nondeductible meals &amp; entertainment expense and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1</TD><TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 11pt">Taxes in respect of prior years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 11pt">Changes in federal tax rate</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30.6</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 11pt">Effective tax rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At April 30, 2019, the Company had total
domestic Federal net operating loss carryovers of approximately $7,185,129 available to offset future taxable income. Federal net
operating loss carryovers (&ldquo;NOLs&rdquo;) expire beginning in 2026. The Company has not filed its 2016 through 2019 Federal
income tax returns. The Company will not be able to utilize these carryovers until the related tax returns are filed. In accordance
with Section 382 of the Internal Revenue Code, deductibility of the Company&rsquo;s NOLs may be subject to an annual limitation
in the event of a change of control as defined under the regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not
be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the
periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled
reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration
of all of the information available and due to the substantial doubt related to the Company&rsquo;s ability to continue as a going
concern and utilize its deferred tax assets, the Company recorded a full valuation allowance of the deferred tax asset. For the
year ended April 30, 2019 the valuation allowance has increased by $1,136,447.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 through 2019 tax years remains
open to examination by the Internal Revenue Service. The IRS has the authority to examine such tax year until the applicable statute
of limitations expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. STOCK-BASED COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2016, the Company&rsquo;s
shareholders approved the Company&rsquo;s 2016 Stock Incentive Plan (the &ldquo;Plan&rdquo;). The Plan provides for the issuance
of a maximum of 12,500,000 shares of the Company&rsquo;s Common Stock to be offered to the Company&rsquo;s directors, officers,
employees, and consultants. On March 1, 2019 the Company&rsquo;s shareholders approved an additional 7,500,000 shares to be available
for issuance under the plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the
underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant.
The options expire between 5 and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to
a vesting period determined at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All options that the Company grants are
granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the issuance of these financial
statements, there was not an active public market for the Company&rsquo;s shares. Accordingly, the fair value of the underlying
options was determined based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available
on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified
method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation
is a non-cash expense because the Company settles these obligations by issuing shares of the Company&rsquo;s Common Stock from
its authorized shares instead of settling such obligations with cash payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of option activity under the
Company&rsquo;s Plan as of April 30, 2019 and 2018, and changes during the years ended are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Outstanding Options</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Available for</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Grant</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; white-space: nowrap">Balance at April 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,875,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,625,000</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.0004</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.00</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,296,250</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 10pt; white-space: nowrap">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">125,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(125,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.0004</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap">Balance at April 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0004</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.00</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,497,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap">Increase to plan shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; white-space: nowrap">Options granted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,210,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,210,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.0000</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; white-space: nowrap">Balance at April 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,290,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,710,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.5228</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.51</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">15,352,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; white-space: nowrap">Options vested and expected to vest at April 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,710,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.4532</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">8.16</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">14,352,000</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; white-space: nowrap">Options exercisable at April 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,045,415</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0682</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.17</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">11,519,708</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value in the table
above represents the total pretax intrinsic value (i.e., the difference between the fair value price on the respective date and
the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options. There have not been any options exercised during the years ended April&nbsp;30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock options granted to employees
and consultants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended April 30, 2018, the
Company did not grant any equity-based awards from the Plan and did not recognize any stock-based compensation expense from previous
grants made pursuant to the Plan. The estimated fair value of stock options granted to employees and consultants during the year
ended April 30, 2019, were calculated using the Black-Scholes option-pricing model using the following assumptions:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center"></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><B>For the Year</B></P>
                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><B>Ended April 30,</B></P></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.00 - 6.25</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: center">83.40%</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2.50% - 2.95%</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">--</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Term:</I> The expected term
represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based
on the mid-point between the vesting date and the end of the contractual term).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Volatility:</I> The Company
uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company does not have trading history for its common
stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility
of its own stock price becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Risk-Free Interest Rate:</I> The Company
based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Dividend:</I> The Company has
not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Performance-contingent stock options
granted to employee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, the Board of Directors
granted 2,000,000 performance-contingent options to the Chief Executive Officer. These options have an exercise price of $1.00
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These options have two separate performance
triggers for vesting based upon our therapies achieving certain FDA approval milestones within a specified timeframe. By definition,
the performance condition in these options can only be achieved after the performance condition of FDA approval has been achieved.
As such, the requisite service period is based on the estimated period over which the market condition can be achieved. When a
performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based compensation expense
commences. In the event any the milestones are not achieved by the specified timelines, such vesting award will terminate and no
longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $1.2 million of general and administrative expense if all of the performance conditions are achieved as stated in the
option agreement. Due to the significant risks and uncertainties associated with FDA approvals, through April 30, 2019, the Company
believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has
been recognized for these awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock issued for license fees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the License Agreement,
during the years ended April 30, 2019 and 2018, the Company issued 2,227,923 and 214,967 shares of its Common Stock and recognized
$2,227,923 and $218,417, respectively, in license fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-based compensation expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s results of operations include expenses relating
to stock-based compensation as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended April 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,227,923</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">218,417</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">396,170</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,624,093</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">218,417</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April 30, 2019, total unamortized
stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $4.1 million.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately 3.6 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8. WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2017, the Company issued
warrants to purchase an aggregate of 5,500 shares of Common Stock at an exercise price equal to $1.20 per share of Common Stock
in connection with the issuance of a promissory note in the aggregate principal amount of $44,000 to DPW Holdings, Inc. (&ldquo;DPW&rdquo;),
a related party (See Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 10, 2019, the Company issued warrants
to purchase 500,000 shares of Common Stock at an exercise price equal to $1.00 per share of Common Stock in connection with entering
into a two-year advisory agreement with a consultant related to identifying sources of capital for the Company. The warrants vest
over five years. The grant date fair value of the warrants was $217,448 and will be expensed over the term of the consulting agreement.
The estimated fair value of warrants granted to the consulting during the year ended April 30, 2019, was calculated using the Black-Scholes
option-pricing model using the following assumptions:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 85%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; white-space: nowrap"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>For the Year</B></FONT></P>
                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Ended April 30,</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt"><B>2019</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Expected term (in years)</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-size: 10pt">2.50</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Volatility</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-size: 10pt">69.35%</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Risk-free interest rate</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-size: 10pt">2.53%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Dividend yield</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;-- </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Term:</I> The expected term
represents the period that the warrants granted are expected to be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Volatility:</I> The Company
uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company does not have trading history for its common
stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility
of its own stock price becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Risk-Free Interest Rate:</I> The Company
based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expected Dividend:</I> The Company has
not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2019, the Company issued 78,672
warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance in connection with a securities
purchase agreements for the purchase of 157,346 shares of Common Stock for a total purchase price of $236,023, or $1.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company issued 5,000,000
warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance to ALSF, a related party, in connection
with a securities purchase agreement (&ldquo;SPA&rdquo;) for the purchase of 10,000,000 shares of Common Stock for a total purchase
price of $15,000,000, or $1.50 per share. The terms of the warrant agreement include full ratchet anti-dilution protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes information about Common Stock
warrants outstanding at April 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="11" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Outstanding</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><B>Exercisable</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; text-align: center">$1.20</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">5,500</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center">1.42</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center">$1.20</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">5,500</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">$1.20</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">$1.00</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4.86</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.00</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">--</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">--</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$3.00</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,078,672</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">5.00</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$3.00</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,672</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">$3.00</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><FONT STYLE="font-size: 10pt">$1.20 - $3.00</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,584,172</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">4.98</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">$1.27</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,172</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">$2.88</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9. OTHER RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, the Company entered into
a Management Services Agreement (&ldquo;Management Agreement&rdquo;) with Avalanche International Corp. (&ldquo;Avalanche&rdquo;),
a related party. The Company&rsquo;s officers and directors are also officers and directors of Avalanche. Further, MCKEA is the
majority member of Philou Ventures, LLC, which is the controlling shareholder of Avalanche. Pursuant to the terms of the Management
Services Agreement, Avalanche shall provide management, consulting and financial services to Alzamend. Such services shall include
advice and assistance concerning any and all aspects of operations, planning and financing of Alzamend and conducting relations
with accountants, attorney, financial advisors and other professionals. The term of the Management Services Agreement, as amended,
is for the period May 1, 2016 to December 31, 2017 and may be extended by written agreement. The Company initially paid $40,000
per month for these services and, beginning February 2017, is currently paying $20,000 per month. During the years ended April&nbsp;30,
2019 and 2018, the Company recognized $160,000 and $240,000, respectively, in management fees. At April&nbsp;30, 2019 and April&nbsp;30,
2018, $75,000 and $3,000, respectively, was included within related party payable on the Company&rsquo;s balance sheet. The MSA
expired as of December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2017, MCKEA and Spartan Capital
Securities, LLC (&ldquo;Spartan&rdquo;) entered into a five-year consulting agreement (the &ldquo;MCKEA Consulting Agreement&rdquo;).
Pursuant to the MCKEA Consulting Agreement, upon the receipt by the Company of no less than $2,500,000 in gross proceeds from the
Confidential Private Placement Memorandum dated August 17, 2017 (the &ldquo;PPM&rdquo;), MCKEA will transfer to Spartan 5,000,000
shares of Alzamend Common Stock. During the term of the MCKEA Consulting Agreement, Spartan will provide consulting services related
to general corporate and other matters related to MCKEA&rsquo;s investment in the Company such as advice on mergers and acquisition
transactions, finance strategies, identification of potential management candidates and other strategic introductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount due at April&nbsp;30, 2019 and
2018, to MCKEA and the Company&rsquo;s officers for reimbursement of expenses paid and incurred by these related parties was $6,736
and $6,636, respectively. The amounts are included within related party payable on the Company&rsquo;s balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During January 2017, the Company entered
into a promissory note to a third party and received net proceeds of $65,000. As consideration for this loan, the Company issued
a promissory note in the aggregate principal amount of $75,000, which included an OID and fees of $10,000. The OID was amortized
as non-cash interest expense over the term of the debt. During the year ended April 30, 2018, interest expense of $3,618 was recorded
from the debt discount amortization. The promissory note accrued interest at 15% per year and during the year ended April 30, 2018,
the Company recorded $16,838 in interest. This loan was repaid during the year ended April 30, 2018. At April 30, 2019 and 2018,
the Company had no outstanding third-party borrowings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11. NOTES PAYABLE, RELATED PARTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At April 30, 2017, the outstanding balance
on short term borrowings from Avalanche, a related party, was $180,100. During the year ended April 30, 2018, Avalanche provided
an additional $123,500 in short term financing. This short-term obligation was non-interest bearing, due upon demand and repaid
during the year ended April 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During January 2017, the Company entered
a promissory note and received net proceeds of $70,000 from, a related party. As consideration for this loan, the Company issued
a promissory note in the aggregate principal amount of $80,000, which included an OID of $10,000. The OID was amortized as non-cash
interest expense over the term of the debt. During the years ended April 30, 2019 and 2018, interest expense of nil and $6,271,
respectively, was recorded from the debt discount amortization. This promissory note accrued interest at 15% per year and during
the years ended April 30, 2019 and 2018, the Company recorded nil and $6,272, respectively, in interest. The Company repaid this
loan during the year ended April 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2017, the Company issued
a promissory note in the principal amount of $47,520 to DPW. The promissory note included an OID of $3,520 resulting in net proceeds
to the Company of $44,000, yielded 8% simple interest on the principal amount, and was due on August 16, 2018. As additional consideration,
the Company also issued to DPW a warrant to purchase 5,500 shares of Common Stock at an exercise price of $1.20 per share. The
Company recorded debt discount of $2,235 based on the estimated fair value of the 5,500 warrants. During the year ended April&nbsp;30,
2018, the Company repaid the outstanding balance to DPW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>12. EQUITY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is
authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board of Directors has designated 1,360,000 shares
as Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Shares&rdquo;), The rights, preferences, privileges and
restrictions on the remaining authorized 8,640,000 shares of Preferred Stock have not been determined. The Company&rsquo;s Board
of Directors is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights,
preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. <FONT STYLE="background-color: white">As
of April 30, 2019, there were 750,000 shares of Series A Preferred Shares and no other shares of Preferred Stock issued or outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series A Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares convey no
dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for
that purpose. Holders of Series A Preferred Shares are entitled to 50 non-cumulative votes per share on all matters presented to
our stockholders for action. In addition, the affirmative vote of the holders of a majority of the Series A Preferred then outstanding,
voting as a separate class, is required for the Company to do any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amend, alter or repeal any of the preferences or rights of the Series A Preferred Shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize any reclassification of the Series A Preferred Shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increase the authorized number of Series A Preferred Shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>create any class or series of shares ranking prior to the Series A Preferred Shares as to dividends or liquidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A Preferred Shares are not entitled
to preemptive rights. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary,
the Holders of Series A Preferred Shares shall be entitled to participate in any distribution out of the assets of the Company
on an equal basis per share with the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Series A Preferred Shares have
the right to convert their shares into shares of Common Stock at any time at a conversion rate equal to twenty (20) shares of Common
Stock for every one (1) Series A Preferred Share. The conversion rate is not subject to anti-dilution adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2016, the Company&rsquo;s Board
of Directors approved a Certificate of Amendment to the Company&rsquo;s Certificate of Incorporation increasing its authorized
shares of Common Stock from 150,000,000 to 300,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An exclusive license agreement with sublicensing
terms was made effective on May 1, 2016, as amended on August 17, 2017, (the &ldquo;Effective Date<B>&rdquo;</B>) by and between
the University of South Florida (the &ldquo;University&rdquo;), and a direct support organization of the University and the Company
(the &ldquo;License Agreement&rdquo;). There are certain license fees and milestone payments required to be paid for the licensing
of an immunotherapy vaccine peptide that is designed to be used both as a treatment and vaccine against Alzheimer&rsquo;s (the
&ldquo;Technology&rdquo;), pursuant to the terms of the License Agreement with the University of South Florida Research Foundation,
Inc. (the &ldquo;Licensor&rdquo;) and the University. Pursuant to the terms of the License Agreement, the Licensor is entitled
to receive that number of shares of the Company&rsquo;s Common Stock equal to five percent (5%) of the total number of issued and
outstanding shares outstanding, subject to additional issuances until such time as the Company has received a total of $5 million
in cash in exchange for the Company&rsquo;s equity securities. During the year ended April 30, 2018, the Company issued 214,967
shares of its Common Stock and recognized $218,417 in license fees pursuant to the License Agreement. During the year ended April
30, 2019, the Company issued 2,227,923 shares of its Common Stock and recognized $2,227,923 in license fees pursuant to the License
Agreement. The amount of the license fees was based on the fair value of the Company&rsquo;s Common Stock on the date of issuance.
Fair value was determined from recent sales of the Company&rsquo;s Common Stock to third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain initial license fees
and milestone payments required to be paid by us to the Licensor pursuant to the terms of the License Agreement. The License Agreement
requires the Company to pay royalty payments of four percent (4%) on net sales of products developed from the licensed technology.
The Company has already paid an initial license fee of $200,000. As an additional licensing fee, the Licensor also received shares
of the Company&rsquo;s Common Stock equal to five percent (5%) of the total number of issued and outstanding shares outstanding
as the Company has received a total of $5 million in cash in exchange for the Company&rsquo;s equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between October 19, 2017 and December 29,
2017, the Company entered into subscription agreements for the purchase of 419.45 units at $10,000 for each unit purchased. Each
unit consisted of 10,000 shares of Common Stock. In aggregate, the 419.45 units represented 4,194,500 shares of Common Stock for
an aggregate purchase price of $4,194,500, or $1.00 per share, pursuant to the terms of a Private Placement Memorandum dated August
17, 2017 (the &ldquo;PPM&rdquo;). In conjunction with the 2017 PPM, the Company incurred $419,450 in placement fees and $93,523
in legal and filing fees, resulting in net proceeds to the Company of $3,681,528 (the &ldquo;2017 Offering&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended April 30, 2018, the
Company received notices of conversion from three investors that had purchased 610,000 shares of Series A Preferred Stock. The
Series A Preferred Stock was converted into 12,200,000 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2019, the Company entered
into securities purchase agreements for the purchase of 157,346 shares of Common Stock for a total purchase price of $236,023,
or $1.50 per share with 78,672 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance.
The purchase price of $236,023 was paid in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2019, the Company and ALSF
entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per
share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total
purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related
party. The note is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution
protection, most-favored nation status, denying the Company the right to enter into a variable rate transaction absent its consent,
a right to participate in any future financing the Company may consummate and to have all the shares of Common Stock to which it
is entitled under the SPA registered under the Securities Act within 180 days of the final closing of an initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Placement Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2017 Offering, the
Company agreed with Spartan Capital Securities, LLC (&ldquo;Spartan&rdquo;), the placement agent in the 2017 Offering, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of Proceeds</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will apply the net proceeds
from the Offering to include the retention of an FDA consulting firm, payment of the IND and all associated costs and the launch
of a First Stage Clinical Trial with up to 20 human patients along with limited operational expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Corporate Governance</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on December
29, 2017, and ending at such time as the Company&rsquo;s Common Stock is listed on a national securities exchange, Spartan will
have the right to designate one member of the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;). If Spartan does
not elect to designate a member of the Board, then the Company will permit a representative of Spartan to attend all meetings of
the Board as an observer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, commencing within twelve (12)
to twenty-four (24) months from December 29, 2017, the Board will be comprised of two inside directors and three independent directors
(as such term is defined by Rule 5605 of the NASDAQ Stock Market). This covenant will expire upon the listing of the Company&rsquo;s
Common Stock on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Registration Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable law or regulations
including but not limited to Rule 415 of the Securities Act the Company, within one hundred and eighty (180) days of the final
closing of an initial public offering of the Company&rsquo;s equity securities, file a registration statement on Form S-1 with
the Securities and Exchange Commission, which registration statement will cover the shares of Common Stock issuable to the Placement
Agent pursuant to the MCKEA Consulting Agreement discussed above as well as the shares of Common Stock issued in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13. COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2016, the Company entered into
the License Agreement with the Licensor pursuant to which the Licensor granted the Company a royalty bearing, exclusive worldwide
license, limited to the field of Alzheimer&rsquo;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled
&ldquo;Amyloid Beta Peptides and Methods of Use&rdquo; (AL002), filed April&nbsp;7, 2009, and granted May 29, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to royalty payments of 4% on
net sales of products developed from the licensed technology, the Company was required to pay a license fee of $100,000 on June
25, 2016, and December 31, 2016. As an additional licensing fee, the Licensor is entitled to receive that number of shares of our
Common Stock equal to five percent (5%) of the sum of the total number of issued and outstanding shares plus any securities that
are convertible into or exercisable or exchangeable for shares of Common Stock, subject to adjustment for additional issuances
until such time as the Company has received a total of $5 million in cash in exchange for our equity securities. As of April 30,
2019 we had issued 3,601,809 shares to the Licensor in full satisfaction of this additional licensing fee. Additionally, the Company
is required to pay milestone payments on the due dates to Licensor for the license of the technology, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: left">&nbsp;Upon IND application filing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Upon IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND application filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">175,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosed in Phase I</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase I Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;24 months from completion of first Phase I Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first Phase II Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II Clinical Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;7 years from the effective date of the agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA BLA Approval</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of these milestones was met as of
April 30, 2019. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Licensor was also granted a preemptive
right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains
the owner of any equity securities of the Company. Further, if the Company issues equity securities at a price per share that is
less than the price paid by purchasers in a transaction for aggregate consideration of at least $5,000,000 (the &ldquo;Investment
Price&rdquo;), then the number of shares owned by Licensor shall be increased upon such issuance. The amount of the increase shall
be determined by multiplying the number of shares then owned by Licensor by a fraction; the numerator of which shall be equal to
the number of shares of Common Stock outstanding immediately after the issuance of additional shares of Common Stock, and the denominator
of which shall be equal to the sum of (i) the number of shares of Common Stock outstanding immediately prior to the issuance of
additional shares of Common Stock plus (ii) the number of shares of Common Stock which the aggregate consideration for the total
number of additional shares of Common Stock so issued would purchase at the Investment Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2018, the Company obtained two
royalty-bearing, exclusive worldwide licenses from the Licensor to a therapy known as AL001 to mitigate extreme agitation and forestall
other deterioration as displayed by patients with up to moderate AD. AL001 is an ionic cocrystal of lithium for the treatment of
Alzheimer&rsquo;s and possibly other neurodegenerative diseases. There are certain license fees and milestone payments required
to be paid for the licensing of the AL001 technology, pursuant to the terms of the two Standard Exclusive License Agreements with
Sublicensing Terms, both dated June 21, 2018, (the &ldquo;AL001 License Agreements&rdquo;) with the Licensor and the University.
In addition, a royalty payment of 3% is required pursuant to License #18110 while License #18111 requires a royalty payment of
1.5% on net sales of products developed from the licensed technology. For the two AL001 licenses, in the aggregate, the Company
was required to pay initial license fees of $50,000 no later than July 31, 2018, and $150,000 no later than March 31, 2019. As
an additional licensing fee, the Licensor is entitled to receive that number of shares of Common Stock equal to three percent (3%)
of the sum of the total number of issued and outstanding shares. Additionally, the Company is required to pay milestone payments
on the due dates to Licensor for the license of the technology, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Due Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Event</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">50,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;November 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: left">&nbsp;Pre-IND meeting</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">65,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;6 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;IND application filing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from IND filing date</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first dosing of patient in a clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from first patient dosing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon Completion of first clinical trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,250,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;12 months from completion of the first Phase II clinical trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon first patient treated in a Phase III Clinical Trial</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;8 years from the Effective Date of the Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;Upon FDA Approval</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of these milestones was met as of
April 30, 2019. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with FASB ASC 855-10, the
Company has analyzed its operations subsequent to April&nbsp;30, 2019 and has determined that it does not have any material subsequent
events to disclose in these financial statements except for the following.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between June&nbsp;25, 2019 and August 15,
2019, the Company entered into subscription agreements for the purchase of 646,433 units at $1.50 for each unit purchased pursuant
to its 2019 private offering (the &ldquo;2019 Offering&rdquo;). Each unit consists of one (1) share of Common Stock and one (1)
warrant to purchase one half (0.5) share of Common Stock. In aggregate, the 646,433 units represents 646,433 shares of Common Stock
and 323,216 warrants with an exercise price of $3.00 per share for an aggregate purchase price of $969,650, or $1.50 per share.
The 2019 Offering is being conducted pursuant to the terms of a Confidential Private Placement Memorandum dated June&nbsp;12, 2019
(the &ldquo;2019 PPM&rdquo;). As of August 15, 2019, in conjunction with the 2019 PPM, the Company incurred $145,448 in placement
fees, resulting in net proceeds to the Company of $824,202.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2019 Placement Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the 2019 Placement Agreement
effective as of June 10, 2019 entered into in connection with the 2019 PPM, the Company has agreed with the Placement Agent to
certain cash compensation payable to the Placement Agent and, without limitation, to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Placement Agent Compensation</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the initial closing of the 2019 Offering
the Company must pay to the Placement Agent a non-refundable fee of Twenty-Five Thousand Dollars ($25,000) and issue to the Placement
Agent 500,000 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the Company has agreed to issue
to the Placement Agent warrants to purchase a number of shares of Common Stock (the &ldquo;Placement Agent Warrants&rdquo;) equal
to ten percent (10%) of the number of shares of Common Stock sold in the 2019 Offering. The Placement Agent Warrants shall be exercisable
for a period of five (5) years after their date of issuance, shall have an exercise price of $1.75 per share and shall contain
provisions pertaining to cashless exercise, standard anti-dilution protection and piggyback registration rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Proceeds</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will apply the net proceeds
from the Offering primarily: (i) for licensing and other fees to the University and the Byrd Institute; (ii) to pay certain fees
to the FDA; (iii) to pay for third-party research; (iv) to pay certain marketing-related fees, and (v) for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Incurrence of Debt</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the two (2) years following the
final Closing, the Company will not, without the prior written consent of the Placement Agent, incur indebtedness for borrowed
money in an aggregate amount in excess of $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Additional Shares Issuable to the Placement
Agent, its Affiliates and the Investors in this Offering</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to take certain
actions within prescribed time periods. If the Company fails to do so on a timely basis, the Company has agreed to issue to the
Placement Agent, its Affiliates and the investors in the 2019 Offering a significant number of additional shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Future Sales of Securities and Conversion
of the Series A Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the final
Closing and ending two years thereafter, provided that no Qualified Financing (as defined below) has occurred, if (i) the Company
issues any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Placement Agent&rsquo;s
consent, or (ii) any holder of the Company&rsquo;s Series A Preferred Stock elects to convert such shares into Common Stock, then
upon any such issuance or conversion, as the case may be, the Placement Agent, its Affiliates and the Investors in this Offering
will be entitled to receive a significant number of additional shares of Common Stock (this provision can thus be deemed the functional
equivalent of weighted average anti-dilution protection). For purposes of the 2019 Placement Agreement, a &ldquo;Qualified Financing&rdquo;
means the sale of equity securities by us in a single transaction or a series of related transactions registered under the Securities
Act resulting in gross proceeds to us of not less than $25,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, during the period commencing
on the final Closing and ending two years thereafter, the Company has agreed not to enter into any transactions with Milton C.
Ault, our chairman of the board and principal stockholder or any Affiliate (as defined in Rule 405 of the Securities Act) thereof
absent the Placement Agent&rsquo;s consent. Notwithstanding the foregoing, the Placement Agent has consented to our potential entry
into an agreement whereby the Company would issue to an Affiliate of Mr. Ault 10,000,000 shares of Common Stock on terms substantially
identical to those of the 2019 Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Failure to File Reports under the Securities
Act</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Company does not
file its annual or semiannual reports with the Commission on a timely basis, then the Placement Agent will have the right to designate
a replacement for one of our members of our Board for a period of one (1) year following any such failure to file a periodic report
on a timely basis, provided that neither Mr. Ault nor William B. Horne shall be subject to this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreement with the Chief
Executive Officer</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon or before the initial Closing of the
2019 Offering, the Company shall have entered into an employment agreement with Stephan Jackman having a term of at least two (2)
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Corporate Governance</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period commencing on the final
closing of the 2019 Offering and ending at such time as the Common Stock is listed on a national securities exchange, the Placement
Agent will have the right to designate one member of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Uplisting Agreement</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Uplisting Agreement effective
as of June 10, 2019, the Company has agreed with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will engage the Placement
Agent as an advisor (in such capacity, the &ldquo;Advisor&rdquo;) to, at our request, provide advisory services (the &ldquo;Services&rdquo;)
to us in connection with a potential public offering (an &ldquo;IPO&rdquo;). The Company expects that any such Services rendered
would consist principally of advising us on how to properly develop and implement strategies that would enhance our ability to
successfully complete an IPO and in connection therewith obtain a listing on a national securities exchange, provided that the
Company meets any such exchange&rsquo;s listing criteria at the applicable time as well as introduce us to appropriate underwriters
that would lead or conduct any such IPO.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Uplisting Agreement, the
Company will, whether the Company requests its assistance or not, be obligated to issue to the Advisor Five Hundred Thousand (500,000)
shares of Common Stock as well as make a cash payment to the Advisor in the amount of $475,000 once the Company has raised no less
than $1,000,000 in gross proceeds in the 2019 Offering and, in the event that the Company successfully consummates an IPO with
an underwriter introduced to us by the Advisor, pay the Advisor a fee equal to two percent (2%) of the gross proceeds raised in
the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If prior to a Qualified Financing the Company
issues any shares of Common Stock or Common Stock equivalents at a per share price below $1.50 absent the Advisor&rsquo;s consent,
then upon any such issuance, the Advisor will be entitled to receive a significant number of additional shares of Common Stock
(this provision can, like its counterpart in the 2019 Placement Agreement described above, thus be deemed the functional equivalent
of weighted average anti-dilution protection).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Company engages in
what the Uplisting Agreement refers to as an &ldquo;Alternative Transaction&rdquo; during the term of such agreement or for a period
of two (2) years thereafter, the Company will be obligated to pay to the Advisor a fee in cash equal to three percent (3%) of the
amount of the consideration paid or received by us and/or our stockholders in the Alternative Transaction. For purposes of the
Uplisting Agreement, an &ldquo;Alternative Transaction&rdquo; means a business combination, including, any merger, acquisition
or sale of stock or assets (whether the Company is the acquiring or the acquired entity), joint venture, strategic alliance or
other similar transaction, and shall extend to any subsidiary of ours on the same terms as will be applicable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of the Uplisting Agreement will
be two (2) years, subject to either party&rsquo;s right to terminate it in the event that the other party to the agreement breaches
it in any material way.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III&mdash;EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Index to Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 11%; border-bottom: black 1pt solid"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 88%; border-bottom: black 1pt solid"><B>Exhibit Description</B></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Certificate of Incorporation (Incorporated by reference to Exhibit 2.1 of Form DOS filed with the Securities and Exchange Commission on August 19, 2016).</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Bylaws (Incorporated by reference to Exhibit 2.2 of Form DOS filed with the Securities and Exchange Commission on August 19, 2016).</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"> Certificate of Designation of Alzamend Neuro, Inc. Series A Convertible Preferred Stock,
    dated May 30, 2016** </TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"> Promissory Note Due April 30, 2020, issued by Ault Life Sciences Fund, LLC, dated April
    30, 2019** </TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Amendment to Note Due
                                    April 30, 2020, by and between Ault Life Sciences Fund, LLC, and Alzamend Neuro, Inc., dated
                                    June 11, 2019** </P>


</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> 3.3 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"> Warrant to Purchase Common Stock issued to Ault Life Sciences Fund, LLC, dated April 30,
    2019* </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Form of Subscription
                                    Agreement.* </P>


</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"> Securities Purchase Agreement with Ault Life Sciences Fund, LLC, dated April 30, 2019** </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Standard Exclusive License Agreement with Sublicensing Terms with the University of South Florida Research Foundation, Inc., dated May 1, 2016 (Incorporated by reference to Exhibit 6.1 of Form DOS/A filed with the Securities and Exchange Commission on September 29, 2016).</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Management Services Agreement, as amended, with Avalanche International Corp., dated May 1, 2016&nbsp;&nbsp;(Incorporated by reference to Exhibit 6.2 of Form DOS/A filed with the Securities and Exchange Commission on September 29, 2016).</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Standard Exclusive License Agreement with Sublicensing Terms Number LIC18110 with the University of South Florida Research Foundation, Inc., dated July 2, 2018 (Incorporated by reference to Exhibit 6.3 of Form 1-K filed with the Securities and Exchange Commission on February 21, 2019)&rsquo;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Standard Exclusive License Agreement with Sublicensing Terms Number LIC18111 with the University of South Florida Research Foundation, Inc., dated July 2, 2018 (Incorporated by reference to Exhibit 6.4 of Form 1-K filed with the Securities and Exchange Commission on February 21, 2019).</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Employment Agreement with Henry Nisser effective May 1, 2019 (Incorporated by reference to Exhibit 6.5 of Form 1-K filed with the Securities and Exchange Commission on August 28, 2019).</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Employment
                                         Offer Letter with Stephan Jackman, dated November 30, 2018* </P>


</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Employment Offer Letter with Kenneth S. Cragun, dated November 30,
    2018** </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">6.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Placement
                                         Agent Agreement with Spartan Capital Securities, LLC, dated June 10, 2019** </P>


</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> 6.9 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Stock Pledge Agreement with Ault Life Sciences Fund, LLC, dated June
    11 2019* </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"> 6.10 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Consulting Agreement with Spartan Capital Securities, LLC, dated June
    28, 2017* </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">8.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Escrow Agreement with SOS Back Office Solutions, LLC, dated January
    30, 2020** </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">11.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Consent of Squar Milner LLP, Independent Registered Public Accounting Firm*</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">11.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Consent of Sichenzia Ross Ference LLP (included in Exhibit 12.1)** </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">12.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> Opinion of Sichenzia Ross Ference LLP** </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> ** Previously filed </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 120; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of Regulation
A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A
and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized on March
12, 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt">(Exact name of issuer as specified in its charter):</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt"><B>Alzamend Neuro, Inc.</B></FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By (Signature and Title):</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephan Jackman</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer).</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering statement has been signed
by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">(Signature):</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kenneth S. Cragun</FONT></TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Title):</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial Officer,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Accounting Officer).</P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Date):</FONT></TD>
    <TD> <FONT STYLE="font-size: 10pt">March 12, 2020</FONT> </TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SIGNATURES OF DIRECTORS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Milton C. Ault, III</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">March 12, 2020</FONT> </TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Milton C. Ault, III, Executive Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Philip E. Mansour</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">March 12, 2020</FONT> </TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ William B. Horne</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"> <FONT STYLE="font-size: 10pt">March 12, 2020</FONT> </TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-3 HLDRS RTS
<SEQUENCE>4
<FILENAME>ex1a-3_3.htm
<DESCRIPTION>EXHIBIT 1A-3.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"> <B>Exhibit 3.3</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>THIS WARRANT AND
THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&ldquo;<U>SECURITIES ACT</U>&rdquo;), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE,
SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE
UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN
LAW AND, IF THE CORPORATION REQUESTS, AN OPINION SATISFACTORY TO THE CORPORATION TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.
</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"> <B><U>WARRANT TO PURCHASE
COMMON STOCK</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> Original Issue Date:
April 30, 2019 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> FOR VALUE RECEIVED,
ALZAMEND NEURO, INC., a Delaware corporation (including any successor, the &ldquo;<B>Company</B>&rdquo;), hereby certifies that
Ault Life Sciences Fund, LLC, or its permitted registered assigns (the &ldquo;<B>Holder</B>&rdquo;), is entitled to purchase from
the Company, from and after the date hereof, up to a total of 5,000,000 shares of common stock, $.0001 par value per share (the
&ldquo;<B>Common Stock</B>&rdquo;), of the Company (each such share, a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares,
the &ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price per share equal to $3.00 per share (the &ldquo;<B>Exercise Price</B>&rdquo;),
all subject to the terms, conditions and adjustments set forth below in this Warrant. Certain capitalized terms used in this Warrant
are defined in <U>Section&nbsp;1</U> hereof. This Warrant is being issued pursuant to that certain Securities Purchase Agreement,
dated April 30, 2019, between the Company and Holder (the &ldquo;<B>Agreement</B>&rdquo;) and is subject to the terms of the Agreement.
Capitalized terms used herein and not defined herein shall have the meanings ascribed thereto in the Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used in this Warrant, the following terms have the respective meanings set forth below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>&ldquo;Board</B>&rdquo;&nbsp;means
the board of directors of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Business
Day</B>&rdquo;&nbsp;means any day, except a Saturday, Sunday or legal holiday on which banking institutions in the city of New
York, New York, are authorized or obligated by law or executive order to close. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Common
Stock</B>&rdquo;&nbsp;means the common stock, par value $0.0001 per share, of the Company, and any capital stock into which such
Common Stock shall have been converted, exchanged or reclassified following the Original Issue Date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Common
Stock Equivalents</B>&rdquo; means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Company</B>&rdquo;&nbsp;has
the meaning set forth in the preamble of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Exercise
Date</B>&rdquo;&nbsp;means, for any given exercise of this Warrant, the date on which the conditions to such exercise as set forth
in <U>Section&nbsp;3</U> hereof shall have been satisfied at or prior to 5:00 p.m., New York time, on a Business Day, including,
without limitation, the receipt by the Company of the Exercise Agreement, this Warrant and the Exercise Price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Exercise
Agreement</B>&rdquo;&nbsp;means an Exercise Agreement in the form attached to this Warrant as <B><U>Exhibit&nbsp;A</U></B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Exercise
Period</B>&rdquo;&nbsp;has the meaning set forth in <U>Section&nbsp;2</U> hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Exercise
Price</B>&rdquo;&nbsp;has the meaning set forth in the preamble of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Fair
Market Value</B>&rdquo;&nbsp;means, as of any particular date, the &ldquo;Fair Market Value&rdquo; of the Common Stock shall be:
(a) if at any time the Common Stock is not listed on any domestic securities exchange or quoted on the OTCQB or similar quotation
system or association, the fair market value per share as determined by mutual consent of the parties, or absent that, by an independent
third-party appraisal, (b) if the Common Stock is listed on any domestic securities exchange or quoted on the OTCQB or similar
quotation system: (1) the volume weighted average of the closing sales prices of the Common Stock for such day on all domestic
securities exchanges on which the Common Stock may at the time be listed; (2) if there have been no sales of the Common Stock
on any such exchange on any such day, the average of the highest bid and lowest asked prices for the Common Stock on all such
exchanges at the end of such day; (3) if on any such day the Common Stock is not listed on a domestic securities exchange, the
closing sales price of the Common Stock as quoted on the OTCQB or similar quotation system or association for such day; or (4)
if there have been no sales of the Common Stock on the OTCQB or similar quotation system or association on such day, the average
of the highest bid and lowest asked prices for the Common Stock quoted on the OTCQB or similar quotation system or association
at the end of such day; in each case, averaged over twenty (20) consecutive Business Days ending on the Business Day immediately
prior to the day as of which &ldquo;Fair Market Value&rdquo; is being determined; <U>provided</U>, that if the Common Stock is
listed on any domestic securities exchange, the term &ldquo;Business Day&rdquo; as used in this sentence means Business Days on
which such exchange is open for trading. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Holder</B>&rdquo;&nbsp;has
the meaning set forth in the preamble of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Original
Issue Date</B>&rdquo;&nbsp;has the meaning set forth on the cover page to this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Person</B>&rdquo;&nbsp;means
any individual, sole proprietorship, partnership, limited liability company, corporation, joint venture, trust, incorporated organization
or government or department or agency thereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Sale
Event</B>&rdquo; means (i)&nbsp;any sale of Common Stock (excluding issuances of Common Stock by the Company) in a single transaction
or a series of related transactions in which the holders of Common Stock immediately prior to such sale of Common Stock do not,
directly or indirectly, own at least a majority of the Common Stock outstanding immediately after such sale of Common Stock, (ii)
any merger, consolidation, reorganization or other business combination of the Company with or into any other corporation or other
entity in which the holders of Common Stock immediately prior to such merger, consolidation, reorganization or business combination
do not, directly or indirectly, own capital stock of the entity surviving such merger, consolidation, reorganization or business
combination representing at least a majority of the combined voting power of the outstanding securities of such entity immediately
after such merger, consolidation, reorganization or business combination, or (iii)&nbsp;a sale, lease or other disposition of
all or substantially all of the assets of the Company to an unrelated person or entity by means of a single transaction or a series
of related transactions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Securities
Act</B>&rdquo;&nbsp;has the meaning set forth in the legend endorsed on the cover page of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Warrant</B>&rdquo;&nbsp;means
this Warrant and all warrants issued upon division or combination of, or in substitution for, this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &ldquo;<B>Warrant
Shares</B>&rdquo;&nbsp;means the shares of Common Stock which may be purchased pursuant to this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
of Warrant</B>. Subject to the terms and conditions of this Warrant, at any time or from time to time after the date hereof and
prior to 5:00 p.m., New York time, on the fifth (5) year anniversary of the date hereof, if such day is not a Business Day, on
the next preceding Business Day (the &ldquo;<B>Exercise Period</B>&rdquo;), the Holder of this Warrant may exercise this Warrant
for all or any part of the Warrant Shares purchasable hereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
of Warrant</B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Procedure</U>. This Warrant may be exercised from time to time on any Business Day during the Exercise Period, for all or any
part of the unexercised Warrant Shares, upon: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;surrender
of this Warrant to the Company at its then principal executive offices (or an indemnification in accordance with <U>Section&nbsp;9
</U>hereof in the case of the loss, theft, destruction or mutilation of this Warrant), together with a duly completed (including
specifying the number of Warrant Shares for which this Warrant is being exercised) and executed Exercise Agreement; and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;payment
to the Company of the Exercise Price in accordance with <U>Section&nbsp;3(b)</U> hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of the Aggregate Exercise Price</U>. Payment of the Aggregate Exercise Price shall be made by delivery to the Company of a certified
or official bank check payable to the order of the Company or by wire transfer of immediately available funds to an account designated
in writing by the Company, in the amount of such Aggregate Exercise Price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Stock Certificates</U>. Upon receipt by the Company of the Exercise Agreement, surrender of this Warrant and payment of the
Aggregate Exercise Price (in accordance with <U>Section&nbsp;3(a)</U> hereof), the Company shall, as promptly as reasonably practicable,
and in any event within ten (10) Business Days thereafter, execute (or cause to be executed) and deliver (or cause to be delivered)
to the Holder a certificate or certificates representing the Warrant Shares issuable upon such exercise, together with cash in
lieu of any fraction of a share, as provided in <U>Section&nbsp;3(d)</U> hereof. The stock certificate or certificates so delivered
shall be, to the extent possible, in such denomination or denominations as the exercising Holder shall reasonably request in the
Exercise Agreement and shall be registered in the name of the Holder or, subject to compliance with <U>Section&nbsp;7</U> hereof,
such other Person&rsquo;s name as shall be designated in the Exercise Agreement. This Warrant shall be deemed to have been exercised
and such certificate or certificates of Warrant Shares shall be deemed to have been issued, and the Holder or (subject to compliance
with <U>Section&nbsp;7</U> hereof) any other Person so designated to be named therein shall be deemed to have become a holder
of record of such Warrant Shares for all purposes, as of the Exercise Date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional
Shares</U>. The Company shall not be required to issue a fractional Warrant Share upon exercise of this Warrant. As to any fraction
of a Warrant Share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay to such Holder
an amount in cash (by delivery of a certified or official bank check or by wire transfer of immediately available funds) equal
to the product of (i) such fraction multiplied by (ii) the Fair Market Value of one Warrant Share on the Exercise Date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrant</U>. Unless the purchase rights represented by this Warrant shall have expired or shall have been fully exercised,
the Company shall, at the time of delivery of the certificate or certificates representing the Warrant Shares being issued in
accordance with <U>Section&nbsp;3(c)</U> hereof, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase
the unexpired and unexercised Warrant Shares called for by this Warrant. Such new Warrant shall in all other respects be identical
to this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Valid
Issuance of Warrant and Warrant Shares; Payment of Taxes</U>. With respect to the exercise of this Warrant, the Company hereby
represents, covenants and agrees that: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Warrant is, and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, duly authorized
and validly issued. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Warrant Shares issuable upon the exercise of this Warrant in compliance with the terms of this Warrant shall be, upon issuance,
and the Company shall take all such actions as may be necessary or appropriate in order that such Warrant Shares are, validly
issued, fully paid and non-assessable, issued without violation of any pre-emptive or similar rights of any stockholder of the
Company and free and clear of all taxes, liens and charges. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall use commercially reasonable efforts to cause the Warrant Shares, immediately upon such exercise, to be listed on
any domestic securities exchange upon which shares of Common Stock or other securities constituting Warrant Shares are listed
at the time of such exercise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall pay all expenses in connection with, and all taxes and other governmental charges that may be imposed with respect
to, the issuance or delivery of Warrant Shares upon exercise of this Warrant; <U>provided</U> that the Company shall not be required
to pay any tax or governmental charge that may be imposed with respect to any applicable withholding or the issuance or delivery
of the Warrant Shares to the Holder or to any other Person permitted to receive Warrant Shares upon exercise of this Warrant,
and no such issuance or delivery shall be made unless and until the Holder or such Person has paid to the Company the amount of
any such tax, or has established to the satisfaction of the Company that such tax has been paid. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditional
Exercise</U>. Notwithstanding any other provision of this Warrant, if an exercise of any portion of this Warrant is to be made
in connection with a public offering or a Sale Event, such exercise may at the election of the Holder be conditioned upon the
consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the
consummation of such transaction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Shares</U>. During the Exercise Period, the Company shall at all times reserve and keep available out of its authorized but
unissued Common Stock or other securities constituting Warrant Shares, solely for the purpose of issuance upon the exercise of
this Warrant, the maximum number of Warrant Shares issuable upon the exercise of this Warrant, and the par value per Warrant Share
shall at all times be less than or equal to the applicable Exercise Price. The Company shall not increase the par value of any
Warrant Shares receivable upon the exercise of this Warrant above the Exercise Price then in effect and shall take all such actions
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares
of Common Stock upon the exercise of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustment
to Exercise Price and Number of Warrant Shares</B>. The Exercise Price and the number of Warrant Shares issuable upon exercise
of this Warrant shall be subject to adjustment from time to time as provided in this <U>Section 4</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price and Warrant Shares Upon Dividend, Subdivision or Combination of Common Stock</U>. If the Company shall, at any
time or from time to time after the date hereof (i) pay a dividend or make any other distribution upon the Common Stock or any
other capital stock of the Company payable in shares of Common Stock, or (ii) subdivide (by any stock split, recapitalization
or otherwise) its outstanding shares of Common Stock into a greater number of shares, then the Exercise Price in effect immediately
prior to any such dividend, distribution or subdivision shall be proportionately reduced and the number of Warrant Shares issuable
upon exercise of this Warrant shall be proportionately increased. If the Company at any time combines (by combination, reverse
stock split or otherwise) its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect
immediately prior to such combination shall be proportionately increased and the number of Warrant Shares issuable upon exercise
of this Warrant shall be proportionately decreased. Any adjustment under this <U>Section 4(a)</U> shall become effective concurrent
at the time such dividend, subdivision or combination becomes effective. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price and Warrant Shares upon Reorganization, Reclassification, Consolidation or Merger</U>. After the date hereof,
in the event of any (i) capital reorganization of the Company, (ii) reclassification of the stock of the Company (other than (x)
a change in par value, from par value to no par value, or from no par value to par value, or (y) as a result of a stock dividend
or subdivision, split-up or combination of shares), (iii) consolidation or merger of the Company with or into another Person,
(iv) sale of all or substantially all of the Company&rsquo;s assets to another Person or (v) other similar transaction (other
than any such transaction covered by <U>Section 4(a)</U> above), in each case which entitles the holders of Common Stock to receive
(either directly or upon subsequent liquidation) stock, securities or assets with respect to or in exchange for Common Stock,
each Warrant shall, immediately after such reorganization, reclassification, consolidation, merger, sale or similar transaction,
remain outstanding and shall thereafter, in lieu of or in addition to (as the case may be) the number of Warrant Shares then exercisable
under this Warrant, be exercisable for the kind and number of shares of stock or other securities or assets of the Company or
of the successor Person resulting from such transaction to which the Holder would have been entitled upon such reorganization,
reclassification, consolidation, merger, sale or similar transaction if the Holder had exercised this Warrant in full immediately
prior to the time of such reorganization, reclassification, consolidation, merger, sale or similar transaction and acquired the
applicable number of Warrant Shares then issuable hereunder as a result of such exercise; and, in such case, appropriate adjustment
(in form and substance determined by the Board in its reasonable discretion) shall be made with respect to the Holder&rsquo;s
rights under this Warrant to insure that the provisions of this <U>Section&nbsp;4</U> hereof shall thereafter be applicable, as
nearly as possible, to this Warrant in relation to any shares of stock, securities or assets thereafter acquirable upon exercise
of this Warrant (including, in the case of any consolidation, merger, sale or similar transaction in which the successor or purchasing
Person is other than the Company, an immediate adjustment in the Exercise Price to the value per share for the Common Stock reflected
by the terms of such consolidation, merger, sale or similar transaction, and a corresponding immediate adjustment to the number
of Warrant Shares acquirable upon exercise of this Warrant without regard to any limitations or restrictions on exercise, if the
value so reflected is less than the Exercise Price in effect immediately prior to such consolidation, merger, sale or similar
transaction). The provisions of this <U>Section 4(b)</U> shall similarly apply to successive reorganizations, reclassifications,
consolidations, mergers, sales or similar transactions. Subject to <U>Section&nbsp;5</U> hereof, the Company shall not effect
any such reorganization, reclassification, consolidation, merger, sale or similar transaction unless, prior to the consummation
thereof, the successor Person (if other than the Company) resulting from such reorganization, reclassification, consolidation,
merger, sale or similar transaction, shall assume, by written instrument substantially similar in form and substance to this Warrant,
the obligation to deliver to the Holder such shares of stock, securities or assets which, in accordance with the foregoing provisions,
such Holder shall be entitled to receive upon exercise of this Warrant. With respect to any corporate event or other transaction
contemplated by the provisions of this <U>Section 4(b)</U>, the Holder shall have the right to elect prior to the consummation
of such event or transaction, to give effect to the exercise rights contained in <U>Section&nbsp;3</U> hereof instead of giving
effect to the provisions contained in this <U>Section&nbsp;4(b)</U> with respect to this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall
sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective
price per share less than the Exercise Price then in effect (such lower price, the &ldquo;<B>Base Share Price</B>&rdquo; and such
issuances collectively, a &ldquo;<B>Dilutive Issuance</B>&rdquo;) (it being understood and agreed that if the holder of the Common
Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions,
floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued
in connection with such issuance, be entitled to receive Warrant Shares at an effective price per share that is less than the
Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance
at such effective price), then simultaneously with the consummation of each Dilutive Issuance the Exercise Price shall be reduced
and only reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that
the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to
the aggregate Exercise Price prior to such adjustment. Such adjustment shall be made whenever such Common Stock or Common Stock
Equivalents are issued. The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance
or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 4(c), indicating therein the applicable
issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the &ldquo;<B>Dilutive
Issuance Notice</B>&rdquo;). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant
to this Section 4(c), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant Shares
based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.
If the Company enters into a variable rate transaction, the Company shall be deemed to have issued Common Stock or Common Stock
Equivalents at the lowest possible conversion or exercise price at which such securities may be converted or exercised. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Events</U>. If any event of the type contemplated by the provisions of this <U>Section&nbsp;4</U> but not expressly provided for
by such provisions occurs, then the Board shall make an appropriate adjustment in the Exercise Price and the number of Warrant
Shares issuable upon exercise of this Warrant so as to protect the rights of the Holder in a manner consistent with the provisions
of this <U>Section&nbsp;4</U>; <U>provided</U>, that no such adjustment pursuant to this <U>Section&nbsp;4(c)</U> shall increase
the Exercise Price or decrease the number of Warrant Shares issuable as otherwise determined pursuant to this <U>Section&nbsp;4</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
as to Adjustment</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
promptly as reasonably practicable following any adjustment of the Exercise Price that results in an increase or decrease of the
Exercise Price of $0.01 or more, but in any event not later than ten (10) Business Days thereafter, the Company shall furnish
to the Holder a certificate of an executive officer setting forth in reasonable detail such adjustment and the facts upon which
it is based and certifying the calculation thereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
In the event: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
the Company shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable
upon exercise of the Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, to
receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive
any other security; or </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of
any capital reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger
of the Company with or into another Person, or sale of all or substantially all of the Company&rsquo;s assets to another Person;
or </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of
the voluntary or involuntary dissolution, liquidation or winding-up of the Company; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> then, and in each such case, the Company
shall send or cause to be sent to the Holder at least twenty (20) days prior to the applicable record date or the applicable expected
effective date, as the case may be, for the event, a written notice specifying, as the case may be, (A) the record date for such
dividend, distribution or other right or action, and a description of such dividend, distribution or other right, or (B) the effective
date on which such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up is proposed
to take place, and the date, if any is to be fixed, as of which the books of the Company shall close or a record shall be taken
with respect to which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon
exercise of the Warrant) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities)
for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution,
liquidation or winding-up, and the amount per share and character of such exchange applicable to the Warrant and the Warrant Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sale
Event</B>. Notwithstanding anything in this Warrant to the Contrary, the Company shall have the right (exercisable in the sole
and absolute discretion of the Board), but not the obligation, in connection with a Sale Event to make or provide for a cash payment
to Holder, in exchange for the cancellation of this Warrant, in an amount equal to the difference between (a) the value as determined
by the Board of the consideration payable, or otherwise to be received by stockholders, per share of Common Stock pursuant to
a Sale Event multiplied by the number of Warrant Shares then issuable under this Warrant and (b) the Aggregate Exercise Price
of all such Warrant Shares, subject to the other terms and conditions of the Sale Event (such as representations and warranties,
holdback and escrow amounts, indemnification obligations and purchase price adjustments) to the extent applicable to Common Stock
holders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions
on Exercise</B>. Notwithstanding anything in this Warrant to the contrary, this Warrant may not be exercised if the issuance of
Warrant Shares upon such exercise or if the method of payment for such Warrant Shares would constitute a violation of any applicable
laws or regulations, including, without limitation, applicable federal and state securities laws and regulations. The Company
may require Holder to make any representations and warranties to the Company as may be required by any applicable law or regulation
(including, without limitation, applicable federal and state securities laws and regulations) before allowing this Warrant to
be exercised. Without limiting the generality of the foregoing, Warrant Shares issued upon exercise of this Warrant may not be
issued in the name of any Person other than Holder unless the transfer conditions referred to in the legend endorsed on the cover
page of this Warrant have been complied with to the satisfaction of the Company. In addition, no Warrant Shares will be issued
pursuant to the exercise of this Warrant unless such issuance and such exercise comply with all relevant requirements of any stock
exchange upon which the Common Stock may then be listed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer
of Warrant.</B> Subject to the transfer conditions referred to in the legend endorsed on the cover page of this Warrant, this
Warrant and all rights hereunder are transferable, in whole or in part, by the Holder without charge to the Holder, upon surrender
of this Warrant to the Company at its then principal executive offices with a properly completed and duly executed Assignment
in the form attached hereto as <B><U>Exhibit&nbsp;B</U></B>, together with funds sufficient to pay any transfer taxes described
in <U>Section&nbsp;3(f)(iv)</U> hereof in connection with the making of such transfer. Upon such compliance, surrender and delivery
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees and in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant, if any, not so assigned and this Warrant shall promptly be cancelled. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holder
Not Deemed a Stockholder; Limitations on Liability</B>. Prior to the issuance to the Holder of the Warrant Shares to which the
Holder is then entitled to receive upon the due exercise of this Warrant, the Holder shall not be entitled to vote or receive
dividends or be deemed the holder of shares of capital stock of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right to vote,
give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise. In addition,
nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon
exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company
or by creditors of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Replacement
on Loss; Division and Combination</B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Warrant on Loss</U>. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and upon delivery of an indemnity reasonably satisfactory to the Company and, in case of mutilation, upon surrender
of such Warrant for cancellation to the Company, the Company at its own expense shall execute and deliver to the Holder, in lieu
hereof, a new Warrant of like tenor and exercisable for an equivalent number of Warrant Shares as the Warrant so lost, stolen,
mutilated or destroyed; <U>provided</U> that, in the case of mutilation, no indemnity shall be required if this Warrant in identifiable
form is surrendered to the Company for cancellation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Division
and Combination of Warrant</U>. Subject to compliance with the applicable provisions of this Warrant as to any transfer or other
assignment that may be involved in such division or combination, this Warrant may be divided or, following any such division of
this Warrant, subsequently combined with other Warrants, upon the surrender of this Warrant or Warrants to the Company at its
then principal executive offices, together with a written notice specifying the names and denominations in which new Warrants
are to be issued, signed by the respective Holders. Subject to compliance with the applicable provisions of this Warrant as to
any transfer or assignment that may be involved in such division or combination, the Company shall at its own expense execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants so surrendered in accordance with such notice. Such
new Warrant or Warrants shall be of like tenor to the surrendered Warrant or Warrants and shall be exercisable in the aggregate
for an equivalent number of Warrant Shares as the Warrant or Warrants so surrendered in accordance with such notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with the Securities Act</B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement
to Comply with the Securities Act; Legend</U>. The Holder, by acceptance of this Warrant, agrees to comply in all respects with
the provisions of this <U>Section&nbsp;10</U> and the restrictive legend requirements set forth on the face of this Warrant and
further agrees that that Holder shall not offer, sell or otherwise dispose of this Warrant or any Warrant Shares to be issued
upon exercise hereof except under circumstances that will not result in a violation of the Securities Act or applicable state
or federal securities laws. This Warrant and all Warrant Shares issued upon exercise of this Warrant (unless registered under
the Securities Act) shall be stamped or imprinted with a legend in substantially the following form: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> &ldquo;THIS WARRANT
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD,
PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE
UNDER THE SECURITIES ACT AND IS QUALIFIED UNDER APPLICABLE STATE AND FOREIGN LAW OR (II) THE TRANSACTION IS EXEMPT FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS UNDER THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE AND FOREIGN
LAW AND, IF THE CORPORATION REQUESTS, AN OPINION SATISFACTORY TO THE CORPORATION TO SUCH EFFECT HAS BEEN RENDERED BY COUNSEL.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
of the Holder</U>. In connection with the issuance of this Warrant and each exercise of this Warrant, the Holder specifically
represents, as of the Original Issue Date and each Exercise Date, to the Company as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder is an &ldquo;accredited investor&rdquo; as defined in Rule 501 of Regulation D promulgated under the Securities Act. The
Holder is acquiring this Warrant and all Warrant Shares issued upon exercise hereof for investment for its own account and not
with a view towards, or for resale in connection with, the public sale or distribution of this Warrant or the Warrant Shares,
except pursuant to sales registered or exempted under the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder understands and acknowledges that this Warrant and the Warrant Shares to be issued upon exercise hereof are &ldquo;restricted
securities&rdquo; under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not
involving a public offering and that, under such laws and applicable regulations, such securities may be resold without registration
under the Securities Act only in certain limited circumstances. In addition, the Holder represents that it is familiar with Rule
144 under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities
Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder acknowledges that it can bear the economic and financial risk of its investment for an indefinite period and has such knowledge
and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the
Warrant and the Warrant Shares. Subject to <U>Section&nbsp;10(b)(iv)</U> below, the Holder has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of the Warrant and the business, properties,
prospects and financial condition of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder acknowledges and agrees that neither the Company, nor any officer, director, employee or representative of the Company,
nor any other Person has made or is making any representations or warranties of any kind or nature whatsoever, express or implied,
beyond those expressly given by the Company in this Warrant and in the Securities Purchase Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant
Register</B>. The Company shall keep and properly maintain at its principal executive offices books for the registration of this
Warrant and any transfers of this Warrant. The Company may deem and treat the Person in whose name the Warrant is registered on
such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the contrary, except
any assignment, division, combination or other transfer of the Warrant effected in accordance with the provisions of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>.
All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be
deemed to have been given: (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee
if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by e-mail of a PDF (or similar
electronic format) document (with confirmation of transmission) if sent during normal business hours of the recipient, and on
the next Business Day if sent after normal business hours of the recipient; or (d) on the fourth day after the date mailed, by
USPS certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective
parties at the addresses indicated below (or at such other address for a party as shall be specified in a notice given in accordance
with this <U>Section&nbsp;12</U>). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">If to the Company:</FONT> </TD>
    <TD STYLE="width: 64%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Alzamend Neuro, Inc. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 3802 Spectrum Blvd., Suite
        112C </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Tampa, FL 33612 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Attention: Investor Relations </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Telephone: (844) 722-6333&nbsp; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">If to the Holder, to their registered <BR>
    address. </FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">Ault Life Sciences, LLC</FONT> </TD></TR>
</TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative
Remedies</B>. The rights and remedies provided in this Warrant are cumulative and are not exclusive of, and are in addition to
and not in substitution for any other rights or remedies available at law, in equity or otherwise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equitable
Relief</B>. Each of the Company and the Holder acknowledges that a breach or threatened breach by such party of any of its obligations
under this Warrant would give rise to irreparable harm to the other party hereto for which monetary damages would not be an adequate
remedy and hereby agrees that in the event of a breach or a threatened breach by such party of any such obligations, the other
party hereto shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach,
be entitled to equitable relief, including a restraining order, an injunction, specific performance and any other relief that
may be available from a court of competent jurisdiction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. This Warrant, together with the Securities Purchase Agreement, constitutes the sole and entire agreement of the
parties to this Warrant with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings
and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the provisions
of this Warrant and the provisions of the Securities Purchase Agreement, the provisions of this Warrant shall control. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successor
and Assigns</B>. This Warrant and the rights evidenced hereby shall be binding upon and shall inure to the benefit of the parties
hereto and the successors of the Company and the successors and permitted assigns of the Holder. Such successors and/or permitted
assigns of the Holder shall be deemed to be a Holder for all purposes hereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Third-Party Beneficiaries</B>. This Warrant is for the sole benefit of the Company and the Holder and their respective successors
and, in the case of the Holder, permitted assigns and nothing herein, express or implied, is intended to or shall confer upon
any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headings</B>.
The headings in this Warrant are for reference only and shall not affect the interpretation of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment
and Modification; Waiver</B>. This Warrant may only be amended, modified or supplemented by an agreement in writing signed by
each party hereto. No waiver by the Company or the Holder of any of the provisions hereof shall be effective unless explicitly
set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect
of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character,
and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any rights, remedy, power or
privilege arising from this Warrant shall operate or be construed as a waiver thereof; nor shall any single or partial exercise
of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other
right, remedy, power or privilege. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
If any term or provision of this Warrant is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other term or provision of this Warrant or invalidate or render unenforceable such term
or provision in any other jurisdiction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law</B>. This Warrant shall be governed by and construed in accordance with the internal laws of the State of New York without
giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction)
that would cause the application of laws of any jurisdiction other than those of the State of New York. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Submission
to Jurisdiction</B>. Any legal suit, action or proceeding arising out of or based upon this Warrant or the transactions contemplated
hereby may be instituted in the federal courts of the United States of America or the courts of the State of New York in each
case located in the New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit,
action or proceeding. Service of process, summons, notice or other document by certified or registered mail to such party&rsquo;s
address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court.
The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in
such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought
in any such court has been brought in an inconvenient forum. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Jury Trial</B>. Each party acknowledges and agrees that any controversy which may arise under this Warrant is likely to involve
complicated and difficult issues and, therefore, to the fullest extent permitted by law, each such party irrevocably and unconditionally
waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Warrant or the
transactions contemplated hereby. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Warrant may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Warrant delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> <B>25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Strict Construction</B>. This Warrant shall be construed without regard to any presumption or rule requiring construction or interpretation
against the party drafting an instrument or causing any instrument to be drafted. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> [SIGNATURE PAGE FOLLOWS] </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B>IN WITNESS WHEREOF</B>,
the Company has duly executed this Warrant on the Original Issue Date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt"><B>ALZAMEND NEURO, INC.</B></FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 40%"> &nbsp; </TD>
    <TD STYLE="text-align: justify; width: 3%"> &nbsp; </TD>
    <TD STYLE="text-align: justify; width: 20%"> &nbsp; </TD>
    <TD STYLE="text-align: justify; width: 37%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">By: </FONT> </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> <FONT STYLE="font-size: 10pt"><I>/s/ Kenneth S. Cragun</I></FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">Name: Kenneth S. Cragun</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-indent: 0in; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="text-indent: 0in"> <FONT STYLE="font-size: 10pt">Title: Chief Financial Officer</FONT> </TD>
    <TD STYLE="text-indent: 0in; text-align: justify"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> EXHIBIT A </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> EXERCISE AGREEMENT </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>ALZAMEND
NEURO, INC.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned Holder hereby exercises the right to purchase _______________ shares of Common Stock of the Company pursuant to the
terms of the attached Warrant, and tenders herewith payment of the aggregate Exercise Price. Capitalized terms used herein and
not otherwise defined shall have the respective meanings set forth in the Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder pays the Aggregate Exercise Price pursuant to Section&nbsp;3(b)(i) with respect to _________________ shares of Common Stock
and the Holder is herewith paying a sum of $___________ to the Company in accordance with the terms of the Warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The undersigned
Holder represents that it is acquiring the shares upon exercise of the Warrant for its own account and not with a view toward,
or for resale in connection with, the public sale or distribution of those shares, except pursuant to sales registered or exempted
under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and that as of the date hereof, the undersigned
is an &ldquo;accredited investor&rdquo; as that term is defined in Rule&nbsp;501(a) of Regulation D promulgated by the Securities
and Exchange Commission under the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"> <FONT STYLE="font-size: 10pt">Name of Holder:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="width: 95%; border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 5%; text-align: left"> <FONT STYLE="font-size: 10pt">Signature of Holder:&nbsp;&nbsp;
    </FONT> </TD>
    <TD STYLE="width: 95%; border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: left"> <FONT STYLE="font-size: 10pt">Name of Authorized </FONT> </TD>
    <TD STYLE="width: 95%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: left"> <FONT STYLE="font-size: 10pt">Signatory (if an entity):&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: left"> <FONT STYLE="font-size: 10pt">Title of Authorized </FONT> </TD>
    <TD STYLE="width: 95%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: left"> <FONT STYLE="font-size: 10pt">Signatory (if an entity):&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 2%; text-align: left"> <FONT STYLE="font-size: 10pt">Dated:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="width: 98%; border-bottom: Black 1pt solid; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>EXHIBIT&nbsp;B</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>ASSIGNMENT</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> (To be signed only on transfer of Warrant) </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> For value received,
the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading &ldquo;Transferees&rdquo;
the right represented by the within Warrant to purchase shares of Common Stock of ALZAMEND NEURO, INC. into which the within Warrant
relates specified under the headings &ldquo;Number of Warrants Transferred,&rdquo; respectively, opposite the name(s) of such
person(s) and appoints each and any officer of the Corporation as attorney to transfer the undersigned&rsquo;s respective right
on the register of warrants maintained by the Corporation with full power of substitution in the premises. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1pt solid; text-align: justify"> <FONT STYLE="font-size: 10pt">Transferees</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 24%; border-bottom: Black 1pt solid; text-align: justify"> <FONT STYLE="font-size: 10pt">Address</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 3%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1pt solid"> <FONT STYLE="font-size: 10pt">Number of
    Warrants<BR>
    Transferred</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 8%; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> <FONT STYLE="font-size: 10pt">Dated:</FONT> </TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 20%"> &nbsp; </TD>
    <TD STYLE="width: 3%; border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 55%"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> <FONT STYLE="font-size: 10pt">(Signature must conform to name of Holder as specified on the face of the
    Warrant)</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="white-space: nowrap"> <FONT STYLE="font-size: 10pt">Address:&nbsp;&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Signature Guarantee</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> ACCEPTED AND AGREED: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>[TRANSFEREE]</B>&#9;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 70%; text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"> <FONT STYLE="font-size: 10pt">(Name)</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The signature of the Holder to this
Assignment must correspond exactly with the name of the Holder as set forth on the face of the Warrant in every particular and
the signature must be guaranteed by a U.S. chartered bank or by a medallion signature guarantee from a member of a recognized
Signature Medallion Guarantee Program. </P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-4 SUBS AGMT
<SEQUENCE>5
<FILENAME>ex1a-4_1.htm
<DESCRIPTION>EXHIBIT 1A-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"> &nbsp; </P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Exhibit 4.1</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><U>SUBSCRIPTION AGREEMENT &ndash;
NOTICE TO INVESTORS</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THIS INVESTMENT INVOLVES A HIGH
DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND
WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS
EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE SECURITIES OFFERED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>SECURITIES ACT</U>&rdquo;), OR ANY STATE SECURITIES
OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE
SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE &ldquo;<U>SEC</U>&rdquo;),
THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE ACT.
THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY,
NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION
AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO PROSPECTIVE INVESTOR IN CONNECTION WITH THIS OFFERING, OVER
THE WEB-BASED PLATFORM MAINTAINED BY SOS BACK OFFICE SOLUTIONS, LLC (THE &ldquo;<U>PLATFORM</U>&rdquo;). </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE SECURITIES CANNOT BE SOLD OR
OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT. IN ADDITION, THE SECURITIES CANNOT BE SOLD OR OTHERWISE TRANSFERRED
EXCEPT IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR &ldquo;BLUE SKY&rdquo; LAWS. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>INVESTORS WHO ARE NOT &ldquo;ACCREDITED
INVESTORS&rdquo; (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE SECURITIES ACT) ARE SUBJECT TO
LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4(g). THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES
SET FORTH BY EACH INVESTOR IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY INVESTOR IN CONNECTION WITH THIS
OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.
</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>PROSPECTIVE INVESTORS MAY NOT TREAT
THE CONTENTS OF THE SUBSCRIPTION AGREEMENT, THE OFFERING CIRCULAR OR ANY OF THE OTHER MATERIALS AVAILIBLE ON THE PLATFORM OR PROVIDED
BY THE COMPANY (COLLECTIVELY, THE &ldquo;<U>OFFERING MATERIALS</U>&rdquo;), OR ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE
COMPANY OR ANY OF ITS OFFICERS, EMPLOYEES OR AGENTS (INCLUDING &ldquo;<U>TESTING THE WATERS</U>&rdquo; MATERIALS) AS INVESTMENT,
LEGAL OR TAX ADVICE. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS
OF THIS OFFERING, INCLUDING THE MERITS AND THE RISKS INVOLVED. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>EACH PROSPECTIVE INVESTOR SHOULD
CONSULT THE INVESTOR&rsquo;S OWN COUNSEL, ACCOUNTANTS AND OTHER PROFESSIONAL ADVISORS AS TO INVESTMENT, LEGAL, TAX AND OTHER RELATED
MATTERS CONCERNING THE INVESTOR&rsquo;S PROPOSED INVESTMENT. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE OFFERING MATERIALS MAY CONTAIN
FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS
INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE
TO THE COMPANY&rsquo;S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS &ldquo;ESTIMATE,&rdquo; &ldquo;PROJECT,&rdquo;
&ldquo;BELIEVE,&rdquo; &ldquo;ANTICIPATE,&rdquo; &ldquo;INTEND,&rdquo; &ldquo;EXPECT&rdquo; AND SIMILAR EXPRESSIONS ARE INTENDED
TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT&rsquo;S
CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY&rsquo;S ACTUAL
RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE
RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE
ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARDLOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT
THE OCCURRENCE OF UNANTICIPATED EVENTS. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE COMPANY MAY NOT BE OFFERING
THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION
IN WHICH THE SECURITIES ARE NOT BEING OFFERED. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE INFORMATION PRESENTED IN THE
OFFERING MATERIALS WAS PREPARED BY THE COMPANY SOLELY FOR THE USE BY PROSPECTIVE INVESTORS IN CONNECTION WITH THIS OFFERING. NO
REPRESENTATIONS OR WARRANTIES ARE MADE AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED IN ANY OFFERING MATERIALS,
AND NOTHING CONTAINED IN THE OFFERING MATERIALS IS OR SHOULD BE RELIED UPON AS A PROMISE OR REPRESENTATION AS TO THE FUTURE PERFORMANCE
OF THE COMPANY. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>THE COMPANY RESERVES THE RIGHT IN
ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT
OR REJECT, IN WHOLE OR IN PART, FOR ANY REASON OR FOR NO REASON, ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY
PROSPECTIVE INVESTOR LESS THAN THE DOLLAR AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED,
THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES,
CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><U>SUBSCRIPTION AGREEMENT</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> This subscription agreement (the &ldquo;<B>Agreement</B>&rdquo;)
is entered into by and between Alzamend Neuro, Inc., a Delaware corporation (hereinafter the &ldquo;<B>Company</B>&rdquo;) and
the undersigned (hereinafter the &ldquo;<B>Investor</B>&rdquo;) as of the date set forth on the signature page hereto. Any term
used but not defined herein shall have the meaning set forth in the Offering Circular. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>RECITALS</B>: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>WHEREAS</B>, the Company desires
to issue a maximum of 6,000,000 shares of common stock (the &ldquo;<B>Shares</B>&rdquo;) of the Company, par value $0.0001 per
share (the &ldquo;<B>Common Stock</B>&rdquo;); and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>WHEREAS</B>, Investor desires to
acquire that number of Shares as is set forth on the signature page hereof for the purchase price set forth herein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>NOW, THEREFORE</B>, for and in consideration
of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subscription</B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Investor hereby irrevocably subscribes for and agrees to purchase the number of Shares set forth on the signature page hereto
at a purchase price of $7.50 per such share (the &ldquo;<B>Per Share Purchase Price</B>&rdquo;), rounded down to the nearest whole
share based on Investor&rsquo;s subscription amount, upon the terms and conditions set forth herein. The aggregate purchase price
for the Shares with respect to each Investor (the &ldquo;<B>Purchase Price</B>&rdquo;) is payable in the manner provided in Section
2(a) below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
understands that the Shares are being offered pursuant to the Offering Circular dated ______ __, 2020 and its exhibits (collectively,
the &ldquo;<B>Offering Circular</B>&rdquo;) as filed with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).
By subscribing to the Offering, the Investor acknowledges that Investor has received and reviewed a copy of the Offering Circular
and any other information required by Investor to make an investment decision with respect to the Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
subscription may be accepted or rejected in whole or in part, for any reason or for no reason, at any time prior to the Termination
Date (as hereinafter defined), by the Company at its sole and absolute discretion. In addition, the Company, at its sole and absolute
discretion, may allocate to Investor only a portion of the number of the Shares that Investor has subscribed for hereunder. The
Company will notify Investor whether this subscription is accepted (whether in whole or in part) or rejected. If Investor&rsquo;s
subscription is rejected, Investor&rsquo;s payment (or portion thereof if partially rejected) will be returned to Investor without
interest and all of Investor&rsquo;s obligations hereunder shall terminate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate number of Shares that may be sold by the Company in this offering shall not exceed $45,000,000 (the &ldquo;<B>Maximum
Offering</B>&rdquo;). This offering will terminate on the earlier of (i) the Company&rsquo;s decision to terminate Offering; (ii)
September 1, 2020, subject to extension for up to ninety (90) days in the sole discretion of the Company; or (iii) the date on
which the Maximum Offering is sold (in either case, the &ldquo;<B>Termination Date</B>&rdquo;). The Company may elect at any time
to close all or any portion of this Offering on various dates at or prior to the Termination Date (each, a &ldquo;<B>Closing</B>&rdquo;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of rejection of this subscription in its entirety, or in the event the sale of the Shares (or any portion thereof) to
an Investor is not consummated for any reason, this Subscription Agreement shall have no force or effect, except for Section 5
hereof, which shall remain in force and effect. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of this Subscription Agreement shall be binding upon Investor and its permitted transferees, heirs, successors and assigns
(collectively, the &ldquo;<B>Transferees</B>&rdquo;); provided, however, that for any such transfer to be deemed effective, the
Transferee shall have executed and delivered to the Company in advance an instrument in form acceptable to the Company in its
sole discretion, pursuant to which the proposed Transferee shall acknowledge and agree to be bound by the representations and
warranties of Investor and the terms of this Subscription Agreement. No transfer of this Agreement may be made without the consent
of the Company, which may be withheld in its sole and absolute discretion. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase
Procedure</B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment.
</U>The Purchase Price shall be paid simultaneously with Investor&rsquo;s subscription. Investor shall deliver payment for the
aggregate purchase price of the Shares by wire transfer to an account designated by the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Escrow
Arrangements</U>. Payment for the Shares by Investor shall be received by SOS Back Office Solutions, LLC, Inc. (the &ldquo;<B>Escrow
Agent</B>&rdquo;) from Investor by transfer of immediately available funds via wire prior to the applicable Closing in the amount
of Investor&rsquo;s subscription using the instructions below. Upon such Closing, the Escrow Agent shall release such funds to
the Company. Investor shall receive notice and evidence of the digital entry of the number of the Shares owned by Investor reflected
in their investor account. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify; text-indent: 0.5in"> Bank
Name: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify; text-indent: 0.5in"> Routing
No. _______________ </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify; text-indent: 0.5in"> Account
Number __________ </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify; text-indent: 0.5in"> Account
Name _______________________ </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Warranties of the Company</B>. The Company represents and warrants to Investor that the following representations and warranties
are true and complete in all material respects as of the date of each Closing: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Standing</U>. The Company is a corporation duly formed, validly existing and in good standing under the laws of the State
of Delaware. The Company has all requisite power and authority to own and operate its properties and assets, to execute and deliver
this Subscription Agreement, the Shares and any other agreements or instruments required hereunder. The Company is duly qualified
and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of
its activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions
in which failure to do so would not have a material adverse effect on the Company or its business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Shares</U>. The issuance, sale and delivery of the Shares in accordance with this Subscription Agreement have been duly
authorized by all necessary corporate action on the part of the Company. The Shares, when issued, sold and delivered against payment
therefor in accordance with the provisions of this Subscription Agreement, will be duly and validly issued, fully paid and non-assessable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority
for Agreement</U>. The acceptance by the Company of this Subscription Agreement and the consummation of the transactions contemplated
hereby are within the Company&rsquo;s powers and have been duly authorized by all necessary corporate action on the part of the
Company. Upon the Company&rsquo;s acceptance of this Subscription Agreement, this Subscription Agreement shall constitute a valid
and binding agreement of the Company, enforceable against the Company in accordance with its terms, except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies and (iii) with respect to provisions relating to indemnification and contribution, as limited by considerations of public
policy and by federal or state securities laws. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Filings</U>. Assuming the accuracy of Investor&rsquo;s representations and warranties set forth in Section 4 hereof, no order,
license, consent, authorization or approval of, or exemption by, or action by or in respect of, or notice to, or filing or registration
with, any governmental body, agency or official is required by or with respect to the Company in connection with the acceptance,
delivery and performance by the Company of this Subscription Agreement except (i) for such filings as may be required under Regulation
A or under any applicable state securities laws, (ii) for such other filings and approvals as have been made or obtained, or (iii)
where the failure to obtain any such order, license, consent, authorization, approval or exemption or give any such notice or
make any filing or registration would not have a material adverse effect on the ability of the Company to perform its obligations
hereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The outstanding shares of Common Stock, options, warrants and other securities of the Company immediately prior to the initial
Closing is as set forth under the title &ldquo;Description of Securities&rdquo; in the Offering Circular. Except as set forth
in the Offering Circular, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights
of first refusal), or agreements of any kind (oral or written) for the purchase or acquisition from the Company of any of its
securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->
                                                                                                                                                                                                                                                                                -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. Complete copies of the Company&rsquo;s financial statements and the accompanying notes thereto for the respective
periods then ended (collectively, the &ldquo;<B>Financial Statements</B>&rdquo;), have been made available to Investor and appear
in the Offering Circular. The Financial Statements are based on the books and records of the Company and fairly present the financial
condition of the Company as of the respective dates they were prepared and the results of the operations and cash flows of the
Company for the respective periods indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as disclosed in the Offering Circular, there is no pending action, suit, proceeding, arbitration, mediation, complaint,
claim, charge or investigation before any court, arbitrator, mediator or governmental body, or to the Company&rsquo;s knowledge,
currently threatened in writing (a) against the Company or (b) to the Company&rsquo;s knowledge, against any consultant, officer,
manager, director or key employee of the Company arising out of his or her consulting, employment or board relationship with the
Company or that could otherwise materially impact the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Warranties of Investor</B>. By subscribing to the Offering, Investor (and, if Investor is purchasing the Shares subscribed
for hereby in a fiduciary capacity, the person or persons for whom Investor is so purchasing) represents and warrants, which representations
and warranties are true and complete in all material respects, as of the date of each Closing: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Requisite
Power and Authority</U>. Investor has all necessary power and authority under all applicable provisions of law to subscribe to
the Offering, to execute and deliver this Subscription Agreement and to carry out the provisions thereof. All actions on Investor&rsquo;s
part required for the lawful subscription to the offering have been or will be effectively taken prior to the Closing. Upon subscribing
to the Offering, this Subscription Agreement will be a valid and binding obligation of Investor, enforceable in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application
affecting enforcement of creditors&rsquo; rights and (ii) as limited by general principles of equity that restrict the availability
of equitable remedies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Experience</U>. Investor has sufficient experience in financial and business matters to be capable of utilizing such information
to evaluate the merits and risks of Investor&rsquo;s investment in the Shares, and to make an informed decision relating thereto.
Alternatively, the Investor has utilized the services of a purchaser representative and together they have sufficient experience
in financial and business matters that they are capable of utilizing such information to evaluate the merits and risks of Investor&rsquo;s
investment in the Shares, and to make an informed decision relating thereto. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investor
Determination of Suitability</U>. Investor has evaluated the risks of an investment in the Shares, including those described in
the section of the Offering Circular entitled &ldquo;Risk Factors,&rdquo; and has determined that the investment is suitable for
Investor. Investor has adequate financial resources for an investment of this character. Investor could bear a complete loss of
Investor&rsquo;s investment in the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration</U>. Investor understands that the Shares are not being registered under the Securities Act of 1933, as amended (the
&ldquo;<B>Securities Act</B>&rdquo;), on the ground that the issuance thereof is exempt under Regulation A of Section 3(b) of
the Securities Act, and that reliance on such exemption is predicated in part on the truth and accuracy of Investor's representations
and warranties, and those of the other purchasers of the Shares in the offering. Investor further understands that the Shares
are not being registered under the securities laws of any states on the basis that the issuance thereof is exempt as an offer
and sale not involving a registrable public offering in such state, since the Shares are &ldquo;covered securities&rdquo; under
the National Securities Market Improvement Act of 1996. Investor covenants not to sell, transfer or otherwise dispose of any Shares
unless such Shares have been registered under the Securities Act and under applicable state securities laws, or exemptions from
such registration requirements are available. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Illiquidity
and Continued Economic Risk</U>. Investor acknowledges and agrees that there is no ready public market for the Shares and that
there is no guarantee that a market for their resale will ever exist. The Company has no obligation to list any of the Shares
on any market or take any steps (including registration under the Securities Act or the Securities Exchange Act of 1934, as amended)
with respect to facilitating trading or resale of the Shares. Investor must bear the economic risk of this investment indefinitely
and Investor acknowledges that Investor is able to bear the economic risk of losing Investor&rsquo;s entire investment in the
Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->
                                                                                                                                                                                                                                                                                -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accredited
Investor Status or Investment Limits</U>. Investor represents that either: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (i) </TD><TD STYLE="text-align: justify"> that Investor is an &ldquo;accredited
                                         investor&rdquo; within the meaning of Rule 501 of Regulation D under the Shares Act;
                                         or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (ii) </TD><TD STYLE="text-align: justify"> that the Purchase Price, together
                                         with any other amounts previously used to purchase Shares in this offering, does not
                                         exceed 10% of the greater of Investor&rsquo;s annual income or net worth (or in the case
                                         where Investor is a non-natural person, their revenue or net assets for such Investor's
                                         most recently completed fiscal year end). </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Investor represents
that to the extent it has any questions with respect to its status as an accredited investor, or the application of the investment
limits, it has sought professional advice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Stockholder Information</U>. Within five days after receipt of a request from the Company, Investor hereby agrees to provide
such information with respect to its status as a stockholder (or potential stockholder) and to execute and deliver such documents
as may reasonably be necessary to comply with any and all laws and regulations to which the Company is or may become subject,
including, without limitation, the need to determine the accredited investor status of the Company&rsquo;s stockholders. Investor
further agrees that in the event it transfers any Shares, it will require the transferee of such Shares to agree to provide such
information to the Company as a condition of such transfer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Valuation</U>.
Investor acknowledges that the Per Share Purchase Price of the Shares to be sold in this offering was set by the Company on the
basis of the Company&rsquo;s internal valuation and no warranties are made as to value. Investor further acknowledges that future
offerings of securities of the Company may be made at lower valuations, with the result that Investor&rsquo;s investment will
bear a lower valuation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Domicile</U>.
Investor maintains Investor&rsquo;s domicile (and is not a transient or temporary resident) at the address provided with Investors
subscription. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Investors</U>. If Investor is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986,
as amended), Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction
in connection with any invitation to subscribe for the Shares or any use of this Subscription Agreement, including (i) the legal
requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such
purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. Investor&rsquo;s subscription
and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of Investor&rsquo;s
jurisdiction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnity</B>.
The representations, warranties and covenants made by Investor herein shall survive the closing of this Subscription Agreement.
Investor agrees to indemnify and hold harmless the Company and its respective officers, directors and affiliates, and each other
person, if any, who controls the Company within the meaning of Section 15 of the Securities Act against any and all loss, liability,
claim, damage and expense whatsoever (including, but not limited to, any and all reasonable attorneys&rsquo; fees, including attorneys&rsquo;
fees on appeal) and expenses reasonably incurred in investigating, preparing or defending against any false representation or
warranty or breach of failure by Investor to comply with any covenant or agreement made by Investor herein or in any other document
furnished by Investor to any of the foregoing in connection with this transaction. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Jurisdiction</B>. All questions concerning the construction, validity, enforcement and interpretation of the Offering Circular,
including, without limitation, this Subscription Agreement, shall be governed by and construed and enforced in accordance with
the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that
all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Subscription
Agreement and any documents included within the Offering Circular (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the documents
included within the Offering Circular), and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is
an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices to it under this Subscription Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. Notwithstanding the foregoing, nothing
contained in this Section 6 shall apply to any action that may arise under the Securities Act or the Securities Exchange Act of
1934, as amended. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 4<!-- Field: /Sequence -->
                                                                                                                                                                                                                                                                                -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>.
Notice, requests, demands and other communications relating to this Subscription Agreement and the transactions contemplated herein
shall be in writing and shall be deemed to have been duly given if and when (a) delivered personally, on the date of such delivery;
or (b) mailed by registered or certified mail, postage prepaid, return receipt requested, in the third day after the posting thereof;
or (c) emailed on the date of such delivery to the address of the respective parties as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If to the Company,
to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Alzamend Neuro,
Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 50 W. Broadway,
3rd Floor, Salt Lake City, UT 84101 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Attn.: Philip Mansour,
Chief Executive Officer </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If to Investor,
at Investor&rsquo;s address supplied in connection with this subscription, or to such other address as may be specified by written
notice from time to time by the party entitled to receive such notice. Any notices, requests, demands or other communications
by email shall be confirmed by letter given in accordance with (a) or (b) above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Miscellaneous</U></B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity
of the person or persons or entity or entities may require. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than as set forth herein, this Subscription Agreement is not transferable or assignable by Investor. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representations, warranties and agreements contained herein shall be deemed to be made by and be binding upon Investor and its
heirs, executors, administrators and successors and shall inure to the benefit of the Company and its successors and assigns. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the provisions of this Subscription Agreement may be waived, changed or terminated orally or otherwise, except as specifically
set forth herein or except by a writing signed by the Company and Investor. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event any part of this Subscription Agreement is found to be void or unenforceable, the remaining provisions are intended
to be separable and binding with the same effect as if the void or unenforceable part were never the subject of agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (f) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
invalidity, illegality or unenforceability of one or more of the provisions of this Subscription Agreement in any jurisdiction
shall not affect the validity, legality or enforceability of the remainder of this Subscription Agreement in such jurisdiction
or the validity, legality or enforceability of this Subscription Agreement, including any such provision, in any other jurisdiction,
it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted
by law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (g) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Subscription Agreement supersedes all prior discussions and agreements between the parties, if any, with respect to the subject
matter hereof and contains the sole and entire agreement between the parties hereto with respect to the subject matter hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms and provisions of this Subscription Agreement are intended solely for the benefit of each party hereto and their respective
successors and assigns, and it is not the intention of the parties to confer, and no provision hereof shall confer, third-party
beneficiary rights upon any other person. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 5<!-- Field: /Sequence -->
                                                                                                                                                                                                                                                                                -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
headings used in this Subscription Agreement have been inserted for convenience of reference only and do not define or limit the
provisions hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (j) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
failure or delay by any party in exercising any right, power or privilege under this Subscription Agreement shall operate as a
waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights
or remedies provided by law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 6<!-- Field: /Sequence -->
                                                                                                                                                                                                                                                                                -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>IN WITNESS WHEREOF,</B> this Subscription
Agreement is executed as of the ______ day of _________, 2016. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 38%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares Subscribed For: </FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 62%; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Purchase
    Price:</FONT> </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of
    Subscriber:</FONT> </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subscriber:</FONT> </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Subscriber:</FONT> </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscriber&rsquo;s
    SS# or tax ID#:</FONT> </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Please designate whether your Shares
should be Issued in Book or Certificate: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> _________Book&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
_________Certificate Issued </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>ACCEPTED BY: Alzamend Neuro, Inc.
</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Authorized Signatory:</FONT> </TD>
    <TD STYLE="width: 38%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT> </TD>
    <TD STYLE="width: 38%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized
    Signatory: </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip E. Mansour,
    President and CEO</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Acceptance:
    </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;_________
    &nbsp;__, 2016</FONT> </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid"> &nbsp; </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>6
<FILENAME>ex1a-6_6.htm
<DESCRIPTION>EXHIBIT 1A-6.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 6.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="alzamend_header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 84%; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt"><B>November 30, 2018</B></FONT> </TD>
    <TD STYLE="text-align: center; width: 16%; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Stephan Jackman,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt"> This letter is
an amendment to the CEO Offer Letter dated October 27, 2018 which detailed terms of your employment agreement. As of this date,
you confirm your continued willingness to serve as the Chief Executive Officer (&ldquo;CEO&rdquo;) of Alzamend Neuro, Inc. (the
&ldquo;Company&rdquo;) on the terms set forth below for a term of four years. This letter shall serve as a binding Memorandum
of Understanding with a more definitive employment agreement detailing the job description and responsibilities, that will be
provided within 30 calendar days of your acceptance of this letter. </P>




        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin: 0pt 0">&nbsp;&nbsp;&nbsp;The Company is pleased to offer you the following compensation
detailed as follows:</P></TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Annual
        cash compensation of $150,000.00 payable in monthly installments according to the Company's regular payroll schedule;
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> Upon
        approval of the FDA IND application for LiProSal, the annual cash compensation will increase to $180,000.00 payable in
        monthly installments according to the Company's regular payroll schedule; and upon approval of the FDA IND application
        for CAO22W, the annual cash compensation will increase to $225,000.00 payable in monthly installments according to the
        Company's regular payroll schedule; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.55pt; text-align: justify; text-indent: -0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> The
        Company shall grant you an option to purchase 5,000,000 shares of the Company&rsquo;s common stock exercisable for a period
        of seven (7) years at the Fair Market Value (&ldquo;FMV&rdquo;), currently $1.00. For purposes of determining the FMV
        of a share of common stock as of any date, the FMV as of that date shall be, unless otherwise determined by the Company&rsquo;s
        Board of Directors (the &ldquo;Board&rdquo;), the closing sale price during regular trading hours of the common stock
        on the date on the principal securities market in which shares of common stock is then traded; or, if there were no trades
        on that date, the closing sale price during regular trading hours of the common stock on the first trading day prior to
        that date. If the common stock is not publicly traded at the time a determination of FMV is required to be made hereunder,
        the determination of such amount shall be made by the Board in such manner as it deems appropriate. The options shall
        vest pursuant to the following schedule: </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt; vertical-align: top"><IMG SRC="ex6_head.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="alzamend_footer.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="alzamend_header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 5%; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 74%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Three
        million options (3,000,000) shall vest ratably over 48 months beginning with the first month after the grant date. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
        million options (1,000,000) shall vest upon approval of a NDA for LiProSal by the FDA within 36 months from November 1,
        2018. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-indent: -0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
        million options (1,000,000) shall vest upon approval of a NDA for CAO2W by the FDA within 48 months from November 1, 2018. </P></TD>
    <TD STYLE="width: 16%; text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">4.</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> During the Employment Period,
        you shall be entitled to an annual bonus (the &ldquo;Annual Bonus&rdquo;) if the Company meets or exceeds criteria adopted
        by the Compensation Committee, or if the Company has not established a Compensation Committee the Board (the &ldquo;Compensation
        Committee&rdquo;), for earning Bonuses which shall be adopted by the Compensation Committee annually. Bonuses shall be
        paid promptly after determination that the relevant targets have been met, it being understood that the attainment of
        any financial targets associated with any bonus shall not be determined until following the completion of the Company&rsquo;s
        annual audit and public announcement. The Annual Bonus may consist of cash, common stock or a combination of the two.
        The Annual Bonus, if any, shall in part be determined based upon the successful attainment of the following milestones: </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -18.05pt"> A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval
        to conduct a Second Phase Clinical Trial for CAO22W; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -18.05pt"> B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval
        to conduct a Third Phase Clinical Trial for CAO22W; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -18.05pt"> C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval
        to conduct a Third Phase Clinical Trial for LiProSal; </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -18.05pt"> D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
        or debt financings. </P></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"> </P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;<IMG SRC="ex6_head.jpg" ALT="">&nbsp; </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">5.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Participation in the Company&rsquo;s medical insurance and
    benefit program as well as in any and all other employment benefit programs offered, as established by the Company.</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">6.</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">During the term of your employment with the Company, and
    for a period of three (3) years thereafter, you shall maintain in strict confidence all information that you have obtained
    or shall obtain from Alzamend which Alzamend has designated as &ldquo;confidential&rdquo; or which is, by its nature confidential,
    relating to Alzamend&rsquo;s business, operations, properties, assets, services, condition (financial or otherwise), liabilities,
    employee relations, customers (including customer usage statistics), suppliers, prospects, technology, or trade secrets, except
    to the extent such information (i) is in the public domain through no act or omission of Alzamend, (ii) is required to be
    disclosed by law or a valid order by a court or other governmental body, or (iii) is independently learned by you outside
    of this relationship.</FONT> </TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="alzamend_footer.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="alzamend_header.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 84%; padding-left: 78.6pt; text-align: justify; text-indent: -0.5in; font-size: 10pt"> <FONT STYLE="font-size: 10pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>Additionally, the Company shall reimburse you for all of your out-of- pocket expenses incurred in connection with your
    duties as the CEO.</FONT> </TD>
    <TD STYLE="width: 16%; font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
                                <P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P></TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;I
         am confident that your work will prove instrumental in helping us build a world-class company. Please confirm your acceptance
         of these terms by signing and dating this letter agreement and returning it to the undersigned. By signing this letter
         agreement, you reconfirm to the Company that you have no contractual commitments or other legal obligations that would
         prohibit you from performing your duties for the Company. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 43%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 41%"><P STYLE="margin-top: 0; margin-bottom: 0">Very truly yours,</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alzamend Neuro, Inc.</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="aultsig.jpg" ALT=""></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: middle; width: 16%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex6_head.jpg" ALT="">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 1pt; color: White">Alzamend Neuro,
Inc. By: Milton C. Ault, III Chairman of the Board of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</TD>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="jackmansig.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 1pt; color: White">Signature of
Stephan Jackman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="alzamend_footer.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>7
<FILENAME>ex1a-6_9.htm
<DESCRIPTION>EXHIBIT 1A-6.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Exhibit 6.9</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> STOCK PLEDGE AGREEMENT </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This STOCK PLEDGE AGREEMENT (&ldquo;Agreement&rdquo;)
is made and entered as of this ____ day of June 11, 2019 by and between Ault Life Sciences Fund, LLC, a Delaware limited liability
company maintaining a business address at 201 Shipyard Way, Suite E, Newport Beach California 92663 (the &ldquo;<B>Pledgor</B>&rdquo;),
and Alzamend Neuro, Inc., a Delaware corporation with offices located at 3802 Spectrum Boulevard, Suite 112C, Tampa, Florida 33612,
the intended beneficiary of the rights, privileges and benefits of this Stock Pledge Agreement (the &ldquo;<B>Beneficiary</B>&rdquo;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> WHEREAS, Pledgor has issued to the Beneficiary
a promissory note in the amount of Fifteen Million Dollars $15,000,000 (the &ldquo;<B>Note</B>&rdquo;) as payment for ten million
(10,000,000) shares of the Beneficiary&rsquo;s Common Stock (the &ldquo;<B>Shares</B>&rdquo;) pursuant to the Securities Purchase
Agreement dated as of April 30, 2019 between the Pledgor and the Beneficiary (the &ldquo;<B>Securities Purchase Agreement</B>&rdquo;); </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> NOW THEREFORE, in consideration of the
promises contained herein and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged,
Pledgor hereby agrees with Beneficiary as follow: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 1. </TD><TD> <U>Pledge of Security</U>. The Pledgor hereby grants and pledges
                                         to Beneficiary, for the benefit of Beneficiary as security for the prompt payment in
                                         full when due, whether at stated maturity or acceleration, of all amounts currently or
                                         hereafter owed by Pledgor to Beneficiary under the Note, a security interest and a lien
                                         upon all of Pledgor&rsquo;s right, title and interest in and to the following (the &ldquo;<B>Pledged
                                         Collateral</B>&rdquo;): </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> The Shares and any interests of Pledgor in the entries and
                                         on the books of any financial intermediary pertaining to the Shares, and all dividends
                                         (other than cash dividends), warrants, rights, instruments and other property or proceeds
                                         from time to time received, receivable or otherwise distributed in respect of or in exchange
                                         for any or all of the Shares; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> To the extent not covered by the security interest granted
                                         pursuant to section 1(a) above, all Proceeds of any or all of the foregoing Pledged Collateral.
                                         For purposes of this Agreement, the term &ldquo;<B>Proceeds</B>&rdquo; includes whatever
                                         is receivable or received when Pledged Collateral or proceeds are sold, exchanged, collected
                                         or otherwise disposed of, whether such disposition is voluntary or involuntary. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 2. </TD><TD> <U>Security For Obligations</U>. This Agreement secures, and
                                         the Pledged Collateral is collateral security for, the prompt payment or performance
                                         in full when due, of the payment obligations of the Pledgor to the Beneficiary under
                                         the Note (the &ldquo;<B>Obligations</B>&rdquo;). </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 3. </TD><TD> <U>Delivery of Pledged Collateral</U>. All certificates or instruments
                                         representing or evidencing the Pledged Collateral shall be delivered to, and held by,
                                         Beneficiary, and shall be in suitable form for transfer by delivery or, as applicable,
                                         shall be accompanied by the appropriate endorsement of Pledgor, where necessary, or duly
                                         executed instruments of transfer or assignment in blank, all in form and substance satisfactory
                                         to Beneficiary. In the event that Pledgor shall fail to make any payment required under
                                         the Note when due (whether by acceleration or otherwise but after taking into account
                                         any applicable grace period set forth in the Note) (an &ldquo;<B>Event of Default</B>&rdquo;),
                                         Beneficiary shall have the right, at any time in its discretion and without notice to
                                         Pledgor, to transfer to or to register in the name of Beneficiary any or all of the Pledged
                                         Collateral. In addition, Beneficiary shall have the right at any time to exchange certificates
                                         or instruments representing or evidencing the Pledged Collateral for certificates or
                                         instruments of smaller or larger denominations. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 4. </TD><TD> <U>Release of Shares</U>. Upon each payment of the principal
                                         amount of the Note, the Beneficiary shall release certificates representing a proportionate
                                         number of pledge Shares. By way of example if thirty percent (30%) of the principal amount
                                         of the Note is paid to the Beneficiary, the Beneficiary shall release certificates representing
                                         thirty percent (30%) of the pledged Shares. Upon the termination of the Note and the
                                         payment to Beneficiary of all amounts due to Beneficiary thereunder, Beneficiary shall
                                         release all certificates representing the pledged Shares to the Pledgor. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 5. </TD><TD> <U>Further Assurance: Pledge Amendments</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> Pledgor agrees that from time to time, at the expense of
                                         Pledgor, Pledgor will promptly execute and deliver all further instruments and documents,
                                         and take all further action that may be necessary or that Beneficiary may reasonably
                                         request, in order to perfect and protect any security interest granted or purported to
                                         be granted hereby or to enable Beneficiary to exercise and enforce its rights and remedies
                                         hereunder with respect to any Pledged Collateral. Without limiting the generality of
                                         the foregoing, Pledgor shall: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (i) </TD><TD> execute and file such financing or continuation statements,
                                         or amendments thereto, and such other instruments or notices, as may be necessary, or
                                         as Beneficiary may reasonably request, in order to perfect and preserve the security
                                         interests granted or purported to be granted hereby; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (ii) </TD><TD> at Beneficiary&rsquo;s request, appear in and defend any
                                         action or proceeding that may affect Pledgor&rsquo;s title to or Beneficiary&rsquo;s
                                         security interest in all or any part of the Pledged Collateral. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> Pledgor further agrees that it shall, upon obtaining any
                                         additional shares of stock or other securities of the Beneficiary, deliver to Beneficiary
                                         a Pledge Amendment, duly executed by Pledgor, in respect of the additional shares or
                                         securities to be pledged pursuant to this Agreement. Pledgor hereby authorizes Beneficiary
                                         to attach each Pledge Amendment to this Agreement and agrees that all securities listed
                                         on any Pledge Amendment delivered to Beneficiary shall for all purposes hereunder be
                                         considered Pledged Collateral; provided that the failure of Pledgor to execute a Pledge
                                         Amendment with respect to any additional securities pledged pursuant to this Agreement
                                         shall not impair the security interest of Beneficiary therein or otherwise adversely
                                         affect the rights and remedies of Beneficiary hereunder with respect thereto. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 6. </TD><TD> <U>Voting Rights; Dividend; Etc.</U> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> The Pledgor shall have no right to exercise voting or consensual
                                         rights with respect to the Pledged Collateral while the Pledge Collateral is subject
                                         to this Agreement. During the time that the Pledged Collateral is subject to this Agreement
                                         any and all dividends paid or payable (whether payable in cash or other than in cash)
                                         and instruments and other property received, receivable or otherwise distributed or in
                                         exchange for, any Pledged Collateral; shall forthwith be delivered to Beneficiary to
                                         hold as Pledged Collateral; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> In order to permit Beneficiary to exercise the voting and
                                         other consensual rights which he may be entitled to exercise pursuant to Section 6(a)
                                         and to receive all dividends and other distributions which he may be entitled to receive
                                         under Section 6(a), Pledgor shall promptly execute and deliver (or cause to be executed
                                         and delivered) to Beneficiary all such proxies, dividend payment orders and other instruments
                                         as Beneficiary may from time to time reasonably request. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 7. </TD><TD> <U>Secured Party Appointed Attorney-in-Fact</U>. Upon the occurrence
                                         and during the continuation of an Event of Default, Pledgor hereby irrevocably appoints
                                         Beneficiary (and any agent of Beneficiary, with full power of substitution and revocation)
                                         as Pledgor&rsquo;s attorney-in-fact, with full authority in the place and stead of Pledgor
                                         and in the name of Pledgor, Beneficiary or otherwise, from time to time in Beneficiary&rsquo;s
                                         discretion, to take any action and to execute any instrument that Beneficiary may deem
                                         necessary or advisable to accomplish the purposes of this Agreement, including without
                                         limitation: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> to file one or more financing or continuation statements,
                                         or amendments thereto, relative to all or any part of the Pledged Collateral without
                                         the signature of Pledgor; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> to ask, demand, collect, sue for, recover, compound, receive
                                         and give acquittance and receipts for monies due and to become due under or in respect
                                         of any of the Pledged Collateral; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (c) </TD><TD> to receive, endorse and collect any instruments made payable
                                         to Pledgor representing any dividend (other than cash dividends), principal or interest
                                         payment or other distribution in respect of the Pledged Collateral or any part thereof
                                         and to give full discharge for the same. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 8. </TD><TD> <U>Secured Party May Perform</U>. If Pledgor fails to perform
                                         any covenant contained herein, Beneficiary may perform, or cause Beneficiary incurred
                                         in connection therewith shall be payable by Pledgor. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 9. </TD><TD> <U>Remedies</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> If any Event of Default shall have occurred and be continuing,
                                         Beneficiary may at its option exercise in respect of the Pledged Collateral, in addition
                                         to all other rights and remedies provided for herein or otherwise available to it, all
                                         the rights and remedies of a secured party on default under the Uniform Commercial Code
                                         as in effect in any relevant jurisdiction (the &ldquo;<B>Code</B>&rdquo;) (whether or
                                         not the Code applies to the affected Pledged Collateral), and Beneficiary may at its
                                         option declare all of the Obligations to be immediately due and payable in full and Beneficiary
                                         may also in its sole discretion, without notice except as specified below, sell or have
                                         sold the Pledged Collateral or any part thereof in one or more parcels at public or private
                                         sale, at any exchange or broker&rsquo;s board or elsewhere, for cash, on credit or for
                                         future delivery, at such time or times and at such price or prices and upon such other
                                         terms as may be commercially reasonable, irrespective of the impact of any such sales
                                         on the market price of the Pledged Collateral. Beneficiary may be the purchaser of any
                                         or all of the Pledged Collateral at any such sale and Beneficiary shall be entitled,
                                         for the purpose of bidding and making settlement or payment of the purchase price for
                                         all or any portion of the Pledged Collateral sold at any such public sale, to use and
                                         apply any of the Obligations as a credit on account of the purchase price for any Pledged
                                         Collateral payable by Beneficiary at such sale. Each purchaser at any such sale shall
                                         hold the property sold absolutely free from any claim or right on the part of Pledgor,
                                         and Pledgor hereby waives (to the extent permitted by applicable law) all rights of redemption,
                                         stay and/or appraisal which it now has or may at any time in the future have under any
                                         rule of law or statute now existing or hereafter enacted. Pledgor agrees that to the
                                         extent notices of sale shall be required by law, at least five (5) days notice to Pledgor
                                         of the time and place of any public sale or the time after which any private sale is
                                         to be made shall constitute reasonable notification. Beneficiary shall not be obligated
                                         to make any sale of Pledged Collateral regardless of notice of sale having been given.
                                         Beneficiary may adjourn any public or private sale from time to time by announcement
                                         at the time and place fixed therefor, and such sale may, without further notice, be made
                                         at the time and place to which it was so adjourned. If the proceeds of any sale or other
                                         disposition of the Pledged Collateral are insufficient to pay all the Obligations, Pledgor
                                         shall be liable for the deficiency and the fees of any attorneys employed by Beneficiary
                                         to collect such deficiency. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> Pledgor recognizes that, by reason of certain prohibitions
                                         contained in the Securities Act of 1933, as from time to time amended (the &ldquo;<B>Securities
                                         Act</B>&rdquo;), and applicable state securities laws, Beneficiary may be compelled,
                                         with respect to any sale of all or any part of the Pledged Collateral conducted without
                                         prior registration or qualification of such Pledged Collateral under the Securities Act
                                         and/or such state securities laws, to limit purchasers to those who will agree, among
                                         other things, to acquire the Pledged Collateral for their own account, for investment
                                         and not with a view to the distribution or resale thereof. Pledgor acknowledges that
                                         any such private sale may be at prices and on terms less favorable than those obtainable
                                         through a public sale without such restriction s(including, without limitation, a public
                                         offering made pursuant to a registration statement under the Securities Act) and, notwithstanding
                                         such circumstances, Pledgor agrees that any such private sale shall be deemed to have
                                         been made in a commercially reasonable manner and that Beneficiary shall have no obligation
                                         to engage in public sales and no obligation to delay the sale of any Pledged Collateral
                                         for the period of time necessary to permit the issuer thereof to register it for a form
                                         of public sale requiring registration under the Securities Act or under applicable state
                                         securities laws, even if such issuer would, or should, agree to so register it. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (c) </TD><TD> Notwithstanding the foregoing, the parties hereto acknowledge
                                         and agree that the remedies provided for herein are not exclusive of any other remedies
                                         available to Beneficiary upon the occurrence of an Event of Default. Beneficiary expressly
                                         reserves any and all other remedies available to him under the Purchase Agreement. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 10. </TD><TD> <U>Application of Proceeds</U>. Except as expressly provided
                                         elsewhere in this Agreement, all proceeds received by Beneficiary in respect of any sale
                                         of, collection from, or other realization upon all or any part of the Pledged Collateral
                                         may, in the discretion of Beneficiary, be held by Beneficiary as Pledged Collateral for,
                                         and/or then, or at any time thereafter, applied in full or in part by Beneficiary against
                                         the Obligations in the following order of priority: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> FIRST: To the payment of all costs and expenses
of such sale, collection or other realization, and all other expenses, liabilities and advances made or incurred by Beneficiary
in connection therewith, and all advances made by Beneficiary hereunder for the account of Pledgor, and to the payment of all
costs and expenses paid or incurred by Beneficiary in connection with the exercise of any right or remedy hereunder, all in accordance
with Section 11 hereof; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> SECOND: To the payment of all other Obligations
in such order as Beneficiary shall elect; and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> THIRD: To the payment to or upon the order of Pledgor,
or to whoever may be lawfully entitled to receive the same or as a court of competent jurisdiction may direct, of any surplus
then remaining from such proceeds. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 11. </TD><TD> <U>Expenses</U>. Pledgor shall pay to Beneficiary upon demand
                                         the amount of any and all costs and expenses, including the reasonable fees and expenses
                                         of their counsel and of any experts and agents, that Beneficiary may incur in connection
                                         with </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (i) </TD><TD> the sale of, collection from, or other realization upon, any
                                         of the Pledged Collateral; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (ii) </TD><TD> the exercise or enforcement of any of the rights of Beneficiary
                                         hereunder; or </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (iii) </TD><TD> The failure by a Pledgor to perform or observe any of the
                                         provisions hereof. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 12. </TD><TD> <U>Continuing Security Interest</U>. This Agreement shall create
                                         a continuing security interest in the Pledged Collateral and shall: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> Remain in full force and effect until the payment in full
                                         of all Obligations; and/or; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> be binding upon Pledgor, its respective heirs, administrators
                                         or other personal representatives; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (c) </TD><TD> inure, together with the rights and remedies of Beneficiary
                                         hereunder, to the benefit of Beneficiary and its successors, heirs, transferees, personal
                                         representatives and assigns. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 13. </TD><TD> <U>Amendments; Etc.</U> No amendment or waiver of any provision
                                         of this Agreement, or consent to any departure by Pledgor herefrom, shall in any event
                                         be effective unless the same shall be in writing and signed by Beneficiary, and then
                                         such waiver or consent shall be effective only in the specific instance and for the specific
                                         purpose for which it was given. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 14. </TD><TD> <U>Notices</U>. All notices and other communications hereunder
                                         shall be in writing and shall be deemed to have been duly given when sent by registered
                                         or certified mail, return receipt requested, postage prepaid, or by overnight courier
                                         guaranteeing next day delivery and requiring a signature upon delivery, to the parties
                                         at the following addresses or such other addresses as either may give notice to the other
                                         as herein provided: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> Notices to Beneficiary shall be directed to: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Alzamend Neuro, Inc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> 3802 Spectrum Boulevard, Suite 112C </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Tampa, Florida 33612 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Attention: Stephan Jackman </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> Notices to Pledgor shall be directed to: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Ault Life Sciences Fund, LLC </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> 201 Shipyard Way, Suite E </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Newport Beach, California 92663 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> Attention: Milton C. Ault </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 15. </TD><TD> <U>Failure or Indulgence Not Waiver; Remedies Cumulative</U>.
                                         No failure or delay on the part of Beneficiary in the exercise of any power, right or
                                         privilege hereunder shall impair such power, right or privilege or be construed to be
                                         a waiver of any default or acquiescence therein, nor shall any single or partial exercise
                                         of any such power, right or privilege preclude any other or further exercise thereof
                                         or of any power, right or privilege. All rights and remedies existing under this Agreement
                                         are cumulative to, and not exclusive of, any rights or remedies otherwise available. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"> &nbsp; </P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 16. </TD><TD> <U>Severability</U>. In case any provision in or obligation
                                         under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction,
                                         the validity, legality and enforceability of the remaining provisions or obligations,
                                         or of such provision or obligation in any other jurisdiction, shall not in any way be
                                         affected or impaired thereby. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 17. </TD><TD> <U>Headings</U>. Section and subsection headings in this Agreement
                                         are included herein for convenience of reference only and shall not constitute a part
                                         of this Agreement for any other purpose or be given any substantive effect. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 18. </TD><TD> <U>Governing Law</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (a) </TD><TD> This Agreement and the rights and obligations of the signatories
                                         hereto shall be governed, construed and controlled by the law of the State of New York
                                         (but without giving effect to principles of conflict of laws) and applicable federal
                                         law as to interpretation, enforcement, validity, construction, effect and in all other
                                         respects. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"> (b) </TD><TD> To induce Beneficiary to accept this Agreement: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (i) </TD><TD> The Pledgor irrevocably agrees that all actions or proceedings
                                         in any way, manner or respect, arising be litigated in a state court in the State of
                                         New York; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (ii) </TD><TD> The Pledgor hereby waives any right it may have to transfer
                                         or change the venue of any litigation brought against it by Beneficiary in accordance
                                         with this section; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"> (iii) </TD><TD> The Pledgor acknowledges that: </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"> (A) </TD><TD> The provisions of this section constitute a material inducement
                                         upon which Beneficiary has relied, is relying and shall rely in entering into or becoming
                                         a Beneficiary of this Agreement; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"> (B) </TD><TD> it has been represented by counsel of its own choosing;
                                         and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"> (C) </TD><TD> it has been advised by such counsel as to the meaning and
                                         effect of this section. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 19. </TD><TD> <U>Counterparts</U>. This Agreement may be executed in one or
                                         more counterparts and by different parties hereto in separate counterparts, each of which
                                         when so executed and delivered shall be deemed an original, but all such counterparts
                                         together shall constitute but one and the same instrument; signature pages may be detached
                                         from multiple separate counterparts and attached to a single counterpart so that all
                                         signature pages are physically attached to the same document. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> IN WITNESS WHEREOF, Pledgor and Beneficiary
have caused this Stock Pledge Agreement to be duly executed and delivered thereunto duly authorized as of the date first written
above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"> &nbsp; </TD>
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 32%"> <B>AULT LIFE SCIENCE FUND, LLC</B> </TD>
    <TD STYLE="width: 15%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> (&ldquo;Pledgor&rdquo;) </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Name: Milton C. Ault </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Title:&nbsp;&nbsp;&nbsp;Authorized Person </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <B>ALZAMEND NEURO, INC.</B> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> (&ldquo;Beneficiary&rdquo;) </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Name:&nbsp;&nbsp;Stephan Jackman </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Title:&nbsp;&nbsp;Chief Executive Officer </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">8</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-6 MAT CTRCT
<SEQUENCE>8
<FILENAME>ex1a-6_10.htm
<DESCRIPTION>EXHIBIT 1A-6.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Exhibit 6.10</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><U>CONSULTING AGREEMENT</U></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> This Consulting
Agreement (the &ldquo;Agreement&rdquo;) is made as of June 28, 2017 (&ldquo;Effective Date&rdquo;) between Spartan Capital Securities,
LLC (the &ldquo;<B>Consultant</B>&rdquo;) and Alzamend Neuro, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;).
The Company and the Consultant are collectively herein referred to as the &ldquo;<B>Parties</B>.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> WITNESSETH </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> WHEREAS, the Consultant
is desirous of providing the Company with consulting services, including but not limited to introducing the Company to sources
of financing, on terms and conditions hereinafter set forth; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> WHEREAS, the Consultant
has been engaged to serve as placement agent with respect to a &ldquo;$500,000 minimum/$4,000,000 maximum&rdquo; private offering
of the Company&rsquo;s Common Stock (the &ldquo;<B>Private Placement</B>&rdquo;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> NOW, THEREFORE,
in consideration of the mutual promises, covenants and agreements hereinafter set forth, the Parties agree as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>.
This Agreement shall be effective as of the date first written above and shall continue in effect for sixty (60) months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 2. </TD><TD STYLE="text-align: justify"> <U>Services</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Services</U>.
During the term of this Agreement, the Consultant will stand ready to provide, as the Company shall reasonably request, consulting
services related to general corporate matters, including, but not limited to (i) advice and input with respect to raising capital,
potential M&amp;A transactions (e.g., candidates and valuations), (ii) identifying suitable personnel for management (including
Chief Executive Officer) and Board of Directors and Advisory Board positions, (iii) developing corporate structure and finance
strategies, (iv) assisting the Company with strategic introductions, (v) assisting management with enhancing corporate and shareholder
value, and (vi) introducing the Company to potential investors (collectively, the &ldquo;<B>Advisory Services</B>&rdquo;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 3. </TD><TD STYLE="text-align: justify"> <U>Compensation</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consulting
</U>Fee. The Company shall pay to the Consultant a consulting fee for the services to be rendered over the sixty (60) month term
of this Agreement which shall not exceed One Million Four Hundred Thousand Dollars ($1,400,000) in the aggregate. Such fee shall
be payable as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (a) An initial service
retainer of Two Hundred Thousand Dollars ($200,000) shall be paid by wire transfer from the escrow account established in connection
with the Private Placement at such time as Two Million Five Hundred Thousand Dollars ($2,500,000) of gross proceeds have been
raised in the Private Placement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (b) To the extent
that the gross proceeds of the Private Placement exceed Two Million Seven Hundred Thousand Dollars ($2,700,000), the Company shall
pay, upon the final closing of the Private Placement by wire transfer from the Escrow Account, an amount equal to the amount by
which the gross proceeds of the Private Placement exceed Two Million Seven Hundred Thousand Dollars ($2,700,000), pro-rated to
the extent that the total gross proceeds of the Private Placement are less than Four Million Dollars ($4,000,000), and subject
to a maximum payment of One Million Two Hundred Thousand Dollars under this Section 3.1(b). By way of example, if the total gross
proceeds of the Private Placement are $3,200,000, the Company shall pay $461,538.36 to the Placement Agent from the proceeds of
the Private Placement (i.e., since the maximum amount of Private Placement proceeds above $2,700,000 is $1,300,000, if $500,000
of such $1,300,000 maximum amount is raised in the Private Placement, Consultant will be entitled to an initial payment equal
to approximately 38.5% of $1,200,000 and the Company shall record such initial payment as a prepaid asset). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provided
that no less than Two Million Seven Hundred Thousand Dollars ($2,700,000) in gross proceeds are raised in the Private Placement,
the Consultant shall be entitled to a monthly consulting fee which shall be paid over the sixty (60) month period following the
final closing of the Private Placement. The monthly fee shall be equal to the amount determined by (i) dividing the dollar amount
of the gross proceeds actually raised in the offering by Four Million Dollars ($4,000,000), (ii) multiplying that quotient by
$1,400,000, (iii) deducting from such product the aggregate amount of the payments made pursuant to Section 3.1(a) and 3.1(b)
above and (iv) dividing the result by sixty (60); provided, however, if the aggregate amount of the prepaid consulting fee exceeds
twelve months and cash on hand is less than One Million Dollars ($1,000,000), then such monthly payment may be delayed, at the
Company&rsquo;s option, until cash on hand exceeds One Million Dollars ($1,000,000), but in no event beyond the term of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Out-of-pocket
expenses</U>. The Consultant shall be reimbursed for reasonable out-of-pocket expenses incurred in connection with the Consultant&rsquo;s
performance of Advisory Services. All such expenses must be approved in advance and in writing by the Company prior to the Consultant
incurring such expenses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disputes</U>.
The Company shall pay each invoice for out-of-pocket expenses within thirty (30) days of receipt of such invoice by the Company,
unless the Company disputes the invoice. The Company shall, within thirty (30) days after such invoice is received, notify the
Consultant that it disputes the accuracy or appropriateness of the invoice and specify the item in such invoice which the Company
considers to be inaccurate or inappropriate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
The Consultant shall be responsible for and pay all federal, state and local taxes that arise in connection with the Services
performed hereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"> 4. </TD><TD STYLE="text-align: justify"> <U>Confidential Information</U>. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term &quot;Confidential Information&quot; means any and all business and technical information, samples, formulas, data and written
and verbal descriptions relating to the Company or any of its subsidiaries disclosed to the Consultant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Confidential Information is being disclosed by the Company to the Consultant in order for Consultant to provide the Services hereunder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Consultant shall not use the Confidential Information for any other purpose other than for the purpose of providing the Services
pursuant to this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Confidential Information disclosed by the Company to the Consultant shall remain the property of the Company and shall not be
disclosed by Consultant to anyone, without prior written permission of the Company. Such Confidential Information shall be promptly
returned to the Company within fifteen (15) days after a written request by the Company, except that Consultant shall have the
right to retain one (1) copy of the Company&rsquo;s Confidential Information so that any continuing obligations to the Company
may be determined. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information does not include any information which: (a) at the time of disclosure was in the public domain, (b) after disclosure
becomes part of the public domain, except through breach of this Agreement by the Consultant, (c) the Consultant can demonstrate
by its written records was in the Consultant&rsquo;s possession prior to the time of disclosure by or on behalf of the Company
hereunder, and was not acquired directly or indirectly from the Company, (d) becomes available to the Consultant from a third
party which, to the knowledge of Consultant, is not legally prohibited from disclosing such Confidential Information, or (e) the
Consultant can demonstrate by its written records was developed by or for the Consultant independently of the disclosure of Confidential
Information by the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant&rsquo;s
obligations regarding Confidential Information shall survive termination of this Agreement and remain enforceable for a period
of five (5) years following termination of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity</U>.
The Consultant shall not refer to the existence of this Agreement in any press release, advertising or other public statement,
written or oral, without the prior written consent of the Company, except as required by applicable law or regulation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership</U>.
The Company shall have complete and exclusive ownership of all work products, as well as all materials (and all intellectual property
rights in and to all of the foregoing) (collectively, &ldquo;<B>Work Product</B>&rdquo;), produced by Consultant under this Agreement.
In furtherance of the foregoing, the Consultant hereby irrevocably assigns to the Company all right, title and interest in and
to such Work Product. The Consultant agrees to execute all documents deemed reasonably necessary by the Company to evidence or
perfect the foregoing assignment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patent
Rights</U>. No right or license, either expressed or implied, under any licensing agreement, patent or proprietary right of the
Company is granted hereunder. Any information or technology, including but not limited to data, products, processes, formulations,
machinery and apparatus, and uses thereof, which Consultant may develop, improve, discover or invent as a result of the Services
(the &ldquo;<B>Technology</B>&rdquo;) shall be considered to be &ldquo;Work Product&rdquo; and shall become the property of the
Company. The Consultant shall immediately disclose any Technology to the Company. The Consultant shall also execute any other
documents reasonably requested by the Company related to the Technology and the Work Product, including documents necessary for
patent or regulatory filings and cooperate with the Company after the filing of patent or regulatory documents for as long as
necessary to vest the rights to the Technology in the Company, including execution of necessary documents in subsequent continuation,
continuation-in-part, divisional, international, and foreign patent applications. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Return
of Materials</U>. Upon the expiration or termination of this Agreement, whichever occurs first, the Consultant shall transfer
to the Company all Work Product, Technology, work in progress, property, Confidential Information and all other materials in the
Consultant&rsquo;s possession or control that are the property of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 9.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>By
the Company</U>. The Company shall defend, indemnify and hold the Consultant harmless in accordance with the indemnification and
other provisions set forth in Exhibit A hereto, which provisions are incorporated herein by reference and shall survive the termination
or expiration of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 9.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>By
Consultant</U>. The Consultant shall defend, indemnify and hold harmless the Company from and against any and all Liabilities
arising out of or from the Consultant&rsquo;s gross negligence or willful misconduct in connection with the performance of this
Agreement. The Consultant&rsquo;s obligations under this Section 9.2 shall survive the termination or expiration of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees, subject to applicable law or regulations including but not limited to Rule 415 of the Securities Act of 1933,
as amended (the &ldquo;<B>Securities Act</B>&rdquo;), to use its commercially reasonable efforts to, within one hundred and eighty
(180) days (the &ldquo;<B>Filing Deadline</B>&rdquo;) of the final (in the case of an underwriter&rsquo;s exercise of an over-allotment
option) closing of an initial public offering of the Company&rsquo;s equity securities registered under the Securities Act, file
a Registration Statement on Form S-1 (the &ldquo;<B>Registration Statement</B>&rdquo;) with the Securities and Exchange Commission
(the &ldquo;<B>SEC</B>&rdquo;), which Registration Statement shall cover (i) the shares of common stock issuable to the Consultant
pursuant to this Agreement, (ii) and the shares of Common Stock issued in the Private Placement (collectively, the &ldquo;<B>Registrable
Shares</B>&rdquo;). The Company shall use commercially reasonable efforts to have the Registration Statement declared effective
within 120 days from the Filing Deadline. The Company shall not (i) file any other registration statements (except for Form S-8
registration statements) until the Registration Statement is declared effective by the SEC, or (ii) include in the Registration
Statement any securities other than the Registrable Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Procedures</U>. In furtherance of its obligations under this Section 10 the Company shall, as expeditiously as reasonably possible: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
its commercially reasonable efforts to (i) cause the Registration Statement to become effective, and (ii) cause the Registration
Statement to remain effective until the earliest to occur of (A) such date as the Consultant and the other selling shareholders
(collectively with the Consultant, the &ldquo;<B>Selling Shareholders</B>&rdquo;) has completed the distribution described in
the Registration Statement and (B) such time that all of such Registrable Shares are no longer, by reason of Rule 144 under the
Securities Act, required to be registered for the sale thereof by the Selling Shareholders. The Company will also use its commercially
reasonable efforts to, during the period that the Registration Statement is required to be maintained hereunder, file such post-effective
amendments and supplements thereto as may be required by the Securities Act and the rules and regulations thereunder or otherwise
to ensure that the Registration Statement does not contain any untrue statement of material fact or omit to state a fact required
to be stated therein or necessary to make the statements contained therein, in light of the circumstances under which they are
made, not misleading; provided, however, that if applicable rules under the Securities Act governing the obligation to file a
post-effective amendment permit, in lieu of filing a post-effective amendment that (i) includes any prospectus required by Section
10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the information
set forth in the Registration Statement, the Company may incorporate by reference information required to be included in (i) and
(ii) above to the extent such information is contained in periodic reports filed pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;) in the Registration Statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepare
and file with the SEC such amendments and supplements to the Registration Statement, and the prospectus used in connection with
the Registration Statement, as may be necessary to comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by the Registration Statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to each Selling Shareholder, once the Registration Statement has been declared effective, such numbers of copies of a prospectus
and such other documents as it may reasonably request in order to facilitate the disposition of Registrable Shares owned by the
Selling Shareholder. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
commercially reasonable efforts to register and qualify the securities covered by the Registration Statement under such other
federal or state securities laws of such jurisdictions as shall be reasonably requested by the Consultant; <U>provided</U>, <U>however</U>,
that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file
a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service
in such jurisdiction and except as may be required by the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
applicable, cause all such Registrable Shares registered on the Registration Statement to be listed on the national securities
exchange on which shares of Common Stock are then listed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperate
with the Selling Shareholders to facilitate the timely preparation and delivery of certificates representing the Registrable Shares
to be sold, which certificates will not bear any restrictive legends. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnish
Information</U>. It shall be a condition precedent to the obligation of the Company to take any action pursuant to this <U>Section
10 </U>with respect to the Registrable Shares that the Consultant shall furnish to the Company such information regarding the
Selling Shareholders, the Registrable Shares held by the Selling Shareholders, and the intended method of disposition of such
securities as shall be reasonably required by the Company to affect the registration of the Registrable Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Expenses</U>. The Company shall bear and pay all registration expenses incurred in connection with any registration, filing or
qualification of the Registrable Shares with respect to registration pursuant to this Section 10 for the Selling Shareholders,
but excluding legal or other expenses of the Selling Shareholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
In the event that any Registrable Shares are included in a Registration Statement under this <U>Section 10</U>: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent permitted by law, the Company will indemnify and hold harmless the Selling Shareholders for Consultant and each person,
if any, who controls, within the meaning of the Securities Act, a Selling Shareholder against any losses, claims, damages, or
liabilities (joint or several) to which they may become subject under the Securities Act or the Exchange Act, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a &ldquo;<B>Violation</B>&rdquo;): (i) any untrue statement of a material fact contained
in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission to state therein a material fact required to be stated therein, or necessary to make the
statements therein not misleading, or (iii) any violation by the Company of the Securities Act, the Exchange Act, or any rule
or regulation promulgated under the Securities Act or the Exchange Act, and the Company will pay to the Selling Shareholders,
as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss,
claim, damage, liability, or action; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Section
10.5(a)</U> shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement
is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable
in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a
Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with
such registration by a Selling Shareholder or any underwriter or controlling person. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Selling Shareholder will indemnify and hold harmless the Company, each of its directors, each of its officers, each person, if
any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Selling Shareholder selling
securities in the Registration Statement and any controlling person of any such underwriter or other Selling Shareholder, against
any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under
the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto)
arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such Selling Shareholder expressly for use in connection
with such registration; and each such Selling Shareholder will pay, as incurred, any legal or other expenses reasonably incurred
by any person intended to be indemnified pursuant to this <U>Section 10.5(b)</U>, in connection with investigating or defending
any such loss, claim, damage, liability, or action; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in
this <U>Section 10.5(b) </U>shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action
if such settlement is effected without the consent of the Selling Shareholder, which consent shall not be unreasonably withheld;
<U>provided</U>, <U>further</U>, that, in no event shall any indemnity under this <U>Section 10.5(b)</U> exceed the dollar amount
of the proceeds received by such Selling Shareholder upon the sale of the Registrable Shares included in the Registration Statement
giving rise to such indemnification obligation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
after receipt by an indemnified party under this <U>Section 10.5 </U>of notice of the commencement of any action (including any
governmental action), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party
under this <U>Section 10.5</U>, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying
party similarly notified, to assume the defense thereof with counsel selected by the indemnifying party and approved by the indemnified
party (whose approval shall not be unreasonably withheld); provided, however, that an indemnified party (together with all other
indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel,
with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained
by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party
and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under this <U>Section 10.5</U>, but the omission so
to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party
otherwise than under this <U>Section 10.5</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the indemnification provided for in this <U>Section 10.5 </U>is held by a court of competent jurisdiction to be unavailable to
an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying
party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative
fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or
omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations.
The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the alleged omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and the parties&rsquo; relative intent, knowledge,
access to information, and opportunity to correct or prevent such statement or omission. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify; text-indent: 1in"> (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company and Consultant under this <U>Section 10.5</U> shall survive the completion of the Offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Transferees</U>. The rights to cause the Company to register Shares granted to the Consultant by the Company under this <U>Section
10</U> may be assigned in full or in part by Consultant in connection with a transfer of the Shares upon the written approval
of the Company, which shall not unreasonably be withheld. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> 10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The rights and obligations set forth in this Section 10 shall survive the expiration or termination of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Contractor</U>. The Consultant shall perform all of Consultant&rsquo;s obligations under this Agreement as an independent contractor
and not as an agent, employee or representative of the Company. The Consultant shall not participate in any insurance programs
or benefits including, but not limited to, workers' compensation insurance, disability insurance or any other employee benefits
available to the Company&rsquo;s employees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>.
The Consultant shall not assign this Agreement or the performance of Consultant&rsquo;s obligations hereunder, without the express
prior written consent of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice consent, authorization of other communication to be given hereunder shall be in writing and shall be deemed duly given
and received when delivered personally, when transmitted by fax, three days after being mailed by first class mail, or one day
after being sent by a nationally recognized overnight delivery service, charges and postage prepaid, properly addressed to the
party to receive such notice, as the following address or fax number (or such other address or fax number as shall hereafter be
specified by such party by like notice): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> a. &nbsp;&nbsp; </TD>
    <TD STYLE="width: 42%"> <I>If to the Company, to</I>: </TD>
    <TD STYLE="width: 6%"> &nbsp; </TD>
    <TD STYLE="width: 5%"> b. &nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 42%"> <I>If to the Consultant</I>: </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> Alzamend Neuro, Inc. </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Spartan Capital Securities, LLC </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> 50 W. Broadway, Suite 300 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> 45 Broadway </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> Salt Lake City, Utah 84101 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> New York, New York 10006. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> Attn: Philip E. Mansour </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Attn: John Lowry&#9; </P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> Telephone: (949) 346-5822 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Telephone: (212) 293-0123 </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.
</U>This Agreement may be executed in one or more counterparts each of which shall for all purposes be deemed to be an original
and all of which shall constitute one and the same instrument. Facsimile signatures shall be treated as original signatures. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If for any reason a court of competent jurisdiction finds any provision of this Agreement, or portion thereof, to be unenforceable,
the remainder of this Agreement shall continue in full force and effect. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Relationship
of Parties</U>. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee
or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except
to the extent, if at all, specifically provided herein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver.
</U>A waiver by either party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed
to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings,
obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other
remedy, right, undertaking, obligation or agreement of either party. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Agreement sets forth the entire agreement between the parties with respect to the specific matters contained
herein, and this Agreement has no bearing or effect on any prior agreements entered into by the Parties. This Agreement may be
modified or amended only in writing signed by the Parties. The descriptive headings of each numbered section of this Agreement
are for convenience only and are not for use in the construction and/or interpretation of this Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law</U>. This Agreement shall be deemed to have been made in the State of New York and shall be construed and governed in accordance
with the laws of the State of New York without regard to the conflicts of laws rules of such jurisdiction. The parties hereby
irrevocably consent to the jurisdiction of the courts located in the State of New York. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>IN WITNESS WHEREOF</B>, the Parties
have caused their respective signature page to this Agreement to be duly executed as of the date first written above. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"> &nbsp; </TD>
    <TD STYLE="width: 5%"> &nbsp; </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 38%"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Spartan Capital Securities, LLC</B></FONT> </TD>
    <TD STYLE="width: 15%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">John Lowry</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Alzamend Neuro, Inc.</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Philip E. Mansour</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">President and Chief Executive Officer</FONT> </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>EXHIBIT A</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INDEMNIFICATION PROVISIONS</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Alzamend Neuro,
Inc. (the &ldquo;Company&rdquo;) agrees to indemnify and hold harmless Spartan Capital Securities, LLC (&ldquo;Consultant&rdquo;)
and each of the other Indemnified Parties (as hereinafter defined) from and against any and all losses, claims, damages, obligations,
penalties, judgments, awards, liabilities, and reasonable costs, expenses and disbursements, and any and all actions, suits, proceedings
and investigations in respect thereof and reasonable legal and other costs, expenses and disbursements in giving testimony or
furnishing documents in response to a subpoena or otherwise (including, without limitation, the reasonable costs, expenses and
disbursements, as and when incurred, of investigating, preparing, pursing or defending any such action, suit, proceeding or investigation
(whether or not in connection with litigation in which any Indemnified Party is a party)) (collectively, &ldquo;Losses&rdquo;),
directly or indirectly, caused by, relating to, based upon, arising out of, or in connection with, Consultant&rsquo;s acting for
the Company, including, without limitation, any act or omission by Consultant in connection with its acceptance of or the performance
or non-performance of its obligations under the Consulting Agreement between the Company and Consultant to which these indemnification
provisions are attached and form a part (the &ldquo;Agreement&rdquo;), any breach by the Company of any representation, warranty,
covenant or agreement contained in the Agreement (or in any instrument, document or agreement relating thereto), or the enforcement
by Consultant of its rights under the Agreement or these indemnification provisions, except to the extent that any such Losses
are found in a final judgment by a court of competent jurisdiction (not subject to further appeal) to have resulted primarily
and directly from the gross negligence or willful misconduct of an Indemnified Party. The Company also agrees that no Indemnified
Party shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection
with the engagement of Consultant by the Company or for any other reason, except to the extent that any such liability is found
in a final judgment by a court of competent jurisdiction (not subject to further appeal) to have resulted primarily and directly
from such Indemnified Party&rsquo;s gross negligence or willful misconduct. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> These indemnification
provisions shall extend to the following persons (collectively, the &ldquo;Indemnified Parties&rdquo;): Consultant, its present
and former affiliated entities, partners, employees, legal counsel, agents and controlling persons (within the meaning of the
federal securities laws), and the officers, directors, partners, stockholders, members, managers, employees, legal counsel, agents
and controlling persons of any of them. These indemnification provisions shall be in addition to any liability which the Company
may otherwise have to any Indemnified Party. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If any action,
suit, proceeding or investigation is commenced, as to which an Indemnified Party proposes to demand indemnification, it shall
notify the Company with reasonable promptness; <U>provided</U>, <U>however</U>, that any failure by an Indemnified Party to notify
the Company shall not relieve the Company from its obligations hereunder unless the Company is prejudiced by such failure. An
Indemnified Party shall have the right to retain counsel of its own choice to represent it, and the reasonable fees, expenses
and disbursements of such counsel shall be borne by the Company. Any such counsel shall, to the extent consistent with its professional
responsibilities, cooperate with the Company and any counsel designated by the Company. The Company shall be liable for any settlement
of any claim against any Indemnified Party made with the Company&rsquo;s written consent. The Company shall not, without the prior
written consent of Consultant, settle or compromise any claim, or permit a default or consent to the entry of any judgment in
respect thereof, unless such settlement, compromise or consent (i) includes, as an unconditional term thereof, the giving by the
claimant to all of the Indemnified Parties against whom it has made a claim of an unconditional release from all liability in
respect of such claim, and (ii) does not contain any untrue factual or legal admission by or with respect to an Indemnified Party
or an untrue adverse statement with respect to the character, professionalism, expertise or reputation of any Indemnified Party
or any action or inaction of any Indemnified Party. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 12</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In order to provide
for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions is made but it
is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification may
not be enforced in such case, even though the express provisions hereof provide for indemnification in such case, then the Company
shall contribute to the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received
by the Company, on the one hand, and the Indemnified Party, on the other hand, and (ii) if (and only if) the allocation provided
in clause (i) of this sentence is not permitted by applicable law, in such proportion as to reflect not only the relative benefits,
but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the other hand, in connection with
the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations. No person found
liable for a fraudulent misrepresentation shall be entitled to indemnification or contribution from any person who is not also
found liable for fraudulent misrepresentation. The relative benefits received (or anticipated to be received) by the Company and
its stockholders, subsidiaries and affiliates shall be deemed to be equal to the aggregate consideration payable or receivable
by such parties in connection with the transaction or transactions to which the Agreement relates relative to the amount of fees
actually received by Consultant in connection with such transaction or transactions. Notwithstanding the foregoing, in no event
shall the amount contributed by all Indemnified Parties exceed the amount of fees previously received by Consultant pursuant to
the Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Neither termination
nor completion of the engagement of Consultant referred to above shall affect these indemnification provisions which shall remain
operative and in full force and effect. The indemnification provisions shall be binding upon the Company and its successors and
assigns and shall inure to the benefit of the Indemnified Parties and their respective successors, assigns, heirs and personal
representatives. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Page 12 of 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-11 CONSENT
<SEQUENCE>9
<FILENAME>ex1a11_1.htm
<DESCRIPTION>EXHIBIT 1A-11.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 11.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We consent to the use in this Amendment No. 2 to the Offering
Statement on Form 1-A of Alzamend Neuro, Inc. of our report dated August 28, 2019, relating to the financial statements of Alzamend
Neuro, Inc. as of April 30, 2019 and 2018 and for each of the years in the two-year period ended April 30, 2019 appearing in the
Offering Circular, which is part of this Offering Statement. We also consent to the reference to our firm under the heading &quot;Experts&quot;
in such Offering Statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Squar Milner LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, CA</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="background-color: Transparent">March 12, 2020</FONT> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>alzamend_footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alzamend_footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M3;K5];U"TTO3+-%>YO;V98((M[K%$FYR-\LTSQP6\*!IKB>2."%))9$1C5Z
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MI7YO95:E/FM;FY).-[7=KVO:[MM=G/)<LI1WY9-7[V=C<K(D* "@ H * "@
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MGI\O7J6WH]'O;S[77Y^FOD>1:1X+\::I\./%/AZP+Z2NN^.K^\@D\<"X.O\
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MXB6&E"5"<^>G[-2C%*23:47&/+:5U9*RZ:'W%7S1PA0 4 % !0 4 % !0 4
M% !0 4 % !0 4 4-/TO3-(ADM]*TZPTRWEN)[R6#3[.WLH9+NZ<R7-U)%;1Q
M(]Q<2$R3SLIEF<EY&9N:+M[@E;96]$7Z "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H HV&F:;I4<T.EZ=8Z;%<W4]]<16%I;V<<][=-ONKR
M9+>.-9;JY?YY[APTLS?-(['FB[>_H&VR\R]0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
< 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>alzamend_header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alzamend_header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M^.OP,_X++?!GX[?M]^-O^"?NA_";XG:+\0?!/CWXV^ +SQSJUSX5D\'7NH_
MZZ\3VNN7MM#9ZO+K:66LGPM=OI(EL1.HN+87D4/[TQ_H.9^'F8Y9PKA^*ZN/
MP53"8G"Y;BXX:FJ_UB,,S5!THR<J:I\U/V\?:6G;W7RMZ7]>OD]:A@*>/E5I
M2IU(49J"Y^=*NHN*=X\MUS*^OH?L57Y\>0% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!!<W5
MM96UQ>7EQ!:6=I!+<W5U<RQP6UM;01M+/<7$\K)%#!#$C22RR,L<<:L[L%!(
M<5*348IRE)J,8Q3;DV[))+5MO1):MC2;:23;;LDE=MO9)=S_ #1OVX?&GQ;_
M ."JO[6_[;7[2_PQL;KQ#\,OV>_A_?\ C#18)FO$71OV=OAKXJT#P+H]QI=K
M(U[':ZGJ\/B#5/BWKNCBYB@B^T>/-2MG*V7D/_9/#.&P' V0\-Y-C9*EC<VQ
M<,/4:47[3-\90JXJI&;7*W"FZ,,!2J6;=L-"7Q77Z1@84<JPF"PU5J-7$5%&
M3TUQ%2,IOF>FD>6-&+WT@M6?UQ_\&]7[8O\ PTY^P?H'PX\1ZH;[XF?LKW=C
M\(/$"3R;[R[^'XM);KX0:VZK#''%:+X7M+OP+;@RSW5Q<?#Z^O[I@UXA;\$\
M6.'_ .Q>**N+HT^7!9Y&684K+W8XKF4<PIK767MY+$O1)+%1C'X3Y/B#"/#8
M^52,;4L5>M&RT]IHJT=]^?\ >/9?O%8_#C_@K9_RL&_LT_\ 8_?L2?\ JPM"
MK]*X$_Y-/G?_ &"<2_\ J'5/;RG_ ))_$_\ 7O&_^FY'[C_MS_\ !>SX"?L)
M?M'>+/V;?'7P3^+WC7Q+X1TGPGJU[X@\)W?@R'0[F/Q;X<T_Q+9Q6J:QK=G?
M[[6UU*&"Y,MO&IN$D\K?&%=OS7AGPMS7B?)\/G&%S++\-1Q$Z\(TL1'$NK%X
M>M.C)R]G2E"TI0;5F]&KZGAX'(L1C\/'$TZU&$92G%1FI\WN2Y7>T6M6M-3Q
MOX"?\'*7[-GQ^^.'P?\ @9H'[/GQQT/7/C'\3? WPOT;6=8OO 3Z3I.J>._$
MNF^&;#4=32R\037C6%E=:G%<7BVL,MP;>.00Q22;4/H9KX.YSE669AF=7-<L
MJTLOP>)QM2G3CBO:5(8:C.M*$.:BH\\HP:CS-*[5VD;8CAS$X>A6KRQ%"4:-
M.=1QBJEVH1<FE>*5W;J?8_\ P4/_ ."R'P$_X)\>-_#?P@U[X=_%;XO?&SQ;
MH=CXET7P)X'T,:;IBZ)J5]>:=IUY>>+M=$5K=R:C>:=J-K9V?A+3/%EY'=64
M]OJL.EN8?-^>X2\/<TXLPU;,*6+P.7Y;AZLJ-7%8JJYS]I"$9SC&A2NX\D9P
ME*5>="+C).#FKG)E^3U\PA*LJE*C0A)QE4J2N^9)-I0CJK)IMS<%9KE;UMX]
M^Q)_P7Q_9M_:Y^-^D_LX>+/AG\2_V<_B]XHG?3_!VE_$+^S=2\/>(_$"13W<
M?A3^V[%;#4-$\2W]A&ESH]IKOA^PT_5I]VE6NJMJ]QH]CJ_H\2>%N<9!EM3.
M*&-P>;Y?07/B)X3GA5HTKJ+K^SESPJ482=JDJ5:<X+WY0]FJDJ>V.R'$X2B\
M1"I3Q-&.LW3NI1CMS\KNG%/23C)N*U:Y;M=G^V7_ ,%P?V=/V'_VJM._9>^+
MGP\^)L\\FF^"-<UWXE:$OA^[\*^'=#\9,[R:G<:8VIKXDU!="LHY;R^M-.TV
M>]NQ&;?3H+F=HT?FX>\-<WXER.>=X#%X))3Q-*G@ZOM8UZU7#VM",U!T8^UD
MU&,IS48WO-I7,\'DF)QN%>*I5*=KSC&F^;GDX=+VY5=Z*[TW9\A_"K_@Z"_9
M \>?&#3? ?C'X1_%?X4_#K7=<&BZ;\7?$5_X9U6RTF*YNUM].UKQQX7T:XFO
M/#VC,C";5[G1M5\62Z.#N-O>6J3W<'OX[P5X@PN7SQ6'Q^!QV+I4O:3R^C&M
M3G-QC>=/#5JD5&M4OI"-2%!5.C4K1?95X8QD*+J0JTJM2,>9T8J2;TNXPF])
M2Z*Z@GW6Q1O_ /@Z1_8[M?B[/X0M/@W\9]1^$\.NII"?&&$^'X+BYL1<QVL_
MB>#X=7-Q'K/]@KF:_MH9]6@\2W&EI$\WAVTU65](AN'@EQ#++UB)9CET,<Z3
MJ?V>_:M*7*Y*@\6DZ?M7I!M4W1C-NU:4%SMKAC&>QYW6HJK:_L?>M_A]JO=Y
MO^W>6_VFM3]T_CA^V5^SE^SQ^SM'^U1\4/B1IFD_!;4=#\.Z[X8\264%WJEU
MXXC\9:='JG@[3?!>C6L+:GK^K^*+&:.\TVRM[=?)T];O6-5ETW1=,U74K'\R
MRSA[.,WS=Y'@L'.IF,*M:E7HR<81PSP\W#$3Q-23Y*5.C-<LY-ZSY:=-3J3A
M"7A4,'B,1B/JM*FW64I1E%V2AR.TW.3TBHM6;?6R5Y-)_@OI_P#P=*?LS2^*
MK%=7_9C_ &@=%^%FHZJVFVWQ%DN/!]WJ 2.:!+FZ?PI#J"V$S6,$INKVQT[Q
MCJ%]%&J)%!/+*B5^H2\$LZ5"7L\ZRJICH0YW@TL1&%VFXQ]NX<RYFE&,IX>$
M7>[:2/>?"^*Y'RXG#RJI7=.TTO3GM?79-P2\TC]</VK?^"F/P'_9D_8]\(?M
MM:=:ZW\;?@YX^U7P9I_A"[^'$FGV]YK%KXVMM2NM.U/R_%$VC-8+9KI=S;:K
MIFI16FM:9J*2:;J&G6M];7<$'P61\&9IG7$&(X;DZ66YAA88B>(CC.=QIRPS
MA&<+T%5YW)SBX3@Y4YP]^,Y1<6_)PF6XC%8R>"?+0K4U-S56]ER-)KW5*][I
MIJ\6M4VFK_DOXZ_X.E?V3_#^G^!)_!OP)^,7CC4O$&C#5_&NG2ZIX3\.1> I
MI[Z>WM= 74'N-8B\3Z\+"W75;^.QAL='L8;_ $VQ&M7.J?VO9:-]YA?!'/:L
M\4L1F>7X:%&I[/#34*]9XI*"<JO(E3=&ESOV<7)RJ2<)R]FH>SE4]6GPOBY.
MISUZ--1DXP=IR]I9?%:T>6-]$VW)V;Y4K.7[6?LH?M[_ +/?[7G[+\_[67@+
MQ!<>&_AIX?L_$S_$E?&T4.D:E\+M2\$:/#K_ (STSQ>\,]WIL8T'0KFUUZ34
MM.OKW3;K0KVRU&&X F>&'\XSWA;-L@SM9#BJ2K8RK*BL']6;J0QL,34=+#SP
M]U&;]K5C*DH3C&<:L90:TN_&Q6 Q&$Q7U2<>:K)Q5/DU555'RP<-G[S]VS2:
MDFC\5_&O_!TQ^R#H'Q)G\-^$_@=\;_'?PXL=6?3[KXEVTGA3P]>:E8P7#02Z
MYX9\#:SJ*7U]IURB_:]+@\2:SX0U:XMI(QJ6G:/=>9:Q?HV&\$>(*N#5:OF6
M6X7&3IJ<<%)5ZJA)JZI5\33@X0G'X9NC3Q%-23Y)U(VD_9APOC)4N:5>A"JX
MW5)\TDF_LRJ15DULW&,U?9M:O\C_ /@DW\1_"_QC_P"#@OQQ\7? ]S=7G@KX
MJ?%G]M?XC^#[R]LYM.O+OPMXXM?BAXF\/W-WI]P!<6-U/I.J6DL]G.!-;2L\
M,H#HPK[[CO!U\O\ "C#8#$Q4<3@<!PW@\1&,E.,:^&E@:-6,9Q]V252$DI+2
M2U6C/6S:G*CD%*E-6G2IX*G-+5*4%3C*SZZIZG]]=?RP?!A0 4 % !0 4 %
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M\*C_ +.^W?V7_P *_P#^$4\>_P#"+_V1_:?_ !,O[&_LK[-_8_\ :/\ I_\
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MWQ;H6F?#V-->T&U\5Z[IGA&RAGN(]5TWX<^!O OA_3=8L]0T.37+[B7'V>O
M8K+ZRPF*HXO!2P,JF*ABJ]>E2EE-')Y5*%6>+?LJLJ%*=>32<)XS%8JK.G*-
M54X9?VKBG2G2ER3C.E[%N:G*<8_5XX>\9.I[LG&+F^CJ3G)JTN5?J17Q)Y@4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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/WMT8[;:;;:;>AM4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>alzamendlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alzamendlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MN$Z?LY5\5_)&R]7_ ,-;YG71K?4\)7Q76$7;U>WX_F0ZWIOQ1_X+8?M]:;\
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M3_R-7QJ_Z\=%_P#0[NOV6KS>*?\ D>5?^W?_ $E'/FG^_2^7Y(**^?//"B@
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MDK*H_.N:$)U)*,5=O9(RBG)V1X"/^"QW_!,4ZX?#W_#9'A/[0!G?NG\G_O\
M>7Y?_CU6OVZ?BC\-?B__ ,$V/BUXU^%'Q T7Q+H]QX!U'R=4T'4XKNW?]R>
M\3,N?;.:]:&69A@L52E7IN*<HZO;='7'#8BC4@YQ:U1_+^/]1_P'^E?U$?\
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M<X'.*^YCB*,I6C--^J_S/;52F]$T9&!Z5_3_ /\ !(K_ )1I?!G_ +$JW_\
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M,,:EG=CV 4$GZ5^;Q3E*R/G-]#^;?XX_&;4?^"H'_!1S7/C!XBN67PK#>?\
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M5S9YPI57#ELVK7OT3[+N?E?T@,8\9X6UI6M:K26]^I]#T5]H?P  .#FO<O\
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M$>&?_!8E'_#('[+W_1"/#/\ X+$KN_UDS_\ Z"9_^!,^7_XAOP'_ -"VC_X
M@_X9 _9>_P"B$>&?_!8E=9X$^&O@'X7Z7)HGP\\(V.CV<TQEDM]/MQ&C.1C<
M0.^ *YL5G6;8ZC[+$5I2CV;NCT<KX-X5R7%K%8#!4Z51)KFC%)V>ZNNYN45Y
%A]*?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>aultsig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aultsig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,BXU /_; $,  @$! 0$!
M @$! 0(" @("! ," @("!00$ P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&" L,"PH,"0H*"O_; $,! @(" @("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_  !$( %$
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HH ** "B@ HH ** ([JZMK&VDO;VYCAAA0O+-*X544#)))X
M'K7S#\4?^"OW[''@K6[GP9\*]3\3?%_Q':S>5<:%\&O"MSXB:"3^[+<6RFVA
MYX.^48/6@#AY_P#@I?\ M_>(D:X^&W_!$SXL26^?W,WBKQEH>ELZ]CY?VB1U
M^A&:IW?_  4^_P""AO@\M=_$7_@A]\5VL8UW37'A/QKHNIR(.Y$0F1F^@YH
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M0=#\,Z9#HOAS1;33[.W0);VEC;K%%&HZ!54  >P%6Z "B@ HH ** "B@ HH
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MN[]RZSVEK&]T]ZIC*!\S0K&4ECVR._F(@!\-_M3_ +.7[;?QZ\%ZQ^V7\/\
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M&_QIH?A1/C5IWBR/P9IT_P"S'K'P]FU[_A%Y/$2FY:6'7ET[=IXB-TMDL_\
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+ 44 %% !10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MG_T5D?\ PR/R_P"IMZ_@'_$-W_T./_+#_P"_/7^EK_M _:K;_GX@_P"_L?\
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M8_\ !G>__'Z/^$A\0?\ 0<UC_P &=[_\?H_XE]G_ -%9'_PR/R_ZFWK^ ?\
M$-W_ -#C_P L/_OSU_I:_P"T#]JMO^?B#_O['_\ %4?:K;_GX@_[^Q__ !5?
MXOW_  D/B#_H.:Q_X,[W_P"/T?\ "0^(/^@YK'_@SO?_ (_1_P 2^S_Z*R/_
M (9'Y?\ 4V]?P#_B&[_Z''_EA_\ ?GK_ $M?]H'[5;?\_$'_ ']C_P#BJ/M5
MM_S\0?\ ?V/_ .*K_%^_X2'Q!_T'-8_\&=[_ /'Z/^$A\0?]!S6/_!G>_P#Q
M^C_B7V?_ $5D?_#(_+_J;>OX!_Q#=_\ 0X_\L/\ [\]?Z6O^T#]JMO\ GX@_
M[^Q__%4?:K;_ )^(/^_L?_Q5?XOW_"0^(/\ H.:Q_P"#.]_^/T?\)#X@_P"@
MYK'_ (,[W_X_1_Q+[/\ Z*R/_AD?E_U-O7\ _P"(;O\ Z''_ )8?_?GK_2U_
MV@?M5M_S\0?]_8__ (JC[5;?\_$'_?V/_P"*K_%^_P"$A\0?]!S6/_!G>_\
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MV#?M5M_S\0?]_8__ (JC[5;?\_$'_?V/_P"*K_%^_P"$A\0?]![6O_!K?_\
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M6W_/Q!_W]C_^*H^U6W_/Q!_W]C_^*K_%^_X2'Q!_T'M:_P#!K?\ _P D4?\
M"0^(/^@]K7_@UO\ _P"2*/\ B7V?_161_P##(_+_ *FWK^ ?\0W?_0X7_A _
M+_J,]?P/]H'[5;?\_$'_ ']C_P#BJ/M5M_S\0?\ ?V/_ .*K_%^_X2'Q!_T'
MM:_\&M__ /)%'_"0^(/^@]K7_@UO_P#Y(H_XE]G_ -%9'_PR/R_ZFWK^ ?\
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M *FWK^ ?\0W?_0X7_A _+_J,]?P/]H'[5;?\_$'_ ']C_P#BJ/M5M_S\0?\
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M^P#<^+H/VD/CW!X=U#QGI]I+X<U77M-TJU\'^'(9M.U#6I_$EKX;U?7X0?\
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M$_[.R_9C_P#5[?#ZO]B2OY=\>O\ DILH_P"Q%#_U88X_(_$/_D;X3_L7P_\
M4C$'\\W_  <S?\HYK#_LM=K_ .J+^/5?YQOA_7]>\*:UI'B;PMKFL>&?$F@W
MUKJNA>(?#VIWVB:[HFJV4B3V6IZ1J^F3VNHZ9J-G,BRVM[97,%S;R 212*X5
MA_IC_P#!?+X1ZQ\??V4?@E\#_#^L:=X>USXP?M=_#;X8:1KNL075UI6C:E\0
M/AO\8_"-AJFI6MD\=W<V&GW>LPWEY!;.)YK:"6.$B5D(_GC_ .(1S]KH\_\
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MQ/\ \I/Y/Z*_K _XA&_VNO\ H\+]G7_PWOQ/_P#EK1_Q"-_M=?\ 1X7[.O\
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M%$4D'^AS_B%5_P""GO\ T.'[&?\ X>7XN?\ T.5'_$*K_P %/?\ H</V,_\
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M\/:;KMMH^F:Q;ZJHU2#5+&R@OXM1 ODN!=*LH_?#_B%5_P""GO\ T.'[&?\
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M_4O\_P N^A_KAPY_T,E_X38W_P"9O-?>?S9T5_29_P 0JO\ P4]_Z'#]C/\
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M_P#P\OQ<_P#H<J/^(57_ (*>_P#0X?L9_P#AY?BY_P#0Y4?\17\/?^BDI?\
MANS?R_ZE_G^7?0_UPX<_Z&2_\)L;_P#,WFOO/PO_ &3/^3N?V1/^SLOV8_\
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M]5:73KV/PMXAO;>V\0VSVD%UI]_I]VUM/YA)^R;\6-!_X)C?%/XH:/\ #O\
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M FK:G:Q?LQ_P5-^%'[2&G_\ !,GQ_P#"3]B&X\=3?$CPIX1^'7A+1X/"NKW
M^*.N?##POJ/A_2_&6E>&]9BDM;^[\6ZIX(L+V&=K*2/5]:A?4K+2TDU6_M8)
M/!QO#6!PN.R/+H9Y1J8C-IT?K%6IA98? Y=0KXJ6%IUZF(J8AU)N].K5J4JF
M'P\J5)4^>2G.4*?FULJP]+$9?AHYA3G4QLJ?M9RHRIT,+"I6=*,Y5)5'.=N6
M4Y1=*FXQY;V;:C^G?BOQIX9\$>$_$OCGQ/J]MI7A3P?H>K^)/$FLRL9+72M%
MT&PN-3U:^N/)$DA2SLK6>9TB225Q&5BC=R%/RG^R'^VUX3_;)^$WB+XY>!?A
M3\9_ OPMM6NKOP+XG^*GA[PUX<3XL>'+5=3W^+/ FGZ3XL\0:C_8;3:7-;J?
M%%MX<U$R20,+ P2></YPO#'[-VC>./'7[<&C?LL_LZ_''P3_ ,$_-;_X)@^)
MK+Q?\./B;\//C%X)\-^.OVU?#*/XK\%WW@[P+\3K:Q\3>(/B3X<&G:1#JGB#
MP_I]Q9ZCKNGZB&O=5?5;&^U?]H/^"0GPHE^$O_!*/X ^$+CP'JG@+Q5>_";Q
M'KGC+PQJVAZEH7B%O&>MWGB!]4N]9T74K>WU*VUG4"ELT\$UK#(_[HI"H9<]
MF:<.97E&35L0\56QF8U<QRBA2IUJ4,'4P&%QF!Q.-KPQ>$I8W$^SQRG1C1G"
M52O2IT94ZD9*K6:H=&+RO"8+ U*CK3KXF6*P5*$9QC1GAZ5?#UJ\U6I0KUE&
MNG2Y))SJ0C"4&O?F^3YI^'W_  </?L\^/O 3_&>/]D7]OS1_V?--UJ?1?%7[
M04GP+\-^)/A/X,N+-[==1F\2Z]X(^(GB>XL[?2_M=JVI&VL[RXM$GB+6[/+$
MC_N3\._BAX!^+/@7P?\ $SX<>*=)\7^!/'_A[3?%7@_Q-I%RLNG:]H&JVD=[
M9:C9M)Y<P1[>56FAGBAN+2026]W#!<PS0Q_Q<?\ !.K]I#XA?LY?\$IOC#^Q
M1=_L,_MF_$[]HOXN:K\;]&\+>"K/]G'QS:^ [BT^+'A*P\+Z5J/BCQAKVFV.
MG6.D6#+=76L0?9+J8PQ1P;4CN)+BW]<M?^"8WQGD\9_\$.?V1?C ?BKX>T#P
M[\!?VNM,_:-\7_"_^V$M?".E^/-+U7Q]J?P@UGX@Z3%=Z5X9'B?3=4N_A/>:
M@FH1-?V]QK$?AJ:5IK-C]-GG!7#]/&8W#TJT\AAA,PS:.%JU,0LT>:9/EN48
M[,I9A2PDZU"O&7ML'2PD:D*RPV(GC(*C#VE"<9>IF&0Y;&O7IQJ2RV-'$8M4
MIRJ+%_6L%A<%7Q<L1"A*=.JI*=&%&,U5]E5E7M3CS4FI?V/B\MR6 E0[(_-;
M#QG;&>0Y^?A&'S*Q^4CG-*UY:I&DLD\,<4GW)'EC6-LC(VOOVMD<@*2<<XQS
M7\H/Q3^#UU^PM^TK^V9\,?"'P7_:2\;?"CXE?\$F=+_9_P#V<=<\'?#GX@?&
M1_%/C'PIHGB/0;_PWX@\6>&](O\ 3-#\0P+=OKVI7'B&?0M.ATFW+VJP)<:!
MI=Y\5?M4^'M)\&?"/_@ECX6_:0C\)^*?"OC3_@FEK/PITKX!_'_QOX[^"_A#
M]GOXV:7X6T.:/]I'Q5=>'_#_ (IU?_A)+6'4(O!^GZ%JW@VTOS<Z)<+9:S:S
M1RFT\3!\!4L=4P;P^;U*F'Q\*=3"3AEU.6(KP>4ULTK*%#^TE3C5PTJ$L+5C
M5Q5.G&HJG[[VL(T*G#0X<CB)4/9XV4J>(4)T9+"Q=2I&6"EBY*--XN,>>G*$
MJ,XRJQBI)^_S\M*7]R7VVUVQO]HAV2N4B82QE97!QM1@V&/L#GJ,9!%3++&[
MO&K O&0'4$$KD C(!)7((QN SU&17\.7Q7_9*L/A!\*_V#-9^#'B!OVYC\,O
MV>?#6FZ'\!O#?P*_:)^(/[,?QQ\3>.OC%XEU;QOX]^!7[0'P;CBT'X7?&RUU
MF\NH-8\1>-;WPUJEKIOA_1]3U.2W:Z;PT/Z</V5-.^#Z?M<?MPZSX.^!?[07
MPS^+NO7'P-N?C=X[^)MMXE;X2_$W4H_!&HCPXGP4U/4_$&I>'M5MO!]E+>Z+
MXJF\/Z1HUHM[)9"W6XL'M67S<ZX5PV5X66*P^9XC'P4,=*_]EO!<DL'F>#P$
M57IXG'+$TJ5:EC(UO;PPU:E'$<N"A*K/ZS5PO)CLHI82C*M3Q57$12Q%G]3]
M@KT,50P_OQJXA5HPE"O&HZD:,XQJVPZYFJLZ/T;X>_:H^&/C'X\>.?@%X-_X
M2+Q5K_PK\/'5_BMXQT324NOAG\-]?FDTZ33/AOXL\:/=16-K\2]5T:_?Q-%X
M2L4OKS3/#UE+J'B!]'^UZ5%J'SE\!O\ @IW\$/C_ /%CPE\,_#_@'XZ^$M&^
M+,/CFX_9\^+WQ!^'D?ASX3_M#P_#=9KCQ@_PLUU-;OM8G^Q:5:WGB#35\5^'
M_"SZ_P"'K*ZU;1%OH(UW_D3^R#X7_:;^"?[0&A>#/"/B#]KK6?C'XQ_:R_:>
M\2_M??!CXD_"*STK]CV_^'?BJ\^)_B'3/C'X>^,?_"MM-M]1U'Q1>I\+3X-U
MBU^)WBOQ+JL=[+X6O/#NG:#I%K8KQ_\ P3D^#'Q"\+?M+_L.NWAW]KC5O%OP
MUTO]I:#]HKX/_'CX4^+?"/[,O[%L_P 0M!UG4C%^S)XGU72[/02^L^,/[.\"
M^!K;0_%OQ5_X2/X7ZMJ]W=7?@Q4%F/7J<*9/AJ&<2EBOK#PV5T\1@JL*M2,I
M3C@\WJ5,55A*C3A3HXG&X##1P<Y.>$JX/%4Z-+$5\97I5CN>38*G2QSE5]HZ
M6$C5H34Y)N2I8Z4JLH^S48QJU\-15*3<Z,Z%>%.G.=>I":_K'HHHK\T/E HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XH^.G_ ">'^PI_
MU\_M+?\ JI+>OLO4;J>QT^_O;;3KW6+FSL[JZM](TY]/BU#5)[>!Y8M.L)=7
MO]+TJ.]OI$6VM7U/4].T])Y4:]O[.V$MQ'\:?'3_ )/#_84_Z^?VEO\ U4EO
M7VO0O2_D[Z_=9_<T!_(U^S5_P66_X*&?$G_@L;\1/V6?%O[.,5W\.6U'5O 6
MH?LT:/XM^$B>._@EI?P_-W?:E\2H?B9=^+].\$^./%D5G?2:CX^T"S\97FCZ
MSIJVVE>!O^)AH=D^J_UQN2$8CJ!Q]?R/\C7\0_[$_P#RM._M,_\ 8U?M,_\
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M]3%TY./[Y.+YL*N9U(TZ,/;T_P!^U&JZ?]M1. 2>@!)_#FOD*']M_P"""?M
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M>6=W;2RV]U:W$4D%Q!+)#+&\;LI^YE_9D_9OP/\ C'[X(G@=?A1X"]/^Q?H
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MC_X:?P%_\S] $W_#27[._P#T7GX,_P#AT? __P O:/\ AI+]G?\ Z+S\&?\
MPZ/@?_Y>U#_PS)^S=_T;]\$?_#3^ O\ YGZ/^&9/V;O^C?O@C_X:?P%_\S]
M$W_#27[._P#T7GX,_P#AT? __P O:/\ AI+]G?\ Z+S\&?\ PZ/@?_Y>U#_P
MS)^S=_T;]\$?_#3^ O\ YGZ/^&9/V;O^C?O@C_X:?P%_\S] $W_#27[._P#T
M7GX,_P#AT? __P O:/\ AI+]G?\ Z+S\&?\ PZ/@?_Y>U#_PS)^S=_T;]\$?
M_#3^ O\ YGZ/^&9/V;O^C?O@C_X:?P%_\S] $W_#27[._P#T7GX,_P#AT? _
M_P O:/\ AI+]G?\ Z+S\&?\ PZ/@?_Y>U#_PS)^S=_T;]\$?_#3^ O\ YGZ/
M^&9/V;O^C?O@C_X:?P%_\S] $W_#27[._P#T7GX,_P#AT? __P O:/\ AI+]
MG?\ Z+S\&?\ PZ/@?_Y>U#_PS)^S=_T;]\$?_#3^ O\ YGZ/^&9/V;O^C?O@
MC_X:?P%_\S] $W_#27[._P#T7GX,_P#AT? __P O:/\ AI+]G?\ Z+S\&?\
MPZ/@?_Y>U#_PS)^S=_T;]\$?_#3^ O\ YGZ/^&9/V;O^C?O@C_X:?P%_\S]
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M_P Q%'_#NW_@G]_T8S^QW_XC)\$__F(H$?7"7&FH@C2XLT0'(1)H549ZX 8
M<\_7FH5_L9&#(=-5EY5E:V5E^A!!'X5\F_\ #NW_ ()_?]&,_L=_^(R?!/\
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M?W_1C/['?_B,GP3_ /F(H ^O/MUE_P _EK_X$1?_ !='VZR_Y_+7_P "(O\
MXNOD/_AW;_P3^_Z,9_8[_P#$9/@G_P#,11_P[M_X)_?]&,_L=_\ B,GP3_\
MF(H ^O/MUE_S^6O_ ($1?_%T?;K+_G\M?_ B+_XNOD/_ (=V_P#!/[_HQG]C
MO_Q&3X)__,11_P .[?\ @G]_T8S^QW_XC)\$_P#YB* /KS[=9?\ /Y:_^!$7
M_P 71]NLO^?RU_\  B+_ .+KY#_X=V_\$_O^C&?V._\ Q&3X)_\ S$4?\.[?
M^"?W_1C/['?_ (C)\$__ )B* /KS[=9?\_EK_P"!$7_Q='VZR_Y_+7_P(B_^
M+KY#_P"'=O\ P3^_Z,9_8[_\1D^"?_S$4?\ #NW_ ()_?]&,_L=_^(R?!/\
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MEO1',]G::EXFUO2;6_O8X9Y;*PDNKN.WG> 1-\T?\%2O^0-^PI_VDC_9B_\
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M]UX>N?$'Q(\/WEOHMCK/BS0_LNK:/>0:+;V?V74;*ZU'3-%,DMC;?KY^U?\
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MS.E1JRQ->AR/!*K2<L9&F\+:M"I&52'LD^:E&C[6ISJJH4_OWXE?\%'OV/\
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MF""30(/%^C:';W&L:MX4DU1?$.FZ;!/>WFFPV\,DB^9_L.?!CXT? GX2>(/
M7QA\6)XABB\?:[?_  JT.;XB>)/C!JGPW^%-SIVC0^'?AWJWQ?\ %_@_P)XI
M^(CZ%JEMKMQI6LZ]X9AU73/#VHZ1X:N-3UP:''JES\\_#[]DC]H;P7\)/B]^
MQ]=3?"J\^ _Q4U[]IVX/Q\TKQYXRT?X[:-X=_:-U;XD>,<W/PU;X;7GAC6O'
MGA?Q1X^32SXK_P"%M:=8ZKH&FQ:@='M-4C&GR^!' Y5[?,8/&MTJ%:E'"25>
MBG+#3]JZ^+E4E05/%U,&HT8O X94ZN,G6E]5K.%%RJ>:L/@_:8F+Q#Y*<X*B
MU4@N:F^9U*LINDHU94DHQ="DH2JRG>C4<*;<OK[P5^V)^S1\1?$"^%O!?QC\
M$Z]KMSHFM^)M'L;74Y(_^$K\->&GV>(O$?@6ZNK:WL_'V@:&=IU76O!=QKVF
M6"RP/<W427$+2;MO^TS\#=1\/?"/Q18?$KP[-X?^/7B#0?"OP>UA);K['X^\
M0^*/"%_X\\/:3H+&V1Y[K5?"&F7_ (@M%E6!'L+25RX<>6?A7PG^R%^T/XGF
M_8Z\&_%:#X%>"_ G[&>BZM9Z5XL^%WB7Q=XF\9?%34&^ GBW]GO1X(/#&N?#
MOP9IOPD\(W>@^+I_&'B3P]%XN^)4MWJ^D:#X?@U!K33O[;F\7^'?[#?[8FE>
M'/V _A1XSM/V=+7P#^Q)\?OAU\0KGQQX:^*/Q%U;Q5\0O!?PW^ 7C'X*:<;?
MP-J7P6T;3/#WB34I-<M?$%[ILGCG5M-MDN)-.@U>X:P^V:AW/*<@E[7ES9TW
M3A.<H2Q.&G[J69^S]E5]A2C7G6^KY;)T:4?:T%C9TJB<Z4JD.CZGEKYFL9*/
M)&<G&56E*]EB_9<DU3C&HZGLL+)TXISI+$.G4O*,G'ZI_9R_;N\(:O\ LQ_"
M#XH_M&^//!OA7XA_%75/C!9:+X<T2SU0ZKXC@^&WQ-\;>&)9_"_@;3'\1^*]
M2MM&\-Z#I5[XEU"QM[VSTV2<WE_-8PW=O'7IG["_[1OB'X]?L1?!G]I3XK76
M@6>M^,O NM>,?%M]H=A=Z3X?M+72];\0PRW=II]S<ZE=VEK!I.E132Q275S(
M&65MY!P/C'X%_L)_M&?LWZW^SY\5/"X^#'Q*\=_#/X,?M"_ OQ?X$\2>.?&/
M@?PZNC?%_P#:)N?CGH7C;P-\0K+X7^-]0MO$&GQ0V7ASQ-H>H^ K6VU*UNI3
M::\BZ5 -2^L_V6/V:/B'\&/^"?W@G]E_QA?^$KCXD:!\)/&O@?4;_P /:IJN
MH^#O[;\22>*I+22SU74- T?5KC3(?[;M5GN9?#UI<#RYC'9,%C$EYO0R&-'&
MO 5J4Y8C/*,J,XU*?[C ^VSR%6CAL/[)5J6'HTO[-FZM6<X8ASI>S452DE6-
MIY=&%=X><).KCZ;A*,H+V>'4\PC.%*E;GA3C'ZK)SG)PJ-PY%%1:.^L_VZ?V
M3M1\.-XOL/C=X,N_##6WA&XT_7+>XU"33_$+^/?/'@^P\(SC3]OC+6M=EM+R
MTM=!\*?VSK4>H65]IES80:A8W=M#=UG]MK]E?P_X3T'QSJ_QL\%67A;Q$OBF
M6QU1[RZ=;2U\"ZC'I'CF_P#$-K#92WWA33? ^K2Q:7XVU+Q3;:-8>$-2ECL?
M$5SIMS(L9^2/B)^PI\2=<_9?_8,^'_AG5_#:_$O]C ?"?4=0T"S^)GQ4^$7A
M'Q[=^%_@)XB^"7C/2='^*WPHLK+XE>!))H?%NI:YX9\5Z=H%U),+(:3X@\.2
MZ3KNIPP>$?'7]@']JSQU\%M=^$WP;E^'GP6\,_%O3OVDY/CCX3B_:F^.GCS7
M/&7C;XI^"O#GACX?>+?$_P >_B#\'?%7Q.\:>'M.N]/US4/'OPPTZS^'NF>(
MVN=$BF\2ZA9VVLVFL5A\KX9KU*2>98FC3GC*]*K4K8G!QA2P]#V]I<SH1KRJ
MXBG3HUZ%2.#GA93Q"P=2K1G"5=%+"934E33Q5:$95ZD)SG6H*,*4'446_P!T
MJCG.,(5(25'V+=14)3C*+JGZJ?$/]JC]G_X5:WI'ASQ[\4O"N@:UKF@V_BRR
MT]KNXU*:'PA=WRZ9:^,=7_L>UU!/#_@^YU%OL-OXLUY]-\.3W4<\,6J.]O<+
M%\F_LN_M]>$_B#\1_P!H/X4_&#X@>!-!\<^$/VT/BM^SW\*="M(+W2VU7PWX
M;MM+N? VF:KJ$\U]I3>,_$,8\0/IMK<W^EWWB8:;,=$T>5;9@>0^$?[-/[6O
MP \::C\2_"&C? ?XD^(_BG^SW^SC\*/B+H'CCXN>/_#5A\//&/[//A[Q/X6M
M=4\%>*=/^"/BN\\=^"O&%CXINM7U30-3\/?#[4M.\16]Y<6]_?1:Y*^FTM*_
M85^+MGX:^(^E3ZU\/?[0\7_\%4O"'[;VF20:OKYM[?X4:)\5?AGXWU#0[B1O
M#(EB\=SZ/X.U:TMM*BCFT.2^N+*"7Q-%;2SW5O%/!9!2I8FA5Q:K.M#!1HXU
M8G#\U.NW"6+E##+#3JT:.%J2G0J*K4D\?3IJMAZU"G)-J%#+8QJTYUE+VD</
M&&(56G[M3FINO*-+V4IPA2;G"7-/_:81YZ4Z<7I^N .>1R/4<T4R,$(H^OZD
MD?SI]?(H\4_/']JW_D\S_@EQ_P!ET_:._P#6+_CM7Z'5^>/[5O\ R>9_P2X_
M[+I^T=_ZQ?\ ':OT.H **_F _P"#JSQ=XK\&_L2_ +4?"'B?Q#X5U"Y_:GT:
MRN+[PWK6I:'>3V;_  E^*T[VDUUIES:SRVS3P03- [M$TL,4A0O&A'[)_P#!
M+_4=0U;_ ()R_L.:IJM]>:GJ>H_LL?!&]U#4=0N9[V_OKRY^'^AS7-W>7=R\
MEQ=7-Q*[RSSSR/++(S/([,Q)^CQ/#M3#<,99Q*\5"=/,LQQ>7QPBI24Z4L)'
MF=5U>=QFIVLHJ$7'NSTJN6RI97A<T=6+CBL37PRH\K4H.BDW-SO9J5]%96[G
MW9117Y ?\%"_C[_P47_96\*?%GX[?"_5_P!B'4/@GX7_ .$9LOAWX&^(/@?X
M[ZO\:O&'BGQ/-X?\*Z#X*2[\,?$3P_X2O_$7BOXA:PND^'TLK*T@AT^\LGOR
M9+6\F?S,KRZKFN,I8&A6PU&O7E"%#ZU4E2A5K5*D*=.C"4:=3]Y.4UR\RC"R
MDY3C97Y\)A98RO'#PJ4J=2HXQI^VE*$9SE.,(PBXPE[S<K^]RQ23;DK'Z_T5
M^!7BK_@I[^T;\(_C[X7^!GQEA_9?\.^,_#WB']ECP5X^^%RQ?$/2?B;\9W^.
MNG:/=?%'XP_L\S7GB;4M$TGX1? 6\U'7HM=G\46?C&._T[X>>+[W7_%7@JYE
MTFQE_5']E;XO?$3X^>$-?^,/B#1M \._"SQMXENK[]GC3;:QU6+QAK7P<ME%
MGX?^(WCB]OM1DL3<_%(PR>./">B:9HFDMH'@;5O#D&L7&I:W=7_V+LS#A[,<
MLPU/&8E4/JU:%&=&M3K1G"M]8BJE%4=$ZO/1?MU*"E34%.$IQKTJM&&N(RW$
MX:C&O55/V4XPE"<9IJI[1*5-0T]YRIOVBMHHJ2;4X2@OJ2BBBO#. ^%O^"C_
M /R:GJ__ &7']C[_ -;"^!%?=-?"W_!1_P#Y-3U?_LN/['W_ *V%\"*^Z: /
MRV_X*E?\@;]A3_M)'^S%_P"DOQ"K]0Y9X;>+S)Y8X8U"YDE8(@W,J+EF(4%G
M=54$\LP Y-?EY_P5*_Y W["G_:2/]F+_ -)?B%7L'_!2'X:^(OB_^Q[\2?AS
MX6\*:EXVUCQ)K_P;3_A&=)@EN+[4=)TSXX_#36?$9CBADBF,-GX;T[5K^\:*
M1)(K&UN958;,UU8*A#%XW!X6I6CAJ>)Q6'P]3$32<:$*U:%.=:2E.G%JE&3F
MU*I!/ELYQ7O+;#TXUL10HSFJ4*M:E3E5:35.,YQC*HTY134$W)IRBG;62W/M
MH:IIK>65O[-A-,]M$1<Q'S;A"0\$>'^>9"K;HERZ[6RHP<2+?V+3R6J7=N]U
M$@DEMDE1KB.-L8D>%29%0Y&&*A3D<\BOYMOVI?V$M;M-(_X*SZA\$/V98[+7
M[SPI^S!XL_8V'@CP58Z:NE_%30O"UO-X^\2? NUTRWMH/"/C!]<T'PY_PFFN
M>$(M&U76;C3K :Q=WH@B=>GL/AW^T2?^"E7P=^*EG^R5=_#GP%X!_:3^+/A_
MQKX]\%?#"RF\3_$OP+\5?@AXI@M?B_\ $[X\7/CU=0\:^$=;^(5_I1MOAM9^
M#SI'PBM/#NE6>HZH^HV_A;1U^FCPU@:N&GB*6>4&H8'$8MPK4\+1G[2GE&6Y
MG1PW+_:-2;G7K9C_ &;S1B^7%X:O>/N^S/6CE-"=+VD,?#3#U:SC.-&$N:&!
MPV,C2Y?K4I<U2>)^JII-*M3J7U7*?L1^UM^T]I7[+/P*\1_&W_A'D^($7A[7
M_AQH<GAJPU^#1KBZ7XA_$SPI\-XKY=1-AJZPQ:7<>)CJ3J;&07G]GRV2RV[2
M-<0?2QU.PC\\37MI$UHD<ET&N(U-M'(,QO< MF%),-L:3:&"G:3@X_FRM/V$
M?%FB_P#!(>#PWH'[.CZ?^USK/C+05URXG\$V>H?%Y_#_ /PVYH/Q!EL=1U"?
MR]?N_"FE^$]&TOQ-%X>_M:#2+/1M'LY;:"V6")XL?Q3^RQ^T;HW@[P]X,\=?
M"/Q[\0OB+X+_ &J]3^.'[7/Q7TKP!X<^//A[]KOP[XH\$^/_  _\-/B-X7\'
M>-=4\)Z/XIT?X0:QJ7A>TF_9BULI<_"BTTRSU7P!I7C^+0].U?6.Q<-9-5HS
MI4\[H0KX7.LTP%3$5(4^;%87#T\"J&)AAUC91CA95OK%*A5I3J5:];%T8NFZ
M-*M5P^JRK!3IN,<=3C4I8[&4)5))<U6E3AA?95(TE6E'V/M)5(0E#FJ5*F(I
MIP=.$I0_HWU_XH_#SPOXE\$>#]?\9>'=*\4?$B?6+?P-H%YJ=M%JOBAO#^DR
MZ[K<NCV9D\ZZM=*TJ+[5?WB)]DMO.LX99EN+ZSBGD\;>.%\&1^$Y!X9\4^)U
M\5^--#\&*?"VGV>H#P^=<%WCQ/XC%YJ>F?8_"FDFT_XG&H6AOKRW$]OY&G76
M]C'_ #]:'^R>W@+Q5^PU\8=9_9J^)WQP^&OPT^)/[7,7B;PUXB_9Y^&VD>/_
M  5H_P 9=.T_6OA99:%\%(_$.L2>$OA+X<^(<'B6Z\'Z1/>6DWPX_MV"]GT'
MPOH[K/!^E'_!0?X;^//B7#^PZ_@/PCKGB8>!/^"A'[.7Q*\9+I%NURWACP'X
M:M/'J>(/%.KM&^+;1](?4;);^[#.D!NHCRIW5Y=;)<OI8W+</2S)5Z&*AC_K
M.*E"%*G1JX3%XVC"'LW756G*="AAZTZ=?V<X_6(<KFI)+EJ8##0KX6G'%1JP
MK+$*I5:C"$*E&M7IPCR^UC.'/&G2J.%3EDE5C;FORGZ$0ZGI]Q*L$-[:RSO&
MTJPQS1O(T:2&&2145BQCCF4PR. 528&)B)!MKEO$OQ(\">#]=\'^&?$_BWP_
MH7B'Q_J.JZ5X,T34]3M;35/$M_H>A:CXFUB'1[*65+B\&EZ%I5_J-_+%&8;6
M")!/+')<6R3?B;^S_P#LD>)/ARO[!7Q#TSX%R^$OBUHO[;/[6.J_&_QI9>%[
M33O&\?P;\?6_[8$NC/X]\001)JM]X&UV\O\ X3RZ58:E=W>F"ZG\*7%G;0RI
M:NGTI^W]\$M-\3?'?]B;X]:]^SNW[0G@+X-^,_C%I7Q4\.:!\.?#?Q.\81:!
M\0_A%XBT'P9?1>$]:47&N>'M(^((TFZU"*S:Y;0KVZM/$)LUCM+F^M8EDN C
MF5+!1S-UZ-2CFLO;TZ5",GB, \QIX:C"#QDZ<UCJF#H.@W6A*<<5"$8WY9RE
MX'#1Q<*"Q3J4Y0Q?OQA3C+VN'>)A3IQ3K2@_;RHTW3;G&ZK15MI/ZU_9M_:6
ML/VAA\:Q'X;_ .$1F^#O[1/Q6^ #03ZW#JTOB6?X6W.D6]SXJMD2PTY["WU4
MZLA&DLE[)8>5M?4;KS P^EEO;-[AK1+JW:Z15D>V65#.B,0%=X@V]58L-K,H
M!R,'D5_.)!^Q]\1=/BU[XOZ!^S]KFB_&^Z_X+<^&/BUIOC:#PO;6WQ'M/V8=
M7^*7A&V\7:M#X@M6;4H/A?>> -0\4P^(-.M-3?0;S3I]3:ZLKIR=U[]G;]E'
MXW^&?VHO VK?%^P^,\7QB\#?M3?%KXF:]\7/ /P"^'UOX2^*/@+QSXD\<2::
M/&W[3L_CNRU_Q%\+=2\!>(] TN;X2:II5SXA\%:MX=T#0_#_ (+_ +/\(:'J
MY]'$\.Y/-8S$8?.\/AZ=&E.<,)*FZU5U*5#GE&$J>)K.=!U>2D\1-P<9UD_9
M<L&GU5LLP4O;U:..ITX4X-QHN#J3<X4E*5N6K-^Q<VH^TE9Q<]8)(_HMN+ZR
MM/\ CZN[>VRKR#SYHX<QQ!3+(/,9<I$)$\Q_NQ[UWD;AE);^R@C2:>[MX89"
MBQRRS1QQ.TG$:I([!&:3_EFH)+\[0<&OSD_:F_9[MOC7^VW^Q#K7C'X2Z?\
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MJN%5O:-T^6I.E.>(J^VQ=2<*M2?O8E_NY)-4X4?W<(*[9\;_ +"-Y\?;_P"
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M*<&[J,4I25N::A%QE+]%Z3 /4#\O\^@I:*^9/*"C\*** $P/0?E2X]OTHHH
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MUBTW2KS6%N?$6MM'/K&L7$+7=OI.E_H>8YAEM3PXX=RZEF&'J9EA<]S+$U\
MH577I4JL-)5%*FJ2A:4'&3FX5>=QI\\J5>-+Z/$XG"RX9RW#0Q%.>*I9ABZM
M3#)3]I"$XQM*5X*'+M9\S4N:T>9PJ*':_LU?"S]IOX:#Q8O[1O[4NG_M,2:O
M)HS^%+BP^ _A/X(+X0CLTU1=8AE@\+>(_$*>(CK3W.FNDUZ]JVF_V8R0+*+Z
M4I\Q?M+_  =^*?[3?[=/[*W@C7O"&L:7^R=^S+'-^U?XG\8S&U;1/BA^T'H^
MH7'A;X.?#BWA2>2X*?#MKG5/B9K!O;06MU/_ &+;P@S0QSI^HU-VC.<'OW/?
MKQG%?(4,VQ%#&5LPC2PJQ53#UZ%-T,+0P='#2KX=X66(PV%P5/#X>C7ITI3=
M*4*24*TOK%G6C&:\>&,J0KSQ*A15:=*=.+IT:="G2=2G[)U*5&A&E2A.,&^5
MQ@DIOVEG47,?G)^VI\*?&_[2WC'PG^SYX=\"V<7P\O?!OB'Q?\=/B?K>B7=E
M'KW@^UN$@\+?LV^$?&EO;I>6W_"Y/$]JR?&(:)?+=:1\']*UK2YQ:W_CW0;E
M?"?^";/BK]N?6?'OB#1/V@=$^,EA\-="^$OAN#QA!\</A;\)OA?:^#_VE(-:
M6T\0>!/V8Q\*[333XU_9PTOPY#=_V-XC\4)XAN56W\-_V;XPU.:\UJSL_P!D
M=HR&QR,X//< ?R'\_4Y4*%S@8SUKIAGDHY54RJ6!P56E*"5&M5IN>(PU9U95
M*V)I5)-N-:M'V5-N'LTJ>&P\&IJG+VFL<P<<)+!O#T)P<4H3G!3J4IN;E4JT
MY/6,ZBY8/EY5R4J::=GS+1117A'GGPM_P4?_ .34]7_[+C^Q]_ZV%\"*^Z:^
M%O\ @H__ ,FIZO\ ]EQ_8^_];"^!%?=- 'Y9_P#!4^2.'0OV%Y976.*+_@I!
M^S)))(Y"QQQI9_$-GDD<X5(T4%G=B%502Q K],AXB\/X'_$\TCH/^8C9^G_7
M:ORL_P""O7@_PI\0?A[^QKX'\=>&M!\9>#/%W_!0C]GCPUXJ\*>*-)L=>\.^
M(_#NOZ)\2](US0M;T;4X;G3]4TG6-*O;S3=2T^]MY[2]L;JXM;F&6":1&]7_
M .'1/_!*I5!?_@G%^PT"0,EOV6_@LN2<>O@_N3^M 'W[_P )%X?_ .@YI'_@
MQL__ (]1_P )%X?_ .@YI'_@QL__ (]7P'_PZ(_X)58S_P .X?V&L<\_\,M_
M!;'&<\_\(=VP<_0T#_@D/_P2K/3_ ()P?L-'Z?LM?!?_ .8Z@#[\_P"$B\/_
M /0<TC_P8V?_ ,>H_P"$B\/_ /0<TC_P8V?_ ,>KX$_X=#_\$J_^D;_[#?\
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ME*,EUBVGHV???_"1>'_^@YI'_@QL_P#X]1_PD7A__H.:1_X,;/\ ^/5\"?\
M#H?_ ()5_P#2-_\ 8;_\1:^"_P#\QU'_  Z'_P""5?\ TC?_ &&__$6O@O\
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M_P#8;_\ $6O@O_\ ,=0!]]_\)%X?_P"@YI'_ (,;/_X]1_PD7A__ *#FD?\
M@QL__CU?S1?"D_\ !#3XN?\ !0GQY_P3CT+_ (),_L[:=\6_A]J7CW3=6\::
MM^R;^S,GPZNY/A]IAU35)-/NK-+OQ*Z7L.([ 7/ANV8RDBX$" .WZQ?\.A_^
M"58Z_P#!.#]AL?\ =K7P7_\ F.KMQV78[+9T*>.PU3#3Q.%H8ZA&IRWJX3%1
M<\/7CRM^Y5BFXWL[;I&]?#8C"RIQKTI4I5:-.O34K7G1K+FIU%9OW9K5=?(^
M^_\ A(O#_P#T'-(_\&-G_P#'J/\ A(O#_P#T'-(_\&-G_P#'J^ Q_P $B/\
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M/3Q'Z@B@#]"_,3^\*/,3^\*_/;_AU'_P3T_Z-@\#_P#@P\7?_-'1_P .H_\
M@GI_T;!X'_\ !AXN_P#FCH _0GS$_O"CS$_O"OSV_P"'4?\ P3T_Z-@\#_\
M@P\7?_-'1_PZC_X)Z?\ 1L'@?_P8>+?_ )HZ /T)\Q/[PH\Q/[PK\]1_P2D_
MX)YDX'[,/@8GT&H^+<_^I'1_PZE_X)Y9Q_PS%X&SZ?VCXMS^7_"1^QH _0KS
M$_O"CS$_O"OSV_X=1_\ !/3_ *-@\#_^##Q=_P#-'1_PZC_X)Z?]&P>!_P#P
M8>+O_FCH _0GS$_O"CS$_O"OSV_X=1_\$]/^C8/ _P#X,/%W_P T='_#J/\
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MXNO##^+%;2]5BTS4K/6))+"9;]OQ+_X)"^*]?\>_#7XE_"C]JW6/@[XOT?\
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M#C3_ !78:)8ZUH=IJMW:>(=3@T.M[]E;_@D/=?LT_$O]@_X@M\>8_&:_L5?
M?XQ_!5]*'PQ?0#\1V^*_B/Q9X@7Q&M\?'FKKX3_L-O%)M3I1M/$/]I?8?.&H
M6 G:.WXC4?\ @BI=:A^PM\>/V,/^&BXH6^-7[86H_M6+\1?^%2NZ^'$O_%7@
MWQ-_P@I\*?\ "QT.JF)?"GV'_A)/^$BTX.]\UU_82^1]FFYG'PV^M1I)U_JO
MUW#1>)]KFRG]3K9OF]'%U7!T7=X/)XY3B</%4XRJ8B<O:+$?OL.L6N%_:1@E
M4]FZ]%.ISXSF5&IB\9"M)Q<=70P<<'6IJ,4YU)RYU57/37E]Y_P4M^,?[/\
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MX:> /$9T"U\4>$_$>NZ1$VE:7K^MZY87D^M7-K:^'_\ A+9Y;:74?V&\%?\
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MM]JNJ7KQQLMKIVF65YJ%].4MK*UN+F6*)Q7>B5V]$EU _B1_8G_Y6G?VF?\
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MA[;^*KK2I=<M_#\GB/3I;$:I-I$-]IDNHI:>9YAM(]0M&EQM$Z=:_+3X[?\
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M$_%/B33+"[^$D7P^T"W\9/X;U6/[-X?U>X^*/B+5=<77_"^J26&G6.FFVO\
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M7=VD$7D7Q8_83^-WB7_@G3\)OV#_ (7?';PGX'N?"WPL^%7P<^)GQ%UKX?\
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MT;7["?\ !*__ )1K_L(?]FG_  *_]5WH-?I69_\ )K.&?^RFSC_TPCZC%_\
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M>@ZL/2@.A. V3[9YXSQZ\>E<ID?#7_"U?^"@_P#T9Q^SK_XF_P"*/_H-J/\
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MA,545.5/#8B<:LHQI2A1J2C4E.<J<8P:BU-RJ0G"*BVW.$HK6+2C_P"%J_\
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ML^5*5-N+N<;_ ,+5_P""@_\ T9Q^SK_XF_XH_P#H-J/^%J_\%!_^C./V=?\
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M-/1I['P5_P +Q_;[_P"C"OAY_P")G:%_\XVC_A>/[??_ $85\//_ !,[0O\
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MG'24)PFE*$D]XR2:ZHB<)TY2A4A*$XNTH3BXRB^THM)I^31\%?\ "\?V^_\
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MP%L](L/#$OAZXT^;0[73;6WL8M->W2VACA"*/QO_ .#MO_DTW]ES_LXC5/\
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ML;^WT>0:1=?\)+ILNL6M_H$;:K%9@_AU^PW^R#^T_P" ?^#@_P#:^_:-\9_
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MOQ@T+X>_LW:C_P $2_A]\8KG1O%LG@[0- N?BMX9N/#>GOK\7BO6K*#6FO\
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MY\3?!L^F:CKNE:_XDT_2=#FGTOPGI?CD>&;/Q;J<FF>(;9H=$O+:V_HQ\??
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MWVAW%A>+<0P2Z+?Z#O\ O35_B_\ \%;O#G_!-3QY^WO\4?VHO 7ARXL?V--
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M6BBBO#///SQ_:M_Y/,_X)<?]ET_:._\ 6+_CM7Z'5^>/[5O_ ">9_P $N/\
MLNG[1W_K%_QVK]#J /Y+/^#MB_L9/V6?V8M/CO+1[^W_ &A-2FGL4N(6O((9
M/AKXBV2S6RN9HXWW+L=T56W+@G(K]@?V7/VB_"'[.G_!)C]B7XL:]X;^(WQ%
MT?PW^R'^R'H>I>&_@KX+U+XH>.Q?ZM\'OA]IB+;^$O#QEU*9+":X2?5FPITZ
MS66ZG4)&:Q_^"G__  1__9Y_X*<:'X1OO&5[=_"WXQ^"-1TN#1/C/X2T>PO_
M !%<^!SJD,_B/P)XDT^ZEM+;Q)I%W8/?S^%Y;^X%SX.\2RQZKILDNE7OB;P_
MXC^\_P!FS]FKX-_LD_!KP;\!O@1X/L_!?PZ\$V0M["QM_P!]J.JZC-M?5/$O
MB35&5;K7?$^O78:^UG6;PM/=W#A$6&TAMK6#[_%Y[DE7@GAK)/\ ;,1C<NSG
M'XW,,+[..&IRP^(:;C3QO-6LZL9*-*:P\Y*4:SJTZ:A2>(^AK9A@9Y%E> _?
M5*^&QV(Q&)I<JI0=*I;W85^:=G)647[.334W.,5&'M/R+_X*R?&[0/VBO^"-
MOQ'^+_ACPM\1?!>B>*?'W[/GV+PY\6/!>J?#SQ[I_P#8O[7OPKT*=M;\(:T%
MU/21<W6F37>G&X ^VZ9-9ZA%^YNHZ]+_ ."L'B[]LC6]%\%_ /\ 9\_9;^*?
MQB^"OQ L-0O/VG_&_P -?&W@'P5XCG^'<9N()?@]X-UCQ7XGTN]T'4/'7V<V
MGCOQ3!I<\VE>!KVXL/#<QUS5FO\ 0OU!^.GP%^%'[2OPSUKX/?&OPHOC7X<^
M(K_PUJ>L^')-7U[0TO;[PAXGT?QEX=G.I^&]4T?68/[.\2Z!I&I!+;488[DV
M@M+U+BQFN+:;UB:WBN+::TF4O!/#);RIN92\4J-'(N]"K*65B-RE6!.00W->
M5A,_P>!IY9['+*>(>6YQGF8T\+CJE6IAX4LRPN34,&O;8>KA:]7$X.>75:BF
MXTJ?M%0J<L[SIPYZ.94*%/!J&$C5>%QV88J-'$2G.G&.*I8"G0_>4IT9SJT)
M864N9QA'F]G*SNU'^3/_ ()W>%&\5_\ !*#X ?M"^-/&/Q1_8KB_8\\"?M*>
M"/#'Q=\/V7PL^)MI\8/@W\7?&DFI^/8M"\"^)M$\3JFJ7'BS0M%\(>#+.2VL
MO%3>.O#B)8VNKZ7KT&GW7UI_P36^,'PF^ OB#2OAOXJ^&7[0@^(/BCQ-\,OV
M3]0^+OB3P_H>K_"#X*ZQ\/?AA!JGP7_8V@\6KXAMO%3>(/!?@B>"7XA^)],\
M!_\ "#>)?CWXH\97K:]9C6-#TRQ_7KPG^Q;^S5X'^&/P9^#/ACX<?V?\+OV?
MO&5O\0/A3X+D\6>-]1T;P_XNLM4U[7=/U?48M3\27DOB]M+U_P 2:IX@TFT\
M9R^(+#2M?_L[6M.M;;4]%T:ZL*Z_L/?LK)^T(O[5"?!W08_CJMV=5/C./4/$
M,=K+X@.AR>&?^$NN?!T>L+X%NO'"^'9I-#C\<W/AF7Q=#I3?88M:2W"QCV<?
MQ7E68RX@IUZ&/CALSQ698O!4Z,*$9T'5QE3%X'#UJLL1+$5*<Z]?$XW%^UQ.
M)HT,354,'A'2515NS$9QA,4\QC5AB%2Q=;%5J,81IITW.M*M0I3G[15)0E5J
M3KUN>I4ITYM0H4>1-2^K 21G&/\ /'8=O_UGK2T@&!@=!2U^>'S1\+?\%'_^
M34]7_P"RX_L??^MA? BONFOA;_@H_P#\FIZO_P!EQ_8^_P#6PO@17W30!^2?
M_!7GPEX<\>_#[]C3P5XOTFVU[PKXK_X*$_L[^'/$>BWOF_9-6T/7=$^)>DZO
MIMUY,D4OV>_TZ\N;2;RY8Y/*F?8ZMAA[ /\ @E%_P3NP/^,5?AQT'\7B+T_[
M#E<%_P %2O\ D#?L*?\ :2/]F+_TE^(5?1O[>?[0?BG]E/\ 8]_: _:*\%Z-
MH/B'Q1\(?AQJ_C/1=$\3KJ#Z!J=]ITEJL5IJJ:5>Z;J+6<@F82?9+^UG&%*2
MC!!Z,)AJV-Q6%P6'2E7QF(H86C&348NKB*L:--2D](Q<YQO)Z)7;V-:-*>(K
M4:%-)U*]6G1IINR=2K.,()MZ).4DFWHMV>8?\.HO^"=W_1JGPX_[Z\1?_+RC
M_AU%_P $[O\ HU3X<?\ ?7B+_P"7E?E]^Q]_P6)_:H\??M(?L9_!C]IKX6_L
MT-X=_;L^$^H?$WX5:M^S;XU\9ZSXN^',5OX4N?%]E:_&#PEXPN[^;29+RSLI
MM/G@L)UAL;Q+JX@U35(].U"WM_U2\*_\%1_^"?WC2\T?3_#_ .U/\+[B[UOP
M#XR^*-G'?:C>Z&L'@#X?7NO:?XP\4:O-KMAIL'A_3]'N/"_B&1AKTFFW-[9:
M3=ZEIMO>:<J73^WF7">?9965*K@*N*3P_P!:5?+HRQ^']C[;&8>4I5<-&HJ3
MA7R_'4Y1JJ$KX6M))PCS'?BLGS#"3Y)8>=9.G[7VF&3Q%+DYZM-MSI*2BXU*
M%:$E/E:=*;LXKF>=_P .HO\ @G=_T:I\./\ OKQ%_P#+RC_AU%_P3N_Z-4^'
M'_?7B+_Y>5/I_P#P52_X)_:K\-/&GQ@T[]I;P9=?#KX=:CX6TWQQXACTWQ8#
MX8;QQ>C3?!VHZKH[^'DU^#P[XGU!A8Z)XJ&EMX9U&[_<6VK22 J/2_&W[>/[
M(GPW\5?%;P7X[^.W@OPIX@^!W@OPU\0OBQ!K4U_9:?X(\)^,WTN/PC?ZOKLM
MB-!-YXHDUK2H_#NA6>IW7B#6GO[<:;I=SOX\^62YQ";IRRG,XU(RE"4)8#%1
MG&47AHRC*+I*2E&6-P:::NGB\*GKB*7/RO XZ,N5X+%J2DXN+PU924DZ2<6G
M"Z:=>BFN]:DO^7D.;RW_ (=1?\$[O^C5/AQ_WUXB_P#EY1_PZB_X)W?]&J?#
MC_OKQ%_\O*[;3?\ @HK^Q7J_P/\ &?[1^G?'[PC<?!GX<ZWI7AOQ_P",!;:_
M&_@O7-<O]+TW1]-\4>&Y='3Q9H<^I7.M:4UD=1T*WBN;.^@U**1].;[4.,;_
M (*G?L&7GPY^.?Q1\._M%^#_ !9X6_9RT33_ !%\5G\+1ZKJNI:1I>M2/;>'
M+K2M,73H[KQ-9^)[U5LO#NJ>'$U+1]5N981;ZB891*7'(\ZDY*.49H_9XB&$
MJ?[!BK4\54E1A##5'[*T*\YXG#QC2FU4E*O12BW4A=K 8^5^7!8M\M2-&5L-
M6M&K-TU&G)\EHU).K248.TG[2%E[T;L_X=1?\$[O^C5/AQ_WUXB_^7E'_#J+
M_@G=_P!&J?#C_OKQ%_\ +ROG'P__ ,%;OA]\:/ '[(?Q ^ 6M?#:*+X[_M ?
M!WX2?$WPM\6IOB/H&O>#8/BCX;UK76\,>"KO3?!9T;Q5\2[=M-2WLA]K?PA*
M\5V)-6:"2&\A^NO%G_!2+]AKP%\8#\ _&/[3/PRT'XL0Z_IGA.^\-7NK3?9M
M*\6:RQ72O"NN>)XK67PGH'B?4)!Y5MX=UK7;#67F*P_8A(Z*VU;AW.Z%3V,\
MKQSQ"CB9U,-3PU>K7HPPE6-&M4K4J=.4J=.,Y0M5?[N49PG&3C)-W/+,PA+D
M>#Q#J6JRE2C1J2J0C1DH5)3A&+E&";7OM<KBU)/EE%OD_P#AU%_P3N_Z-4^'
M'_?7B+_Y>4?\.HO^"=W_ $:I\./^^O$7_P O*T/B?_P5'_8#^"_Q"\9_"KXJ
M?M,^!/!'Q!^'>K>'=%\;>&=;@\10WGAR]\56D%]HDNHS1:)+9)I4]M=V3W>N
MQW4FAZ2]_I\&KZC8SZA913K^VY\2/VW? _@+0?B/^Q-H'[+?C7PYHOA7QQXU
M^*$_[0'B'XD:>TGA_1M%TO7?#$OPZ_X5Q:W-OJDNHV47B)[\ZO>6UNVS1?L,
MRI<7<T>5+)<QE6P5+$8>IE\<Q5\'B<SIU<#A*\?91JQE3Q->G&G4C.$Z7)*F
MY*3K4M?WD6YA@,4ZE"%6E+#+$_P:N*C+#T:BY8SO&K54823C*%G%M/GA;XE?
M._X=1?\ !.[_ *-4^''_ 'UXB_\ EY1_PZB_X)W?]&J?#C_OKQ%_\O*_,?\
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M##PCKNE"(ZO_ ,)5K&D_&;6]6LK;2OM%L+U['1-0F3[3"8X)@PKU</DF9XK
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M8>E5H7Q"<)>V4Z=2-D[.$Z5.5Y*$8K^*3]J[X(_'&_\ '_\ P4BT?XA_ _\
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M%-2C6FG'E>7<T:%H_N*$XY?%>PA>*G7KSNU)07RY^QU<^+[W]BK]ER[^(/\
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M<'F\L'4K3AAX257,<%C^7G<8P^I5:]6-%)0:<9^WY>;3D4%[DKV7\L/[1/\
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MW7YE*"A*FU&%?DAS1;A[*#@XIRB_X=[?]GCQG=?L+?%BT\>6GQ^^&WB/0?\
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MHN\*D:4(T'AZK=&=)QK<UW65.]*/M'+F<^9G\ZGA#Q%;?$[]E3XM_M!?#O\
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MX] QSD_\-<_\$[^!C_>'YCUH _H-\4W6A6'A[6-2\4-IT7AW2]/NM5UN?5A
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M*<JJPN(E[2454IO$<D+1A&1^+OA;]O?]IW6O!O\ P3YU71KGP9XL\8?M#?\
M!/;]I/\ :'\9^'K[3=&T+2_&'QB^&?PN^%_B;P+;+J?GV*>$M NO%/B?5K+5
M8[>[L;%+>X/VB:WBL1+#P_A7]I3_ (*0_$3X?_$_XF_ KQ#XR^-'@>/PC^RY
MKWP\U;Q'^S[X.^"OB/QF_C*ZOO$7[3FD? OPE\1]-\++X_\ %/@;P7I-E/\
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MBZ1J]C;ZAK7A?7YM"?2[&]LHK;\H]2_X*._M+Z/\"O\ @H9KGAOQE>^+-4^
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M'JFH\C?)[*I7P;=2$E.K'"MU-6H2^0OVAKOXSS?MW?LC^"?!GQZ\6_#;X?\
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M7&5.1]"/Y@?G1>^P'YO?\.J_V7?^AQ_;;_\ %E?_  4/_P#HGJ/^'5?[+O\
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M_P"AQ_;;_P#%E?\ P4/_ /HGJ_2.B@#\W/\ AU7^R[_T./[;?_BRO_@H?_\
M1/4?\.J_V7?^AQ_;;_\ %E?_  4/_P#HGJ_2.B@#\W/^'5?[+O\ T./[;?\
MXLK_ ."A_P#]$]1_PZK_ &7?^AQ_;;_\65_\%#__ *)ZOTCHH _-S_AU7^R[
M_P!#C^VW_P"+*_\ @H?_ /1/4?\ #JO]EW_H<?VV_P#Q97_P4/\ _HGJ_2.B
M@#\W/^'5?[+O_0X_MM_^+*_^"A__ -$]1_PZK_9=_P"AQ_;;_P#%E?\ P4/_
M /HGJ_2.B@#\W/\ AU7^R[_T./[;?_BRO_@H?_\ 1/4?\.J_V7?^AQ_;;_\
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MIHH _-;_ (=1_LM?]#E^V_\ ^+,?^"BO_P!%#1_PZC_9:_Z'+]M__P 68_\
M!17_ .BAK]*:* /S6_X=1_LM?]#E^V__ .+,?^"BO_T4-'_#J/\ 9:_Z'+]M
M_P#\68_\%%?_ **&OTIHH _-;_AU'^RU_P!#E^V__P"+,?\ @HK_ /10U^)_
M_!5[]C3X9?L__$G]FR/X3>,_VA;/5O&OA3QG97.M_%#]IS]H+]I"71)-+_:S
M_P""?XT_4/#>C_M)_$?XN>'-%O()-1N);C[!HT$.JF*R35DO$L;$6O\ 6S7\
M[G_!;_\ Y*O^QQ_V OB'_P"M:_\ !/&@#]5C^SG^T?GC_@H'\>L?]DC_ &/_
M /Z':D_X9S_:0_Z2!_'K_P -'^Q__P#0[5]G44 ?&/\ PSG^TA_TD#^/7_AH
M_P!C_P#^AVH_X9S_ &D/^D@?QZ_\-'^Q_P#_ $.U?9U% 'QC_P ,Y_M(?])
M_CU_X:/]C_\ ^AVH_P"&<_VD/^D@?QZ_\-'^Q_\ _0[5]G44 ?&/_#.?[2'_
M $D#^/7_ (:/]C__ .AVH_X9S_:0_P"D@?QZ_P##1_L?_P#T.U?9U% 'QC_P
MSG^TA_TD#^/7_AH_V/\ _P"AVH_X9S_:0_Z2!_'K_P -'^Q__P#0[5]G44 ?
M&/\ PSG^TA_TD#^/7_AH_P!C_P#^AVH_X9S_ &D/^D@?QZ_\-'^Q_P#_ $.U
M?9U% 'QC_P ,Y_M(?]) _CU_X:/]C_\ ^AVH_P"&<_VD/^D@?QZ_\-'^Q_\
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MH_X9S_:0_P"D@?QZ_P##1_L?_P#T.U?9U% 'QC_PSG^TA_TD#^/7_AH_V/\
M_P"AVH_X9S_:0_Z2!_'K_P -'^Q__P#0[5]G44 ?&/\ PSG^TA_TD#^/7_AH
M_P!C_P#^AVH_X9S_ &D/^D@?QZ_\-'^Q_P#_ $.U?9U% 'QC_P ,Y_M(?])
M_CU_X:/]C_\ ^AVH_P"&<_VD/^D@?QZ_\-'^Q_\ _0[5]G44 ?&/_#.?[2'_
M $D#^/7_ (:/]C__ .AVH_X9S_:0_P"D@?QZ_P##1_L?_P#T.U?9U% 'QC_P
MSG^TA_TD#^/7_AH_V/\ _P"AVH_X9S_:0_Z2!_'K_P -'^Q__P#0[5]G44 ?
M&/\ PSG^TA_TD#^/7_AH_P!C_P#^AVH_X9S_ &D/^D@?QZ_\-'^Q_P#_ $.U
M?9U% 'QC_P ,Y_M(?]) _CU_X:/]C_\ ^AVH_P"&<_VD/^D@?QZ_\-'^Q_\
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M\_\ #0_L>_\ T.U?9U% 'QC_ ,,Y?M'_ /207X^?^&A_8]_^AVH_X9R_:/\
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M$TKP_'+)J/@Q/"%G%,X34[_48'_8SX^_\$I_V6/V@_B+X_\ B1KQ^+7@._\
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M6T\2>$K:S3QII.I3:1HTWB;3M:O=+ATJZUW6O#\*ZQ:Z-BQ\2_VC?B1\$_\
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MP];"U'1KPY*J5Y0O%RCJTE+E;2;2YHZ^]"49J\9)LK^=S_@M_P#\E7_8X_[
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M:^%O^"C_ /R:GJ__ &7']C[_ -;"^!%?=- 'YA_\%/?^0/\ L.?]I&/V:/\
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MW#87UYX.T74+3Q;HEG<6,MK;WMFMZ?\ 2HU^D](_X*0?LE:IX-^,/CRY\?\
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M2T?[/.A_!+P-\9?".AV5]^U]^TM\;_BSHMEXC^)/@C3?B9\(_CG\3_C%\0M
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M#X&C";PV)]NU7Y*>NLJ2GB5*I*/LX\MXPP\H^]K[26CVA])T445\^>:%%%%
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M/&T\-K<VVCZ?K"VETVMZM8VMW^B5]?Z=IMF]]J-S;V-C;H9);N\GBMK:WC!
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M6(O"4NM6%WIM[>>1Z)^S9\+OB)\+_BCKWPSTV>+]H'2?VGK7XZ^-/V>?A?\
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M?#8FO3KX>I.?M*2E5I2AR1P]1MRE2A:G1B]6Y3<(2A*HY5%5J2J24"OYW/\
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M%J/AL="^%?\ 9/AOQCX7^$WQ8\9ZM8_L^^%/AQJVMZSHVB>&M0\4^ C:Z?\
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M@17W30!^8?\ P4]_Y _[#G_:1C]FC_TE\?U^G8Z#Z#^5?G5_P4D^'?Q6\=^
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M?^D7W[0O_B0'[$W_ -$369)^C]%?G!_PV3^UC_TB^_:%_P#$@/V)O_HB:/\
MALG]K'_I%]^T+_XD!^Q-_P#1$T ?H_17YP?\-D_M8_\ 2+[]H7_Q(#]B;_Z(
MFC_ALG]K'_I%]^T+_P") ?L3?_1$T ?H_17YP?\ #9/[6/\ TB^_:%_\2 _8
MF_\ HB:/^&R?VL?^D7W[0O\ XD!^Q-_]$30!^C]%?G!_PV3^UC_TB^_:%_\
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MUS_X*?V;/_HFJ/\ A^A\ /\ HVS]KG_P4_LV?_1-4 ?MG17XF?\ #]#X ?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex6_head.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex6_head.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,BXQ /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )0
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M4L]04*&=;>93-$#C!F@;;/#G(P)8T/(]:EIK= ;%( H * "@ H * "@ H *
M"@#D_%7C/1/"%J)]4N-UQ*I^R:=;E7O+IAW2,E1'"I^_/*R1+T!:0K&[46^G
MSZ ?+OBKXI>)?$C2P13MH^EM\JV-A(RR2*>,7=XNR>?.3N1?)MV&-UN2"QU4
M$O/U_P @./TCP]KNOR^5H^F7FH,&VN\,1\B)F[373[+>'.<_OI4'.:=TM+I
M>H:=\#?$]RH?4+W2],!V_N]\M[.IR"VY842WX&<%;E\MQ@#YJES71-@=-'\
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M*RD%6!((((K$!] !0 4 % 'R-\8O%!UKQ$=(MY";#0=]N0K?)+J+X^V2GL3
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M_C32H@H <Z=:Q*;^0\Y+W&Z*&<X8O]KE).26K*"O*_;7YO\ JX'AOP\\,_\
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M?J1(^=;B=5*6['D_Z)"$@*Y*^:LKK@25E)W?DM@.\J0"@ H * "@ H * "@
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M:?87EMJ5S?->WCVS)/!%$J*L#2[@8V)))4+@\8JHRN[6_K[@-?X$?\C'J_\
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MTV2U6Y2":X6*47%O.OF1V\<LVUUB9 T<;D.5W*$+.MS3:T[@?07_  MKX?\
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J !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jackmansig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 jackmansig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MB :%% !10 44 %% !10 44 %% !10 44 ?F/_P %3_\ @H!^T[^T)^UC8_\
M!%[_ ():Z^NF_$C5K$7?Q:^)RY,7@71V52^UEY6X*.AW#YE\R-$P[[D^G/\
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MK\VWHKB11]W-?85 !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10!^./QHG;_@C[_P<@:)^T!=C^S_A#^U]IO\ 8_B.Z8[;>S\0JT:B
M1CP WG^3(2<_+>S'UKWG_@Y5_;:\%? /_@GCX[_9NT?3KW7_ (@?$WP=?0:;
MX?T8%Y[#28P/MNKW&T'RK6%,KN; 9V50?O$ 'M/_  11_9*^"7[('_!-;X5^
M#_@CI@$'B3PAI_B77-5D4&?5-0OK2*>6>1AUQO"*.BHB@=,GZLH *_/O]LK0
M5^&7_!?G]DOX[3V^VU\:^ ?%W@>>XQ@">*(7T"$^K;YB!_L&@#S;_@NEJW_#
M=_[9/[.__!&OX<WS7,VM>,+?QY\6VM6#?V5X?L2Q02?W7E_>[<]Q'D8<&NM_
MX)_>&U_94_X+L_M5?LJ^%8([/PC\0/".A?$W1]+C4+'!>2L;6[:-1\JAY2^<
M#_EFOH* .-_X))6S?#;_ (+T_MY?![PC,G_"-WEYHGB":W@4".'4)T+N.. <
MSR\>U?JE0 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 ?G5_P<C>$O@1^T)^QO9?L?ZGIE_K_ ,:O&.M0W/P*\+^&8EEU9M8@/-W@
MD>19I$TBSSN5148\[@M>%?\ !"'PU\.?^"@O['G[0GAC]I/7M8UC]IK6;&^^
M'_QDU/QHRR7VF62PR6UA;6\8"^3:(4+,B@;KB*1G+';@ ^EO^#>#]H[5OB%^
MPE:_LG_%</8_$_\ 9WU*;P#XZT.\;_2+<6;M'9S;3R8W@555AD,8FP37WI0
M5^3_ /P<M_\ !0+X'?LQ6/P:U3X=_$71=6^/'PV^+>F^*/"_@2.X,LDEL8IK
M>X2\\L_Z-%)%-M&\J6S\H.,@ ^@/^".__!.3XG?LTV7BW]LS]M7Q!#XD_:,^
M,URM_P".M65@\6B6G!@T>U(X6*(!=VW@E5496-2?FW]L_P#;O^ O["7_  7O
M\?\ [2?QH\606FE^#?V1;*TDTR.4?:M7U*;5YY;:Q@3J\KAE]E4[FP 30![-
M_P &_/[*_P 9O"'PR^)'_!0/]JKP[)I/Q._:6\8-XIU#1;B,K)I&D_-]AM6!
M *L5D=R" 0K1@@$$5^AE !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M !10 44 %% !7XQ_\%VO^"DW[>WQ2_;T\"_\$B/^"2OC]]/\::A9_;O&6M>'
M[Z%;B&5@[?9I+@[OLL<,$;3R]'PZCT! *?PQ_P""#/\ P76^"7QLU+]J7P!_
MP5R\):E\1M>T6WT[6=>\6>')[Z9[:/!%JLL\4Q2$-V14#$ D9KY=_:R\"_\
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M+XPD\&3?&*^TCP]>7UC<6ENDD]M=7T>DVX%O/.K37$8BC9A<.0\2R+5^"O\
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M&/POI"$-#8#!*J_$>Y 2$6&-<EMYK]#* "B@ HH ** "B@ HH ** "B@ HH
M** "B@ HH ** "B@ HH ** "B@ HH ** "B@"GKGASP]XGL_[.\2:#9ZA;YS
MY%]:I,F?7:P(JGX<^'O@'P=,]QX1\#Z/I4DBXDDTW3(H&8>A**,T ;%% !10
< 44 %% !10 44 %% !10 44 %% !10 44 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
